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Abstract: Ehlers–Danlos syndromes (EDS) are a group of heritable connective tissue disorders
(HCTDs) characterized by a variable degree of skin hyperextensibility, joint hypermobility and tissue
fragility. The current EDS classification distinguishes 13 subtypes and 19 different causal genes
mainly involved in collagen and extracellular matrix synthesis and maintenance. EDS need to be
differentiated from other HCTDs with a variable clinical overlap including Marfan syndrome and
related disorders, some types of skeletal dysplasia and cutis laxa. Clinical recognition of EDS is not
always straightforward and for a definite diagnosis, molecular testing can be of great assistance,
especially in patients with an uncertain phenotype. Currently, the major challenging task in EDS is to
unravel the molecular basis of the hypermobile EDS that is the most frequent form, and for which the
diagnosis is only clinical in the absence of any definite laboratory test. This EDS subtype, as well
as other EDS-reminiscent phenotypes, are currently investigated worldwide to unravel the primary
genetic defect and related pathomechanisms. The research articles, case report, and reviews published
in this Special Issue focus on different clinical, genetic and molecular aspects of several EDS subtypes
and some related disorders, offering novel findings and future research and nosological perspectives.
Keywords: Ehlers–Danlos syndrome; heritable connective tissue disorders; differential diagnosis;
next generation sequencing (NGS); transcriptomics; integrated omics approaches
Ehlers–Danlos syndromes (EDS), with an estimated prevalence of about 1/5000, belong to the
large group of heritable connective tissue disorders (HCTDs) and are characterized by a variable
degree of skin hyperextensibility, joint hypermobility (JHM), and tissue fragility. The clinical and
genetic heterogeneity of these conditions has long been recognized, but the subjective interpretation
of some semiquantitative clinical signs, such as skin hyperextensibility, skin texture, JHM, tissue
fragility and bruising, led to diagnostic ambiguity and confusion regarding the type of EDS and the
inclusion of similar phenotypes under the broad diagnosis of EDS. With more systematic research
on clinical data and with the clarification of the molecular basis and associated pathomechanisms of
several of these EDS phenotypes, different classification systems have been formulated in the past
50 years. A first classification with five main types was introduced in 1970 by Beighton [1], followed
by the Berlin classification with 11 types [2], and the Villefranche nosology of 1997, in which six EDS
types were included [3]. The rapid development of genetic techniques has allowed the recognition
of many distinct disorders that, while dissimilar from the initially-described classic EDS types, have
been given the umbrella term of EDS as an image of the presence of generalized connective tissue
fragility. Hence, the last version of the EDS classification published in 2017, which recognized 13 types
with 19 different causal genes mainly involved in collagen and extracellular matrix (ECM) synthesis
and maintenance, has been expanded to include a wide range of clinically heterogenous disorders [4].
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It should be noted that in an important percentage of EDS patients, no pathogenic variant in any of
the known EDS-associated genes is identified. Therefore, it is expected that by taking advantage of
next generation sequencing (NGS) technologies, further EDS types will be molecularly defined, thus
demanding updating of the existing classification.
It always has been, and still is, a challenge to classify single patients in one of the existing EDS
subtypes because the currently defined clinical criteria remain relatively unspecific. Often it is not
possible to reach a clinical diagnosis and, therefore, the identification on molecular genetic testing
of a clear pathogenic variant in a specific gene can be of great assistance, especially in patients with
a clinical presentation that does not completely fit into one of the existing subtypes. The difficulty
of clinical diagnosis is, among other reasons, due to the clinical overlap not only between many of
the EDS subtypes but also with other HCTDs, such as Marfan, Loeys–Dietz, and arterial tortuosity
syndromes, as well as some types of skeletal dysplasia and cutis laxa [4–10].
The major challenging task in EDS today is to unravel the molecular basis of the most frequent
EDS type, namely hypermobile EDS (hEDS), the diagnosis of which remains reliant on clinical findings
for the absence of any definite laboratory test. This EDS subtype as well as other EDS-reminiscent
phenotypes are currently investigated worldwide to unravel the primary genetic defect and related
pathomechanisms. In 2018, the groundbreaking “Hypermobile Ehlers Danlos Genetic Evaluation”
(HEDGE) was launched by the International EDS Society (https://www.ehlers-danlos.com). There has
never been such a worldwide collaborative effort before dedicated to discovering the underlying
genetic markers for hEDS. Until the end of 2020, the HEDGE study aims to recruit, screen and undertake
NGS on 1000 individuals who have been diagnosed with hEDS by the most recent clinical criteria
established in 2017, which are stricter than the Villefranche criteria, in order to form homogeneous
cohorts for research purposes [4]. Understanding the genetic causes of hypermobile EDS is undeniably
central to the EDS community, since it will allow us to make unequivocal diagnoses for a huge number
of patients. Furthermore, understanding the genetic pathways and etiopathomechanisms leading to
hEDS will advise the search for possible therapeutic approaches for this disorder.
The original research articles, case report and reviews published in this Special Issue focus on
different clinical, genetic, biological and molecular aspects of several EDS subtypes and some related
disorders. When the first edition of McKusick’s book entitled “Heritable disorders of connective tissue”
was published in 1956, less than 100 manuscripts had been dedicated to EDS; they were mainly case
reports [11]. Nowadays, the search term “Ehlers–Danlos syndrome” in PubMed yields more than
4000 papers including the 14 contributions of this Special Issue, demonstrating how significant and
fertile scientific research is for rare genetic diseases such as EDS and related HCTDs.
The relevance of clinical and genetic research in the continuous definition of new EDS types is
exemplified in the original research article by Ritelli et al. [12], who describe a novel patient with the
classical-like EDS type 2 (clEDS 2) that is caused by recessive variants in AEBP1, and review the clinical
and molecular findings of the few patients reported to date. This rare EDS type in differential diagnosis
with the more frequent classical EDS (cEDS) is not yet included in the current EDS classification, since
the first description was noted in 2018 [13], but certainly it will be incorporated in the forthcoming
revision of the EDS nosology. Two original research articles, respectively by Rymen et al. [14] and
Micale et al. [15], further define the phenotype of the other classical-like EDS type (TNXB deficiency) by
reporting three novel patients and performing a literature review. The authors highlight that clEDS 1 is
likely underdiagnosed due to the complex structure of the TNXB locus which complicates diagnostic
molecular testing. Rymen et al. [14] also provide an in vitro characterization of the clEDS 1 cellular
phenotype, demonstrating the disorganization of the type I, III and V collagen ECMs in patient’s
fibroblasts. The case report by Angwin et al. [16] underscores the importance of molecular analysis for
a definite cEDS diagnosis by showing that patients with pathogenic COL5A1 variants can have an
absence of collagen flowers on skin biopsy transmission electron microscopy (TEM) analysis, which
for many years has been recommended as a first line of investigation to confirm or exclude a cEDS
diagnosis. The original research article of Miller et al. [17] provides novel clinical and instrumental
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findings on hEDS, cEDS, and vascular EDS (vEDS) by performing the assessment of pulse wave velocity
measurement in a large patient cohort, which is recognized as a gold standard for determining the
stiffness of arteries. The authors evidenced an increased arterial elasticity in all EDS subtypes that was
associated with lower supine and seated systolic and diastolic blood pressure, thus likely contributing
to the orthostatic symptoms frequently encountered in EDS, especially hEDS.
The paper by Chiarelli et al. [18] offers a wide overview on molecular mechanisms likely
involved in cEDS, vEDS, and hEDS that could direct future studies to possible therapeutic strategies.
The authors review their previous transcriptome and protein studies on patient dermal fibroblasts,
emphasizing that these cells, despite sharing a common ECM remodeling, show differences in
the underlying pathomechanisms. In cEDS and vEDS fibroblasts, key processes such as collagen
biosynthesis/processing, protein folding quality control, endoplasmic reticulum (ER) homeostasis,
autophagy, and wound healing emerged as perturbed. In hEDS cells, gene expression changes
related to cell–matrix interactions, inflammatory/pain responses, and the acquisition of an in vitro
pro-inflammatory myofibroblast-like phenotype seem to contribute to the complex pathogenesis
of this molecularly unsolved EDS type. The evidence that the application of untargeted general
omics approaches may serve as a valuable tool to identify novel proteins or pathways involved in
the pathogenesis of the different EDS types is also documented in the original research article by
Lim et al. [19] that focuses on the very rare kyphoscoliotic EDS (kEDS) type, which groups two clinically
indistinguishable disorders caused by biallelic variants in either PLOD1 or FKBP14. This article also
proves that nowadays it is possible to perform a high-profile scientific investigation for very rare genetic
disorders which have been neglected for too long. The authors performed transcriptome profiling by
RNA sequencing of kEDS patient-derived skin fibroblasts that revealed the differential expression of
genes encoding ECM components that are unique between PLOD1-kEDS and FKBP14-kEDS, as well as
genes involved in inner ear development, vascular remodeling, ER stress and protein trafficking that
were differentially expressed in patient cells compared to controls, addressing possible pharmacological
targets to improve disease symptoms.
We recommend reading two papers of the Special Issue together, namely first the research article
by Caraffi et al. [20] and then the paper by Ritelli et al. [21], since they present stimulating results
offering nosological viewpoints concerning the so-called linkerophaties (LKs), which are caused by
defects in genes involved in the glycosaminoglycan (GAG) biosynthesis. Specifically, LK genes encode
for enzymes that add GAG chains onto proteoglycans via a common tetrasaccharide linker region.
LKs include two different subtypes of the spondylodysplastic EDS (spEDS type 1 and 2) and further
related disorders that are characterized by a variable mixed phenotype with signs of EDS and skeletal
dysplasia. Of note, some of these conditions are in fact included either in the 2017 EDS classification [4]
or in the 2019 nosology of skeletal dysplasia [10]. In the original research article by Caraffi et al. [20],
the clinical and molecular findings of three spEDS patients are reported. Through the description of
one patient with B4GALT7- and two patients with B3GALT6-spEDS and a review of previous literature
reports, the authors contribute to a more accurate definition of the clinical features associated with
these rare conditions. Ritelli et al. [21] report on a patient fulfilling the diagnostic criteria for spEDS
according to the 2017 nosology, in whom, however, NGS identified compound heterozygosity for two
pathogenic variants in B3GAT3 that is not recognized as an EDS-causing gene. The authors review the
spectrum of B3GAT3-related disorders and provide a comparison of all LK patients reported at the time
of writing, corroborating the notion that LKs are a phenotypic continuum bridging EDS and skeletal
disorders. Following these papers, we suggest reading the research article by Kumps et al. [22] that
further accentuates the existing nosological confusion concerning these very rare syndromes with huge
clinical overlap. Indeed, the authors describe four patients with recessive variants in SLC39A13 that
are associated with spEDS type 3, even if the encoded gene product, namely a putative zinc transporter
(contrariwise to the proteins encoded by B4GALT7 and B3GALT6), is not involved in GAG biosynthesis.
Given that the clinical presentation of this condition in childhood consists mainly of short stature and
characteristic facial features, the authors propose that the differential diagnosis is not necessarily that of
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a connective tissue disorder and that SLC39A13 should be included in gene panels designed to address
dysmorphism and short stature. In the outstanding review by Kosho et al. [23], the authors discuss
recent advances in the pathophysiology of the rare musculocontractural EDS (mcEDS), which is caused
by biallelic variants in CHST14 and DSE (which are also involved in GAG synthesis). By describing
novel glycobiological, pathological, and animal model-based findings, the authors highlight the critical
roles of dermatan sulfate (DS) and DS-proteoglycans in the multisystem development and maintenance
of connective tissues and provide fundamental evidence to support future etiology-based therapies.
Finally, three papers deal with different HCTDs in differential diagnosis with EDS. Beyens et al. [24]
describe the clinical and molecular characteristics of two novel and 32 previously reported patients
with occipital horn syndrome (OHS), previously known as EDS type IX or X-linked cutis laxa [2],
caused by pathogenic variants in ATP7A (encoding a copper transporter). The main clinical features
of OHS, such as cutis laxa, bony exostoses and bladder diverticula, are attributed to defective
ATP7A trafficking and decreased activity of lysyl oxidase, a cupro-enzyme involved in collagen
crosslinking, in line with a pathogenetic scheme shared with many EDS types. The authors explored
the pathomechanisms of OHS by performing TEM analysis on skin biopsies and collagen biochemical
analysis on fibroblast cultures that showed increased collagen diameter, elastic fiber abnormalities
and multiple autophagolysosomes. Fusco et al. [25] report two unrelated individuals with Marfan
syndrome (MFS) and Mitral valve–Aorta–Skeleton–Skin (MASS) syndrome, respectively, which were
associated with different intronic variants in FBN1, pointing out the importance of intronic sequence
analysis and the need for integrative functional studies in the diagnosis of MFS and related disorders.
Camerota et al. [26] report on a cohort of 34 patients with Loeys–Dietz syndrome (LDS) with a defined
molecular defect either in TGFBR1, TGFBR2, SMAD3, or TGFB2. The study broadens the clinical and
molecular spectrum of LDS, corroborates and expands previously delineated genotype–phenotype
correlations, and shows that a phenotypic continuum emerges as more patients are described, paving
the way for a gene-based classification of the different disease subtypes.
In conclusion, this Special Issue, by offering novel findings and future research perspectives,
will be of interest not only to a wide range of investigators but also to patients with EDS and related
disorders, as well as to all healthcare practitioners who may encounter such syndromes during their
work and we hope they will enjoy reading it.
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Abstract: Ehlers-Danlos syndrome (EDS) comprises clinically heterogeneous connective tissue
disorders with diverse molecular etiologies. The 2017 International Classification for EDS recognized
13 distinct subtypes caused by pathogenic variants in 19 genes mainly encoding fibrillar collagens
and collagen-modifying or processing proteins. Recently, a new EDS subtype, i.e., classical-like EDS
type 2, was defined after the identification, in six patients with clinical findings reminiscent of EDS,
of recessive alterations in AEBP1, which encodes the aortic carboxypeptidase–like protein associating
with collagens in the extracellular matrix. Herein, we report on a 53-year-old patient, born from
healthy second-cousins, who fitted the diagnostic criteria for classical EDS (cEDS) for the presence of
hyperextensible skin with multiple atrophic scars, generalized joint hypermobility, and other minor
criteria. Molecular analyses of cEDS genes did not identify any causal variant. Therefore, AEBP1
sequencing was performed that revealed homozygosity for the rare c.1925T>C p.(Leu642Pro) variant
classified as likely pathogenetic (class 4) according to the American College of Medical Genetics
and Genomics (ACMG) guidelines. The comparison of the patient’s features with those of the other
patients reported up to now and the identification of the first missense variant likely associated with
the condition offer future perspectives for EDS nosology and research in this field.
Keywords: classical Ehlers-Danlos syndrome; classical-like Ehlers-Danlos syndrome type 2;
AEBP1; aortic carboxypeptidase-like protein; differential diagnosis; high-frequency ultrasonography;
reflectance confocal microscopy
1. Introduction
Ehlers-Danlos syndrome (EDS), with an estimated prevalence of 1/5000, comprises a group
of clinically heterogeneous heritable connective tissue disorders (HCTDs) with diverse molecular
etiologies. The 2017 revised EDS classification recognized 13 distinct subtypes caused by pathogenic
variants in 19 genes mainly encoding fibrillar collagens, collagen-modifying proteins, or processing
enzymes [1]. Classical EDS (cEDS) (MIM #130000), with an estimated prevalence of 1/20,000,
is an autosomal dominant disorder primarily characterized by cutaneous and articular involvement.
Indeed, cEDS is suggested by skin hyperextensibility plus atrophic scarring that must be present
together with the other major criterion, i.e., generalized joint hypermobility (gJHM) evaluated
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according to the Beighton score (BS ≥5/9), and/or with at least three of the minor criteria
among easy bruising, soft, doughy skin, skin fragility, molluscoid pseudotumors, subcutaneous
spheroids, hernia (or a history of thereof), epicanthal folds, JHM complications (e.g., sprains,
luxation/subluxation, pain, flexible flatfoot), and family history of a first-degree relative who meets
clinical criteria [1–3]. Furthermore, cEDS patients may present distinctive facial features, premature
rupture of fetal membranes, scoliosis, osteoporosis, gastroesophageal reflux, and cardiac and blood
vessel fragility [2,4–8]. Skin is hyperextensible if it can be stretched over a standardized cut off in the
following areas: 1.5 cm for the distal part of the forearms and the dorsum of the hands; 3 cm for neck,
elbow and knees; 1 cm on the volar surface of the hand (palm) [1,2,5]. Atrophic scarring can range
in severity; however, most cEDS patients have wide atrophic scars in different body areas that can
variably assume a cigarette paper, papyraceous, or hemosiderotic appearance [1,2,5].
Point mutations or intragenic rearrangements of the COL5A1 and COL5A2 genes encoding type V
collagen are recognized in over 90% of patients [4,9], the recurrent heterozygous COL1A1 c.934C>T
(p.Arg312Cys) substitution is rarely found [4,10,11]. Negative molecular testing does not exclude the
diagnosis, as specific types of mutations (e.g., deep intronic variants) may go undetected by standard
diagnostic molecular techniques. Nevertheless, alternative diagnoses should be taken into account in
the absence of a COL5A1, COL5A2, and COL1A1 mutation [1].
Recognition of cEDS is straightforward in the patient with the typical cutaneous signs and BS ≥5.
However, intra- and interfamilial variability tells a much broader clinical presentation and significant
overlap with other EDS types and HCTDs [1,2,4–6,12]. Differential diagnosis of cEDS should include
the hypermobile EDS (hEDS), particularly in patients without a striking cutaneous involvement [1,12].
Indeed, hEDS shares with cEDS gJHM and many mucocutaneous signs, but generally a lower
grade of skin hyperextensibility and only few small atrophic or post-surgical enlarged scars are
observed [13,14]. In case of a family history compatible with autosomal recessive transmission,
differential diagnosis comprises the rare classical-like EDS type 1 (MIM #606408) due to biallelic
TNXB mutations. These patients show marked skin hyperextensibility, easy bruising, and joint laxity,
but unlike cEDS patients, they do not have atrophic scarring or poor wound healing. Furthermore,
minor criteria such as foot deformities, edema in the legs, mild proximal and distal muscle weakness,
axonal polyneuropathy, and atrophy of muscles in hands and feet facilitates the differential [1,11].
Severe progressive cardiac-valvular problems distinguish the cardiac-valvular EDS type (COL1A2)
from cEDS, severe skin fragility and unusual craniofacial features discriminates the dermatosparaxis
EDS (ADAMTS2), whereas (congenital) kyphoscoliosis and muscle hypotonia differentiates the
kyphoscoliotic EDS (PLOD1, FKBP14), which are other rare recessive EDS types. Bilateral congenital
hip dislocation differentiates the autosomal dominant arthrochalasia EDS (COL1A1, COL1A2) [1,11,12].
Recently, in six individuals from four unrelated families who presented with a constellation
of clinical findings reminiscent of cEDS such as gJHM, redundant and hyperextensible skin with
poor wound healing and abnormal scarring [15–17], and recessive alterations in the AEBP1 gene,
which encodes the aortic carboxypeptidase-like protein (ACLP) associating with collagens in the
extracellular matrix, were recognized, thus defining a new EDS form labelled as classical-like EDS
type 2 (MIM #618000).
Herein, we describe an additional patient with a homozygous missense AEBP1 causative variant
and compare her clinical features with those of the other patients reported so far, offering future
perspectives for EDS nosology and research in this field.
2. Patient and Methods
2.1. Molecular Analyses
The patient was evaluated at the specialized outpatient clinic for the diagnosis of EDS and
related connective tissue disorders, i.e., the Ehlers-Danlos Syndrome and Inherited Connective
Tissue Disorders Clinic (CESED), at the University Hospital Spedali Civili of Brescia. Molecular
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analysis was achieved in compliance with the Italian legislation on genetic diagnostic tests and
the patient provided written informed consent for publication of clinical data and photographs
according to the Italian bioethics laws. Since this report is based on data obtained through routine
clinical care and is not considered research at the involved institutions; formal ethics review was
not obtained. Genomic DNA was extracted from peripheral blood leukocytes using standard
procedures; the exons and intron-flanking regions of COL5A1, COL5A2, and exon 14 of COL1A1
(c.934C>T (p.Arg312Cys) were amplified by PCR and directly sequenced using an ABI PRISM®
3130XL Genetic Analyzer (Life Technologies, Carlsbad, CA, USA), as previously reported [4]. For the
multiplex ligation-dependent probe amplification (MLPA), the commercially available SALSA MLPA
kits P331 and P332 for COL5A1 gene were used, according to the manufacturer’s recommendations
(MRC-Holland, Amsterdam, The Netherlands), as previously described [4]. The primers for AEBP1
Sanger sequencing (Supplementary Table 1) were designed for all coding exons, including the
intron-exon boundaries, and primer sequences were analyzed for the absence of known variants
using the GnomAD database [18]. The sequences were analyzed with the Sequencher 5.0 software and
variants were annotated according to the Human Genome Variation Society (HGVS) nomenclature by
using the Alamut Visual software version 2.11. To evaluate the putative pathogenicity of the AEBP1
missense variant, which was submitted to the LOVD Ehlers–Danlos Syndrome Variant Database [19],
we used the following mutation prediction programs: Mutation Assessor [20], PhD-SNP [21],
Align GVD [22], SIFT [23], Mutation Taster [24], PolyPhen2 [25], PROVEAN [26], MutPred [27],
M-CAP [28], CADD [29], DANN [30], Fathmm-MKL [31], and VEST [32]. The nucleotide and protein
accession numbers correspond to the AEBP1 (NM_001129.4, NP_001120.3) reference sequences.
2.2. High-Frequency Ultrasonography and In Vivo Reflectance Confocal Microscopy
To investigate patient’s skin by a non-invasive approach, we performed high-frequency ultrasonography
(HF-USG) and in vivo reflectance confocal microscopy (RCM) as previously described [33–35].
Briefly, HF-USG was performed on the dorsal and volar side of the forearm of the patient and
10 age- and gender-matched healthy individuals with the same skin phototype and similar sun
exposure history by digital 50-MHz ultrasonography B mode scanning (DUB-USB Skin Scanner,
Taberna Pro Medicum Company, Lueneburg, Germany). For ultrasound transmission, water was
employed as a coupling medium between the transducer and the skin surface. The usable depth of
signal penetration was 4 mm, and the gain was 40 dB. Ultrasonography images were collected under
standard conditions (environmental temperature was 20–23 ◦C and the patient remained in a lying
position for at least 10 min before examination). Acquired images were exported into a dedicated
database and were evaluated using specific image-analysis software to assess epidermal and dermal
thickness (μM) and lesional echogenicity.
RCM investigation on the same sides of the forearm was achieved with a Vivascope 1500®
microscope (MAVIG GmbH, Lucid Technologies, Henrietta, NY, USA) to visualize in vivo the
horizontal optical skin sectioning at cellular-level resolution (lateral resolution = 0.5–1 μM,
axial resolution = 3–5 μM) from the epidermis to the papillary dermis (200–250 μM in depth).
The system uses a laser source with a wavelength of 830 nm and a power <35 mW at the tissue level.
The microscope objective is attached to the skin through an adhesive ring to diminish motion artefacts
during investigation. Water was used between the adhesive window and the skin, and ultrasound
gel (Aquasonic 100 Gel; Parker Laboratories Inc., Fairfield, NJ, USA) was used between the adhesive
window and the lens as detailed in [35]. VivaScan 7.0, Viva StackTM and Viva BlockTM software (Lucid
Technologies, Henrietta, NY, USA) was employed to acquire blocks of 4 × 4 mm horizontal optical
sections, obtained from 64 individual horizontal optical sections (500 × 500 μm images). The system
saves images in bitmap format with digital resolution of 1000 × 1000 pixels and 256 levels of grey.
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3. Results
3.1. Clinical Findings
The proband (LOVD ID AN_006205) was an Italian 53-year-old woman, born from healthy
second-cousins parents, and had two healthy brothers. Clinical history was remarkable for premature
birth at 30 weeks (height 44 cm, weight 1.2 kg) associated with perinatal respiratory distress. Neonatal
severe hypotonia and delayed motor development, i.e., delays in walking (she took her first steps at
four years of age) and acquisition of fine motor skills, were also reported. Medical history further
included propensity to develop ecchymoses either spontaneously or upon minimal trauma often
occurring for motor clumsiness, surgically treated umbilical hernia in infancy, myopia and astigmatism
since childhood, and complete dental loss due to unspecified periodontitis at 14 years old. At age 18,
a clinical diagnosis of unspecified EDS was given for gJHM, skin hyperextensibility, delayed wound
healing, and easy bruising; genetic analyses were not performed. The patient suffered from recurrent
dislocations of knees and occasionally of shoulders and elbows since the age of 10; the objective
patellar instability was surgically treated by capsuloplasty and transposition of the insertion of the
common patellar tendon by tibial tuberosity transplantation followed by skin plastic surgery at the
age of 29 leading to a wide atrophic post-surgical scar (Figure 1A). At 21 and 23 years old, respectively,
she underwent bilateral saphenectomy for symptomatic varicosities with pain, fatigability, heaviness,
and recurrent superficial thrombophlebitis and surgical removal of nodules on vocal cords. At age
41, the patient was subjected to operative treatment of rotator cuff disease in the setting of weakness
and substantial functional disability. Since age 42, she suffered from Achilles tendinopathy with pain
and stiffness, especially at the back of the ankle, treated with on-demand NSAIDs use, conservative
physical therapy, and orthotic insoles for severe pes planus. At 43 years of age, metatarsal osteotomy
on the 3rd toe of the right foot for metatarsalgia and aggravating Achilles tendinopathy was performed.
In the same period, she developed disabling bilateral gonarthrosis, treated with arthroscopic abrasion,
epitrochleitis, and subacromial shoulder impingement associated with night pain. Hypotrophy of the
scapular girdle and weak osteotendinous reflexes were observed at age 50, when she also experienced
the dislocation of the left ankle with soft tissue effusion without reabsorption.
On examination, at 52 years of age, she presented with a height of 150 cm (genetic target 157 cm,
arm span/height ratio 1.03, normal value <1.05), a weight of 52 kg, hyperextensible, soft, doughy,
fragile and redundant skin, with an old-aging appearance of face and extremities, and multiple
atrophic papyraceous scars, especially on knees, defective wound healing, easy bruising, spheroids
on the elbows, and BS 5/9 (Figure 1A). She also showed multiple papules with some follicular
prominence that looked like a diffuse poikiloderma of Civatte (PoC-like dermatitis) more pronounced
in photo-exposed sites, androgenetic alopecia, high palate, elongated uvula, scoliotic attitude, mobile
patellae and flat feet (even though surgical intervention and orthotics, respectively), hallux valgus,
bilateral piezogenic papules, peripheral artery disease (i.e., intermittent claudication, peripheral
cyanosis, and cold skin), and varicose veins (Figure 1A). The patient reported persistent lumbar back
pain and sporadic pain of hips, knees, left ankle, elbows, shoulders, and feet. Multidimensional
fatigue inventory (MFI) questionnaire was suggestive for chronic fatigue (total score 69, higher score
in the questions investigating physical fatigue). Cognitive development and mentation were normal.
Heart ultrasound detected normal cardiac/valve morphology and function. Dual-energy X-ray
absorptiometry (DXA) disclosed femoral osteopenia (T-score left femoral neck −1.5 SD, T-score total
hip −1.6 SD); lumbar BMD was normal (T score −0.9 DS) in the presence of marked degenerative
arthritis. Nevertheless, we found a mild dorsal vertebral deformity (T10) in the presence of a low
TBS value (1.23). The patient also presented mild scoliosis and lumbar spine rectilinization. Due to
hypovitaminosis D, Cholecalciferol 50,000 UI monthly was commenced. Other bone metabolism blood
and urinary samples and markers of bone remodeling were normal.
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Figure 1. Clinical and molecular findings of the patient. (A) Old-aging appearance of face and
androgenetic alopecia (a,b); laxity of the thumb (c), laxity of the fifth finger (d); hyperextensible skin in
different body areas: neck (e), elbow (f), dorsum of the hand (g) and forearm (h); flat feet and piezogenic
papules (i); subcutaneous spheroid on elbow (j), diffuse PoC-like dermatitis and easy bruising (k);
skin redundancy, atrophic papyraceous scars on knees, postsurgical enlarged scar after right knee
capsuloplasty and skin plastic surgery (l). (B) Sequence chromatograms showing the position of the
c.1925T>C p.(Leu642Pro) variant (arrow) identified in homozygosity in exon 16 of the AEBP1 gene
(seq. Ref.: NM_001129.4, NP_001120.3) and in silico prediction of the pathogenicity of the p.(Leu642Pro)
missense substitution by using 13 different algorithms [20–32].
3.2. Molecular Findings
The patient’s phenotype was suggestive for cEDS, since she fulfilled both major (skin
hyperextensibility plus atrophic scarring and gJHM) and 6 minor criteria according to the 2017 EDS
nosology, i.e., easy bruising, soft, doughy skin, skin fragility, subcutaneous spheroids, a history of
hernia, and JHM complications. Therefore, after written informed consent was obtained, we performed
Sanger sequencing of COL5A1, COL5A2, and of exon 14 of COL1A1 (p.Arg312Cys), integrated by
MLPA analysis of COL5A1, which did not identify any pathogenic variant. Although negative
molecular testing, a clinical diagnosis of cEDS was maintained, since the other EDS types in differential
diagnosis with cEDS (including periodontal EDS) were excluded clinically. Following the discovery
of AEBP1 biallelic variants [15,16], Sanger sequencing of this gene was achieved, which revealed
the homozygosity for the rare c.1925T>C p.(Leu642Pro) variant in exon 16 (Figure 1B), leading to
the substitution of a highly conserved leucine residue with a proline at position 642 within the
metallocarboxypeptidase-like domain of the protein. This variant has been observed in 3 individuals
in GnomAD (rs753531562, 3/282140, no homozygotes, total MAF: C = 0.00001063). Its putative
pathogenicity was estimated through an array of 13 different in silico prediction algorithms that agreed
to define p.(Leu642Pro) as high impacting variant. Given that the variant is located in a critical and
well-established functional domain without benign variation, the extremely low frequency in publicly
available population databases, the multiple lines of computational evidence supporting a deleterious
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effect on the gene product, and the patient’s phenotype highly suggestive for a disease with a single
genetic etiology, the p.(Leu642Pro) missense variant is classified as likely pathogenic (class 4) according
to the guidelines of the ACMG. Samples of the healthy parents or brother were not available for
molecular analyses.
3.3. Instrumental Findings on Patient’s Skin
In order to investigate the skin by a non-invasive approach, HF-USG and in vivo RCM were
performed on selected skin areas, i.e., dorsal and volar side of the forearm, showing clinically significant
differences between our patient and 10 healthy individuals (Table 1 and Figure 2). Digital 50-MHz
ultrasonography scanning demonstrated an increase in epidermal entrance echo (highly echogenic
band produced by the differences of the acoustic impedance between gel and skin) corresponding to
increased epidermal thickness, but a decrease in dermal thickness compared to control skin of age- and
gender-matched healthy individuals with the same skin phototype II and similar sun exposure history.
The patient’s epidermis (dorsal thickness = 172 μM; volar thickness = 141 μM) was thicker than that of
healthy controls (dorsal thickness (mean ± standard deviation, SD) = 121 ± 22 μM; volar thickness
(mean ± SD) = 102 ±12 μM), likely due to the multiple and diffuse papules (Table 1). The increased
thickness was more evident on the dorsal side of the forearm that is chronically more photoexposed
compared to the volar side. Contrariwise, the patient’s dermis appeared thinner (dorsal dermal
thickness = 570 μM; volar epidermal thickness = 289 μM) compared to healthy controls (dorsal dermal
thickness (mean ± SD) = 1108 ± 320 μM; volar epidermal thickness (mean ± SD) = 983 ± 205 μM)
(Table 1). Moreover, the considerable hypoechogenicity of the dermal layer suggests disruption of
collagen fibers and accumulation of elastotic material that is typical of chronological and photoinduced
skin aging (Figure 2A). This ultrastructural pattern is known as subepidermal low echogenic band
(SLEB) and derives from skin elastosis and accumulation of glycosaminoglycans that have increased
water-binding capacity [33]. In vivo RCM investigation demonstrated loss of the typical honey-comb
pattern (corresponding to alteration of epidermal thickness), irregularity of the dermal-epidermal
junction and the disarray of the dermis, which was characterized by coarse and fragmented collagen
fibers both on the dorsal and volar side of patient’s forearm (Figure 2B). These alterations are
independent of sun exposure, given that they are present both on dorsal and volar side of the forearm,
suggesting a pronounced and diffuse skin aging due to AEBP1-defect.
Table 1. Epidermal and dermal thickness of patient’ s forearm evaluated by high-frequency ultrasonography
(HF-USG) compared to 10 healthy individuals.
Dorsal Forearm Volar Forearm
Patient Controls(mean ± SD) Patient
Controls
(mean ± SD)
Epidermal thickness (μM) 172 121 ± 22 141 102 ± 12
Dermal thickness (μM) 570 1108 ± 320 289 983 ± 205
4. Discussion
Recently, taking advantage from NGS, a new, autosomal recessive type of EDS has been discovered
due to variants in the AEBP1 gene. This EDS type is very rare and, so far, found in only seven
individuals (including the present patient) from four unrelated families (Table 2). The International
Consortium on EDS and Related Disorders has not yet classified and named this type, but in OMIM
it is labeled as classical-like EDS type 2 (MIM #618000). Indeed, the few patients reported hitherto
(Table 2) share many similarities representative of the classical type as much as they all fulfill the
cEDS diagnostic criteria of the 2017 nosology [1,2] for the presence of the pathognomonic cutaneous
involvement, i.e., soft, doughy and very hyperextensible skin, delayed wound healing with abnormal
atrophic scarring, JHM, and other minor criteria such as easy bruising, subcutaneous spheroids
(observed only in our patient), and JHM complications such as dislocations/subluxations (shoulders,
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knees, hips, ankles, elbows, clavicula, wrist, mandibular and distal radioulnar joints, in some cases
requiring surgical treatment), sprain, pain, and flexible flatfoot (Table 2)
Figure 2. Instrumental findings on patient’s skin. (A) Ultrasonography (50 MHz) images of the forearm
skin from the patient and a representative age- and gender-matched healthy individual (control).
E, epidermis, D, dermis, S, subcutaneous adipose tissue (depth of imaging: 4 mm). Disorganization of
collagen fibers and elastosis in patient’s skin appears as a significant thinning and hypoechogenicity
of the dermal layer both on dorsal (left) and volar side (right) compared to control (B) Reflectance
confocal microscopy images of the forearm skin from patient and control (magnification: 500 × 500 μm).
Epidermis: typical honey-comb pattern on dorsal (left) and volar (right) side in healthy skin are
not detectable in patient’s skin. Dermal-epidermal junction: regular edge papillae [rings of basal
keratinocytes surrounding dark circular structures corresponding to dermal papillae (*)] on dorsal
and volar side of control skin are reduced both in number and definition in patient’s skin. Dermis:
Irregular and fragmented collagen fibers that appear bright and coarse on both dorsal and volar side of
patient’s skin compared to control. An increased brightness of all skin structures, corresponding to
chronological and photoinduced skin aging, is present on the dorsal side of healthy skin but not on
the volar side that usually is not photoexposed, whereas in the patient this pronounced skin aging is
present at both sides.
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Consistent with the multisystemic presentation of EDS in general, there are also variable features
including congenital hip dislocation, hypotonia, delayed motor development, acrogeria, prominent
superficial veins in the chest region, hernias, dental anomalies, gastrointestinal (bowel rupture) and
vascular complications (mitral valve prolapse, aortic root dilation needing surgery), early-onset
varicose veins, and several skeletal anomalies (Table 2). In particular, bone involvement seems
a common feature of classical-like EDS type 2 with osteopenia/osteoporosis affecting hips, femurs,
and spine that are present, at variable degree, in all of the patients reported so far, with the exception
of the two siblings, reported by Hebebrand and coworkers [17], who were not tested for osteopenia.
In addition, degenerative arthritis, (kypho)scoliosis, arachnodactyly, positive wrist and thumb signs,
mild pectus excavatum, T10 vertebral deformity (our patient), narrowing of the interpedicular distance
of the lumbar spine, shortened and squared iliac bones, and remodeling of long bones of the lower
extremities are also encountered (Table 2). In addition, all subjects have severe foot deformities
including bilateral pes planus, hammertoes, hallux valgus, hindfoot deformity, and sandal gap,
which are observed in more than a few other EDS subtypes as well [1]. Although in cEDS patients
a variable degree of low bone mineral density and a high prevalence of radiological vertebral fractures
were reported [7,36], AEBP1-related EDS seems to display a more severe bone involvement that
could potentially facilitate the differential with cEDS. Nevertheless, considering the limited number
of individuals with AEBP1 defect known so far, a larger cohort of patients is needed to confirm this
preliminary observation.
The adipocyte enhancer binding protein 1 gene (AEBP1) encodes a 1158-amino acid secreted
aortic carboxypeptidase-like protein (ACLP) composed of an N-terminal signal sequence, a charged
lysine, proline, and glutamic acid-rich domain, a collagen-binding discoidin domain and
a metallocarboxypeptidase (MCP)-like domain [37,38]. This latter domain is inactive toward standard
MCP substrates, as it lacks several critical active sites and substrate-binding residues that are necessary
for activity [37,38]. Indeed, ACLP acts as an extracellular matrix (ECM)-binding protein rather than as
active MCPs that shows similar embryonic expression pattern as other ECM proteins and is found at
high levels particularly in collagen-rich tissues comprising the dermal layer of the skin, the medial layer
of blood vessels, the basement membrane of the lung, and the periosteum. Consistently, ACLP plays
fundamental roles in both embryonic development and adult tissue homeostasis, particularly in repair
processes [38–43]. Indeed, AEBP1 knock-out mice show ventral wall defects, develop spontaneous
skin ulcerations, and have significantly delayed healing of dermal punch wounds [38]. This cutaneous
phenotype is consistent with the defective wound healing and abnormal scar formation observed
in individuals with AEBP1 defects and suggest that ACLP has a crucial role in damage sensing and
ECM remodeling following injury by regulating fibroblast proliferation and mesenchymal stem cell
differentiation into collagen-producing cells [42,43]. Blackburne and coworkers demonstrated that
ACLP also binds collagens type I, III, and V and is able to promote the polymerization of collagen type
I in vitro [16]. In line with these findings, the ultrastructural study performed by the same authors
on a patient’s skin biopsy revealed reduced dermal collagen and irregular disrupted collagen fibers,
as well as our HF-USG and RCM investigations that disclosed abnormal collagen fibers deposition
together with a reduced dermal thickness. Moreover, we recognized an increase of the epidermal
thickness likely correlating with the diffuse PoC-like dermatitis, which is probably not related to
classical-like EDS type 2. The use of these non-invasive diagnostic techniques may be promising
for the investigation of the qualitative and quantitative cutaneous alterations, but further studies
including electron microscopy on skin as golden standard of reference on large cohorts of patients
are warranted. In our case, we did not perform skin biopsy because of the patient’s will due to
psychological reluctance for her important skin fragility with delayed wound healing.
The AEBP1 variants discovered before our patient’s characterization were all loss-of-function
(LOF) mutations (Table 2) and included compound heterozygous variants [(c.1470del;
p.Asn490_Met495delins40) and (c.1743C>A; p.Cys581*] in the first individual (P1); a homozygous
variant (c.1320_1326del; p.Arg440Serfs*3) in the second individual (P2); a homozygous splice
16
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variant leading to skipping of the last 22 bp of exon 13 (c.1630+1G>A) in the two siblings from
the third family (P3, P4), and a homozygous nonsense variant (c.917dup; p.Tyr306*) in the two
siblings from the fourth family (P5, P6). Hebebrand and coworkers performed the analysis of all
AEBP1 LOF variants reported in multiple databases showing that these are distributed throughout
the protein and by using conservative criteria for pathogenic LOF variants (nonsense, frameshift,
canonical splice sites, or initiation-codon) these authors estimated a carrier frequency of 1/829 for the
gnomAD database. The analysis of CADD scores for all possible missense variants showed a higher
predicted deleteriousness for positions close to the discoidin and the MCP-like domains, whereas the
unstructured N-/C-terminal parts showed lower scores. The high deleteriousness scores observed for
missense variants within these domains cite evidence in support of additional mutational mechanisms
leading to aberrant function and the authors thus argued that the relatively low estimated carrier
frequencies could be significantly higher if missense variants contribute to a comparable fraction of
disease variants [17]. The present c.1925T>C; p.(Leu642Pro) homozygous variant disclosed within
the MCP-like domain of the protein corroborates this hypothesis, since it represents the first likely
pathogenic AEBP1 missense substitution (ACMG class 4) associated with classical-like EDS type 2.
The variant is predicted in silico to affect the tertiary structure of the protein by disrupting an α-helix
located in a highly conserved domain, thus likely interfering with its function in terms of impaired
partner binding capability. Nevertheless, a definite proof of variant’ s causality is lacking, since the
effective functional consequences on the ECM organization, particularly of collagens, and on the
other not yet well-defined roles of the ACLP protein were not studied, because the patient refused
skin biopsy.
5. Conclusions
Our findings expand the knowledge of the clinical phenotype of this recently defined autosomal-
recessive EDS subtype, provide the first evidence that missense variants contribute to the allelic
repertoire of AEBP1, and suggest that in the diagnostic process of a cEDS patient this gene should
be investigated when a recessive inheritance is compatible and no causal variant is identified in the
other cEDS genes. Further reports are needed to better characterize the AEBP1-related phenotype,
define specific clinical criteria that might facilitate the differential with the other EDS forms, delineate
genotype-phenotype correlations, and collect natural history data for prognostication. Finally, ACLP
function needs to be explored more in-depth to provide insights into molecular mechanisms involved
in the pathophysiology of AEBP1-related EDS that may represent a starting point for identifying
potential therapeutic options.
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Abstract: The Ehlers-Danlos syndromes (EDS) constitute a clinically and genetically heterogeneous
group of connective tissue disorders. Tenascin X (TNX) deficiency is a rare type of EDS, defined
as classical-like EDS (clEDS), since it phenotypically resembles the classical form of EDS, though
lacking atrophic scarring. Although most patients display a well-defined phenotype, the diagnosis of
TNX-deficiency is often delayed or overlooked. Here, we described an additional patient with clEDS
due to a homozygous null-mutation in the TNXB gene. A review of the literature was performed,
summarizing the most important and distinctive clinical signs of this disorder. Characterization of the
cellular phenotype demonstrated a distinct organization of the extracellular matrix (ECM), whereby
clEDS distinguishes itself from most other EDS subtypes by normal deposition of fibronectin in the
ECM and a normal organization of the α5β1 integrin.
Keywords: Tenascin X; TNXB; Ehlers-Danlos syndrome; EDS; connective tissue; collagen
1. Introduction
The Ehlers-Danlos syndromes (EDS) constitute a clinically and genetically heterogeneous group
of connective tissue disorders. Patients present with joint hypermobility, skin hyperextensibility and
tissue fragility, giving rise to easy bruising and atrophic scarring. Although most EDS are caused by
mutations in genes coding for the fibrillar collagens or collagen-modifying enzymes, over the last two
decades, several disorders due to defects in other components of the extracellular matrix (ECM) have
been delineated [1].
Tenascins comprise a family of glycoproteins, which modulate the adhesion of cells to their ECM.
Tenascin X (TNX) is ubiquitously expressed, but the highest levels are found in muscle and loose
connective tissue [2]. TNX is thought to regulate fibril spacing by direct binding to the distinct collagen
fibrils in the ECM or by indirect binding via decorin [3]. Additional roles for TNX in elastic fiber
remodeling and regulating the expression of certain ECM components, e.g., collagen VI, proteoglycans
and matrix metalloproteases have been suggested [4–7].
The clinical relevance of TNX-deficiency was first proposed in 1997 by the identification of a
patient presenting both congenital adrenal hyperplasia and an EDS-like phenotype. Genetic analysis
revealed a contiguous deletion of the partially overlapping genes CYP21B and TNXB on chromosome
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6. Although a TNX null-phenotype was verified both on the protein and on the mRNA level, a
mutation on the second allele could not be identified [8]. In 2001, Schalkwijk et al. demonstrated that
isolated TNX-deficiency resulted in an autosomal recessive form of EDS, resembling the classical type,
however lacking atrophic scarring [9]. In 2017, TNX-deficiency was officially classified as “classical-like
EDS” (clEDS), with generalized joint hypermobility, hyperextensible, soft and/or velvety skin without
atrophic scarring and easy bruising being the typical clinical hallmarks of the disorder [1].
In 2002, Mao et al. developed a TNX-deficient mouse model, mimicking the EDS phenotype.
Indeed, as observed in humans, Tnxb-/- mice were morphologically normal at birth, but displayed
progressive hyperextensibility of the skin over time. The group showed that the phenotype did not
relate to aberrant collagen fibrillogenesis, but was rather due to altered deposition, and therefore,
reduced density of collagen in the ECM [10].
Although most TNX-deficient patients display a well-defined clinical phenotype, the diagnosis is
often delayed or overlooked. The former is attributed to the molecular analysis of the TNXB gene being
complicated by the presence of a highly homologous pseudogene and to the fact that the measurement
of TNX in serum is not widely available [11]. The latter is mainly caused by poor clinical awareness,
which unfortunately applies to many rare disorders.
Here, we reported on an additional patient with clEDS and a novel homozygous disease-causing
variant in TNXB to further elaborate the clinical phenotype. Furthermore, we reviewed the clinical
features of the clEDS patients described to date, in order to create a well-defined description of the
phenotype and increase clinical awareness.
2. Materials and Methods
2.1. Ethical Compliance
This study is in accordance with the Helsinki declaration and its following modifications. Ethics
approval has been granted (KEK Ref.-Nr. 2014-0300 and Nr. 2019-00811) in the presence of a signed
informed consent of the patient for genetic testing, skin biopsy and the publication of clinical pictures.
The patient was evaluated at the University Children’s Hospital of Zürich. Targeted next-generation
sequencing (NGS) panel for 101 connective tissue disorders (Supplementary Table S1) was performed
at the Institute of Medical Genetics of the University of Zürich. TNXB mutational screening by
Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) was achieved at
the Division of Biology and Genetics, Department of Molecular and Translational Medicine, of the
University of Brescia.
2.2. Cell Culture
As part of the diagnostic workup of EDS, a punch biopsy of the patient’s skin for establishing
fibroblast cultures for collagen biochemical analysis was previously obtained. The biological material
was stored in the Biobank of the Division of Metabolism at the Children’s Hospital Zürich. Fibroblasts
from the patient and from sex- and age-matched healthy individuals were routinely maintained at
37 ◦C in a 5% CO2 atmosphere in Earle’s Modified Eagle Medium (MEM) supplemented with 2 mM
L-glutamine, 10% FBS, 100 μg/ml penicillin and streptomycin (Life Technologies, Carlsbad, CA, USA).
Fibroblasts were expanded until full confluency and then harvested by 0.25% trypsin/0.02% EDTA
treatment at the same passage number.
2.3. Molecular Analysis
Mutational screening was performed on genomic DNA purified from peripheral blood leukocytes
using standard procedures. In particular, all exons and their intron-flanking regions of the TNXB gene
(NM_0019105.7, NP_061978.6) were PCR amplified with the GoTaq Ready Mix 2X (Promega, Madison,
WI, USA) by using optimized genomic primers that were analyzed for the absence of known variants
using the GnomAD database (https://gnomad.broadinstitute.org/). For the pseudogene-homolog region
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(exons 32–44), Sanger sequencing was performed by nested PCR, using a TNXB-specific long-range
PCR product encompassing the 3’-end of TNXB as a template (for details on primer sequences and
PCR conditions see Supplementary Table S2). PCR products were purified with ExoSAP-IT (USB
Corporation, Cleveland, OH, USA), followed by bidirectional sequencing with the BigDye Terminator
v1.1 Cycle Sequencing kit on an ABI3130XL Genetic Analyzer (Thermo Fisher Scientific, South San
Francisco, CA, USA). The sequences were analyzed with the Sequencher 5.0 software (Gene Codes
Corporation, Ann Arbor, MI, USA) and variants were annotated according to the Human Genome
Variation Society (HGVS) nomenclature with the Alamut Visual software version 2.11 (Interactive
Biosoftware, Rouen, France). Deletion/duplication analysis of TNXB was performed using the MLPA
assay P155, according to manufactures’ instructions (MRC-Holland, Amsterdam, the Netherlands).
2.4. RNA Extraction and Quantitative Real-Time PCR
Total RNA was purified from skin fibroblasts of the patient and 3 healthy individuals using the
Qiagen RNeasy kit, according to the manufacturer’s instructions (Qiagen, Hilden, Germany). RNA
quality control was performed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). Relative expression levels of the TNXB transcript were analyzed by quantitative real-time PCR
(qPCR). Of the total RNA, 3 μg was reverse-transcribed with random primers by a standard procedure.
qPCR reactions were performed in triplicate with the SYBR Green qPCR Master Mix (Thermo Fisher
Scientific, South San Francisco, CA, USA), 10 ng of cDNA, and with 10 μM of each primer set by
using the ABI PRISM 7500 Real-Time PCR System with standard thermal cycling conditions. The
HPRT, GAPDH and ATP5B reference genes were also amplified for normalization of cDNA loading.
Relative mRNA expression levels were normalized to the geometric mean of these reference genes
and analyzed using the 2−(ΔΔCt) equation. Amplification plots, dissociation curves and threshold
cycle values were generated by ABI Sequence detection system software version 1.3.1. Statistical
analyses were performed with the GraphPad Prism software (San Diego, CA, USA). The results were
expressed as the mean values of relative quantification ± Standard Error of the Mean (SEM). Statistical
significance between groups was determined using one-way ANOVA. P-values were corrected for
multiple testing using the Tukey’s method.
2.5. Collagen Biochemical, Ultrastructural and Immunofluorescence Microscopy Studies
Collagen steady state analysis in patient’s cultured fibroblasts was conducted prior to genetic
analysis to assess possible anomalies in collagen biosynthesis and secretion, as previously described [12].
Briefly, radioactively labeled and pepsinized procollagens from the patient and one healthy individual
were separated on a 5% Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
and visualized by autoradiography.
To analyze ECM organization of collagen type I (COLLI), collagen type III (COLLIII), collagen type
V (COLLV) and fibronectin (FN), skin fibroblasts derived either from the patient or an unrelated control
individual were grown for 72 hours in the presence of 50 μM ascorbic acid (for COLLI only), refed after
24 hours and immunoreacted as previously reported [13–15]. In brief, cold methanol fixed fibroblasts
were immunoreacted with 1:100 anti-COLLI, anti-COLLIII, anti-COLLV (Millipore-Chemicon Int.,
USA), and anti-FN (Sigma Chemicals, St. Louis, MO, USA) antibodies (Ab). The ECM of TNX was
investigated on methanol-fixed cells immunoreacting with 2 μg/ml anti-TNX Ab (Santa Cruz Biotec.
Inc., USA). For the analyses of the α2β1, α5β1 and αvβ3 integrin receptors, cells were fixed in 3%
paraformaldehyde (PFA)/60 mM sucrose and permeabilized with 0.5% Triton X-100 as previously
reported [13,14,16]. In particular, fibroblasts were reacted for 1 hour at room temperature with 4 μg/ml
anti-α5β1 (clone JBS5), anti-α2β1 (clone BHA.2) and anti-αvβ3 (clone LM609) integrin monoclonal Abs
(Millipore-Chemicon Int., USA). The cells were then incubated for 1 h with Alexa Fluor 488 anti-rabbit
and Alexa Fluor 555 anti-mouse Ab (Thermo Fisher Scientific, South San Francisco, CA, USA), or
with rhodamine-conjugated anti-goat IgG (Calbiochem-Merck, Germany). Immunofluorescence (IF)
signals were acquired by a black-and-white CCD TV camera (SensiCam-PCO Computer Optics GmbH,
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Germany) mounted on a Zeiss fluorescence Axiovert microscope and digitalized by Image Pro Plus
software (Media Cybernetics, Silver Spring, MD, USA).
3. Results
3.1. Case Report
The patient was referred to our center at the age of 41 years because of a suspected connective
tissue disorder. She was the first child of consanguineous parents of Swiss origin. The family history
was unremarkable. The patient displayed a congenital dislocation of the left hip. Due to recurrent
dislocations, an arthrodesis was performed at the age of 2 years. Immediately after surgery, a fracture
of the left femur occurred, requiring osteosynthesis. Over the years, multiple joint dislocations ensued,
mainly of the shoulders. During childhood, the patient developed a progressive kyphoscoliosis, which
was left untreated. At present, the patient displays a right sided gibbus deformity (Figure 1). Upon
radiography of the spine, a Cobb angle of 22, 38 and 15 degrees was measured at the cervical, thoracic
and lumbar level, respectively.
 
Figure 1. X-ray images of the vertebral column of the patient at the age of 41 years. (a) Side view
demonstrating the pronounced kyphosis; (b) close-up of the pronounced cervical and thoracic scoliosis;
(c) close-up of the lumbar scoliosis.
In addition, the patient presented a progressive arthrosis of the knee and degenerative changes of
the spine. Bone densitometry at the age of 41 years was normal. Generalized joint hypermobility was
absent (Beighton score 3/9). The patient reported mild muscular weakness. Computed tomography of
the abdomen demonstrated fatty degeneration of the abdominal, gluteal and pelvic floor musculature.
The patient was noted to have a soft, dough-like skin texture associated with skin hyperextensibility.
In addition, the skin was thin and translucent with multiple varicose veins and edema of the lower
extremities (Figure 2c). Redundant and sagging skin was found on both knees (Figure 2a). Striae were
already present at young age. Feet and hands were short and broad, with the presence of brachydactyly
(Figure 2d,g). Acrogeria of the hands was noticed, with an increased amount of palmar skin creases
(Figure 2e). Several subcutaneous nodules were present at the interphalangeal joints of the fingers.
Piezogenic papules were present on both feet (Figure 2f). While standing upright, the subcutaneous
tissue of the feet was pushed aside, leading to neurogenic pain and the inability to walk barefoot
or to go longer distances (Figure 2f). The patient reported large hematomas to occur after minimal
trauma. Atrophic scarring was not present (Figure 2b). However, wound healing was clearly delayed
with wound dehiscence after surgery. The patient presented with an inguinal and umbilical hernia
at the age of 27 and 36 years, respectively, requiring surgical correction. The patient mothered three
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children, all born through C-section. A urogenital or rectal prolapse did not occur. The patient did,
however, suffer from hemorrhoids. Colonoscopy at the age of 40 years demonstrated asymptomatic
diverticulosis of the sigmoid colon. The patient presented with one episode of ileitis of unknown
origin. In addition, the patient had two episodes of dactylitis and suffers from recurrent aphthous
stomatitis. No biochemical indication of an underlying inflammatory disease was found. At the age of
42 years, a spontaneous perforation of the small bowel occurred, necessitating surgery and resection of
the involved bowel loop. The intestinal specimen obtained during surgery was reported to be very
fragile. An echocardiography at the age of 41 years demonstrated an intact mitral valve and normal
dimensions of the aorta. The patient was known with a mild myopia. Hearing was normal to date.
 
Figure 2. Clinical features of the patient. (a) Redundant and sagging skin on both knees; (b) widened
scar on the left knee after surgery. No atrophic features are present; (c) chronic ankle edema in the
absence of cardiac failure; (d) plane flat feet with broad forefeet and short digits; (e) increased palmar
skin creases; (f) piezogenic papules; (g) short and broad acrogeric hands. Note the hyperextensibility of
the thumb.
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3.2. Molecular and Biochemical Findings
3.2.1. Molecular Analysis
Previous molecular investigations of the patient, all with negative results, included molecular
genetic analysis of COL1A1 and COL1A2 on cDNA for the suspicion of arthrochalasis EDS, and an NGS
panel for 101 connective tissue disorders. Given that the TNXB gene was not present in the NGS panel
and considering the clinical presentation of the patient that was suggestive for clEDS, we sequenced
TNXB by traditional Sanger method. Sequencing of all exons and exon-intron boundaries of TNXB
(NM_0019105.7, NP_061978.6) revealed the homozygous c.5362del, p.(Thr1788Profs*100) variant in
exon 15 (Figure 3a), which was absent in all public variant databases. Hence, the novel pathogenic
TNXB variant (identifier #0000591583) was submitted to the Leiden Open Variation Database (LOVD,
https://databases.lovd.nl/shared/genes/TNXB).qPCR analysis on cDNA obtained from patient’s dermal
fibroblast showed that the c.5362del transcript, which leads to frameshift and formation of a premature
termination codon (PTC) p.(Thr1788Profs*100), represents a null-allele undergoing nonsense-mediated
mRNA decay (Figure 3b). Consistently, IF analysis on the patient’s fibroblasts with a specific Ab
against TNX demonstrated a complete absence of the protein in the ECM (Figure 3c).
Figure 3. The TNXB c.5362del pathogenic variant causes nonsense-mediated mRNA decay and absence
of the tenascin X protein in the ECM. (a) Sequence chromatograms showing the position of the novel
c.5362del; p.(Thr1788Profs*100) variant (arrow) identified in homozygosity in exon 15 of the TNXB gene
by Sanger sequencing; (b) qPCR analysis on cDNA obtained from patient’s dermal fibroblasts showed
that the transcript with the p.(Thr1788Profs*100) frameshift variant undergoes nonsense-mediated
mRNA decay. The relative quantification (RQ) of the TNXB transcript levels was determined with
the 2−(ΔΔCt) method normalized with the geometric mean of the HPRT, GAPDH and ATP5B reference
genes. Bars represent the mean ratio of target gene expression in patients’ fibroblasts compared to
three unrelated healthy individuals. qPCR was performed in triplicate, and the results are expressed
as means ± SEM. The relative mRNA level of TNXB in the patient versus controls (about 142-fold
decrease) is expressed as Log10 transformed value. Statistical significance (*** P < 0.001) was calculated
with one-way ANOVA and the Tukey post hoc test. (c) IF analysis on patient’s skin fibroblasts with a
specific antibody against TNX showing the absence of the protein in the ECM compared to control cells.
Scale bar: 10 μm.
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3.2.2. Collagen Biochemical and Immunofluorescent Analysis
To assess the effects on collagen biosynthesis and secretion, we performed collagen steady-state
and pulse-chase analyses in dermal fibroblasts from the patient. Normal relative proportions of COLLI,
COLLIII and COLLV were present in the cell lysate and in the medium (Supplementary Figure S1).
There were no indications for altered modification of the different collagens.
To investigate the effect of TNX-deficiency on COLLI-, COLLIII-, COLLV- and FN-ECM
organization and on the expression of their integrin receptors, dermal fibroblasts from the patient and
one healthy individual were investigated by IF (Figure 4). Control fibroblasts organized a reticular
ECM of COLLIII and COLLV, rare fibrils of COLLI, an abundant FN-ECM and expression of the
canonical α2β1 and α5β1 integrins, whereas patient’s fibroblasts showed a lack of organized COLLI,
COLLIII, and COLLV in the ECM, though proteins were present at different levels inside the cells.
The disorganization of the COLLs-ECM is associated with a strong reduction of their canonical α2β1
integrin receptor (Figure 4a). Contrarily, the FN-ECM organization and the expression of its canonical
integrin receptor α5β1 were not affected in TNX-deficient cells. Therefore, the alternative FN-receptor
αvβ3 was almost undetectable both in control and patient cells (Figure 4b).
Figure 4. TNX-deficiency leads to the disarray of collagens type I, type III and type V in the ECM
together with the reduction of the α2β1 integrin. (a) IF analysis with specific Ab demonstrates that
TNX-deficient cells are characterized by the lack of organized COLLI, COLLIII and COLLV in the ECM,
though proteins are present at different levels inside the cells. The disorganization of the COLLs-ECM
is associated with a strong reduction of their canonical α2β1 integrin receptor. (b) TNX-deficient cells
deposit FN in the ECM and express its canonical integrin receptor α5ß1 similarly to control fibroblasts.
The alternative αvβ3 integrin is almost undetectable both in control and patients’ cells. Scale bars:
10 μm.
4. Discussion
Most known EDS subtypes are autosomal dominant inherited disorders due to defects in genes
coding for the fibrillar collagens or collagen-modifying enzymes. TNX-deficiency differs from the
more frequent subtypes not only in its autosomal recessive inheritance pattern but also in the fact
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that it is caused by a defect in an ECM component other than collagen. The presumed role of TNX
in the stabilization and maturation of the collagen- and elastin-ECM is reflected in the cellular and
clinical phenotype of the patients described to date [2–7]. Similar to the data in Tnxb-/- mice, we could
demonstrate that collagen biosynthesis and secretion were unaffected in our patient’s fibroblasts,
whereas a disarray of the COLLI-, COLLIII- and COLLV-ECM and a strong reduction of their canonical
α2β1 integrin receptor was observed in vitro (Figure 4a) [10]. Unlike the typical EDS cellular phenotype,
our patient’s fibroblasts were characterized by a normal organization of the FN-ECM and therefore a
normal expression of its canonical integrin receptor α5β1 (Figure 4b) [10,17].
Thus far, about 30 patients with complete TNX-deficiency have been described in literature [8,9,
18–26]. Most patients displayed either a complete lack of TNX in serum or biallelic mutations in TNXB
leading to nonsense-mediated mRNA decay (Supplementary Table S3). As expected, those presenting
missense mutations had milder or late-onset clinical manifestations [17,24].
As its name implies, TNX-deficiency or classical-like EDS (clEDS) phenotypically resembles the
classical form of EDS (cEDS), with the triad of soft/velvety hyperextensible skin (20/20), generalized
joint hypermobility (15/19) and a varying degree of tissue fragility (20/20) as its main clinical features
(Table 1) [9]. Unlike cEDS, atrophic scarring is absent in patients with clEDS. However, about 50% of
TNX-deficient patients present delayed wound healing with wound dehiscence upon suture removal
and widened scars (Figure 2b). Data in Tnxb-/- mice suggest that, contrary to cEDS, abnormal wound
healing in clEDS is not due to altered matrix deposition in the early phases of wound healing, but is
rather caused by decreased ECM stabilization and maturation during the later stages. Indeed, contrary
to the high levels of TNXB in normal skin, its expression during the early phase of wound healing is
non-existing and only increases over time [27].
Whereas joint hypermobility seems to decrease with age, recurrent dislocations of the large joints
(18/19) remain a problem over time and can be considered as the most frequent debilitating finding in
the TNX-deficient patients described to date (Table 1).
Interestingly, several patients display deformities of the hands and feet, most of which can be
ascribed to the underlying connective tissue weakness, such as pes planus, hallux valgus, piezogenic
papules and acrogeric hands. Conversely, the presence of brachydactyly and broad hands and feet point
to a role of TNX in development [28]. In addition, our patient presented chronic venous insufficiency,
varicose veins and non-pitting ankle edema, which has thus far been observed in almost 30% of the
TNX-deficient population (Table 1). The venous insufficiency and its consequences might be explained
by the aberrant elastic fiber remodeling observed in TNX-deficient dermal fibroblasts and possible
changes in endothelial cell proliferation [5,29,30]. Indeed, the interaction between TNX and vascular
endothelial growth factor B (VEGF-B) is known to stimulate endothelial cell proliferation [30,31].
Bone is considered to be a target organ of osteogenesis imperfecta rather than EDS. However,
premature osteopenia or osteoporosis have been published in various types of EDS and have been
mainly attributed to abnormal COLLI fibrillogenesis and ECM deposition [32]. Although bone loss
due to an increased number of multinucleated osteoclasts has been found in Tnxb-/- mice, thus far,
indications for skeletal fragility in clEDS have not been reported [33]. Moreover, in our patient, bone
densitometry at the age of 41 years was normal.
Over time, neuromuscular symptoms have been increasingly recognized in various types of EDS,
ranging from muscle weakness to myalgia and easy fatigability [21]. Indeed, a normal composition of
the ECM and intact innervation are important for adequate functioning of the muscle [34]. Considering
the cellular phenotype of clEDS, neuromuscular involvement is not surprising. Collagen VI, which is
deficient in two myopathies, i.e., Ullrich congenital muscular dystrophy and Bethlem myopathy, is
downregulated, although with conserved organization of the ECM, in as well TNX-null fibroblasts and
Tnxb-/- mice [7,34,35]. In addition, TNX is widely distributed in peripheral nerve and its deficiency
causes axonal polyneuropathy in almost 40% of the patients (Table 1) [21]. Our patient had a low
muscular mass on clinical examination and reported distal muscle weakness. Computed tomography
of the abdomen demonstrated fatty degeneration of the muscles as an incidental finding, a well-known
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phenomenon in myopathies of various origins. Interestingly, the neuromuscular phenotype seems to
be mild or absent in children and progresses with age.
Table 1. Summary of clinical features of patients with biallelic TNXB variants.
Present Patient clEDS* Total (%)
Major criteria
Skin hyperextensibility
(with velvety skin and absence
of atrophic scarring)
+ 19/19 20/20 (100)
GJH (Beighton Score > 5/9)
(+/− recurrent dislocation)
− 15/18 15/19 (79)
Easy bruising + 19/19 20/20 (100)
Minor Criteria
Articular (sub)luxation + 17/18 18/19 (95)
Feet deformities
(broad/short feet, brachydactyly,
pes planus, hallux valgus)
+ 14/18 15/19 (79)
Hand deformities
(acrogeric hands, mallet fingers,
clinodactyly and brachydactyly)
+ 4/17 5/18 (28)
Mild proximal and distal
muscle weakness
+ 9/19 10/20 (50)
Polyneuropathy NA 7/18 7/18 (39)
Edema in the legs in absence
of cardiac failure
+ 4/17 5/18 (28)
Other features
Congenital joint dislocation + 1/17 2/18 (11)
Delayed wound healing + 7/18 8/19 (42)
Vaginal/uterus/rectal prolapse − 5/17 5/18 (28)
Inguinal/umbilical/wound
herniation
+ 4/19 5/20 (25)
Varicose veins + 3/17 4/18 (22)
Piezogenic papulae + 13/18 14/19 (74)
High arched/narrow palate +/−
dental crowding
+ 4/17 5/18 (28)
Refractive error + 8/17 9/18 (50)
Mitral valve abnormalities − 4/19 4/20 (20)
Diverticulosis/diverticulitis + 4/18 5/19 (26)
Spontaneous bowel perforation + 1/18 2/19 (11)
Note: 19 out of 30 patients reported in literature were included. Patient 3 reported in Schalkwijk et al. [9], the
index patient reported in Burch et al. [8], the three patients published in Chen et al. [25] were excluded because of
concomitant congenital adrenal hyperplasia. The patient described in Mackenroth et al. [26] was excluded because
of concomitant COL1A1 mutation. Patient 4 and 5 reported in Schalkwijk et al. [9] were excluded because a lack of
clinical data. The patient described in O’Connell et al. [24] and the two patients described by Lindor et al. [18] were
excluded because no mutation analysis was performed.
Extra-articular symptoms in clEDS, such as gastrointestinal and cardiovascular complications,
do not seem to be associated with certain mutations, but are rather related to age and have been
reported after the 3rd–4th decade [18,22,23,25]. Gastrointestinal manifestations, although rare, can
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lead to life-threatening situations. Spontaneous perforation of hollow organs is a complication mainly
seen in patients with vascular EDS (vEDS) due to mutations in COLLIII and has only sporadically been
described in other EDS subtypes. Compared to other non-vEDS, a higher prevalence seems to exist in
clEDS, ranging from tracheal or esophageal rupture to spontaneous perforation of colon, diverticula or
small intestine [18,20,22,23,25,36]. Therefore, patients and treating physicians should be aware of this
risk in order to minimize the occurrence of iatrogenic perforation and to not delay the diagnosis and
treatment of spontaneous events. Contrary to patients with vEDS, aortic root dilatation or aneurysms
are not common in clEDS, and have only been described in one non-published case [23]. Peeters et
al. suggested that the co-expression of tenascin-C (TNC) in large blood vessels might compensate
for the TNX-deficiency, giving rise to a normal arterial vessel wall [37,38]. Conversely, mitral valve
involvement (i.e., mitral valve prolapse, thickening and/or insufficiency) has thus far been reported in
20% of clEDS patients, highlighting the need for cardiovascular follow-up (Table 1).
5. Conclusions
Although TNX-deficiency phenotypically resembles cEDS, absent atrophic scarring, the presence
of short broad feet, brachydactyly, edema of the lower extremities, acrogeria or the occurrence of
hollow organ perforation should initiate targeted diagnostics for clEDS, either by measuring the TNX
concentration in serum or by mutation analysis of the TNXB gene.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/11/843/s1,
Figure S1: Steady-state analysis of collagen in the medium and the cell layer, Table S1: 101 genes analyzed by
means of an NGS panel for connective tissue disorders, Table S2: Primer sequences and PCR conditions for TNXB
sequencing, Table S3: Published TNXB pathogenic variants.
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Abstract: TNXB-related classical-like Ehlers-Danlos syndrome (TNXB-clEDS) is an ultrarare type
of Ehlers-Danlos syndrome due to biallelic null variants in TNXB, encoding tenascin-X. Less than
30 individuals have been reported to date, mostly of Dutch origin and showing a phenotype
resembling classical Ehlers-Danlos syndrome without atrophic scarring. TNXB-clEDS is likely
underdiagnosed due to the complex structure of the TNXB locus, a fact that complicates diagnostic
molecular testing. Here, we report two unrelated Italian women with TNXB-clEDS due to compound
heterozygosity for null alleles in TNXB. Both presented soft and hyperextensible skin, generalized
joint hypermobility and related musculoskeletal complications, and chronic constipation. In addition,
individual 1 showed progressive finger contractures and shortened metatarsals, while individual
2 manifested recurrent subconjunctival hemorrhages and an event of spontaneous rupture of the
brachial vein. Molecular testing found the two previously unreported c.8278C > T p.(Gln2760*) and
the c.(2358 + 1_2359 − 1)_(2779 + 1_2780 − 1)del variants in Individual 1, and the novel c.1150dupG
p.(Glu384Glyfs*57) and the recurrent c.11435_11524+30del variants in Individual 2. mRNA analysis
confirmed that the c.(2358 + 1_2359− 1)_(2779 + 1_2780− 1)del variant causes a frameshift leading to a
predicted truncated protein [p.(Thr787Glyfs*40)]. This study refines the phenotype recently delineated
in association with biallelic null alleles in TNXB, and adds three novel variants to its mutational
repertoire. Unusual digital anomalies seem confirmed as possibly peculiar of TNXB-clEDS, while
vascular fragility could be more than a chance association also in this Ehlers-Danlos syndrome type.
Keywords: Classical-like; Ehlers-Danlos syndrome; haploinsufficiency; tenascin-X; TNXB
1. Introduction
Ehlers-Danlos syndromes (EDS) are a clinically variable and genetically heterogeneous group of
hereditary connective tissue disorders mainly featured by abnormal skin texture and repair, tissue
and vascular fragility, and joint hypermobility. The 2017 international classification identifies 13 EDS
types due to deleterious variants in 19 different genes [1]. More recently, a 14th type of EDS with
features overlapping classical type and due to recessive variants in the AEBP1 gene was added to this
nosology [2,3]. Among them, classical, vascular, and hypermobile EDS are the most common, while
the others are rarer and their frequency in the general population remains mostly unknown.
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Classical-like EDS due to biallelic variants in TNXB, encoding tenascin-X (TNXB-clEDS), is a
second EDS type resembling classical EDS but distinguished from the latter by recessive pattern
of inheritance and lack of atrophic scarring [1]. Tenascin-X is a large extracellular matrix–forming
glycoprotein, whose deficiency was firstly involved in the etiology of EDS in 1997, by the description
of a novel contiguous gene syndrome combining congenital adrenal hyperplasia (CAH) and EDS, and
due to the deletion of the CYP21A2 (OMIM 201910) and TNXB neighbouring genes [4]. Subsequently,
it was clear that this rare type of EDS is a recessive disorder caused by homozygous or compound
heterozygous null alleles in TNXB [5]. Only 24 individuals with TNXB-clEDS have been described
to date and most of them are of Dutch origin [6]. A recent cross-sectional study on 17 individuals
suggests possible phenotypic hallmarks of TNXB-clEDS and hypothesizes that it is underdiagnosed
with EDS-like symptoms outside The Netherlands due to the complex molecular structure of the TNXB
locus [7].
TNXB maps on chromosome region 6p23.1 within the human leukocyte antigen histocompatibility
complex in a module characterized by highly homologous sequences between functional genes,
CYP21A2 and TNXB, and their corresponding pseudogenes CYP21A1P and TNXA. This genomic
structure is prone to non-homologous recombinations. Misalignment events during meiosis result
in pathogenic CYP21A2/CYP21A1P and TNXA/TNXB chimeric genes. To date, three major types of
TNXA/TNXB chimera have been identified [4,8]. In particular, CAH-X chimera 1 (CH-1) and CAH-X
chimera 2 (CH-2) have TNXB exons 35–44 and 40–44, respectively, replaced with TNXA [4,9,10]. CH-1
is characterized by a 120-bp deletion (c.11435_11524 + 30del) due to the substitution of TNXB exon 35
by TNXA that is causative of tenascin-X haploinsufficiency in CAH-X CH-1; this region is the only
well-documented discrepancy between TNXB and TNXA homologous portion. CH-2 is characterized
by the variant c.12174C > G p.(Cys4058Trp) derived from the substitution of TNXB exon 40 by TNXA
with a likely dominant negative effect [10]. The third chimera, termed CAH-X chimera 3 (CH-3),
has TNXB exons 41–44 substituted by TNXA and is characterized by a cluster of three pseudogene
variants: c.12218G > A p.(Arg4073His) in exon 41, and c.12514G > A p.(Asp4172Asn), and c.12524G >
A p.(Ser4175Asn) in exon 43. This chimera has been reported in one patient, and its clinical significance
is still preliminary [8].
Due to such a complex molecular architecture of the genomic region surrounding TNXB,
Demirdas et al. [7] proposed a multistep molecular diagnostics workflow including: (i) a mixed
approach of next-generation sequencing (NGS) for the non-homologous TNXB sequence and Sanger
sequencing for the TNXA/TNXB homology region to exclude TNXB point variants and rare TNXA/TNXB
chimera, (ii) followed by TNXB deletion/duplication analysis aimed to investigate the presence of the
recurrent c.11435_11524 + 30del resulting from the common TNXA/TNXB chimeric fusion and other
rarer rearrangements. Following this approach, this group was able to identify 12 different TNXB
variants associated with TNXB-clEDS [7].
Here, we describe the first two Italian individuals affected by TNXB-clEDS. Molecular testing
investigated the full range of possible molecular mechanisms leading to TNXB null alleles and found
three novel variants.
2. Materials and Methods
Patients were enrolled for this study after obtaining written informed consent for publishing
pictures (individual 2) and clinical data (both individuals). This study was approved by the local
ethical committee, and is in accordance with the 1984 Helsinki declaration and subsequent versions.
Part of the results of molecular investigations presented in this work was obtained from the routine
clinical diagnostic activities of the involved institutions.
2.1. Sample Preparation and Next Generation Sequencing Analysis
Genomic DNA was extracted from patients’ and unaffected relatives’ peripheral blood leucocytes
by using Bio Robot EZ1 (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
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The DNA was quantified with Qubit spectrophotometer (Thermo Fisher Scientific, Waltham, MA,
USA). Probands’ DNA first underwent sequencing with a HaloPlex gene panel (Agilent Technologies,
Santa Clara, CA, USA) designed to selectively capture known genes associated with the various forms
of EDS (ADAMTS2, AEBP1, B3GALT6, B4GALT7, CHST14, COL1A1, COL1A2, COL3A1, COL5A1,
COL5A2, COL12A1, C1R, C1S, DSE, FKBP14, PLOD1, FLNA, PRDM5, SLC39A13, TNXB and ZNF469)
according to the current nosology. For TNXB, NGS sequencing is effective for exons 1 to 31 only,
which correspond to the non-homologous TNXB sequence. Libraries were prepared using the
Haloplex target enrichment kit (Agilent Technologies, Santa Clara, CA, USA) following manufacturer’s
instructions. Targeted fragments were then sequenced on a MiSeq sequencer (Illumina, San Diego,
CA, USA) using a MiSeq Reagent kit V3 300 cycles flow cell. Reads were aligned to the GRCh37/hg19
reference genome by BWA (v.0.7.17). BAM files were sorted by SAMtools (v.1.7) and purged from
duplicates using Mark Duplicates from the Picard suite (v.2.9.0). Mapped reads were locally realigned
using GATK 3.8. Reads with mapping quality scores lower than 20 or with more than one-half
nucleotides with quality scores less than 30 were filtered out. The GATK’s Haplotype Caller tool was
used to identify variants. Variants were annotated by ANNOVAR, with information about allelic
frequency (1000 Genomes, dbSNP 151, GO-ESP 6500, ExAC, TOPMED, GnomAD, NCI60, COSMIC),
reported or computationally estimated pathogenicity (ClinVar, HGMD, LOVD, or SIFT, Polyphen2,
LRT, MutationTaster, MutationAssessor, FATHMM, PROVEAN, VEST3, MetaSVM, MetaLR, M-CAP,
CADD, DANN, fathmm-MKL, Eigen, GenoCanyon), and amino acids conservation (fitCons, GERP++,
phyloP100way, phyloP20way, phastCons100way vertebrate, phastCons20way mammalian, SiPhy
29way). Selected variants were interpreted according to the American College of Medical Genetics and
Genomics/Association for Molecular Pathology (ACMGG/AMP) [11]. Specifically, variants without
clinical significance at the time of reporting (i.e., benign and likely benign) were excluded by the
presence of one or more criteria for benignity. Variants which passed this preliminary selection
were selected for further investigation and classified as pathogenic, likely pathogenic or uncertain
significance by using the following criteria: (i) null (nonsense, frameshift) variant in a gene previously
described as disease-causing by haploinsufficiency or loss-of-function; (ii) missense variant located in
a critical and well-established functional domain; (iii) variant affecting canonical splicing sites (i.e., ±1
or ±2 positions); (iv) variant absent in allele frequency population databases; (v) variant reported in
allele frequency population databases but with a minor allele frequency significantly lower than the
known disease frequency in the general population; (vi) variant predicted as pathogenic/deleterious in
ClinVar and/or LOVD; (vii) missense variant predicted as pathogenic/deleterious in most (≥75%) of
the selected in silico predictors; (viii) variant co-segregating in two or more affected relatives; ix) the
predicted pathogenic effect has been confirmed by an appropriate functional study/studies.
2.2. Sanger Sequencing.
The variants identified by NGS were confirmed by Sanger sequencing. Primer sequences are
reported in Table 1. The amplified products were subsequently purified by using ExoSAP-IT PCR
Product Cleanup Reagent (Thermo Fisher Scientific, Waltham, MA, USA) and sequenced by using
BigDye Terminator v1.1 sequencing kit (Thermo Fisher Scientific, Waltham, MA, USA). The fragments
obtained were purified using DyeEx plates (Qiagen, Hilden, Germany) and resolved on ABI Prism
3130 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA). Sequences were analyzed using
the Sequencer software (Gene Codes, Ann Arbor, MI, USA). The identified variant was resequenced in
independent experiments.
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Table 1. Primers used in this study.
Primers Sequence Tm (◦C) Size (bp)
TNXB-LongPCR-F GTCTCTGCCCTGGGAATGA
60 4900TNXB-LongPCR-R TGTAAACACAGTGCTGCGA
TNXB frag1 For GGCCAAGCCTGGAAGATAAA
60 662TNXB frag1 Rev GATTGGAGACAGAAGCACAC
TNXB frag2 For CCAGGGAGAGAGGATGGAT
60 671TNXB frag2 Rev GTCCCCAGGAATGGAAGT
TNXB frag3 For GACCTAGTGCCTCAGCCA
60 733TNXB frag3 Rev GGCTCTCTCTACTCCGTG
TNXB frag4 For ATGGGTGGGAGTTGAGAG
60 727TNXB frag4 Rev TGGAAGCTGAGCAGGTAG
TNXB frag5 For TCTCCTCTTCCTGCTTTCCC
60 643TNXB frag5 Rev CCCCATCAGTCTCCATGTC
TNXB frag6 For CAGGACCAGCACCATCTT
60 741TNXB frag6 Rev TTGAGGTTGGCGTAGTGG
TNXB frag7 For GCTGTCTCCTACCGAGGG





2.3. Analysis of the TNXA/TNXB Homology Region
For the analysis of the TNXA/TNXB homology region, the whole genomic sequence of TNXB,
encompassing exons 32–44 was amplified by employing a Long-PCR reaction using the primers
reported in Table 1 and the protocol previously reported [7]. The PCR reaction was performed in a
total 50 uL volume reaction containing 5 uL Buffer 1 (10 ×), dNTP (0.625 mM final concentration),
primers (10 pmol each), 3U Expand Long Template Enzyme mix (Roche, San Francisco, CA, USA).
Cycling conditions were as follows: initial denaturation at 95 ◦C, 3 min, followed by 30 cycles of 95 ◦C,
30 s, 62 ◦C, 30 s, 72 ◦C, 11 min, final elongation at 72 ◦C, 7 min. The 4987 bp PCR product was checked
on ethidium bromide (EtBr) stained 1% agarose gel and then used as template for seven nested PCR
amplifications with the primers listed in Table 1. Reactions were performed in a 25 uL volume reaction
containing 2.5 uL Buffer (10 ×), dNTP (0,25 mM final concentration), primers (10 pmol each), 1.25 U
AmpliTaq Gold DNA Polymerase (Thermo Fisher Scientific, Waltham, MA, USA). Cycling conditions
were the following: initial denaturation at 95 ◦C, 10 min, followed by 30 cycles of 95 ◦C, 30 s, 60 ◦C, 30 s,
72 ◦C, 30 s, final elongation at 72 ◦C, 7 min. The overlapping Nested PCR products were then checked
on EtBr stained 2% agarose gel, purified with ExoSap-IT kit (Thermo Fisher Scientific, Waltham, MA,
USA) and sequenced with a ready reaction kit (BigDye Terminator v1.1 Cycle kit, Thermo Fisher
Scientific, Waltham, MA, USA).
2.4. Multiplex Ligation-Dependent Probe Amplification (MLPA) and Quantitative PCR (qPCR) Analysis
MLPA was carried out using the commercial kit (SALSA MLPA KIT P155-D2 Ehlers-Danlos
syndrome III & IV, MRC Holland, Amsterdam, The Netherlands). The kit includes 17 probes for
TNXB with amplification products between 130 and 490 nucleotides. This kit also comprises two
probes mapping within the region upstream of TNXB, located in the ATF6B and BAK1 genes, and two
additional probes mapping within CYP21A2. Complete probe sequences and the identity of the genes
detected by the reference probes is available online. Hybridization, ligation, and PCR amplification
were performed according to the manufacturer's instructions. DNAs from three healthy individuals
were included as controls. Coffalyser. Net software (MRC Holland, Amsterdam, The Netherlands)
was used for data analysis. Detected deletion was confirmed by qPCR. Primers designed for the
amplification of DNA fragments by qPCR, including TNXB exon 4 to 8 probes, were listed in Table 1.
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The qPCR was performed using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific,
Waltham, MA, USA) on ABI 7900HT real time PCR system (Thermo Fisher Scientific, Waltham, MA,
USA). Control DNA fragments were located on different chromosomes. Samples were run in triplicate
using standard conditions.
2.5. Chromosome Microarrays Analysis (CMA)
CMA of the individual 1 was performed using the CytoScan™XON array (Thermo Fisher Scientific,
Waltham, MA, USA). This array contains 6.85 million empirically selected probes for whole-genome
coverage including 6.5 million copy number probes and 300,000 SNP probes for LOH analysis, duo-trio
assessment. The sensitivity of the platform is 95% for the detection of exon-level copy number variations
(CNVs). The CytoScan™ XON assay was performed according to the manufacturer’s protocol, starting
with 100 ng of patient DNA. Data analysis was performed using the Chromosome Analysis Suite
software version 4.2 (Thermo Fisher Scientific, Waltham, MA, USA). A CNV was validated if at least 25
contiguous probes showed an abnormal log2 ratio.
2.6. Conservation of the Variant.
Evolutionary conservation of p.Gln2760 residue of tenascin-X was investigated with protein
sequence alignment generated by Clustal Omega and compared with data provided by UC Santa Cruz
Genome Browser
2.7. Total RNA Analysis.
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany), treated with
DNase-RNase free (Qiagen, Hilden, Germany), quantified by Nanodrop (Thermo Fisher Scientific,
Waltham, MA, USA) and reverse-transcribed using QuantiTect Reverse Transcription Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. PCR amplification and Sanger
sequencing were carried out with primers listed in Table 1.
2.8. Variant Designation.
Nucleotide variant nomenclature follows the format indicated in the Human Genome Variation
Society (HGVS) recommendations. DNA variant numbering system refers to cDNA. GenBank
Accession Number NM_019105.6 was used as reference sequences for TNXB. Nucleotide numbering
uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation
codon as codon 1.
3. Results
3.1. Case Report: Individual 1
This is a 25-year-old woman, first child of healthy and unrelated parents. Her younger brother
was described as unaffected. She was born at term, from an uneventful pregnancy and uncomplicated
vaginal delivery. Birth parameters were normal. Psychomotor development and education were within
normal limits. She recalled congenital contortionism (i.e., positive five-point questionnaire). At 3 years
of age, the mother noted trigger fingers of multiple digits in both hands, and this was treated surgically
at 16 years of age with complete resolution. She also requested ortodontic therapy for dental crowding
and high-arched palate. No visual nor auditory troubles were registered. The patient suffered from
constipation since infancy. At 14 years of age, she received the diagnosis of rectal prolapse. She always
suffered from easy bruising and tendency to arterial hypotension. More recently, the patient requested
rheumatological consultation for proneness to soft-tissue injuries and easy fatigability, although she
did never complain of dislocations and fractures. According to the patient’s past clinical history, the
rheumatologist requested medical genetics consultation for a suspicion of hereditary connective tissue
disorder. At examination, she displayed normal upper limb span/height ratio, bilaterally positive wrist
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sign, bilaterally negative thumb sign, Beighton score (7/9) with genua recurvata, marked hypermobility
of the fingers and toes, flatfeet, brachydactyly (due to shortened metatarsals—brachydactyly type E),
of the 2nd and 3rd toes bilaterally, brachydactyly type D of the hands (i.e. shortened and broad distal
phalanx of the thumbs), soft, doughy and significantly hyperextensible skin, absence of distrophic
scars, palmoplantar hyperlinearity, mild palpebral ptosis and bilateral euryblepharon. Of relevance,
no other close family members had brachydactyly. Heart ultrasound showed minimal insufficiency
of the mitral valve. Bone densitometry showed reduced bone mass at the femoral head (T-score-1.7).
Hand X-rays showed “swan neck” deformity of the interphalangeal distal joint of 1st, 2nd and 3rd
left fingers.
3.2. Case Report: Individual 2
This is a unique child of unaffected and unrelated parents. Pregnancy and delivery were
uneventful, and psychomotor development and education were normal. She came at our medical
genetics outpatient service at 26 years of age due to a long history of polyarticular intense pain
(visual analogic scale: 7/10) and (sub)luxations of the shoulders, fingers and temporomandibular joints.
Additional musculoskeletal and neurological symptoms included moderate pain (visual analogic scale
4-5/10) of the spine, hands and feet, as well as recurrent myalgias, occipital headache, occasional
migraine with aura, post-exertional malaise and chronic fatigue. She also reported easy bruising, an
episode of spontaneous rupture of the right brachial vein, multiple episodes of ruptures of cystic
lesions of the elbows with leakage of a yellowish and filamenotous substance (presumably, molluscoid
pseudotumors), eye dryness, recurrent subconjunctival hemorrhages, gastroesophageal reflux with
cardia incontinence, esophageal erosions and severe constipation with coprostasis. At examination, at
26 years of age, the patient showed normal anthropometry, Beighton score 7/9, marked hypermobility
of the digits, temporomandibular joints and shoulders, bilateral hallux valgus, genua valga, lumbar
hyperlordosis, mild thoracic scoliosis, reduced muscle tone, painful movements, soft, doughy and
hyperextensible skin (Figure 1a), normal scar formation, residual elbow scars from recurrent ruptures
of (likely) mulluscoid pseudotumors (not visible at the time of examination; Figure 1b), a small
subcutaneous spheroid of the pretibial region on the left, multiple cutaneous hematomas, piezogenic
papules (Figure 1c), palmoplantar hyperlinearity, bluish sclerae, absence of the lingual frenulum and
acrocianosis. Heart ultrasound was normal. Bone densitometry showed mildly reduced bone mass at
the femural neck. We were also able to carry out physical examination of individual 2’s parents and both
had positive Beighton score according to age and sex (i.e., generalized joint hypermobility). The father
also showed mildly soft and hyperexensible skin, although both did not report any significantly
related complaints.
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Figure 1. Selected clinical features of individual 2, and schematic diagram showing the genomic
structure of TNXB and the secondary structure of tenascin-X. (a) Markedly hyperextensible skin of
the dorsum of the hands. (b) Residual scar from recurrent molluscoid pseudotumors of the elbow.
(c) Piezogenic papules of the heel. (d) Coding regions are highlighted with white boxes and introns with
black horizontal lines. Tenascin-X is characterized structurally from N-terminus to C-terminus by: (i) an
N-terminus with a series of repeats that resemble epidermal growth factor (EGFL repeats); (ii) a stretch
of fibronectin type III repeats (FBIII1-31); and (iii) a large C-terminal domain structurally related to
fibrinogen (Fibrinogen C). Previously identified variants associated with TNXB-clEDS are represented
in black. Variants identified in the individuals 1 and 2 are represented in blue and red, respectively.
3.3. Molecular Findings: Individual 1
NGS analysis performed on DNA from individual 1 identified the novel heterozygous c.8278C> T
variant located in the exon 24 of TNXB (Figure 1d), which is predicted to incorporate a premature stop
codon [p.(Gln2760 *)]. No other candidate variants were found in the remaining genes. The c.8278C >
T p.(Gln2760 *) variant was not reported in major databases, including dbSNP, ExAC, 1000 Genomes,
and GnomAD. This suggests that the variant represents a rare event and was interpreted as likely
pathogenic according to the ACMGG/AMP criteria (i.e., a variant absent in population databases and
predicted to generate a null allele in a gene previously known as disease-causing with this molecular
mechanism). The result was confirmed by direct Sanger sequencing of proband’s DNA (Figure 2a).
Protein sequences alignment of the homologous regions including the Gln2760 residue of human
TNXB was generated by using the Clustal Omega tool and showed that the affected residue was
evolutionarily conserved (Figure 2b). The Gln2760 residue is located in the 19th fibronectin domain
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of tenascin-X (Figure 1d) and, thus, the truncated protein presumably loses the last multiple 19–31
fibronectin domains as well as the fibrinogen C motif.
As TNXB-clEDS is caused by a complete lack of tenascin-X due to biallelic inactivating variants
in TNXB, in order to detect the potential presence of a second variant in TNXB, we simultaneously
performed the long PCR/Sanger sequencing analysis of the TNXA/TNXB homologous region and
MLPA analysis. The long PCR/Sanger sequencing analysis did not reveal any variant in exons 32–44.
On the contrary, MLPA analysis detected a TNXB intragenic deletion which includes entirely the exon
5 (Figure 2c). To narrow the proximal deletion breakpoints within the region encompassing the exon
5, qPCR analysis was employed on DNA extracted from patient’s, unaffected parents, and control
individuals blood. This approach detected a TNXB deletion which include both the whole exons 5 and
6 (Figure 2d).
To better molecularly refine the extension of the deletion, we performed a chromosome microarrays
analysis using the CytoScan™ XON array. CMA confirmed an interstitial heterozygous microdeletion
at chromosome 6p21.33, covered by 62 array probes and spanning 5 Kb, which encompasses the
exons 5 and 6 and flanking intronic regions of TNXB (Figure 2e). The molecular karyotype of the
patient, accordingly with the International System for Human Cytogenomic Nomenclature 2016 was
arr [GRCh37] 6p21.33 (32056115_32061375) x1.
Next, we characterized the deletion at the transcriptional level by direct DNA sequencing of
in vitro amplified cDNA product generated from total RNA extracted from patients’ peripheral blood
leucocytes (Figure 2f). We showed that the variant c.(2358 + 1_2359 − 1)_(2779 + 1_2780 − 1)del
generates a frameshift with the insertion of a premature stop codon in exon 7 [p.(Thr787Glyfs*40)]
(Figure 1d). In light of its absence in population databases, the predicted generation of a null allele and
the subsequent demonstration by mRNA study, this variant was interpreted as pathogenic according
to the ACMGG/AMP rules. Segregation analysis in both unaffected parents was performed by Sanger
sequencing and MLPA/qPCR analysis. We detected the c.8278C > T and (2358 + 1_2359 − 1)_(2779 +
1_2780 − 1)del variants in the proband’s father and mother, respectively (Figure 2a,d,f). Both TNXB
c.8278C > T p.(Gln2760 *) and (2358 + 1_2359 − 1)_(2779 + 1_2780 − 1)del p.(Thr787Glyfs*40) variants
have been submitted to the LOVD (Leiden Open Variation Database, https://databases.lovd.nl/shared/
variants/0000598484, individual ID # 00266303 https://databases.lovd.nl/shared/variants/0000598485,
individual ID # 00266303, respectively).
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Figure 2. Molecular findings of individuals 1 and 2. (a) Electropherograms showing DNA sequencing
analysis of PCR product amplified with primers targeting exon 8 of TNXB. Nucleotide sequences are
provided. The position of the identified variant is indicated with an asterisk. (b) Protein sequence
alignment of TNXB generated by Clustal Omega showed that the affected Gln 2760 residue of tenascin-X
is evolutionary conserved. (c) Bar chart generated by Coffalyser.net- MLPA analysis software. MLPA
was performed on DNA from the individual 1, her unaffected parents and controls (data not showed).
A probe ratio of 1 indicates a normal DNA copy number; a probe ratio of 0.5 indicates a heterozygous
deletion. MLPA analysis reveals a deletion of exon 5 of TNXB in individual 1. (d) Profiles of qPCR
assay performed to map the deletion breakpoints within the region encompassing the exons 3 to 8
of TNXB. Relative DNA quantity of each exon was determined for the patient (red), her asymptomatic
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mother and father, (green and purple, respectively), and a pool of DNA controls (CNTs, orange).
(e) Results of chromosomal microarray analysis in the Individual 1. Intensity data (Summarized log
2 ratio value) of each probe is drawn along chromosome 6 from 32,000 to 32,080 kb (USCS Genome
Browser build February 2009, hg19). The red box indicates the interstitial microdeletion (62 probes
with decreased signal) identified, encompassing the exons 5 and 6 of the TNXB gene (lower panel).
(f) Electropherograms showing cDNA Sanger sequencing of a transcript region of TNXB amplified with
primers targeting exon 3 to 8 of Individual 1 and her mother. (g) Sanger sequence of a PCR product
amplified with primers targeting exon 3 of TNXB of individual 2 and her unaffected parents. The position
of the identified variant is indicated with an asterisk. (h) Bar chart generated by Coffalyser.ne-MLPA
analysis performed on DNA from the individual 2, her unaffected father and controls (data not showed).
MLPA analysis reveals the common partial deletion of exon 35 of TNXB in individual 2.
3.4. Molecular Findings: Individual 2
NGS platform targeted for EDS genes revealed that individual 2 carries out a single base deletion
c.1150dupG located in exon 3 of TNXB (Figure 1d). This heterozygous variant was predicted to generate
a premature stop codon at residue 441 [p.(Glu384Glyfs*57)]. No other candidate variants were found
in the remaining genes. The c.1150dupG variant was not reported in major databases. Therefore, the
variant was interpreted as likely pathogenic according to the ACMGG/AMP guidelines. This result
was confirmed by direct Sanger sequencing of proband’s DNA. The novel variant was also detected in
the proband’s mother while it was absent in the father (Figure 2g). MLPA analysis (Figure 2h) detected
the recurrent pseudogene-derived 120 bps deletion including the exon 35, previously described by
Schalkwijk et al. as the likely result of a common TNXA/TNXB fusion gene (CAHX-CH1). This
variant was inherited from the healthy carrier father.Both TNXB c.1150dupG p.(Glu384Glyfs*57) and
c.11435_11524 + 30del variants have been submitted to the LOVD (https://databases.lovd.nl/shared/
variants/0000598486, individual ID # 00266304¸ https://databases.lovd.nl/shared/variants/0000598487,
individual ID #00266304, respectively).
4. Discussion
In this work, we described the first two Italian patients with TNXB-clEDS, confirming a wider
distribution of this rare EDS type in Europe, and the efficacy and reproducibility of the diagnostic
approach published by Demirdas et al. [7]. We also identified three novel disease-alleles in TNXB,
which expand the known mutational spectrum of TNXB associated with clEDS (Figure 1d).
These two adults manifest the previously defined phenotypic spectrum of TNXB-clEDS. Scarring
was apparently normal in our patients, which is in line with the lack of atrophic/dystrophic scarring
as a distinguishing feature, together with recessive inheritance, of TNXB-clEDS from classical EDS.
Intriguingly, individual 2 reported a history of recurrent ruptures of elbow cystic lesions resembling
molluscoid pseudotumors, which are additional cutaneous features considered highly suggestive
for classical EDS. This expands the cutaneous similarities between TNXB-clEDS and classical EDS;
a fact that complicates the differential diagnosis of these disorders on clinical groups and reinforces
the opportunity to consider TNXB molecular testing in all individuals with a clinical diagnosis
of classical EDS resulted negative to COL5A1, COL5A2, and COL1A1 (recurrent variants) analysis.
Individual 2 also testifies for a possible vascular involvement in TNXB-clEDS. In fact, this patient
reported recurrent subconjunctival hemorrhages, a feature previously annotated in multiples subjects
by Demirdas et al. [7], as well as spontaneous rupture of the brachial vein. The latter is an apparently
novel feature of TNXB-clEDS and could indicate, if confirmed by other observations, a more severe
vascular involvement in this condition.
Demirdas et al. [7] pointed out a peculiar appendicular phenotype of TNXB-clEDS featured by
foot brachydactyly and small joint (apparently acquired) contractures. Our individual 1 supports this
hypothesis, as she showed shortened metatarsals and a history of multiple acquired finger contractures
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with residual swan neck deformities of the left fingers. Furthermore, constipation and evacuation troubles
represented major complaints in both individuals. While these features are not rare within the EDS
community of syndromes and are highly represented in adults with hypermobile EDS and hypermobility
spectrum disorders [12], this observation in TNXB-clEDS confirms the opportunity to better investigate the
long-range manifestations of these disorders in order to improve quality of life of individuals with EDS.
To date, a total of 15 different TNXB deleterious variants, including the three novel reported in this
paper were described. These variants are frameshift (7/15), stop codon (4/15), or splicing (2/15) and lead
to the insertion of a premature stop codon with a presumed loss of expression of the protein. Two out of
these 15 variants (2/15) are missense which have detrimental effects on the proper protein folding and
stability [10,13]. Among the 15 variants, 11 are identified in single patients/families. A 2 bp deletion
(c.3290_3291del), a 30Kb deletion generating a TNXB/TNXA fusion gene, and a pseudogene-derived
missense variant (c.12174C > G) were found in more than one patient (Figure 1d). Nevertheless, the
current nosology of EDS and related disorders clearly states that only “null alleles” in TNXB can be
considered causative of TNXB-clEDS [1,6]. Therefore, missense TNXB variants should be considered
supportive of the diagnosis in a clinical setting only if they appear convincing for haploinsufficiency.
In this study, individual 1 carries two novel TNXB variants, c.8278C>T located in the exon 24 and
(2358 + 1_2359 − 1)_(2779 + 1_2780 − 1)del which results in the non in frame deletion of whole exons 5
and 6. Both variants are predicted to generate a premature stop codon. Individual 2 is a compound
heterozygote for c.1150dupG and c.11435_11524 + 30del variants. The c.1150dupG is a novel variant
located in exon 3 of TNXB and is predicted to create a premature stop codon. The c.11435_11524 +
30del variant, which abolishes part of exon 35 and intron 35 of TNXB, has been previously described
and TNXA/TNXB chimeric recombination type 1 [5,7,10]. This deleted region represents the only large
TNXB-specific sequence in the TNXA-homolog region of TNXB. The TNXA-derived variation is a
molecular event which often takes place between a functional gene and a pseudogene. Although this
TNXA/TNXB fusion gene has been previously characterized, its molecular effect is not yet known.
However, tenascin-X serum measurement in affected individuals by previous studies indicate that this
variant likely results in a null allele [5,9]. In this work, we were not able to carry out a serum dosage of
tenascin-X in our patients. Nevertheless, we are confident that the molecular features of the identified
variants are convincing for the generation of a not functional allele.
Due to the complex nature of the genomic region spanning around TNXB, the underdiagnosis
of TNXB-clEDS in the routine diagnostic activities of most laboratories is a likely scenario. In fact,
molecular testing of TNXB is challenging due to the presence of the pseudogene TNXA, which is more
than 97% identical to TNXB at its 3′ end (exons 32–44). With the only exception of exon 35, which
partially shows a TNXB specific sequence (see above), exon and intron sequences in this region are
(nearly) identical in both TNXB and TNXA. Our experience confirms the need of a multistep and
multi-technique approach (comprising NGS for the non-homologous region, Sanger sequencing with a
long-PCR and nested-PCR system for the TNXA/TNXB homologous segment, and quantitative analysis
for intragenic and intergenic rearrangement) for an efficient analysis of the entire TNXB coding region,
with only slight modifications from the methodology proposed by Demirdas et al. [7] Tenascin-X serum
concentration measurement in patients with suspected TNXB-clEDS is an alternative in the absence of
effective molecular diagnostic facilities.
In summary, we reported two additional individuals with TNXB-clEDS. Our findings support
the previously defined phenotype, which shows similarities with classical EDS but also include some
possible distinguishing features and potentially underreported, clinically relevant manifestations.
We also expanded the mutational spectrum of TNXB and highlighted the need of a high level of
specialty for an efficacious TNXB molecular screening in a clinical setting.
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Abstract: Two probands are reported with pathogenic and likely pathogenic COL5A1 variants
(frameshift and splice site) in whom no collagen flowers have been identified with transmission
electron microscopy (TEM). One proband fulfils the clinical criteria for classical Ehlers-Danlos
syndrome (cEDS) while the other does not and presents with a vascular complication. This case
report highlights the significant intrafamilial variability within the cEDS phenotype and demonstrates
that patients with pathogenic COL5A1 variants can have an absence of collagen flowers on TEM
skin biopsy analysis. This has not been previously reported in the literature and is important when
evaluating the significance of a TEM result in patients with clinically suspected cEDS and underscores
the relevance of molecular analysis.
Keywords: classical Ehlers-Danlos Syndrome; electron microscopy; collagen flowers; COL5A1
1. Introduction
The Ehlers-Danlos syndromes (EDS) consist of 13 subtypes with overlapping features including
joint hypermobility, skin, and vascular fragility and generalised connective tissue friability [1,2].
Current major criteria for classical EDS (cEDS) are (1) skin hyperextensibility and atrophic scars
and (2) joint hypermobility. Minor criteria are easy bruising, soft doughy skin, skin fragility,
molluscoid pseudotumors, subcutaneous spheroids, hernia(s), epicanthal folds, complications of
joint hypermobility, and an affected first degree relative. The minimal criteria for a diagnosis of cEDS
are major criterion 1 plus either major criterion 2 or 3 of the 9 minor criteria [3].
In patients who satisfy the main criteria of cEDS according to the Villefranche criteria [4], the variant
detection rate in either COL5A1 or COL5A2 is over 90% [5,6]. However, intrafamilial variability in
classical EDS has been reported [7]. There are 194 reported unique variants reported in the COL5A1
gene [8]. These genes encode collagen type V, a fibrillar heterotrimer ([α1(V)]2 α2(V)) that is present in
Genes 2019, 10, 762; doi:10.3390/genes10100762 www.mdpi.com/journal/genes45
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a wide variety of tissues but is particularly prevalent in bone, skin and tendon [9]. Collagen type V
accounts for approximately 5% of total body collagen and has a role in maintaining the deposition
and structure of other more abundant collagens, particularly collagen type I [9]. Rarely, a diagnosis of
cEDS is due to dominant variants in COL1A1 or COL1A2 [3,10,11].
For many years, skin biopsies for electron microscopy (EM) have been recommended as a first
line of investigation to confirm or exclude a diagnosis of cEDS [3,12]. This was due to the occurrence
of collagen flowers visible by EM. Collagen flowers in individuals with classical EDS were described
by Vogel et al. who reported collagen fibrils with an abnormally large diameter and a highly irregular
and lobulated contour interspersed with normal appearing fibrils with a mean diameter larger than
that of collagen fibrils in normal skin [13]. A longitudinal section showed that the large atypical fibrils
were seen to be poorly integrated filamentous aggregates. Variation in frequency of very large highly
irregular fibrils differed per patient but in general constituted approximately 5% [13]. These very large
highly-irregular fibrils are often described as longitudinally splayed and loosely packed fibrils, which in
cross section produce the collagen flower pattern. Although it is known that collagen flowers can be
found in other collagen disorders including osteogenesis imperfecta and Ullrich congenital muscular
dystrophy, typical collagen flowers were thought to be invariably present in people with cEDS [3,14,15].
Given the high detection rates of pathogenic variants in cEDS, current recommendations are that
electron microscopy based on a skin biopsy should no longer the first line of investigation but could be
used to clarify inconclusive molecular results, or to guide further testing if initial molecular testing is
negative [3]. Interestingly, it was mentioned that “the absence of typical collagen flowers would go
against the diagnosis, as there are no known reports of patients with type V collagen abnormalities
without collagen flowers on EM” [3]. Here, we report for the first time two patients, one fulfilling
the clinical diagnosis of classical EDS and one not, with (likely) pathogenic variants in COL5A1 and
absence of collagen flowers on EM.
2. Materials and Methods
2.1. Skin Biopsy
Skin biopsies in probands 1 and 2 were taken in the form of a punch biopsy from the medial surface
of the arm. P1 was 44 years and P2 was 39 years when the skin biopsy was performed. The sample
for transmission electron microscopy (TEM) (3 mm) was preserved in 4% glutaraldehyde in 0.1 M
phosphate buffer. This publication does not constitute research and does not require formal Research
Ethics approval or Research and Development Approval as stipulated by the UK Policy Framework
for Health and Social Care Research and the Health Research authority decision tool.
2.2. DNA Analysis
Sanger sequencing of the COL5A1 and COL5A2 genes and MLPA of the COL5A1 gene was
performed in proband 1. Sanger sequencing and MLPA of the COL3A1 gene was performed in
proband 2. Proband 2 was included in a large research project aimed at identifying new pathogenic
variants with next-generation sequencing in patients with an EDS phenotype [16]. The sequencing data
of patient 2 have been deposited to the EDS and OI databases: https://www.le.ac.uk/genetics/collagen.
3. Clinical Report
3.1. Family 1
Proband 1 is a 47-year-old woman, born at 36 weeks gestation, with a childhood history of
clumsiness, tissue fragility, and joint hypermobility (Figure 1A–C). She would bruise easily and
recalls some episodes of significant swelling after mild injury, occasionally requiring drainage when
this involved the knees. There was no history of dislocation or fracture. As an adult she reports
myalgia and arthralgia in the ankles, hips, wrists, and shoulders. Other medical history includes
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endometrial polyps removed without complication at age 32, varicose veins treated surgically at age 41,
hiatus hernia, diverticular disease, a urethral cyst, and hypotension associated with fainting episodes.
Neurocardiology investigations found a high tendency towards POTS (postural orthostatic tachycardia
syndrome) with no evidence of autonomic failure. Cardiac investigations have shown right bundle
branch block and trivial aortic regurgitation, tricuspid regurgitation, and mitral regurgitation.
She fulfilled the criteria for cEDS on physical examination. There were no craniofacial dysmorphic
features except for epicanthic folds. She had soft, doughy, and hyperextensible skin—particularly at
elbows, neck, and knees—with redundancy at the knees and Achilles tendons. She had scarring over
the forehead, wrist, and lower legs. Lower leg scars were widened and atrophic with erythema and
hemosiderin deposition. There were thread veins and varicose veins in the lower limbs. Her feet had
bilateral hallux valgus deformities with piezogenic papules. Hands had bilateral hitchhikers’ thumb and
increased palmar markings. She had generalized joint hypermobility (gJHM) with a (Beighton score 5/9).
Family history: The proband’s parents, four older brothers and their children are healthy with no
reported features of cEDS. One brother was tested for the COL5A1 variant as well. He did not meet the
criteria for cEDS and was found not to have the COL5A1 variant.
Figure 1. Pedigrees and clinical photographs of probands 1 and 2. (A) Family pedigree of proband
1. E1 denotes clinical diagnosis of cEDS, E2 denotes presence of (likely) pathogenic COL5A1 variant,
* denotes documented evaluation. Shading denotes having a clinical diagnosis of cEDS and presence
of (likely) pathogenic COL5A1 variant. (B) Knee area of proband 1 demonstrating redundancy of
skin, atrophic and widened scarring and varicose veins. (C) Hyperextensible skin at the elbow in
proband 1. (D) Family pedigree of proband 2. (E) Knees area of proband 2 show no atrophic scarring
or haemosiderin deposition but minor redundancy of skin. (F) Widened, atrophic scar at the elbow.
3.2. Family 2
Proband 2 is a woman who was diagnosed with an acute, spontaneous, left carotid artery dissection
presenting with left sided headache, and Horner’s syndrome at 37 years old (Figure 2D–F). This was
successfully treated conservatively. She had no past medical history and was a non-smoker with normal
cholesterol levels. Her past surgical history included bilateral bunion surgery at age 13 and three
Caesarean sections, the first for fetal distress and the others as routine following without complication.
On physical examination she did not have craniofacial dysmorphic features [17]. Her skin was
mildly hyperextensible over face, neck, and elbows with delayed recoil and slight redundancy of the
skin around the knees. The skin was not thin and no bruising was visible. A widened, atrophic scar at
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a site of trauma over the elbow and thin, well healed post-operative scars from bunion surgery were
observed. There was bilateral hallux valgus She did not have gJHM. (Beighton score 3/9) and did not
fulfil the current clinical criteria for cEDS. She had a normal echocardiogram.
Family history: The mother of the proband has the COL5A1 variant and had a healthy childhood
but developed hypertension later in life. Findings on clinical examination at the age of 81 were that
of skin hyperextensibility with significantly delayed recoiling probably due to her advanced age,
abdominal striae, a mild spinal scoliosis, and bilateral hallux valgus. The father of the proband had
a history of joint hypermobility and hallux valgus and passed away at the age of 81. He had a healthy
childhood and later in life developed hypertension, bowel cancer, skin cancer, and cardiovascular
disease, requiring a double coronary artery bypass graft post myocardial infarction.
The proband has two siblings, a sister and a brother. There is no clinical information available
regarding her brother. The proband’s sister has a cardiovascular history with bicuspid aortic valve
requiring replacement, and aortic root dilatation. She does not have the COL5A1 variant found in her
mother and sister.
The proband has three sons, all born by caesarean section. The oldest son, 9 years old, experienced
foetal distress and oxygen deprivation in the womb, requiring emergency caesarean section and
developed cerebral palsy with significant spasticity. On examination, there was minimal bruising,
atrophic scarring over the forehead and occiput, mild hyperextensibility of the skin, and a Beighton score
of 2/9 and therefore did not meet the current clinical criteria for cEDS. He had a normal echocardiogram
and was found to have the COL5A1 variant. The middle son, 7 years old, had had a healthy childhood.
On examination he had hyperextensible skin, atrophic scarring on the forehead and lower legs, bruising
over the shins and a Beighton score of 7/9 and therefore met the current clinical criteria for cEDS. He
had a normal echocardiogram and he was found to have the COL5A1 variant. The youngest son,
4 years old, had had a healthy childhood and did not have any clinical features of cEDS. He therefore
did not meet the current clinical criteria for cEDS and was found not to have the COL5A1 variant.
4. Results
4.1. Skin Biopsy TEM Results
Proband 1: TEM was concluded to be relatively normal but showed some minor deformation of
the outline of certain collagen fibrils (Figure 2a). No large collagen flowers were observed. Elastic
fibres and fibroblasts appeared normal.
Proband 2: TEM showed collagen clumps within the reticular dermis. Within these, the collagen
fibrils themselves were of relatively even diameter and had a symmetrical circular outline (Figure 2b),
although longitudinally sectioned fibres showed occasional kinking. No abnormal collagen flowers
were seen within the biopsy (Figure 2b). The other structures including elastic fibres and fibroblasts
were normal in appearance. The conclusion was one of a normal skin biopsy. After the molecular
result, re-examination identified rare, slightly deformed fibrils (Figure 2b) with slight variation in
collagen fibril diameter but no further abnormalities and no typical collagen flowers as described
previously (Figure 2c). It should be noted that collagen flowers are concentrated within the reticular
dermis and rarely observed in the papillary dermis. Therefore, care is required to ensure the correct
area of the skin biopsy was examined.
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Figure 2. Electron micrographs of the reticular dermis of skin biopsy from proband 1 (a), proband 2 (b)
and a case of classical EDS (c). Bars represent 100nm. (a) Cross section of collagen fibres from proband
1 showing a number of fibres presenting an irregular outline (arrowheads). Insert: detail of an irregular
fibre. (b) Cross section through a clump if collagen fibres of proband 2 showing a relatively normal
circular outline although very rare slightly irregular fibres were observed (insert). (c) Cross section of
collagen fibres from a case of classical EDS showing a number of irregular fibres and large collagen
flowers (arrowheads).
4.2. DNA Analysis
Proband 1: DNA analysis identified the heterozygous COL5A1 variant c.4414del, p.(Leu1472Serfs*16).
This variant results in a pathogenic frameshift in exon 57 of COL5A1 (NM_000093.4; NP_000084.3), predicted
to result in a premature termination codon, nonsense-mediated RNA decay, and consequent type V
collagen haploinsufficiency.
Proband 2: DNA analysis of COL3A1 in which variants cause vascular EDS, did not identify
pathogenic variants. The patient was referred for further sequencing as part of a large research project
looking at Mendelian inheritance [16] and the likely pathogenic variant c.4068G>A; p.(Ala1356=) in the
COL5A1 gene was identified. This silent variant has been previously published is predicted to result in
abnormal splicing of exon 51 of the COL5A1 gene [7]. Splice site prediction software (Alamut visual
software) indicated that the variant would destroy the splice donor site leading to disruption of normal
splicing with skipping of exon 51, leading to the production of a shortened protein [7]. The same
variant was identified in the mother of the proband as well as the proband’s two older sons, associating
with the clinical diagnosis of cEDS. The variant was not identified in the youngest son (Figure 1B).
5. Discussion
We report two patients with a (likely) pathogenic COL5A1 variant who did not have collagen
flowers on electron microscopy although minor deformation of the outline of certain collagen fibrils
were observed in proband 1, which are similar to the initial stage of collagen flower formation
(cf Figure 2a,c). Large collagen flowers on electron microscopy have previously been used to confirm
or exclude a clinical diagnosis of cEDS. One other report describes a 12-year-old boy with marked
clinical features of cEDS, without collagen flowers on electron microscopy. Interestingly, investigation
showed disorganisation, variation of fibril diameter, and irregular fibril outlines. However, this patient
did not have molecular investigations, and the underlying molecular basis is unknown [18].
5.1. Phenotype
Proband 1 clearly fulfilled the criteria for cEDS. Proband 2 did not fulfil the clinical criteria for
cEDS. Moreover, she presented with a vascular complication (carotid artery dissection) which is not
a common feature in cEDS [19]. In a recent systemic review, 12/110 (11%) patients with COL5A1/2
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variants had vascular complications of which six had arterial dissection, three had arterial aneurysms,
and one had intracerebral haemorrhage. It is not certain whether the vascular complication in this
proband is linked to the COL5A1 variant. It has been hypothesized that glycine substitutions near or at
the C-terminal end of collagen type V, may predispose to vascular events [20], but at this point there is
not enough evidence to support this hypothesis.
There is clear intrafamilial variability across the generations of the family of proband 2, as the
mother of the proband was 81 years old with skin hyperextensibility as the only major feature whereas
one grandson with the same variant had hyperextensible skin and atrophic scarring, clearly fulfilling
the clinical criteria for cEDS. Wide variability between family members with the identical COL5A1
variant has been previously reported [6,17].
5.2. Transmission Electron Microscopy
In proband 1, who fulfilled the clinical criteria for cEDS, minor deformation of the outline of
certain collagen fibrils were observed but no collagen flowers were present. The appearances were
similar to early changes seen in fibrils in cEDS (Figure 2a,c). These changes were sufficient for
the abnormality to be highlighted in the EM report but not significant enough to conclude that it
concerned an abnormal biopsy. In proband 2, no collagen flowers or other abnormalities were observed.
Unfortunately, the family members of proband 2, who had pathogenic COL5A1 variant (mother and
sons of proband), did not consent for a skin biopsy to be performed and as such no TEM results are
available. While the presence or absence of collagen flowers is reported, it should also be noted that
incidence and size/complexity of the collagen flowers can vary markedly between patients but the
significance of this to the clinical features and the underlying genetic cause is unknown (Ferguson
unpublished observations).
5.3. COL5A1 Variants
The variant identified in proband 1, who fulfils clinical criteria for cEDS, is a pathogenic frameshift
variant in exon 57 predicted to result in a premature termination codon leading to haploinsufficiency.
The likely pathogenic variant in COL5A1 c.4068G>A identified in proband 2, who does not fulfil
clinical criteria for cEDS, is a splice site variant and expected to result in skipping of exon 51 which
is in-frame and as such would lead to a shortened protein and exert a dominant-negative effect.
One variant was described by Symoens et al., COL5A1 c.4068G>T which demonstrated skipping
of exon 51 on mRNA analysis; p.(Gly1339_Ala1356del). The proband had skin hyperextensibility,
atrophic scarring, joint hypermobility, and no history of vascular events. TEM was not performed [5].
Colombi et al, identified an identical variant. The proband in this case did not fulfil the clinical criteria
for cEDS, and reported joint instability, gastrointestinal symptoms, and soft skin with a few small
atrophic scars over the knees. She had historical generalised joint hypermobility. Predictive software
(Alamut visual software) projected a similar functional outcome as the previous COL5A1 c.4068G>T
variant [7], both reduce the donor site strength to similar extents so a similar protein effect would
be expected. According to the ACMG guidelines [21] this variant is classified as likely pathogenic
fulfilling PP3: Multiple lines of computational evidence support a deleterious effect on the gene or
gene product (conservation, evolutionary, splicing impact, etc.); PM2: Absent from controls (or at
extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome
Aggregation Consortium and PS1: Same amino acid change as a previously established pathogenic
variant regardless of nucleotide change.
Hypotheses for this incomplete cEDS phenotype included protective lifestyle factors, potential for
this variant to result in only partial activation of abnormal splicing of exon 51 and the existence of
protective variants in other genes, which may counteract the loss of collagen V function during the
deposition of structural collagens [7].
Of the 194 unique variants reported in the COL5A1 gene, 31 have been reported as splice site
variants [8]. Most pathogenic COL5A1 variants (including splice site variants that introduce a premature
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stop codon) lead to haploinsufficiency for COL5A1 mRNA. This is expected to be the case for the
variant reported in P1. Structural variants exerting a dominant-negative effect are a minority and most
commonly involve splice site variants resulting in exon skipping which is the case for the variant
reported in P2 and variants that result in the substitution for glycine in the triple-helical region [22].
Collagen type V is thought to perform a regulatory function in collagen fibrillogenesis. It has been
hypothesized that the final common pathway for all COL5A1 variants is reduced availability of collagen
type V, and that clinical phenotypes result from disrupted fibrillogenesis [5,8,23,24].
6. Conclusions
In conclusion, we present two probands with (likely) pathogenic COL5A1 variants (frameshift and
splice site) in whom no collagen flowers were identified, although minor deformation of the outline of
certain collagen fibrils was observed in proband 1. Proband 1 fulfils the clinical criteria for cEDS but
proband 2 does not and presents with a vascular complication. The mother and two sons of proband 2
also have the COL5A1 variant, one of whom fulfils clinical criteria of cEDS. This case report highlights
the significant intrafamilial variability within the cEDS phenotype. We demonstrate that patients with
(likely) pathogenic COL5A1 variants can have an absence of collagen flowers on biopsy. It is currently
unclear whether the absence of collagen flowers can be linked to the (severity of) clinical features and/or
the specific genetic cause. It is also uncertain whether the vascular complication in P2 is caused by the
COL5A1 variant. Absence of collagen flowers in patients with (likely) pathogenic COL5A1 variants has
not been previously reported in the literature but is important when evaluating the significance of
a TEM result in patients with suspected cEDS and underscores the relevance of molecular analysis.
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Abstract: Ehlers-Danlos Syndromes (EDS) are a group of heritable disorders of connective tissue
(HDCT) characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Orthostatic
intolerance (OI) is highly prevalent in EDS however mechanisms linking OI to EDS remain poorly
understood. We hypothesize that impaired blood pressure (BP) and heart rate control is associated
with lower arterial stiffness in people with EDS. Orthostatic vital signs and arterial stiffness were
assessed in a cohort of 60 people with EDS (49 female, 36 ± 16 years). Arterial elasticity was assessed
by central and peripheral pulse wave velocity (PWV). Central PWV was lower in people with EDS
compared to reference values in healthy subjects. In participants with EDS, central PWV was correlated
to supine systolic BP (r = 0.387, p = 0.002), supine diastolic BP (r = 0.400, p = 0.002), and seated
systolic BP (r = 0.399, p = 0.002). There were no significant correlations between PWV and changes in
BP or heart rate with standing (p > 0.05). Between EDS types, there were no differences in supine
hemodynamics or PWV measures (p > 0.05). These data demonstrate that increased arterial elasticity
is associated with lower BP in people with EDS which may contribute to orthostatic symptoms and
potentially provides a quantitative clinical measure for future genotype-phenotype investigations.
Keywords: Ehlers-Danlos syndromes; pulse wave velocity; blood pressure; orthostatic intolerance
1. Introduction
Ehlers-Danlos syndromes (EDS) are a collection of heritable disorders of connective tissue
characterized by joint hypermobility, mild skin hyperextensibility, and tissue fragility [1]. Common
symptoms of EDS include joint instability, chronic pain, gastrointestinal issues, and sleep
disturbances [2]. Many people with EDS have persistent symptoms of orthostatic intolerance (OI)
including lightheadedness, fatigue, nausea, and palpitations [3]. Additionally, the prevalence of EDS is
higher in patients with orthostatic intolerance compared to the general population [4]. The association
between EDS and autonomic cardiovascular dysfunction is most prevalent in people with hEDS [5–7],
but there is also evidence of orthostatic intolerance in classical EDS [8]. The high prevalence of OI
in EDS demonstrates a need to understand cardiovascular pathophysiology in all EDS types, as the
pathophysiology explaining the high rate of OI in EDS is unknown. The leading theory connecting the
two disorders is that generalized connective tissue laxity in EDS increases vascular compliance, leading
to insufficient vasoconstriction and venous insufficiency when upright resulting in symptoms of OI [3].
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Despite its wide acceptance, there is only data to support this theory in small samples of people with
vascular EDS and there is no published evidence to support this theory across other types of EDS.
Pulse wave velocity (PWV) has emerged as the gold standard method for measuring stiffness
of the arteries because of its reliability and reproducibility [9]. PWV is a non-invasive technique that
involves placing pressure transducers on the skin that can sense the velocity of blood traveling in
the arteries, which is a function of the stiffness or elasticity of the arteries. Central PWV, the most
widely used and accepted measurement for PWV, measures the stiffness or elasticity of the central
cardiovascular system from the carotid to femoral arteries. Using this technique, increased PWV
(implying increased arterial stiffness) has been shown to predict future hypertension, coronary heart
disease, stroke, adverse cardiovascular events, and mortality [10].
While PWV is well accepted as a measure of arterial stiffness, it has been used far less often to
measure arterial elasticity, which is the mathematical inverse of stiffness. More distensible arteries
will stretch more as pulse waves travel, resulting in lower (slower) pulse wave velocity. Few studies
have sought to identify people, including those with EDS, with suspected increased arterial elasticity
and hence decreased PWV. One study evaluated PWV in nine people with comorbid hypermobile
EDS and postural tachycardia syndrome (POTS) and found PWV measurements were not different
compared to healthy controls [11]. Two studies examined PWV in people with vascular EDS. One study
found decreased PWV in about 20% of genetically related people with vascular EDS [12]. The other
study found that PWV measurements in people with vascular EDS were similar to those of healthy
volunteers [13].
Therefore, the current study is the first assessment of PWV measurements in a large heterogeneous
sample of people with EDS. We hypothesized that the collagen changes in EDS would confer
an increased distensibility of the vasculature in all EDS types, and that this would contribute to
orthostatic intolerance. In this study, we investigated central and peripheral arterial stiffness in people
with EDS using the non-invasive measurement of pulse-wave velocity (PWV). We hypothesize that
impaired blood pressure (BP) and heart rate control is associated with increased arterial elasticity in
people with EDS.
2. Materials and Methods
The National Institute on Aging (NIA) study Clinical and Molecular Manifestations of HDCT was
designed to investigate the natural history of the most common HDCT. Emphasis was placed on the
cardiovascular, musculoskeletal, and neurological complications of HDCT and the natural history of
these complications. The original study protocol was designed to collect clinical and family history
data, and to use this information to clarify the clinical distinctions between diagnoses. Consenting
participants were initially classified based on diagnostic criteria in place at the time of their clinical visit
at the NIA (2001–2013). Subjects contributing only biological samples were diagnosed either through
a limited onsite evaluation or through review of submitted medical records. The HDCT NIA Dataset v.
2016 consented cohort includes 1009 participants with an average age of 39 ± 18 years (range 2–95,
median 40). One hundred and ninety-four participants were 18 years or younger.
The NIA study Clinical and Molecular Manifestations of HDCT began by assembling consented
cohorts with a wide range of heritable HDCT, under an umbrella protocol (Protocol 2003-086, later
changed to 03-AG-N330). After the study was closed to enrollment, the Institutional Review Board
approved the reorganization and migration of the data into a relational database repository and
approved re-contacting participants to determine if they would be interested in participating in
future research. The HDCT cohort data are provided in SAS datasets, PDF, Excel, MRI DICOM
file formats and are now under the umbrella of protocol 11-AG-N079, Sample and Data Repository
Protocol for NIA Studies. Participants were recruited from the pool of patients previously seen by the
principal investigators and from patient support groups nationally. An authorized guardian provided
consent for minor participants, with age-appropriate assent by the minor. In 2016, a signed Data
Transfer Agreement between NIA and Penn State University resulted in transfer of a copy of the
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HDCT NIA Dataset v.2016 data repository to the Penn State University Clinical Translational Science
Institute (PSU-CTSI). Datasets were accompanied by copies of original CRFs and SAS dataset codebook
descriptions [14].
Participants were stratified by EDS type including: classical, hypermobile, vascular, or other or
unclassified according to the Villefranche nosology [15] as previously described for this cohort [14].
Briefly, classical EDS was determined by joint laxity and skin that is extremely hyperextensible, fragile,
bruises easily, and has thin atrophic scars. Hypermobile EDS was classified by history of dislocations,
generalized joint laxity, and velvety texture of skin with an absence of extreme skin extensibility and
profoundly abnormal scars. Vascular EDS was determined by genetic testing for variation in the
COL3A1, the gene encoding type III collagen. The other and unclassified EDS category included
patients with the rarer types of Ehlers–Danlos syndromes. A molecular diagnosis was used for the
arthrochalasia and kyphoscoliotic types. Some patients had features overlapping with two or more
types of EDS, and classification proved to be difficult in those cases, and such patients were diagnosed
as “EDS, unclassified”. If there was the clinical impression of EDS but they did not meet the diagnostic
criteria for any of the known types, we assigned a diagnosis of “EDS, unclassified”.
The analytic cohort for the present study was a subset of the EDS cohort from this NIA study of
HDCT consisting of 60 participants who had both orthostatic BP recordings and PWV measurements.
BP and heart rate were measured by brachial artery oscillometry in triplicate following 5 min in the
supine, seated, and standing postures. Central arterial stiffness was measured by carotid to femoral
PWV and peripheral stiffness by carotid to radial PWV.
2.1. PWV Measurements
The methods used to assess PWV in this study were the same methods used in the Baltimore
Longitudinal Study of Aging [16]. In short, PWV data were collected using a SphygmoCor device
(AtCor Medical) that utilizes an EKG and high-fidelity tonometer to acquire waveforms from carotid,
femoral, and radial pulses. The software determines the velocity of the pulse wave, i.e., estimated
time that it takes the pulse wave to travel between pulse sites divided by the distance between sites.
Central PWV is calculated by measuring pulse waves at the carotid and femoral arteries, representing
the stiffness of the central vascular tree. Peripheral PWV is calculated by measuring pulse waves at
the carotid and radial arteries indicating blood flow to peripheral vascular beds. Reference values of
pulse wave velocity in healthy humans were collected using similar methods (pulse wave tonometry
divided by distance between sites) [16].
2.2. Orthostatic Vital Sign Measurements
Orthostatic vital signs were measured by a brachial artery BP cuff on both arms. BP was measured
supine then seated then during standing. Study participants stayed in each posture (supine, sitting,
and standing) for 5 min prior to BP recordings. BP was measured in triplicate in each position with
one minute between recordings. If BP varied by 15 mmHg or heart rate by 10 beats/minute in one
position, a fourth recording was measured. All BP and heart rate measurements on the left arm were
averaged for each participant in each posture.
2.3. Data Analysis
Descriptive statistics include demographic data and EDS type. Comparison of characteristics
among types was performed using ANOVA with post-hoc Tukey-Kramer tests when justified.
Pearson’s correlations were run between BP, heart rate, and PWV measurements for the entire
cohort. We performed a stratified analysis of central PWV measurements by age in the EDS participants
of all types and compared those values to age-matched reference values from a large cohort of healthy
participants (n = 1455, Reference Values for Arterial Stiffness, 2010) [17].
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3. Results
Overall our data set included 60 (49 female) EDS participants age 13–70 years. There were no
differences in age, height, weight, and body mass index between EDS participants of different types
(Table 1).
3.1. Pulse Wave Velocity in EDS
Arterial elasticity did not differ by EDS type (Table 1). Grouped together, central PWV is lower in
participants with EDS (4.73 ± 0.16 cm/s) compared to reference values in a large sample of healthy
participants (Figure 1). PWV increases with age in healthy populations but the increase in arterial
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Figure 1. Pulse wave velocity (PWV) by age in participants with Ehlers-Danlos syndromes (EDS)
compared to reference values in healthy humans’ data from normal subjects in Reference Values for
arterial Stiffness Collaboration (RVASC) [17] (n = 1455). Data are shown as mean ± standard deviation.
3.2. Orthostatic Blood Pressure in EDS
In the supine posture, BP and heart rate did not vary by EDS type (Table 1). In the standing
posture, there was more variability in BP and heart rate measurements within each EDS type as shown
by higher standard deviations compared to supine measurements demonstrating a wide range in
responses to orthostasis (Table 1). Systolic BP in the standing posture was different between EDS types
(ANOVA, p = 0.003). Post-hoc analysis showed that standing systolic BP was lower in participants
with vascular EDS compared to those with hypermobile EDS (p = 0.021) and other/unspecified EDS
(p = 0.002). Standing diastolic BP and heart rate also trended lower in the vascular EDS group (p = 0.087,
Table 1.)
3.3. Correlations between Pulse Wave Velocity and Blood Pressure
Correlations of central and peripheral PWV to BP and heart rate are shown in Table 2. Central
PWV did not correlate to HR or orthostatic BP changes over a 5 min period. Central PWV correlated
significantly with supine (r= 0.387) and seated (r= 0.399) systolic BPs and supine diastolic BP (r= 0.400).
Peripheral PWV did not correlate to HR or orthostatic BP. Peripheral PWV was correlated to diastolic
BP in the supine (r = 0.322), seated (r = 0.383), and standing (r = 0.323) postures. All significant
correlations were positive indicating that lower PWV (more elasticity) is associated with lower BP in
our cohort of EDS participants.
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Table 2. Correlations of pulse wave velocity to orthostatic hemodynamics in Ehlers-Danlos syndromes
Carotid to Femoral PWV Carotid to Radial PWV
SBP (supine) 0.387 * 0.076
SBP (seated) 0.399 * 0.098
SBP (standing) 0.199 0.008
Δ SBP (standing-seated) −0.077 −0.066
DBP (supine) 0.400 * 0.322 *
DBP (seated) 0.204 0.383 *
DBP (standing) 0.078 0.323 *
Δ DBP (standing-seated) −0.158 −0.062
HR (supine) 0.015 0.185
HR (seated) 0.044 0.234
HR (standing) −0.039 0.165
Δ HR (standing-seated) −0.111 −0.048
Pearson’s r-correlations are shown. Change in (Δ), Systolic blood pressure (SBP), diastolic blood pressure (DBP),
heart rate (HR). * Significant correlation at p ≤ 0.05 level.
4. Discussion
4.1. Overall Findings
This study used PWV to evaluate arterial stiffness in a diverse sample of people with different
EDS types. This study provides three novel findings. We demonstrated that PWV is lower in people
with EDS compared to reference values in the healthy population implying that their arteries are more
elastic. We also found that lower PWV (indicating greater elasticity) is associated with lower systolic
and diastolic BP in people with EDS. These findings may help explain the connection between EDS
and impaired autonomic cardiovascular control. We also found no differences in PWV measurements
among EDS types which suggests that the elasticity of the vasculature is similar among the diverse
types of EDS.
4.2. Significance of Decreased Pulse Wave Velocity in Ehlers-Danlos Syndrome
The clinical association between EDS and orthostatic intolerance was identified in 1999 by Rowe
et al. who first hypothesized that the mechanism connecting these two disorders is an increased
enhanced elasticity in the arteries of people with EDS, predisposing them to OI [8]. Two decades later,
this theory has become widely accepted despite the lack of empirical data to support it [3].
PWV has become the gold standard for assessing arterial structure because it is reproducible and
aligns with more invasive measures. Its ease of use means it is available for testing in larger cohorts [9].
PWV has become a popular and validated method to assess increased stiffness of the central and
peripheral vascular system in healthy humans and disease populations ranging from cardiovascular to
neurological disease [9,10]. However, this technique is less commonly used to assess populations with
increased arterial elasticity.
Three studies have previously measured PWV in people with EDS [11–13]. In a single family
of 27 people with vascular EDS, Francois et al. utilized an older method for measuring pulse wave
velocity involving piezo crystal microphones over the carotid, femoral, and dorsal arteries, and reported
significantly decreased PWV (outside 2 standard deviations of normal values) in 5/27 participants
studied [12]. A more recent study used the ultrafast ultrasound technique in 102 healthy participants
and 37 vascular EDS participants and found that that central PWV was not significantly different in
vascular EDS participants compared to controls [13]. Cheng, et al. employed a similar tonometry
technique as was used in the current study to assess PWV in nine people with comorbid hypermobile
EDS and POTS and nine age, sex, and BMI matched healthy controls, and found a trend to lower central
PWV measurements in the people with EDS/POTS compared to controls [11]. Our study adds to the
current literature by measuring both central and peripheral PWV in a larger and more heterogeneous
group of people with EDS. In contrast to prior studies, we found that central PWV was significantly
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decreased in people with EDS compared to reference ranges for healthy subjects. This is likely due to
our larger and more diverse sample.
The issue of age-associated changes in vascular function in people with vascular EDS was
addressed by Mirault et al. using ultrafast ultrasound imaging (a method used by this group to
measure PWV). They reported that the age-associated increase in vascular stiffness was attenuated in
the vascular EDS participants [13]. We observed a similar phenomenon, namely that the PWV increased
very little with progressive age deciles (Figure 1) which differs from reference values derived from
healthy humans. High PWV (implying increased arterial stiffness) is related to adverse cardiovascular
events in large epidemiology studies [18–20]. While one may speculate that lower PWV may be
cardio-protective, it is unclear whether increased arterial elasticity is beneficial in people with EDS.
Whether PWV has prognostic value in EDS deserves further investigation.
4.3. Association between Pulse Wave Velocity and Blood Pressure
Overall, lower PWV is related to lower BP measurements but is not directly indicative of orthostatic
tolerance in EDS. These findings are consistent with measurements in healthy subjects and in other
patient populations in which PWV tracks similarly to BP [10]. All significant correlations were positive
indicating that lower PWV (more elasticity) is associated with lower BP in our cohort of people with
EDS. We cannot infer causation from these data.
4.4. Comparisons between EDS Types
We did not see a difference in most orthostatic vital signs between EDS types. Systolic BP was
slightly lower in vascular EDS which may reflect a difference in physiology or medications taken.
Overall, there was a huge range in BP and heart rate responses to orthostasis which demonstrates
inconsistent hemodynamic responses in this population and may reflect the presence of different types
of OI. According to Roma, et al., about half of people with EDS have POTS (increase in heart rate of
30 beats/minute while standing) but others have orthostatic hypotension or hypertension [3]. It has
been thought that vascular EDS was unique in terms of increased arterial distensibility. Our data are
the first to compare arterial elasticity among EDS types in a single study, and demonstrate no difference
in PWV among types of EDS. This is an important point, and it provides a possible explanation for the
common presence of orthostatic intolerance in all EDS types.
4.5. Strengths
Strengths of this this study are the large sample size with a diverse EDS cohort including several
EDS types, and the concomitant measurement of orthostatic vital signs and PWV. We compared central
PWV measurements to published reference values in a large cohort. To our knowledge, there are
no peripheral PWV reference values from large populations. The methods used in this study were
consistent with study protocols used in the Baltimore Longitudinal Study of Aging [16].
4.6. Limitations
This study had several limitations. First, we did not include a contemporaneous control group
in this study. However, we used reference values from a large cohort of healthy volunteers for
comparison [16]. Second, participants were accessed while on medications which may impact BP,
heart rate, and PWV assessments. Orthostatic vital signs were measured following 5 min in the
supine posture then after 5 min sitting then 5 min of standing. This limits the ability to diagnose
orthostatic intolerance as current diagnostic criteria for orthostatic intolerance involves hemodynamic
measurements from the supine to standing posture after at least 10 min [21]. Finally, we acknowledge
the heterogeneity of our EDS participants as a potential problem. Since these data were collected prior
to the 2017 reclassification of EDS [1,14,15]. It is possible that some participants classified as having
hypermobile or unspecified EDS would be categorized as hypermobility spectrum disorders using
current criteria.
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5. Conclusions
Overall, this is the first report of increased arterial elasticity in all types of EDS. The increased
arterial elasticity was associated with lower supine and seated systolic and diastolic blood pressure in
all types of EDS. We did not see differences in PWV in different types of EDS but standing systolic and
diastolic blood pressure were lower in vascular EDS compared to the hypermobile and unspecified
types. Our findings suggest that increased arterial elasticity may be related to impaired blood pressure
control in EDS. Further studies are needed to determine whether this pathophysiological finding relates
to orthostatic symptoms in people with EDS.
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Abstract: The Ehlers-Danlos syndromes (EDS) constitute a heterogenous group of connective tissue
disorders characterized by joint hypermobility, skin abnormalities, and vascular fragility. The latest
nosology recognizes 13 types caused by pathogenic variants in genes encoding collagens and other
molecules involved in collagen processing and extracellular matrix (ECM) biology. Classical (cEDS),
vascular (vEDS), and hypermobile (hEDS) EDS are the most frequent types. cEDS and vEDS are caused
respectively by defects in collagen V and collagen III, whereas the molecular basis of hEDS is unknown.
For these disorders, the molecular pathology remains poorly studied. Herein, we review, expand,
and compare our previous transcriptome and protein studies on dermal fibroblasts from cEDS, vEDS,
and hEDS patients, offering insights and perspectives in their molecular mechanisms. These cells,
though sharing a pathological ECM remodeling, show differences in the underlying pathomechanisms.
In cEDS and vEDS fibroblasts, key processes such as collagen biosynthesis/processing, protein folding
quality control, endoplasmic reticulum homeostasis, autophagy, and wound healing are perturbed.
In hEDS cells, gene expression changes related to cell-matrix interactions, inflammatory/pain responses,
and acquisition of an in vitro pro-inflammatory myofibroblast-like phenotype may contribute to the
complex pathogenesis of the disorder. Finally, emerging findings from miRNA profiling of hEDS
fibroblasts are discussed to add some novel biological aspects about hEDS etiopathogenesis.
Keywords: autophagy; collagen III; collagen V; Ehlers-Danlos syndrome; endoplasmic reticulum;
extracellular matrix; fibroblast-to-myofibroblast transition; miRNA; transcriptome; wound healing
1. The Extracellular Matrix: An Overview
Connective tissues have an extracellular matrix (ECM) with a specific composition generated
during embryogenesis and maintained in adult life. The ECM is a complex network that provides
a structural scaffold to the surrounding cells and is a reservoir of bioactive molecules such as
cytokines and growth factors that control cell behavior [1]. The main ECM components include
proteoglycans, hyaluronic acid, adhesive glycoproteins such as fibronectin and laminins, and fibrous
proteins like collagens and elastin [2]. Matricellular proteins such as thrombospondins, osteopontin,
periostin, and tenascins are non-structural ECM proteins, primarily acting as mediators of cell–matrix
interactions, which are abundantly expressed during embryonic development, wound healing,
and tissues renewal [3].
The human matrisome consists of about 300 macromolecules comprising the “core matrisome”, which is
composed of many different collagens, proteoglycans (e.g., aggrecan, versican, perlecan, and decorin),
and glycoproteins (e.g., laminins, elastin, fibronectin, thrombospondins, and tenascins) [4]. Matrisome also
includes many matrisome-associated proteins and ECM-regulators, i.e., ECM-cross-linking (e.g., lysyl
oxidases, transglutaminases) and ECM-modifying enzymes (e.g., proteases and their inhibitors)
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together with secreted factors including transforming growth factor β (TGFβ), wingless integrated
(Wnt), and multiple cytokines [5].
Collagens represent the major ECM structural components and play a central role in providing
the structural integrity of several connective tissues (e.g., cartilage and bone) and various organ
systems including skin, lungs, blood vessels, and cornea. Collagens are also involved in cell adhesion,
chemotaxis, and migration [1,2]. The dynamic interplay between cells and collagens regulates tissue
remodeling during growth, differentiation, morphogenesis, and wound healing [6,7]. The common
molecular feature of collagens is their triple helical structure, which consists of three collagenous
α-chains with the typical recurring (Gly-Xaa-Yaa)n tripeptide sequence. The presence of glycine
residues in the collagenous domain is essential for stability and correct assembly of the triple helix.
Collagen biosynthesis, assembly, and maturation require a sequence of well-controlled intracellular
and extracellular events (for review see [8,9]). Collagen I is the most abundant type expressed in bone,
cornea, dermis, and tendon. Collagen III is primarily present in the tunica media of the blood vessels
and hollow organs (e.g., uterus, intestine). Collagen V is widely distributed, especially in dermis,
tendons, and muscles, playing a central role in collagen I fibrillogenesis [9]. These fibrillar collagens
form structures necessary to ensure the strength and structural integrity of the ECM of all connective
tissues and organs of the body [10].
Fibronectin is a dimeric and fibrillar glycoprotein ubiquitously organized in the ECM of all tissues
and is also present in soluble form in the plasma. Cellular fibronectin self-assembles in fibers and
binds collagens, fibrin, proteoglycans, and cell surface receptors, providing cell growth, adhesion,
and migration. During wound healing, it forms a provisional matrix with fibrin and enters in the
granulation tissue formation in the late phase of re-epithelization [11].
In addition to ensuring physical support and structural integrity, the proper ECM composition
and organization are crucial for cell health. ECM undergoes a continuous turnover either under
physiological or in pathological circumstances, and its homeostasis is critical for connective tissues
architecture and function [12,13]. Integrins are specific cell surface receptors that mediate the complex
cell-matrix interactions. These bridging molecules, which are heterodimeric transmembrane receptors
containing α and β subunits, connect ECM to cytoskeleton by interacting via their extracellular domain
with collagens and other matrix molecules and via their cytoplasmic tails with cytoskeleton components
(e.g., actin, vinculin, talin, paxillin), thus mediating cell adhesion and motility [14,15].
2. Pathological ECM Remodeling and Perturbation of Cellular Homeostasis
Cell-matrix interaction via integrins is crucial for cell survival and tissue homeostasis. Prolonged
loss of integrin-mediated cell–ECM adhesion leads to anoikis [16]. Under physiological conditions,
ECM detachment triggers anti-apoptotic signals as a cell survival mechanism to delay the onset of
anoikis. One of such signaling pathways is autophagy, which is a highly conserved cellular catabolic
process that promotes homeostasis and mitigates the stress due to ECM detachment [17]. Autophagy is
essential for cellular maintenance and homeostasis by promoting the turnover of macromolecules and
organelles via the lysosomal degradative pathway [18]. Physiological and pathological changes in the
ECM composition play a crucial role in modulating autophagy activity [19,20]. For instance, deficiency
of collagen VI, which is associated with a spectrum of different myopathic conditions, perturbs ECM
architecture, impairs the autophagic flux, and activates pro-apoptotic signals [21]. Autophagy, in turn,
contributes to the maintenance of endoplasmic reticulum (ER) function by mediating its turnover
through the autophagic sequestration of ER fragments into autophagosomes, the so-called ER-phagy
process [22].
ECM components also modulate immune cell migration into inflamed tissues and their activation
and proliferation [23]. The stimulation of the innate immunity results from the recognition of specific
mediators, namely pattern recognition receptors, which, in turn, recognize molecules, referred
as danger-associated molecular patterns, which are released from damaged tissues [24]. It is well
documented that different ECM components or their fragments including the fibronectin 1 extra domain
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A, one of the alternative spliced regions of fibronectin encoding gene, tenascin-C, fibrinogen, and several
proteoglycans, serve as danger signals and trigger immune responses following tissue damage or in
response to pathological ECM remodeling [24,25]. In fibrotic conditions, increased ECM production,
accumulation of ECM fragments, augmented secretion of cytokines, fibroblast-to-myofibroblast
transition, and activation of immune responses, dependent on toll-like receptors, occur [26].
The regulation of ECM synthesis and remodeling is central for human health, as recognized in
different heritable connective tissue disorders [1,27]. Indeed, molecular defects in a large range of
ECM-related genes, including those encoding enzymes involved in biosynthesis or processing of ECM
proteins, cause a myriad of connective tissue disorders, e.g., Ehlers–Danlos syndromes, Osteogenesis
imperfecta, Marfan syndrome, Loeys–Dietz syndromes, arterial tortuosity syndrome, and numerous
skeletal dysplasias [1,27]. These disorders are characterized by a multisystem involvement in terms of
cardiovascular, skeletal, and cutaneous features [28], highlighting the functional relevance of the ECM
in ensuring the integrity and function of several connective tissues.
The pathological consequences of defects in ECM components depend on the balance between
extracellular effects, e.g., reduced protein secretion and export of misfolded proteins, and intracellular
consequences such as apoptosis activation, ER dysfunction, and autophagy perturbation that impact
in different ways on the molecular pathology and disease severity [27,29–31].
3. Ehlers-Danlos Syndromes
Ehlers-Danlos syndromes (EDS) represent a clinically and genetically heterogeneous group of
conditions that share a variable combination of skin hyperextensibility, joint hypermobility, and internal
organ and vessel fragility [32]. The 2017 international classification of the Ehlers-Danlos syndromes
recognizes 13 subtypes, which are caused by pathogenic variants in 19 different genes, mainly encoding
fibrillar collagens and collagens-modifying proteins [32]. EDS types are grouped based on the
underlying genetic and pathogenetic mechanisms in disorders related to (i) collagens primary structure
and processing (COL1A1, COL1A2, COL3A1, COL5A1, COL5A2 and ADAMTS2), (ii) collagens folding
and cross-linking (PLOD1 and FKBP14), (iii) structure and function of the myomatrix, i.e., the specialized
ECM of muscle (TNXB and COL12A1), (iv) glycosaminoglycans biosynthesis (B4GALT7, B3GALT6,
CHST14, and DSE), (v) complement pathway (C1S and C1R), and (vi) intracellular processes (SLC39A13,
ZNF469, and PRDM5). The classical (cEDS), vascular (vEDS) and the molecularly unsolved hypermobile
(hEDS) EDS forms account for more than 90% of patients. Recently, a new and very rare EDS variant
has been identified that is caused by biallelic mutations in the AEBP1 gene (Table 1) [33–36].
The new nosology proposed for each subtype a set of major, minor, and minimal criteria addressing
clinical suspicion for a specific EDS type and confirmatory molecular testing. For a comprehensive
overview of all EDS forms see the landmark work by Malfait and colleagues [32].
The decrease in the tensile strength and integrity of skin, joints, and hollow organs is a common
disease mechanism shared by the different EDS types [37]. This mechanical weakness is considered
the driving factor of connective tissue fragility, even if it is likely that multiple cell-matrix interplays
and involvement of distinct intracellular signaling pathways contribute to the molecular pathology of
the different EDS phenotypes [38].
In the following chapters, we will review and expand the results derived from our previous
transcriptome and in vitro studies on cEDS, vEDS, and hEDS patients’ dermal fibroblasts. Taken together,
these studies highlighted that the alteration of the ECM structural integrity is a common disease factor
contributing to the pathogenesis of all these conditions.
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Table 1. EDS types grouped according to the underlying genetic defect and pathomechanisms.
EDS Type IP Gene Protein
Group A: disorders of collagen primary structure and collagen processing
Classical EDS (cEDS) AD Major: COL5A1, COL5A2Rare: COL1A1
COLLV
COLLI
Vascular EDS (vEDS) AD COL3A1 COLLIII
Arthrochalasia EDS (aEDS) AD COL1A1, COL1A2 COLLI
Dermatosparaxis EDS (dEDS) AR ADAMTS2 ADAMTS-2
Cardiac-valvular EDS (cvEDS) AR COL1A2 COLLI
Classical-like 2 EDS A (cl2EDS) AR AEBP1 ACLP
Group B: disorders of collagen folding and collagen cross-linking
Kyphoscoliotic EDS (kEDS) AR PLOD1FKBP14
LH1
FKBP22









Group D: disorders of glycosaminoglycan biosynthesis
Spondylodysplastic EDS (spEDS) AR B4GALT7B3GALT6
β4GalT7
β3GalT6
Musculocontractural EDS (mcEDS) AR CHST14DSE
D4ST1
DSE
Group E: disorders of complement pathway
Periodontal EDS (pEDS) AD C1RC1S
C1r
C1s
Group F: disorders of intracellular processes
Spondylodysplastic EDS (spEDS) AR SLC39A13 ZIP13
Brittle Cornea Syndrome (BCS) AR ZNF469PRDM5
ZNF469
PRDM5
EDS type molecularly unsolved
Hypermobile EDS (hEDS) AD Unknown Unknown
A New EDS variant recently defined in [33–36]. AD: autosomal dominant; AR: autosomal recessive; IP:
inheritance pattern.
In cEDS and vEDS fibroblasts, the ECM disarray is a direct consequence of molecular defects in
respectively collagen V and collagen III that impair common molecular functions essential to guarantee
adequate folding and maturation of proteins and biological processes crucial for cell survival and
homeostasis. The ECM disorganization observed in hEDS cells may be a consequence of an excessive
pathological turnover, mainly due to ECM-degrading enzymes and other so far unknown factors,
which might be primary contributors involved in the transition to a pro-inflammatory myofibroblast-like
phenotype. Consistently, the perturbation of distinct transcriptional patterns observed in cEDS, vEDS,
and hEDS fibroblasts pointed out different disease mechanisms underlying the pathophysiology of
these EDS cell types.
Altogether, these insights represent a starting point for future investigations on the numerous
pathobiological aspects underlying these conditions. An overview of the biological findings emerged
from transcriptome and in vitro studies on dermal fibroblasts from cEDS, vEDS, and hEDS patients is
summarized in Table 2.
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Table 2. Overview of the biological processes dysregulated in cEDS, vEDS, and hEDS patients’ dermal
fibroblasts emerged from transcriptome and in vitro studies.
Insights in the Pathogenesis of





Perturbed Biological Processes cEDS vEDS hEDS cEDS vEDS hEDS
ECM disorganization + + + + + +
Altered cell-matrix interactions − − + + + +
Disturbed cell-cell contacts − − + − − +
Fibroblast-to-myofibroblast transition − − + − − +
Altered inflammatory responses + − + − na +
Perturbed cell migration + + − + + +
Defective wound healing + + − + na na
Survival from anoikis − − − + + na
Collagens biosynthesis/processing + + − na + na
ER homeostasis/protein folding + + − na + na
+: detected by transcriptome or in vitro studies, −: not experimentally detected by transcriptome or in vitro studies,
na: not ascertained.
4. Classical Ehlers-Danlos Syndrome
Classical EDS (cEDS, OMIM#130000) is characterized by marked skin involvement, generalized
joint hypermobility, and abnormal wound healing [32,39]. Most patients harbor point mutations
or chromosomal rearrangements in COL5A1 or COL5A2 genes encoding the collagen V [40,41].
This collagen is abundantly distributed in a variety of tissues as heterotrimers, which co-assemble with
collagen I to form heterotypic fibrils [42].
Collagen V knockout mice synthesize and secrete normal amounts of collagen I, but collagen
fibrils are absent, and the animals die at the onset of organogenesis, supporting the crucial role of
collagen V for embryonic development [43].
Collagen V haploinsufficiency is the most common molecular defect caused by COL5A1 null
alleles, whereas rare COL5A1 variants and the majority of COL5A2 mutations reported so far affect
collagen V structural integrity by exerting a dominant negative effect [40,41].
5. Altered ECM Turnover, Wound Healing, and Inflammation in cEDS Fibroblasts
Although the reduced availability of collagen V is crucial in the pathogenesis of cEDS, the molecular
aspects contributing to the pathophysiology of the disorder remain poorly characterized. Our in vitro
findings demonstrated that cEDS patients’ fibroblasts show disassembly of many ECM components,
including collagen V and III, fibronectin, and fibrillins, and disorganization of collagen- and
fibronectin-specific α2β1 and α5β1 integrin receptors [44–47]. cEDS cells also exhibit a reduced
in vitro migration capability, an abnormal wound healing response, and a crosstalk involving the αvβ3
integrin and epidermal growth factor (EGF) receptor that rescues them from anoikis [44–50]. In line
with these in vitro findings, Col5a1 and Col5a2 deficient mice show a defective wound healing response
and reduced cell migration [51,52].
Transcriptome profiling of cEDS fibroblasts added new insights into the complex molecular
mechanisms involved in the maintenance of ECM homeostasis and proper wound healing, since patients’
cells showed the dysregulated expression of many genes encoding matricellular and soluble proteins
with prominent functions in cell proliferation and migration, collagen assembly and ECM remodeling
during wound healing, i.e., SPP1, POSTN, EDIL3, IGFBP2, and C3 [47]. Wound healing is a highly
controlled multistep process involving several growth factors, cytokines, matrix metalloproteases,
and cellular receptors, as well as proper crosstalk of different ECM constituents essential for ensuring
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tissue regeneration [53]. In addition to ECM glycoproteins and collagens, many other matricellular
proteins including osteopontin, periostin, and tenascins are required for the formation of a provisional
ECM during wound repair [54,55].
Osteopontin encoded by SPP1, which shows a decreased expression in patients’ cells, is involved
in several physiological processes related to inflammation, biomineralization, cell viability, and wound
healing [56,57]. Through its interaction with the αvβ3 integrin, osteopontin facilitates the adhesion
of bone cells during bone tissue formation by stimulating a mineralized collagen ECM [58,59].
Finally, the functional role of osteopontin in the ECM reorganization during wound healing is crucial,
since Opn-deficient mice show ECM disorganization and disassembly of collagen fibrils in the deep
layers of wound sites [60].
In cEDS fibroblasts, the decreased expression of periostin encoded by POSTN may also contribute
to the generalized ECM disarray and in vitro poor wound healing [44,48]. Indeed, periostin plays
an important role in ECM structure and organization and particularly in collagen assembly, by acting
as a scaffold protein for the bone morphogenetic protein 1, which facilities the proteolytic activation of
lysyl oxidase that, in turn, catalyzes the covalent cross-link formation of collagens [61]. Consistently,
Postn-deficient mice exhibit marked reduction of collagen cross-linking and increased levels of collagen
fragments owing to proteolytic digestion [62,63]. Periostin also acts as a pro-survival protein in
many cellular circumstances by interacting with αvβ3 and αvβ5 integrin receptors and mediating the
activation of several intracellular signaling pathways [64]. In wound sites, it promotes activation of
fibroblasts during wound contraction and stimulates collagen assembly and ECM reorganization [65,66].
POSTN not only shows a diminished expression in vEDS cells but also in dermal fibroblasts from
patients with FKBP14-kEDS [67], further emphasizing the crucial role of periostin as a scaffold
matricellular protein necessary for collagen assembly and ECM stability.
EDIL3 (EGF-like repeat- and discoidin I-like domain-containing protein 3), the most
down-regulated transcript in cEDS fibroblasts, encodes an ECM-associated protein that promotes
angiogenesis in vitro through binding to αvβ3 and αvβ5 integrins [68]. It stimulates cell migration and
proliferation, mediates apoptotic cell phagocytosis, regulates neutrophil recruitment to the inflamed
tissue, and prevents chondrocyte anoikis through its interaction with the αvβ3 integrin [69–71].
IGFBP2 (insulin-like growth factor-binding protein 2), the most up-regulated gene in cEDS cells,
enhances cell migration in different cell types through its binding to αvβ3 and α5β1 integrins [72,73].
Its high expression in cEDS cells might represent a transcriptional response in the attempt to counteract,
at least in vitro, their reduced migration capability [48,49].
Of note is also the marked up-regulation of the complement factor C3 belonging to a complex
network of plasma and membrane proteins involved in the innate immunity [74]. Complement
can modulate the inflammatory response during wound healing to restore tissue injury; however,
its unbalanced or prolonged activation can exacerbate inflammation, delaying the physiological wound
healing [75]. Specifically, C3 functions as a negative regulator of tissue healing, since C3-deficient mice
exhibit an increased wound healing and angiogenesis [76].
Taken together, these gene expression abnormalities expand the current understanding of altered
molecular mechanisms underlying the deficient wound healing response observed in cEDS cells.
Additional functional work might help to establish the concrete involvement of these proteins
including the αvβ3 integrin in the impaired wound healing, which likely leads to the cutaneous
manifestations of cEDS [39,77].
6. Perturbation of ER Homeostasis and Autophagy in cEDS Fibroblasts
ER is a fundamental cellular organelle involved in the maintenance of numerous aspects of cell
health by ensuring folding and exporting of secretory or transmembrane proteins [78]. The biosynthesis,
processing, and integrity of collagens and other ECM structural constituents are critical for intracellular
proteostasis [79]. To restore intracellular equilibrium, the ER counteracts the accumulation of aggregated
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or misfolded proteins by means of quality control mechanisms such as unfolded protein response,
ER-associated degradation, and autophagy [80].
In cEDS fibroblasts, a possible unbalance of ER homeostasis and autophagy was assumed given
the decreased expression of many associated genes such as DNAJB7, ATG10, CCPG1, and SVIP [47].
DNAJB7 encodes a member of the J protein/heat shock protein family acting as ER chaperones in the
quality control of aggregate protein [81]. ATG10 is a member of the autophagy related proteins family
that participates to the generation and expansion of autophagosomes [22]. The protein encoded by
CCPG1 acts as an ER-phagy cargo receptor facilitating the attachment to growing autophagosomes of
the microtubule-associated LC3 protein that is crucial for autophagosome maturation [22,78,82].
CCPG1 plays a key role in the ER proteostasis, since its deficiency causes accumulated insoluble
proteins and consequent ER dilation [83]. A recent study reported the contribution of ER-phagy in
the selective degradation of misfolded procollagen I molecules via a calnexin-FAM134B complex [84].
Furthermore, inefficient procollagen folding in the ER may induce autophagy as a cytoprotective
mechanism [85]. Based on these findings, it is reasonable to speculate a possible role of CCPG1 in
this autophagy-dependent mechanism and that its decreased expression in cEDS fibroblasts might
impair the ER quality control. The disturbance of ER homeostasis in cEDS is also suggested by the
decreased transcription of the small VCP/p97-interacting protein (SVIP), which is a modulator of the
ER-associated degradation pathway [86,87]. Previous and recent data highlighted the contribution
of SVIP in the regulation of autophagy, since its overexpression is associated with increased LC3
lipidation and attenuation of hepatic fibrosis by the induction of the autophagic flux [88,89].
The impairment of ECM organization, matrix-cell interactions, and the activation of
ECM-dependent intracellular signaling may elicit autophagy [18,19]. Cell detachment from the
ECM activates the autophagy pathway that, in turn, protects cells from anoikis [90]. Moreover,
depletion of autophagy regulators is associated with induction of pro-apoptotic signals, decrease of
collagen degradation via lysosome pathway, and regulation of cell adhesion [90,91]. In line with these
observations, the aberrant expression of collagen V and defective remodeling of ECM in cEDS cells
might affect ER homeostasis and autophagy, and consequently activate a pro-survival mechanism
mediated by a crosstalk between αvβ3 integrin and EGF receptor [45,50]. Additional studies are needed
to better elucidate the contribution of these processes in the molecular pathology of cEDS.
7. Vascular Ehlers-Danlos Syndrome
Among the different EDS forms, vascular EDS (vEDS, OMIM#130050) is the most severe type and
is primarily characterized by life-threatening features of tissue fragility leading to arterial dissection or
aneurysm, gastrointestinal ruptures, and pregnancy complications at a young age [92,93].
vEDS is caused by mutations in COL3A1 encoding collagen III that shows a predominant
expression in blood vessels and hollow organs [94]. Most disease-causing variants in COL3A1 are
glycine substitutions that destroy the triple helical winding, thus altering the structural integrity
of collagen III due to misfolded procollagen III in the ER, and thereby impairing the secretion and
deposition into the ECM of functionally mature molecules [95,96].
Col3a1 deficient mice show a reduced lifespan mainly due to arterial ruptures and abnormalities
of collagen fibril organization in several collagen-rich organs, i.e., aorta, skin, lung, and bowel [10].
Our previous protein findings on cultured patients’ fibroblasts showed that dominant negative
mutations in COL3A1 lead to the reduced secretion of collagen I into the ECM [44], consistent with
the known regulatory role of collagen III in synthesis and deposition of heterotypic fibrils that largely
contain collagen I [96].
8. Disturbance of ECM Organization, Collagens Processing, and ER Homeostasis in vEDS Fibroblasts
Although it is well known that the disruption of the collagen III triple helical structure leads
to abnormal protein folding, different biological aspects of the vEDS pathogenesis are not yet fully
studied. In line with cEDS and hEDS transcriptome profiling, vEDS fibroblasts show the differential
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expression of several genes encoding structural constituents of the ECM, further supporting the notion
that abnormal ECM remodeling is a common denominator of these conditions [50,97].
vEDS cells showed a marked decrease in expression of the fibrillin 2 encoding gene (FBN2).
Fibrillins are essential structural ECM components involved in the organization of blood vessels
and dermis, and in combination with elastic fibers they act as scaffold to ensure tissue elasticity [98].
Moreover, fibrillins interact with elastin microfibril interface-located proteins (EMILINs) and facilitate
their incorporation into the dermal ECM [99].
Fibrillins also regulate the bioavailability of the TFGβ through the interaction with latent TFGβ
binding proteins [99]. Specifically, fibrillin 2 plays a role in bone and soft connective tissue morphology
by influencing the collagen cross-linking [100].
Besides its role in elastogenesis and ECM stability, fibrillin 2 also has a role during wound
healing [101]. About this, vEDS fibroblasts share with cEDS cells the decreased expression of the related
periostin-encoding gene and show reduced migration capability [49]. Consistently, both altered wound
healing and reduced total collagen content were reported in a Col3a1 transgenic mouse model [102].
Our protein findings confirmed the pathological ECM remodeling of vEDS fibroblasts,
as a generalized fibrillin disarray in combination with the disassembly of EMILINs and elastin
network was revealed, consistent with the extreme vascular fragility observed in vEDS patients [97].
The disorganization of core proteins of the proteoglycans perlecan, versican, and decorin, which are
involved in the formation of collagen fibrils, further emphasizes the widespread ECM disarray and
altered collagens biosynthesis/secretion of vEDS cells that are consequent to collagen III defect [97].
The biosynthetic pathway of fibrillar collagens is a highly regulated process involving folding
enzymes, molecular chaperones, and post-translational modifications essential for proper protein
assembly, stability of collagen fibrils, and their transport to the cell surface [8,9]. In vEDS cells,
this complex machinery seems to be perturbed given the reduced expression of many ER-resident
enzymes involved in different steps of collagen biosynthesis, i.e., P4HA2, P4HA3, LOXL3, and FKBP14.
P4HA2 and P4HA3 encode the α-subunit of the collagen prolyl-4-hydroxylase, which catalyzes the
hydroxylation of collagen prolyl residues necessary to provide thermal stability to the collagen triple
helix. Lysyl oxidase-like 3 (LOXL3) stabilizes the formation of intra- and intermolecular crosslinks
during assembly of collagen and elastin fibrils. FKBP14 encodes a peptidyl-prolyl cis-trans isomerase
(FKBP22) that catalyzes in the ER lumen collagen folding and it functions as a molecular chaperone
for different collagens including collagen III [8,103]. Dermal fibroblasts of FKBP14-deficient patients
show a generalized perturbation of protein folding and a consequent enlargement of ER cisternae [104].
The marked decrease of FKBP22 protein levels observed in vEDS cells suggests an ER accumulation of
misfolded proteins, consistent with the possible dilation of ER cisternae evinced by immunofluorescence
analysis with the ER marker PDI [97].
Structural mutations in different collagen types disturb the assembly into hetero- or homotrimers or
lead to abnormal triple helix folding. The consequent accumulation of misfolded collagen molecules into
the ER lumen activates the proteasomal degradation system to re-establish ER proteostasis [27]. In vEDS
cells, this quality control machinery might not work properly, given the decreased transcription of
several genes encoding different catalytic and non-catalytic subunits of the proteasome complex, such as
PSMA6, PSMB6, PSMC3, and PSMD2. In addition, the reduced transcription of members belonging
to the DnaJ heat shock protein family, i.e., DNAJB7, DNAJB11, DNAJC3, DNAJC10, and DNAJC24,
and to the thioredoxin superfamily, i.e., TXN, PDIA4, PDIA5, and PDIA6, which all act as intracellular
mediators for correct protein folding and intracellular redox balance [105], further corroborates
a perturbed ER proteostasis in vEDS fibroblasts.
This imbalance can be overcome by the activation of stress-related pathways, such as unfolded
protein response and autophagy to restore basal cellular equilibrium [80]. The alteration of the ER
redox state may also trigger pro-death signals through the regulation of members of the Bcl-2 family
and activation of caspase-dependent apoptosis [106,107]. Consistently, we previously demonstrated
that vEDS fibroblasts are in a pre-apoptotic state, due to downregulation of the Bcl-2 anti-apoptotic
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protein and increased levels of caspase enzymes, and activate a cell survival mechanism through
an αvβ3-EGFR crosstalk [45,50]. However, in vEDS cells an enhanced expression of unfolded protein
response-related genes was not identified, consistent with the recent findings on cultured dermal
fibroblasts from Col3a1 transgenic mice that did not show elevated levels of the unfolded protein
response markers Bip and Chop [102]. In line with this evidence, a recent transcriptome analysis of
dermal fibroblasts from FKBP14-kEDS patients did not reveal a high expression of genes associated
with ER stress and unfolded protein response activation [67], though early data on this EDS cell type
suggested an enlargement of ER [104]. Nevertheless, given that different reports highlighted the role
of ER stress in the pathogenesis of several collagenopathies [27,108,109], further work is warranted
to explore the possible ER perturbation as a disease mechanism of vEDS to identify novel potential
therapeutic targets.
9. Hypermobile Ehlers-Danlos Syndrome
Hypermobile EDS (hEDS, OMIM#130020), mainly characterized by generalized joint hypermobility
and its complications, minor skin changes, and apparently segregating with an autosomal dominant
pattern, is still without a known molecular basis. The phenotypic spectrum of hEDS is wide-ranging
and heterogeneous and further complicated by multiple associated symptoms shared with other
heritable or acquired (autoimmune) connective tissue disorders and chronic inflammatory systemic
diseases [32,110,111].
Despite the significant advances in molecular genetic techniques, attempts to disclose the genetic
cause(s) of hEDS have been so far inconclusive. Several studies struggled to define its genetic etiology
but without compelling evidence, corroborating the hypothesis of a high genetic heterogeneity of
the condition [112–115]. The introduction of more selective clinical criteria for hEDS in the novel
classification aimed to minimize heterogeneity allows for the formation of homogeneous cohorts to
facilitate scientific research to discover the underlying genetic cause(s) of the condition [32]. Nowadays,
hEDS is considered at one end of a continuous spectrum of phenotypes, which originates from isolated
non-syndromic joint hypermobility and passing through the recently defined hypermobility spectrum
disorders (HSD) [111]. HSD refers to patients who present symptomatic joint hypermobility but do
not fulfill the new diagnostic criteria of hEDS. Recently, given the clinical continuity between hEDS
and HSD and our data on patients’ dermal fibroblasts [49], it was proposed that these disorders
might be considered as a single entity, referred to as hEDS/HSD [116], as already occurred for the
hypermobility type of EDS and joint hypermobility syndrome [117]. Until now, no validated biological
biomarkers have been identified for recognizing hEDS/HSD, which are dominated by extremely
variable phenotypes and chronic disability affecting patients’ quality of life [111,116].
In this intricate scenario, the integration of various biological knowledge could be an effective
strategy to delineate molecular mechanisms contributing to the disease pathophysiology. Transcriptome
and proteome profiling can be useful to reveal specific biological signatures, thus providing insights
not only for the understanding of the pathomechanisms but also for the identification of reliable tools
for therapeutic options [118–122].
Previous findings based on transcriptome and protein studies on a cohort of hEDS/HSD
patient-derived dermal fibroblasts represent up to now the main effort to unravel their complex
etiopathogenesis [48,123]. Proteome profiling of patients’ cells is currently ongoing to corroborate
these data, since the gene expression profiling and cellular studies on patients’ fibroblasts provided
significant clues that are likely relevant for the disease pathogenesis. In the following paragraphs we
review our past findings and discuss some novel emerging aspects, offering future perspectives for
molecular research in this field.
10. Pathological ECM Remodeling and Defective Cell-Cell Interactions in hEDS/HSD Cells
Although hEDS/HSD etiology remains elusive, patients’ skin fibroblasts show a disorganization
of the ECM like that observed in cells derived from the other EDS types. In particular, hEDS/HSD,
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cEDS, and vEDS fibroblasts exhibit a marked disorganization of collagen and fibronectin ECM and
their specific α2β1 and α5β1 integrin receptors and showed the preferential expression of the αvβ3
integrin [44,49,50,123].
Transcriptome of hEDS/HSD fibroblasts revealed the dysregulated expression of several genes
encoding either ECM glycoproteins such as elastin (ELN) and sparc/osteonectin (SPOCK), ECM
regulators, i.e., metalloproteinases (MMP16, PAPPA2) and transglutaminase (TGM2), or ECM associated
secreted factors such as secreted frizzled-related protein 2 (SFRP2) and transforming growth factor
alpha (TGFA). This ECM signature is in common with cEDS and vEDS cells, underlining that the matrix
perturbation may act as a key driving factor for the EDS pathogenesis, irrespective of the underlying
molecular defects [50].
Cells sense the intrinsic mechanical properties of the ECM and convert these stimuli into
intracellular signals [124]. In addition to integrins that primarily mediate this cell response, intracellular
signals may be triggered also through the cadherin superfamily, which are calcium-dependent
transmembrane proteins forming complex adhesions and connect to the actin cytoskeleton via numerous
proteins [125,126]. Interestingly, transcriptome profiling of hEDS/HSD cells revealed a differential
expression of many adhesion molecule-encoding genes including members of cadherins and
protocadherins, i.e., CDH2, CDH10, PCDH9, PCDHB16, PCDHB18, claudins (CLDN11), and desmosomes
(desmoplakin, DSP), which are involved in the formation of specialized cell-cell junction complexes
essential for maintaining epithelial integrity, morphogenesis, and tissue architecture [127,128].
Since these adhesion proteins can act as signaling modulators of intracellular pathways, such as Wnt,
Hippo, NF-kB, JAK-STAT that are crucial for development and organogenesis [128], their altered
expression could impact on multiple biological processes essential for embryogenesis and
tissue homeostasis.
These transcriptional changes suggested a fibroblast-to-myofibroblast transition of hEDS/HSD
cells. This phenomenon induces the formation of cells with muscle-like features that are characterized
by increased cell contractility, formation of alpha smooth muscle actin (α-SMA)-stress fibers, together
with the reorganization of cell-matrix and cell-cell contacts and cytoskeletal architecture [127,129–131].
Our in vitro studies confirmed the phenotypic conversion of hEDS/HSD fibroblasts into migrating
myofibroblast-like cells, since they express the typical markers α-SMA and cadherin-11 and show
augmented levels of the protease MMP9 and an altered expression of the inflammation mediators CYR61
and CTGF [49]. This phenotypic switch is elicited by a signal transduction pathway involving the αvβ3
integrin that signals through the integrin linked kinase (ILK) and the transcription factor Snail1 [49,50].
This myofibroblast-like phenotype observed in vitro might reflect a persistent in vivo inflammatory-like
condition consistent with the patients’ systemic clinical manifestations, comprising gastrointestinal
dysfunction, increased susceptibility to osteoarthritis, chronic generalized musculoskeletal pain,
inflammatory soft-tissue lesions, and neurological features [110,111].
Activation of myofibroblasts is itself part of physiological wound repair following tissue
injury, whereas in chronic injury and inflammatory fibrotic conditions their persistent activation
exacerbates the disease progression [132–135]. During fibroblast-to-myofibroblast transition, a complex
mechanochemical signaling is activated involving profibrotic secreted factors such as TGFβ and Wnt
and ECM-degrading enzymes and intracellular effectors required for stress fiber contractility [127,131].
At molecular level, the cytokine TGFβ is considered the master regulator of profibrotic processes.
A growing body of evidence has highlighted the regulation of the Wnt/β-catenin pathway by TGFβ as
well as the involvement of their downstream molecular effectors in the fibroblast-to-myofibroblast
transition and fibrotic responses [136].
As revealed by transcriptome analysis, several signaling pathways essential for cell growth and
proliferation were found to be likely perturbed in hEDS/HSD fibroblasts, i.e., TGFβ, TNF, Jak-STAT,
and PI3K-Akt [123]. Transcriptomics data also suggested the differential expression of different
Wnt-related genes including the up-regulated frizzled receptor 3 (FZD3) and the down-regulated Wnt
negative regulators PRICKLE1 and SFRP2. SFRP2, the most down-regulated transcript in patients’ cells,
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acts as a critical Wnt modulator, since it directly binds to Wnt proteins and prevents their interactions
with FZD receptors [137].
The synergistic crosstalk between TGFβ and Wnt signaling in the myofibroblast activation is
documented as well as the inhibitory role of SFRP2 in the TGFβ-dependent myofibroblast formation
and post-inflammatory fibrosis [138,139]. In this view, a possible involvement of these signaling
pathways in the pathomechanisms of hEDS/HSD can be envisaged. Our findings may offer further
clues to address important questions concerning the activation of these pathological mechanisms,
and it remains to be clarified which growth factors, i.e., TGFβ, CTGF, and key regulatory pathways
sustain the fibroblast-to-myofibroblast transition of hEDS/HSD cells.
11. Differential Expression of Genes Involved in Inflammatory, Immune, and Pain Response in
hEDS/HSD Cells
Over the past few years, clinical research described the presence of comorbidities in hEDS/HSD
patients, such as functional gastrointestinal and eosinophilic disorders [140,141], increased prevalence
of asthma [142], and chronic pain syndromes, i.e., chronic fatigue, fibromyalgia, irritable bowel disease,
and inflammatory joints conditions [111,143], though specific underlying causes and mechanisms
remain to be explored. In this regard, transcriptome of hEDS/HSD cells revealed the aberrant
transcription of a range of genes related to inflammation, pain, and immune responses, i.e., AQP9, CFD,
SPON2, PRLR, and NR4A receptors, which might impair biological functions and molecular pathways
with a potential role in the disease’s pathogenesis. Among them, patients’ cells showed the enhanced
expression of AQP9, a member of the family of water-selective membrane channels that play a role
both in antimicrobial defense and skin barrier permeability [144]. A high expression of this transporter
was detected in synovial tissues and fibroblast-like synoviocytes from osteoarthritis and rheumatoid
arthritis patients and may have a role in the pathogenesis of inflammatory synovitis [145,146].
In line with this finding, patients’ cells also showed increased mRNA levels of complement
factor D (CFD), a component of the alternative complement pathway [147], which is involved in
pathophysiological mechanisms of osteoarthritis and is considered as a potential predictive biomarker
of joint pain in patients with hip and knee osteoarthritis [148–150].
In hEDS/HSD no reliable biomarkers have been identified. A previous study identified elevated
basal serum tryptase levels due to increased TPSAB1 copy number associated with hereditary alpha
tryptasemia in individuals with multisystem complaints, i.e., joint hypermobility, sleep disruption,
irritable bowel syndrome, body pain, headache, arthralgia, and chronic gastroesophageal reflux,
partly overlapping with those frequently observed in hEDS/HSD patients [151]. In our hEDS/HSD
patients, no elevated basal serum tryptase level was observed, suggesting the absence of the association
between their clinical features and copy number variations in the TPSAB1 gene.
Other inflammation-related genes dysregulated in hEDS/HSD include SPON2, up-regulated in
patients’ cells, which encodes an ECM protein with multifunctional properties in the innate immune
system and inflammatory cell recruitment [152–154], and PRLR, showing a decreased expression
in hEDS/HSD cells, which encode the prolactin receptor implicated in inflammatory responses and
immune cells regulation [155,156]. The prolactin-PRLR axis contributes to the activation of pain-related
pathways through the sensitization of transient receptor potential channels that promote painful
sensations [157,158]. Chronic pain represents a common complaint among hEDS/HSD patients affecting
their quality of life [111,116], though specific molecular pathways or mediators of pain are still unknown.
As further evidence of unbalanced inflammatory responses in patients’ cells, transcriptome
revealed a decreased expression of the NR4A nuclear receptors (NR4A1, NR4A2, NR4A3), which act
as transcriptional regulators of inflammatory responses mediated by NF-kB signaling [159–161].
These receptors attenuate inflammatory events through inhibition of the NF-kB nuclear translocation
and induction of the expression of its inhibitor NFKBIA, which, in turn, blocks the NF-kB nuclear
localizing sequence [159]. The concomitant decreased mRNA levels of NR4A1 and NFKBIA in patients’
cells may be related to aberrant NF-kB signaling.
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Despite additional work being required to support these hypotheses, our findings depict the
complex sequence of transcriptional events that should stimulate more investigations to provide new
insights into the pathomechanisms underlying the molecular networks related to aberrant inflammatory
responses associated with hEDS/HSD.
12. Emerging Aspects of hEDS/HSD Pathophysiology by microRNAs Profiling
Transcriptome analysis may be a valuable strategy also to delineate distinct molecular signatures
related to the differential expression of microRNAs (miRNAs). miRNAs are small non-coding RNA
molecules ranging from 20–25 nucleotides in length that act mainly as negative regulators of gene
expression by promoting the degradation of target mRNAs or repressing their translation [162,163].
Aberrant miRNA expression has been reported in several pathological conditions including cancer,
musculoskeletal disorders, painful peripheral neuropathies, and fibromyalgia [164–166].
Our previous expression profiling of hEDS/HSD fibroblasts identified 19 dysregulated
miRNAs [123]. Here, we report some examples that might offer interesting clues about the possible
involvement of miRNAs in the regulation of potential targets and molecular pathways related to
inflammation and Wnt signaling that seem to have a role in the disease pathogenesis.
The most overexpressed miRNA in patients’ cells was the miR-378-3p, which is considered
a modulator of the epithelial-to-mesenchymal transition and is associated with inflammation and
fibrosis through the positive modulation of NF-kB and TNFα pathways [167,168]. miRNA-224, which is
also up-regulated in hEDS/HSD cells, is associated with the activation of the Wnt/β-catenin signaling
through the inhibition of the expression of glycogen synthase kinase 3β and SFRP2, which are known
Wnt suppressors [169]. Therefore, it is likely reasonable to assume that the enhanced expression of
this miRNA may contribute to the decreased mRNA level of SFRP2 observed in hEDS/HSD cells,
supporting the hypothesis that the aberrant signaling of the Wnt/β-catenin axis might play a role in the
disease mechanisms of hEDS/HSD.
We previously demonstrated the involvement of the ILK in the fibroblast-to-myofibroblast
switch of hEDS/HSD cells. The ILK acts downstream of the phosphatidylinositol 3-kinase signaling
pathway and negatively regulates the action of the glycogen synthase kinase 3β by phosphorylation of
a specific serine residue, further strengthening our assumption that Wnt/β-catenin signaling is involved
in hEDS/HSD pathogenesis [49,50]. Consistently, patients’ fibroblasts show a reduced expression
of the miRNA-23a, which is implicated in the Wnt pathway regulation as well, by inhibiting the
expression of FDZ5 and FDZ7 receptors [170]. Decreased levels of this miRNA were also found in
cerebrospinal fluid and serum of patients with fibromyalgia [171], a painful disorder in differential
diagnosis with hEDS/HSD [172], which might suggest a possible involvement of specific miRNA
signatures or a common disease pattern in both conditions. In addition, the altered expression of this
miRNA in synovial fibroblasts of psoriatic arthritis patients, results in the enhanced expression of
pro-inflammatory mediators and matrix degrading enzymes, further promoting joint degeneration
and synovial inflammation [173].
Several studies highlighted the contribution of miRNAs in the modulation of the expression of
ECM structural proteins and related signaling molecules, thus emphasizing the close relationship
between ECM homeostasis and inflammatory pain related conditions [174–176].
As the expression of miRNAs can be modulated to mediate the expression of their target
genes, in-depth in vitro studies on a large cohort of patients’ cells could provide further evidence
on mechanisms of action of miRNAs and their impact on diverse target genes and altered pathways
relevant for the pathophysiology of hEDS/HSD, thus offering new perspectives to identify potential
molecular therapeutic targets.
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13. Conclusions and Perspectives
Transcriptome and in vitro analyses on cEDS, vEDS, and hEDS/HSD dermal fibroblasts expanded
the knowledge about molecular mechanisms involved in the pathophysiology of these connective
tissue disorders (Figure 1).
Figure 1. Schematic illustration summarizing the processes likely involved in the pathogenesis of cEDS,
vEDS, and hEDS/HSD derived from transcriptome and in vitro studies of patients’ skin fibroblasts.
Our findings indicate that these cells share a deregulated expression of many matrix-related
genes and a widespread disarray of several ECM structural constituents, thus highlighting the
functional relevance of a proper organization and function of the ECM in providing stability
to connective tissues. In cEDS and vEDS dermal fibroblasts, the pathological ECM turnover is
directly caused by the underlying molecular defect causing abnormal expression of collagen V and
collagen III, which, in turn, perturbs key physiological processes critical for collagen processing itself
and to maintain cell homeostasis. In the absence of a known genetic etiology, the abnormal ECM
organization present in hEDS/HSD cells may be a functional consequence of excessive remodeling due
to increased levels of ECM-degrading enzymes and concomitant acquisition of a pro-inflammatory
myofibroblast-like phenotype. hEDS/HSD transcriptome profiling for the first time has shed light on
different pathobiological aspects of the disease. The dysregulated expression of genes involved in
cell-matrix interactions and specific intracellular signaling pathways may have a role in the phenotypic
switch of hEDS/HSD cells. Transcriptional changes of different genes and miRNAs involved in
molecular pathways related to pain and inflammatory response might provide further clues to dissect
the intricate biological events involved in chronic and musculoskeletal pain affecting hEDS/HSD
patients. To deepen the knowledge on hEDS/HSD pathophysiology, proteome profiling of patients’
cells is currently ongoing to decipher the complex protein network and identify potential bioactive
molecules involved in the disease pathogenesis to offer therapeutic options for hEDS/HSD patients.
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Abstract: Kyphoscoliotic Ehlers–Danlos Syndrome (kEDS) is a rare genetic heterogeneous disease
clinically characterized by congenital muscle hypotonia, kyphoscoliosis, and joint hypermobility.
kEDS is caused by biallelic pathogenic variants in either PLOD1 or FKBP14. PLOD1 encodes the
lysyl hydroxylase 1 enzyme responsible for hydroxylating lysyl residues in the collagen helix,
which undergo glycosylation and form crosslinks in the extracellular matrix thus contributing to
collagen fibril strength. FKBP14 encodes a peptidyl-prolyl cis–trans isomerase that catalyzes collagen
folding and acts as a chaperone for types III, VI, and X collagen. Despite genetic heterogeneity, affected
patients with mutations in either PLOD1 or FKBP14 are clinically indistinguishable. We aim to better
understand the pathomechanism of kEDS to characterize distinguishing and overlapping molecular
features underlying PLOD1-kEDS and FKBP14-kEDS, and to identify novel molecular targets that
may expand treatment strategies. Transcriptome profiling by RNA sequencing of patient-derived skin
fibroblasts revealed differential expression of genes encoding extracellular matrix components that are
unique between PLOD1-kEDS and FKBP14-kEDS. Furthermore, we identified genes involved in inner
ear development, vascular remodeling, endoplasmic reticulum (ER) stress, and protein trafficking that
were differentially expressed in patient fibroblasts compared to controls. Overall, our study presents
the first transcriptomics data in kEDS revealing distinct molecular features between PLOD1-kEDS
and FKBP14-kEDS, and serves as a tool to better understand the disease.
Keywords: kyphoscoliotic Ehlers–Danlos Syndrome; EDS type VI; transcriptomics; connective tissue;
extracellular matrix; PLOD1; FKBP14
1. Introduction
According to the 2017 revised Nosology of the Ehlers–Danlos syndrome (EDS) [1], kyphoscoliotic
EDS (kEDS, OMIM 225400 and 614557) groups two rare autosomal recessive disorders which are
clinically indistinguishable, but genetically distinct as they are caused by pathologic biallelic variants
in either procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (PLOD1) or FK506-binding protein 14
(FKBP14). PLOD1 encodes the lysyl hydroxylase 1 (LH1) enzyme, which hydroxylates lysyl residues
of Xaa-Lys-Gly tripeptide motif in collagens. Subsequently, the hydroxylated lysyl residues undergo
glycosylation with the attachment of galactose or glucosyl-galactose units and after collagen secretion
Genes 2019, 10, 517; doi:10.3390/genes10070517 www.mdpi.com/journal/genes85
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into the extracellular matrix (ECM) they form inter- and intra-molecular crosslinks known to contribute
to collagen fibril strength and thus to tissue stability [2]. The lack or loss of function of LH1 leads to
underhydroxylation and underglycosylation of lysyl residues in the helical domain of collagen, thereby
impairing collagen cross-linking and consequentially causing mechanical instability of the affected
connective tissues. Patients deficient in LH1 have an increased ratio of urinary lysyl-pyridinoline to
hydroxylysyl-pyridinoline (LP/HP) due to underhydroxylation of collagen lysyl residues. Only recently,
pathogenic variants in FKBP14 have been described in a group of patients with a clinical diagnosis
of kEDS but a normal LP/HP ratio [3,4]. FKBP14 encodes the endoplasmic reticulum (ER)-resident
FKBP22 protein, a 22kDa member of the family of FK506-binding peptidyl-prolyl cis–trans isomerases.
FKBP22 catalyzes the cis–trans isomerization of prolyl peptide bonds, which is the rate limiting step in
procollagen protein folding due to its abundance in proline residues, and has been shown to catalyze
the folding of collagen type III [5]. FKBP22 also functions as a chaperone for collagen types III, VI and X
where it is thought to prevent premature interactions between collagen during its assembly in the ER [5].
Despite harboring mutations in two genes with different functions, PLOD1-kEDS and
FKBP14-kEDS patients share a common clinical phenotype with major criteria consisting of congenital
muscle hypotonia, congenital or early onset kyphoscoliosis, and generalized joint hypermobility; shared
minor criteria include skin hyperextensibility, rupture, or aneurysm of medium-sized arteries, easy
bruising of skin, and osteopenia or osteoporosis. Gene-specific minor criteria for PLOD1-kEDS include
skin fragility, while that of FKBP14-kEDS include congenital hearing impairment [1]. Pronounced
inter- and intrafamilial variability of the clinical presentation have been described in both genetic
forms of kEDS [3,4]. In the absence of genetic information, collagen type VI-related myopathies
which present with severe neonatal hypotonia, delayed motor development, kyphoscoliosis and joint
hypermobility [6–8] represent the major differential diagnosis to kEDS.
Currently, there is no pharmacological treatment for kEDS and the treatment of manifestations
aims to alleviate symptoms and focuses on the musculoskeletal and hearing systems [3,4,9]: physical
therapy for muscular hypotonia, bracing of unstable joints, corrective surgeries for kyphoscoliosis and
prescription of hearing aids for hearing impairment.
The aim of our study is to better understand the pathomechanism of kEDS and to identify overlapping
and distinguishing molecular signatures of PLOD1-kEDS and FKBP14-kEDS. The application of an
untargeted general omics approach may serve as a valuable tool to identify novel proteins or pathways
involved in the pathogenesis of kEDS that can be pharmacologically targeted to improve the disease
symptoms. As a first step towards this goal, by performing RNA sequencing on an in vitro cell culture
model of kEDS we obtained and compared the transcriptome profiles of normal control, PLOD1-kEDS
and FKBP14-kEDS patients. Furthermore, the transcriptome profiles of kEDS patients were compared to
published transcriptomics data of patients with collagen VI-associated myopathies [10].
2. Materials and Methods
2.1. Subjects and Cell Culture
This study was conducted according to the Declaration of Helsinki for Human Rights and
approved by Swiss Ethics (KEK-ZH-Nr. 2019-00811) in the presence of a signed informed consent of
the patients or their parents.
As part of the diagnostic workup of kEDS, punch biopsies of the skin for electron microscopy
investigations and establishment of fibroblast cultures were previously obtained. The biological
material was stored in the Biobank of the Division of Metabolism at the Children’s Hospital Zurich.
For this study, fibroblasts of three FKBP14-kEDS patients, three PLOD1-kEDS patients and four healthy
controls were used (Table S1). Pathological mutations and clinical findings of the patients are recorded
in Table 1. Cells were cultured at 37 ◦C and 5% CO2 in Dulbecco’s Modified Eagle’s Medium (Gibco,
31966-021) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 0.25 mg/ml Amphotericin B.
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2.2. Gene Expression Profiling
Cells were passaged into T75 flasks, fed fresh medium 24 hours after passaging, and RNA was
isolated 24 hours later for transcriptome profiling. RNA was harvested using miRNeasy Mini Kit
(QIAGEN, 217004) according to the manufacturer’s instructions. RNA quality control was performed
on an Agilent 2100 Bioanalyzer with RNA integrity number (RIN) values between 9.6 and 10.0.
Poly-A purified libraries were prepared using the TruSeq mRNA sample preparation kit (Illumina,
20020595). RNA sequencing was performed on an Illumina HiSeq 4000 instrument at the Functional
Genomics Center Zurich. The raw reads were cleaned by removing adapter sequences, trimming low
quality ends, and filtering reads with low quality (phred quality <20). Sequence alignment of the
resulting high-quality reads to the human genome (build GRCh38.p10) and quantification of transcript
expression was carried out using RNA-Seq by Expectation Maximization (RSEM, version 1.3.0) with
Ensembl gene models of release 89. A count-based negative binomial model implemented in the
software package edgeR (R-version 3.5.1, edgeR 3.24.2) was applied to detect differentially expressed
genes (DEGs). DEGs were defined as genes with p-value <0.05 and log2(fold change) >0.5 or <−0.5.
To identify enriched biological processes and cellular components, over-representation enrichment
analysis (ORA) using a list of DEGs generated with a more stringent cutoff of p-value <0.01 and
gene set enrichment analysis (GSEA) using ranked gene lists were performed with the online toolkit
WebGestalt (2017 version) [13,14]. The RNA sequencing data, including raw sequence files for each
subject, is available on the European Nucleotide Archive (ENA) and the Gene Expression Omnibus
(GEO) database under the accession number PRJEB31335.
2.3. Quantitative RT-PCR for Validation
Candidate genes were selected from the lists of DEGs for validation by quantitative RT-PCR
in four independent replicates. RNA was harvested using RNeasy Mini Kit (QIAGEN, 74104)
according to manufacturer’s instructions, and reverse transcribed to cDNA using the High-Capacity
RNA-to-cDNA Kit (Applied Biosysyems, 4387406). cDNA was diluted in RNase-free water to 3 ng/μl
for quantitative RT-PCR using Taqman assays (Table 2) on a 7900HT Fast Real-Time PCR System
machine (Applied Biosystems). Fold change in gene expression was calculated by the 2–ΔΔCt method
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control.
Table 2. Taqman gene expression assays used for quantitative RT-PCR.
Gene Symbol Gene Name Assay ID
GAPDH glyceraldehyde-3-phosphate dehydrogenase Hs02758991_g1
ELN elastin Hs00355783_m1
POSTN periostin Hs01566750_m1
WNT4 Wnt family member 4 Hs01573505_m1
COL15A1 collagen type XV alpha 1 Hs00266332_m1
EFEMP1 EGF-containing Fibulin-like extracellular matrix protein 1 Hs00244575_m1
ALDH1A3 aldehyde dehydrogenase 1 family member A3 Hs00167476_m1
OLFM2 olfactomedin 2 Hs01017934_m1
TM4SF1 transmembrane 4 L six family member 1 Hs01547334_m1
SCAMP5 secretory carrier membrane protein 5 Hs01547727_m1
FGF11 fibroblast growth factor 11 Hs00182803_m1
PLXNA2 plexin A2 Hs00300697_m1
PLEKHA2 Pleckstrin homology domain-containing family A member 2 Hs00952489_m1
3. Results
3.1. Transcriptome Profiling and Differential Expression Analysis
Transcriptome profiling by RNA sequencing identified 298 DEGs in PLOD1-kEDS patient-derived
fibroblasts compared to controls, of which 139 genes were up-regulated and 159 genes were
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down-regulated in the patients’ cells, as represented in a volcano plot (Figure 1A, Tables S2 and
S3). 488 DEGs were identified in FKBP14-kEDS patient-derived fibroblasts compared to controls,
of which 309 genes were up-regulated and 179 genes were down-regulated (Figure 1B, Tables S4
and S5). The low numbers of DEGs observed in our datasets may be contributed by heterogeneity
in multiple factors such as ethnicity, age of biopsy, and sex of patients. Nevertheless, several genes
encoding proteins related to ECM composition, protein trafficking, vasculature development, and
inner ear development were identified in the lists of DEGs, which can potentially contribute to the
pathogenesis as discussed later in this paper.
Figure 1. Transcriptome profiles of PLOD1-kEDS and FKBP14-kEDS patient-derived fibroblasts. Volcano
plots of DEGs in (A) PLOD1-kEDS versus controls and (B) FKBP14-kEDS versus controls. (C–E) Venn
diagrams showing number of overlapping and non-overlapping DEGs at p< 0.05 (C: all, D: up-regulated,
E: down-regulated). (F–H) Venn diagrams showing number of overlapping and non-overlapping DEGs
at p < 0.01 (F: all, G: up-regulated, H: down-regulated).
To further explore the similarities and differences between PLOD1-kEDS and FKBP14-kEDS
patient-derived fibroblasts, we compared DEGs with p< 0.05 and log2 (fold change)>0.5 or<−0.5 in both
patient groups, and found 58 overlapping genes (Figure 1C). Of these 58 genes, 37 were up-regulated
(Figure 1D) and 18 were down-regulated (Figure 1E) in both PLOD1-kEDS and FKBP14-kEDS compared
to controls. Furthermore, from the more stringent list of DEGs with p < 0.01, 11 genes overlapped
between PLOD1-kEDS and FKBP14-kEDS fibroblasts (Figure 1F). Of these 11 DEGs, 9 genes were
up-regulated (Figure 1G) in both groups, 1 gene was down-regulated (Figure 1H) in both groups,
and 1 gene was up-regulated in PLOD1-kEDS but down-regulated in FKBP14-kEDS fibroblasts (further
discussed in Figure 2A).
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Figure 2. (A) Venn diagram depicting unique DEGs contributing to the enrichment of ECM in
PLOD1-kEDS and FKBP14-kEDS patient-derived fibroblasts versus controls. (B) Heatmap depicting
expression levels of DEGs encoding ECM components per subject. Top panel consists of genes that
are differentially regulated in PLOD1-kEDS versus controls. Bottom panel consists of genes that are
differentially regulated in FKBP14-kEDS versus controls. (C) Heatmap depicting expression levels
of ECM genes that are significantly different between PLOD1-kEDS and FKBP14-kEDS. The colors
indicate the log2 difference relative to the average expression of all samples within the comparison.
3.2. Gene Ontology and Pathway Analyses
Due to limitations in obtaining patient skin fibroblasts in a rare disease with newly described
gene mutations, the sample size in our study was inevitably inadequate to generate a list of DEGs
adjusted for false discovery rate (FDR). Instead, using the WebGestalt toolkit, we analyzed the RNA
sequencing datasets with two approaches: (i) by setting a more stringent p-value cutoff whereby DEGs
with p < 0.01 in PLOD1-kEDS and FKBP14-kEDS patient-derived fibroblasts were used to identify
over-represented biological processes and cellular components by ORA and (ii) by performing GSEA
in which a list of all detected genes ranked by their average fold change is used to calculate enrichment
scores of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Gene ontology terms with an
FDR <10% were considered significantly enriched in both approaches.
In the ORA using DEGs with p < 0.01, the significantly enriched biological processes and cellular
components are summarized in Table 3; DEGs that contribute to these enriched Gene Ontology (GO)
terms are listed in Tables S6 and S7. Notably, genes encoding ECM proteins were enriched in the
DEGs in both PLOD1-kEDS and FKBP14-kEDS patient-derived fibroblasts; each patient group was
compared to control fibroblasts. However, comparison of DEGs that contributed to over-representation
of ECM components demonstrated only one overlapping gene, EFEMP1, which was up-regulated in
PLOD1-kEDS and down-regulated in FKBP14-kEDS fibroblasts (Figure 2A). The expression levels of
each DEG encoding ECM components in individual control and patient-derived fibroblasts are depicted
in a heatmap (Figure 2B). To further investigate the differential expression in ECM-related genes
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between PLOD1-kEDS and FKBP14-kEDS, we performed ORA of the DEGs between PLOD1-kEDS
and FKBP14-kEDS fibroblasts with p-value <0.01 and log2 (fold change) >0.5 or <−0.5 (Table S8) using
WebGestalt and observed an enrichment of ECM genes (GO:0005578) with an enrichment ratio of 7.64
and FDR of 6.41 × 10−5. The expression of these ECM genes that are significantly different between
PLOD1-kEDS and FKBP14-kEDS are summarized in a heatmap (Figure 2C). Hence, the RNA sequencing
datasets revealed distinct ECM signatures between PLOD1-kEDS and FKBP14-kEDS fibroblasts at the
transcriptome level.
Table 3. Over-represented gene ontology terms among DEGs in FKBP14-kEDS and PLOD1-kEDS
patient-derived fibroblasts versus controls.
Gene Ontology Description Enrichment Ratio p-value FDR
FKBP14-kEDS: Biological Process
GO:0003012 muscle system process 5.52 3.19 × 10−5 2.42 × 10−2
GO:0007586 digestion 14.1 1.74 × 10−4 6.60 × 10−2
FKBP14-kEDS: Cellular Component
GO:0005578 proteinaceous extracellular matrix 5.07 3.90 × 10−4 5.77 × 10−2
GO:0043235 receptor complex 5.28 8.53 × 10−4 6.32 × 10−2
PLOD1-kEDS: Biological Process
GO:0007219 Notch signaling pathway 8.86 1.26 × 10−5 9.58 × 10−3
GO:0007423 sensory organ development 4.77 3.84 × 10−5 1.46 × 10−2
GO:0030048 actin filament-based movement 10.7 9.73 × 10−5 2.02 × 10−2
GO:0045730 respiratory burst 31.2 1.07 × 10−4 2.02 × 10−5
GO:0060326 cell chemotaxis 7.34 1.56 × 10−4 2.38 × 10−2
GO:0070098 chemokine-mediated signaling pathway 23.0 2.77 × 10−4 3.50 × 10−2
GO:0050920 regulation of chemotaxis 6.74 8.43 × 10−4 9.16 × 10−2
GO:0042490 mechanoreceptor differentiation 14.6 1.10 × 10−3 9.61 × 10−2
GO:0001655 urogenital system development 4.30 1.14 × 10−3 9.61 × 10−2
PLOD1-kEDS: Cellular Component
GO:0005578 proteinaceous extracellular matrix 5.73 1.77 × 10−4 2.61 × 10−2
GO:1990351 transporter complex 6.36 1.03 × 10−3 5.96 × 10−2
GO:0044420 extracellular matrix component 7.88 1.56 × 10−3 5.96 × 10−2
GO:0031594 neuromuscular junction 12.7 1.61 × 10−3 5.96 × 10−2
GO:0043235 receptor complex 4.98 3.03 × 10−3 8.97 × 10−2
GSEA of the ranked gene lists from PLOD1-kEDS fibroblasts did not identify significantly
enriched KEGG pathways. In contrast, KEGG pathways involved in carbohydrate metabolism, namely
fructose and mannose metabolism (Figure 3A) as well as glycolysis and gluconeogenesis (Figure 3B),
were positively enriched in FKBP14-kEDS fibroblasts. Furthermore, genes involved in cell cycle
(Figure 3C) and DNA replication (Figure 3D) were over-represented by down-regulated genes in
FKBP14-kEDS fibroblasts, suggesting alterations in cell proliferation.
The findings from the ORA and GSEA analyses collectively suggests different molecular signatures
between PLOD1-kEDS and FKBP14-kEDS.
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Figure 3. Gene set enrichment analysis (GSEA) plots depicting positive enrichment of (A) fructose and
mannose metabolism and (B) glycolysis / gluconeogenesis and negative enrichment of (C) cell cycle
and (D) DNA replication in FKBP14-kEDS versus control fibroblasts.
3.3. Comparison of Transcriptome Profiles between kEDS and Collagen VI-Related Muscular Dystrophies
Due to the overlaps in clinical presentation between collagen VI-related muscular dystrophies
(COL6-RD) and kEDS patients, we compared the transcriptome profiles of patient-derived fibroblasts
from PLOD1-kEDS and FKBP14-kEDS (DEGs with p < 0.01) with that of COL6-RD patients available
through GEO Series accession number GSE103270 [10]. Only one gene, OLFM2, was significantly
up-regulated in all three patient groups; EFEMP1 was significantly up-regulated in PLOD1-kEDS and
COL6-RD but down-regulated in FKBP14-kEDS (Figure 4A). While the ECM component, which is
biologically relevant to disorders of the connective and muscle tissues, was over-represented in the
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DEGs from all three groups (Table 3 and [10]), comparison of DEGs encoding ECM components also
revealed only a few overlapping genes among the three patient groups (Figure 4B). Furthermore,
the over-representation of muscle system process in FKBP14-kEDS fibroblasts (GO:0003012, Table 3)
prompted us to compare the genes contributing to this GO term in FKBP14-kEDS to the DEGs in
COL6-RD fibroblasts. Of the nine genes contributing to the enrichment of muscle system process, only
two were significantly differentially regulated in COL6-RD fibroblasts carrying dominant negative
(DN) collagen VI mutations; six of these nine genes (three at p < 0.01, three at p < 0.05) were also
differentially regulated in PLOD1-kEDS (Figure 4C). These suggest that each disease group have a
unique transcriptome profile.
Figure 4. Comparison of transcriptome profiles of PLOD1-kEDS, FKBP14-kEDS and collagen VI-related
muscular dystrophies (COL6-RD) patient-derived fibroblasts. (A) Venn diagram depicting number
of overlapping and non-overlapping DEGs among three patient groups. (B) Venn diagram depicting
number of overlapping and non-overlapping DEGs encoding ECM components among three patient
groups. (C) List of genes contributing to over-representation of muscle system process in FKBP14-kEDS
versus control fibroblasts and significance of their differential expression in PLOD1-kEDS and COL6-RD
fibroblasts. DN = dominant negative COL6-RD mutations allowing incorporation of abnormal collagen
VI chains; Null = recessive COL6-RD mutations that do not allow incorporation of abnormal chains as
described in Butterfield et al., 2017; gene expressions that are non-significantly altered are represented
by dashes (-).
3.4. DEGs with Biological Functions that May Contribute to the Pathogenesis of kEDS
From our transcriptomics analysis, we also identified several DEGs with biological functions
that may contribute to the pathogenesis of kEDS. We validated the differential expression of these
candidate genes by quantitative RT-PCR (Figure 5). How the encoded products of these genes could
contribute to the disease pathology is further discussed under Section 4.1 to Section 4.6.
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Figure 5. Quantitative RT-PCR was performed to validate the RNA sequencing results. Gene expression
levels were measured in four independent replicates per subject, and t-tests were performed (ns = not
significant, * = p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001). Data are expressed as mean ± SEM.
4. Discussion
kEDS represents a paradigm heterogeneous connective tissue disorder in that genetic defects in
two different proteins, LH1 and FKBP22, involved in the biosynthesis of collagens lead to a similar
clinical phenotype. As an explanation thereof, we hypothesize that PLOD1 and FKBP14 mutations
might lead to similar alterations of the ECM of connective tissue, either by affecting the same molecular
pathways, or by converging the different altered pathways to the same target molecules. To answer
this question, we have applied an untargeted omics approach to the identification of common and
distinct molecular pathways altered in FKBP14-kEDS and PLOD1-kEDS.
Our studies were performed in patient-derived primary skin fibroblasts, which are clinically
relevant to connective tissue disorders since they are the major cell type producing ECM proteins,
and are relatively easy to obtain via skin biopsies. We do, however, acknowledge that clinical
characteristics of kEDS patients extend beyond abnormalities in the skin and that the functions of some
DEGs may appear more relevant in other ECM-producing cells, including chondrocytes, osteoblasts,
and muscle fibroblasts. Nevertheless, the transcriptomics datasets will help to identify candidate DEGs
for functional characterization when the other cell types or animal models eventually become available.
Here, we present the outcome of our investigations by transcriptomics of cultured dermal
fibroblasts from individuals with FKBP14-kEDS and PLOD1-kEDS which led to the identification
of over-represented biological processes and cellular components. By GSEA, we observed positive
enrichment of fructose and mannose metabolism, as well as glycolysis and gluconeogenesis in
FKBP14-kEDS fibroblasts. Additionally, cell cycle and DNA replication were negatively enriched in
FKBP14-kEDS fibroblasts, suggesting that cells deficient in FKBP22 may undergo a metabolic switch
and alteration in cell proliferation. In vitro studies using mammary epithelial cells have shown that
changes in the density of the ECM lead to alterations in glucose metabolism [15]. In another study,
up-regulation of glycolysis was observed in healthy skin from the footpad of mice with a dense ECM
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compared to the abdominal skin with a thinner ECM; glycolysis was also up-regulated in fibrotic skin
compared to healthy skin [16]. Reciprocally, perturbations in metabolism can cause alterations in
the ECM. In particular, gene and protein expression of ECM components are down-regulated upon
suppression of glycolysis [16]. As such, it will be interesting to investigate whether the abnormal
deposition of ECM proteins by FKBP22-deficient cells as previously shown [4] cause metabolic changes
which can eventually alter cellular bioenergetics and proliferation, or whether alterations in metabolism
affects the formation of the ECM by the fibroblasts.
From the transcriptome profiling analysis, we also observed differential expression of several
genes encoding products with biological functions that may contribute to the pathogenesis of kEDS
(Figure 5). In the following sections, we discuss how the encoded products of these DEGs could
contribute to the disease pathology.
4.1. ECM Components
Gene ontology analysis showed significant enrichment of the ECM by DEGs in both PLOD1-kEDS
and FKBP14-kEDS. We validated the up-regulation of ELN (encoding elastin), POSTN (encoding
periostin) and WNT4 (encoding Wnt family member 4) specifically in PLOD1-kEDS (Figure 5A).
Elastin, like collagens, is a structural component of the ECM that is rich in glycine and proline.
However, elastin adopts random coil conformations rather than a triple helix structure that give rise to
its stretchable properties.
Periostin is preferentially expressed in connective tissues under constant mechanical stress.
It accelerates collagen cross-linking through promoting the proteolytic activation of lysyl oxidase
(LOX) by bone morphogenetic protein-1 (BMP-1) and serves as a scaffold for collagen and BMP-1 [17].
Periostin also facilitates the formation of ECM meshwork by interacting with other ECM components,
including fibronectin and tenascin-C [18]. The protective role of periostin is demonstrated by its
induction upon skin injury to promote wound healing [19–21]. Overexpression of periostin has also
been described in hypertrophic scar and keloid formation [22] and linked to the pathogenesis of
skin fibrosis in systemic sclerosis [23,24]. In contrast, despite elevated POSTN expression in the skin
fibroblasts (Table 1 and Figure 5A), PLOD1-kEDS patients present with poor wound healing and
atrophic scarring. A plausible explanation for this observation is the under-hydroxylation of lysine
residues in the collagen helical domain due to LH1 deficiency, which impairs collagen cross-linking
and fibril assembly, and cannot be compensated for by the activation of LOX by periostin.
The physiological role of WNT4 has been described in the formation of synovial joints [25]
and neuromuscular junctions [26]. Up-regulation of Wnt4 expression during wound healing was
demonstrated in a mouse model [27], which could facilitate wound closure by promoting cell
migration [28].
Notably, the transcript levels of ELN, POSTN and WNT4 can be up-regulated in response to
transforming growth factor-beta1 (TGF-β1) stimulation [29–31]. Hence, it remains to be elucidated
whether the elevated expression of ELN, POSTN and WNT4 is a consequence of enhanced TGF-β
signaling in PLOD1-kEDS patient fibroblasts, and if so, via which mechanism(s) TGF-β signaling
is enhanced.
The down-regulation of COL15A1 (encoding collagen type XV alpha 1 chain) in FKBP14-kEDS
was confirmed by quantitative RT-PCR (Figure 5B). Type XV collagen is present widely in the basement
membrane zones of cardiac and skeletal myocytes [32]. Studies performed in Col15a1-knockout mice
demonstrated that deficiency in type XV collagen led to progressive skeletal muscle degeneration
and variation in muscle fiber size starting from 13 weeks of age, and increased susceptibility to
exercise-induced muscle injury [33]. However, the absence of these abnormal muscular phenotypes in
newborn mice suggest that suppressed COL15A1 expression unlikely explains for the presentation of
congenital muscle hypotonia in FKBP14-kEDS patients. Nevertheless, rescuing COL15A1 expression
could be a potential therapeutic target to prevent worsening of the muscular phenotype with age in
FKBP14-kEDS patients.
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Interestingly, EFEMP1 is down-regulated in FKBP14-kEDS patient-derived fibroblasts (Figure 5C).
EFEMP1 encodes the EGF-containing fibulin-like extracellular matrix protein, also known as fibulin-3.
It is noteworthy that 47% of the FKBP14-kEDS patients described [3,4] developed inguinal or umbilical
hernias, a phenotype that is also observed in Efemp1-knockout mice. Moreover, Efemp1-knockout
mice have less elastic fibers in the dermis, which also appear more fragmented than elastic fibers
in wildtype mice [34]. Therefore, we examined electron micrographs of skin biopsies taken from
a control, a PLOD1-kEDS patient and two FKBP14-kEDS patients and observed fragmentation of
elastic fibers in FKBP14-kEDS patients but not in the PLOD1-kEDS patient (Figure 6). Furthermore,
a reduced incorporation of elastin into the network of elastic fibers in FKBP14-kEDS patients was
observed. These observations, in concordance with the observations by McLaughlin and co-workers in
Efemp1-knockout mice, suggest that fibulin-3 contributes to the maintenance of ECM integrity and
particularly in the formation of elastic fibers. We are currently investigating whether there is indeed a
reduction in fibulin-3 protein secretion by FKBP14-kEDS fibroblasts in vitro, and whether addition of
recombinant fibulin-3 protein can overcome the deficiency and facilitate the formation of elastic fibers
in an in vitro model.
Figure 6. Electron micrographs of skin biopsies from (A) a healthy control, (B) a PLOD1-kEDS patient
and (C,D) two unrelated FKBP14-kEDS patients. Elastic fibers are indicated by red arrows. Electron
micrographs were taken at the Center for Microscopy and Image Analysis, University of Zurich with a
Philips CM 100, a 100 KV transmission electron microscope equipped with a digital charge-coupled
device (CCD) camera for image acquisition.
Contrary to EFEMP1 down-regulation in FKBP14-kEDS, EFEMP1 was up-regulated in
PLOD1-kEDS. The overexpression of EFEMP1 in a chondrogenic cell line in vitro led to suppressed
chondrocyte differentiation and dampened expression of aggrecan and types II and X collagen [35].
Thus, whether elevated expression of EFEMP1 contributes to the pathogenesis of PLOD1-kEDS via
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altering cartilage development remains to be explored, despite the absence of reports on cartilage
growth-plate pathologies in both human patients and Plod1-knockout mice.
4.2. Inner Ear Development
Sensorineural hearing loss has been reported in 73% of FKBP14-kEDS patients [3,4], but not
in PLOD1-kEDS patients. The transcriptome profiles showed an elevated expression of ALDH1A3
encoding aldehyde dehydrogenase 1 family member A3 enzyme in FKBP14-kEDS patient-derived
fibroblasts only, which was confirmed by quantitative RT-PCR (Figure 5D). During normal inner ear
canal formation, Aldh1a3 is repressed by the chromatin remodeler Chd7. Deficiency in Chd7 causes
abnormally high levels of Aldh1a3 expression and inner ear malformation; inner ear development
is rescued by the loss of Aldh1a3 expression in mice deficient in Chd7 [36]. Hence, we postulate a
molecular link between enhanced ALDH1A3 expression and hearing loss in FKBP14-kEDS patients
that warrants further investigation.
4.3. Vasculature Integrity
We sought to identify DEGs in PLOD1-kEDS and FKBP14-kEDS that are involved in modulating
the vasculature, since rupture or aneurysm of medium-sized arteries have been described in both
PLOD1-kEDS [12,37] and FKBP14-kEDS [3,38,39] and serves as a minor criteria in the diagnosis of
kEDS [1]. We observed an up-regulation of OLFM2 expression (encoding olfactomedin 2) in both
PLOD1-kEDS and FKBP14-kEDS patient-derived fibroblasts (Figure 5E). OLFM2 is also significantly
up-regulated in COL6-RD patient-derived fibroblast [10], although vascular complications involving
medium-sized arteries have not been reported in COL6-RD to our knowledge; instead, fenestration
and narrow lumens in capillaries have been described in some cases of Ulrich congenital muscular
dystrophy [40]. Olfm2 is up-regulated in balloon-injured arteries and involved in smooth muscle cell
phenotypic modulation and vascular remodeling. Olfm2-deficient mice are more protected against
injury-induced suppression of smooth muscle cell markers and neointimal hyperplasia [41], suggesting
that enhanced expression of OLFM2 may correlate with poorer vascular phenotypes. Notably, OLFM2
expression was not significantly altered in fibroblasts of vascular EDS patients [42]. Hence, whether
elevated OLFM2 expression contributes to the causation and/or severity of vascular complications
in kEDS remains an interesting topic to be explored. The up-regulation of OLFM2 in PLOD1-kEDS,
FKBP14-kEDS, and COL6-RD also warrants further investigation into whether olfactomedin 2 plays a
physiological role in skeletal muscles, which has not yet been described.
In addition, we noted that TM4SF1 expression was down-regulated in FKBP14-kEDS and
up-regulated in PLOD1-kEDS (Figure 5E). TM4SF1 encodes the transmembrane-4-L-six-family-1
protein, also known as L6 cell surface antigen, and is highly expressed in the vascular endothelium. In a
previous study, knockdown of TM4SF1 in human umbilical vein endothelial cells (HUVEC cell line)
resulted in a senescence phenotype and poor migration in a wound healing assay in vitro. Moreover,
the authors showed that the angiogenesis inducer Vascular Endothelial Growth Factor A (VEGF-A)
enhanced Tm4sf1 expression in vivo in mice, while knockdown of Tm4sf1 blunted the angiogenic effect
of VEGF-A, thus demonstrating the importance of TM4SF1 in vessel maturation [43]. As such, it would
be interesting to determine if the dysregulation of TM4SF1 expression contributes to vascular fragility
in kEDS.
4.4. Unfolded Protein Response (UPR)
Another striking observation described in the first cohort of FKBP14-kEDS patients is the
enlargement of ER in skin biopsies [4]. This dilatation of ER is thought to arise from the accumulation
of misfolded proteins, in particular of collagens since the rate limiting step in collagen protein folding
involves cis–trans isomerization of the prolyl peptide bonds which is catalyzed by FKBP22. ER dilatation
coupled with the induction of UPR involving binding immunoglobulin protein (BiP) activation has
been demonstrated in several models of connective tissue disorders, including (i) the Osteogenesis
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Imperfecta (OI) Aga2 mouse model harboring Col1a1 mutations which ablates the conserved C-terminal
cysteine C244 residue and introduces additional amino acids into the C-terminal propeptide [44], (ii) in
skin fibroblasts isolated from OI patients carrying COL1A1 mutations in the C-terminal propeptide
domain [45], and (iii) in engineered cells with COL10A1 mutations modelling Schmid metaphyseal
chondrodysplasia [46]. However, the transcriptome profiles and gene ontology analyses revealed that
genes associated with classical ER associated degradation and UPR, including CANX, CALR, HSPA5,
ATF4, and DDIT3, were not differentially expressed in FKBP14-kEDS patient-derived fibroblasts;
the same trend was observed in PLOD1-kEDS patient-derived fibroblasts (Table S9). The absence of
classical UPR activation was also previously observed in other connective tissue disorders, such as
in OI patients with mutations in COL1A1 disrupting triple helix formation [45] and in vascular EDS
patients carrying COL3A1 mutations [42].
Nevertheless, one of the most up-regulated genes in FKBP14-kEDS patient-derived fibroblasts
was SCAMP5 encoding the secretory carrier-associated membrane protein 5, which was also induced
in PLOD1-kEDS patient-derived fibroblasts albeit at a smaller magnitude (Figure 5F). SCAMP5
expression can be rapidly induced by autophagic stimulation under the control of the master autophagy
transcriptional regulator transcription factor EB (TFEB), and its elevated expression was previously
described in the striatum of Huntington disease patients [47,48]. Interestingly, SCAMP5 enhances the
aggregation of mutant huntingtin by impairing endocytosis [47], yet promotes Golgi fragmentation
and unconventional secretion of α-synuclein via exosomes [48]. This warrants for future exploration
into the role of SCAMP5 in kEDS patient-derived fibroblasts in relation to ER stress, autophagy and
whether it promotes the retention or non-classical secretion of misfolded collagen proteins.
4.5. Bone Remodeling
Osteopenia or osteoporosis is a minor criteria in the diagnosis of kEDS [1], and occurrence
of fractures were described in 13% of FKBP14-kEDS [3,4]. We observed elevated expression of
FGF11, which encodes the intracellular fibroblast growth factor 11, in both PLOD1-kEDS and
FKBP14-kEDS (Figure 5G). Bone resorption by osteoclasts is mediated by hypoxic conditions which
lead to overexpression of FGF11 and knockdown of FGF11 lead to inhibition of bone resorption by
osteoclasts in response to hypoxic stimulation [49]. Furthermore, FGF11 protein is strongly expressed
in osteoclasts in osteolytic diseases such as rheumatoid synovium and giant cell tumor of bone [49],
suggesting that it plays a role in pathological bone resorption. Thus, it will be interesting to determine
if FGF11 levels are also elevated in the osteoclasts of kEDS patients, and whether FGF11 is a driver of
the bone phenotype in kEDS.
4.6. Others
The expression of PLXNA2 is down-regulated in PLOD1-kEDS and FKBP14-kEDS patient
fibroblasts (Figure 5H). PLXNA2 encodes the transmembrane protein plexin-A2, a member of
the plexin-A family of semaphorin co-receptors, and is demonstrated to be involved in axon
guidance [50]. However, nerve conduction appeared normal in FKBP14-kEDS patients [3,4] and
PLOD1-kEDS patients [12,51]. Nevertheless, the suppression of PLXNA2 expression was of a higher
magnitude in FKBP14-kEDS patients, in which sensorineural hearing loss has been reported. Hence,
whether diminished PLXNA2 expression has a causal effect on sensorineural hearing impairment in
FKBP14-kEDS patients requires further investigation.
In another study, knockdown of Plxna2 blocked osteoblast differentiation and mineralization
in vitro, highlighting the pro-osteogenic role of Plxna2. Thus, it may be interesting to investigate whether
PLXNA2 expression is also suppressed in mesenchymal cells of PLOD1-kEDS and FKBP14-kEDS
patients, which may hinder osteoblast differentiation and bone remodeling.
The expression of PLEKHA2 is diminished in both PLOD1-kEDS and FKBP14-kEDS patient
fibroblasts compared to controls (Figure 5I). PLEKHA2 expression in dermal fibroblasts of patients
with COL6 dominant negative mutations, where mutant type VI collagen chains are incorporated
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into the collagen fibers, is also significantly lower [10]. PLEKHA2 encodes pleckstrin homology (PH)
domain-containing family A member 2, which is also known as Tandem PH domain-containing
protein 2 (TAPP2). TAPP2 is recruited to the plasma membrane via its interaction with
phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) [52,53]. The physiological role of TAPP2 has been
well characterized in B-cells, where mice carrying knock-in inactivating mutations of TAPP2 that
disrupt its interaction with PI(3,4)P2 develop chronic germinal centers, hyperactive B-cells with higher
survival and produce more autoantibodies that worsened with age [54]. Autoimmune phenotypes
have, however, not yet been characterized in kEDS patients. Additionally, TAPP2 has also been shown
to facilitate the migration of esophageal squamous cell carcinoma cells [55] and malignant B-cells [56]
via cytoskeleton reorganization. Hence, further studies on the role of TAPP2 in fibroblast survival,
activity, and migration may shed light on its relation to the pathogenesis of kEDS.
5. Conclusions
We have performed the first transcriptomics studies on kEDS which revealed distinct transcriptome
signatures between PLOD1-kEDS and FKBP14-kEDS despite clinical similarities. ECM components are
enriched by DEGs in both PLOD1-kEDS and FKBP14-kEDS, although the genes are unique to each
genetic form of kEDS. We aim to validate the candidate DEGs on more patient samples when they
become available to strengthen the findings reported here. Proteomics analysis of the ECM component
and functional characterization of candidate genes described are currently ongoing and these promise
to deepen our understanding of the pathomechanism(s) underlying kEDS.
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Abstract: Variations in genes encoding for the enzymes responsible for synthesizing the linker
region of proteoglycans may result in recessive conditions known as “linkeropathies”. The two
phenotypes related to mutations in genes B4GALT7 and B3GALT6 (encoding for galactosyltransferase
I and II respectively) are similar, characterized by short stature, hypotonia, joint hypermobility,
skeletal features and a suggestive face with prominent forehead, thin soft tissue and prominent
eyes. The most outstanding feature of these disorders is the combination of severe connective
tissue involvement, often manifesting in newborns and infants, and skeletal dysplasia that becomes
apparent during childhood. Here, we intend to more accurately define some of the clinical features of
B4GALT7 and B3GALT6-related conditions and underline the extreme hypermobility of distal joints
and the soft, doughy skin on the hands and feet as features that may be useful as the first clues for
a correct diagnosis.
Keywords: beta-1,3-galactosyltransferase 6 (B3GALT6); beta-1,4-galactosyltransferase 7 (B4GALT7);
spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL1; SEMDJL-Beighton type); Ehlers–Danlos
syndrome (EDS); spondylodysplastic Ehlers–Danlos syndrome (spEDS); spEDS-B3GALT6;
spEDS-B4GALT7; extreme laxity of distal joints; soft; doughy skin on the hands and feet
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1. Introduction
The extracellular matrix (ECM) of connective tissues like cartilage, bone, tendon, ligaments and
skin is a complex interacting arrangement of proteins, glycoproteins and proteoglycans (PGs) that
forms the scaffold of the human body and also constitutes the vital environment supporting cell
growth and differentiation. PGs are macromolecules that are complex in their structures and represent
an important component of both the ECM and of cell membranes. PGs have mechanical and osmotic
functions but are strongly involved in signaling pathways controlling cell-to-cell interactions as well
as cell growth and differentiation and tissue repair [1–3]. PGs are composed of a core protein and
one or more glycosaminoglycan (GAG) chains that are long polysaccharides consisting of repeating
disaccharide units. On the basis of the composition of these units, the PGs are subdivided into heparan
sulfate (HS) PGs and chondroitin sulfate (CS)/dermatan sulfate (DS) PGs [4]. The biosynthesis of the
GAG side chain begins with the creation of a common tetrasaccharide, a so called “linker”, covalently
linked to the hydroxyl group of serine residues on the core protein (O-glycosylation).
The linker region is synthesized through a coordinated mechanism involving specific
glycosyltransferases. It starts with the transfer of a xylose residue by xylosyltransferase I or II (encoded
by XYLT1, OMIM *608124, and XYLT2, OMIM *608125), followed by the addition of two galactose
residues by galactosyltransferase I, encoded by B4GALT7 (OMIM 604327) and galactosyltransferase II
encoded by B3GALT6 (OMIM *615291) (Figure 1). Subsequently there will be a transfer of glucuronic
acid by glucuronosyltransferase I encoded by B3GAT3 (OMIM *606374). The so-called “linkeropathies”
are recessive conditions caused by variations in genes encoding the enzymes responsible for the
synthesis of the linker region of PGs.
Figure 1. A. Galactosyltransferases I (B4GALT7) and II (B3GALT6) catalyze the addition of galactose
units at specific positions of the tetrasaccharide region linking Serine residues on the protein backbone to
glycosaminoglycan (GAG) chains. Xyl=Xylose, Gal=Galactose, GlcA=Glucuronic Acid. B. Functional
defects of B4GALT6 or B4GALT7 inhibit addition of one or both Gal monosaccharides, respectively,
and prevent GAG chain polymerization.
Variants of the XYLT1 gene are responsible for skeletal dysplasias, including Baratela–Scott
syndrome (OMIM 615777, formerly erroneously called Desbuquois dysplasia type 2) [5–10], variants
of XYLT2 are the cause of the spondylo-ocular syndrome (OMIM 605822) [11–13], while variants of
B3GAT3 cause a Larsen-like syndrome and a more severe skeletal dysplasia (OMIM 245600) [14–20].
In particular, variants in the B4GALT7 and B3GALT6 genes are the cause of a combined skeletal
and connective tissue phenotype.
A B4GALT7-related condition was initially described as “progeroid type 1” Ehlers–Danlos
syndrome (EDS), due to the phenotype characterized by premature aging and loose elastic skin in
one reported patient [21–30]. Subsequently, Cartault et al. in 2015 described a unique homozygous
B4GALT7 mutation, p.Arg270Cys, in a large cohort of patients affected by the so-called Larsen
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of Reunion Island syndrome [31]. This contributed to define the currently known phenotype of
B4GALT7-related EDS, with round flat face, proptosis, short stature, hypotonia, radioulnar synostosis,
osteopenia, hyperextensible skin and joint hypermobility (OMIM #130070) [24,25,31–33].
B3GALT6 variants cause a single disorder that was alternatively described as spondyloepimetaphyseal
dysplasia (SEMD) with joint hypermobility (SEMDJL1 or SEMDJL Beighton type; OMIM #271640)
in the “Nosology and classification of genetic skeletal disorders: 2015 revision” [34–43] or as severe
EDS-like disorder (OMIM #615349) because of the striking joint laxity and muscular hypotonia in
infancy [44,45]. Affected patients generally present clinical features of connective tissue weakness in
infancy, and subsequently develop signs of skeletal dysplasia; sometimes these signs are already present
at birth. Some patients develop life-threatening complications, such as aortic dilatation, aneurysms
and cervical spine instability.
Due to the mixed phenotype, with signs of EDS and signs of skeletal dysplasia, the B4GALT7
and B3GALT6-related syndromes have been called ”spondylodysplastic EDS” (spEDS) in the recently
revised EDS classification of 2017 [46–48].
Hereby we present the clinical features of 3 patients with spEDS. Two are novel patients: Pt. 1
with B4GALT7-related EDS, and Pt. 3 with a severe B3GALT6-related EDS. Pt. 2 was originally reported
as B3GALT6-related SEMDJL by Nakajima et al. in 2013, but is included here because his clinical
description was largely unpublished and his condition has undergone a significant evolution. Through
the description of these patients and a review of previous literature reports, we contribute to a more
accurate definition of the clinical features associated with B4GALT7- and B3GALT6-related syndromes.
In particular, we point out the extreme distal joint hypermobility and skin hyperextensibility (more
evident in hands and feet) these two conditions have in common, and the peculiar radiological signs of
each syndrome. The combination of these features is the main indicator for clinicians to suspect these
ultra-rare conditions.
2. Materials and Methods
2.1. Metabolic Labeling of Fibroblast Cultures and PG Synthesis Analysis
Skin fibroblasts from the patient and controls were cultured in minimum essential medium (MEM)
with 10% fetal calf serum and antibiotics at 37 ◦C in a humidified atmosphere containing 5% CO2.
Confluent cells in 10-cm2 petri dishes were preincubated for 4 h with or without 1 mM p-nitrophenyl
β-D-xylopyranoside in MEM containing 250 μM cold Na2SO4 without FCS in 5% CO2 at 37◦C. Cells
were then labeled with 150 μCi/ml Na2[35S]O4 in the same medium for 24 h, as described previously [49].
At the end of the labeling period, an equal volume of 100 mM sodium acetate buffer, pH 5.8, containing
8 M urea, 4% Triton X-100, 20 mM ethylenediaminetetraacetic acid, 20 mM N-ethylmaleimide, and 1mM
phenylmethanesulfonyl fluoride was added to the medium. The cell layer was harvested in 50 mM
sodium acetate buffer, pH 5.8, containing 2 M urea, 2% Triton X-100, and an aliquot was used for
protein content determination with the bicinchoninic acid Protein Assay (Pierce), while the remainder
was added to the medium. Samples were loaded on 1 ml DEAE SephacelTM columns; after column
washing with 50 mM sodium acetate buffer, pH 6.0, 8 M urea, 0.15 M NaCl, 0.5% Triton X-100 and
proteinase inhibitors, PGs were eluted with 1 M NaCl in the same buffer, recovered by precipitation
with 9 volumes of ethanol. The pellet was washed with 70% ethanol and then solubilized in water;
PGs were quantified by measuring the 35S-activity using a liquid scintillation counter and normalized
to the protein content.
Labeled PGs synthesized by cells in absence of p-nitrophenyl β-D-xylopiranoside and purified as
described above, were lyophilized, dissolved in 4 M guanidinium chloride, 50 mM sodium acetate
buffer, pH 6.0, 0.5% Triton X-100, and analyzed by Size Exclusion Chromatography. Samples were then
loaded on a Superose 6 10/300GL column (GE Healthcare) and eluted in the same buffer at 0.2 ml/min.
Fractions of 0.4 ml were collected and 35S-activity was measured by scintillation counting [50].
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2.2. Molecular Genetic Testing
Genomic DNA of each patient was isolated from peripheral blood mononuclear cells and analyzed
using a capture-based IonAmpliSeq custom panel on an Ion Torrent series S5 instrument (Thermo
Fisher Scientific). Results were filtered for the B4GALT7 and B3GALT6 genes. Identified variants
were confirmed by PCR amplification and subsequent bidirectional Sanger sequencing, using primers
encompassing the entire exon and intron–exon boundaries comprising the variants in the case of
B4GALT7, or the entire coding sequence and surrounding untranslated regions in the case of B3GALT6
single exon. In parallel, DNA samples from the respective parents were analyzed by Sanger sequencing
in order to evaluate parental segregation. Primer sequences are available upon request.
3. Patients and Results
3.1. First Patient
3.1.1. Clinical Report
The boy is the first child of healthy, non-consanguineous parents. The pregnancy was unremarkable
and the mother was not exposed to any known teratogens during pregnancy. Fetal movements were
described as normal. He was born by cesarean delivery at week 38 with birth weight of 2520 g
(3rd–10th centile), length 43 cm (<3rd centile), and head circumference of 32 cm (3rd–10th centile).
Apgar scores were 9/10. He presented with mesomelic shortening of upper limbs, ulnar deviation of
fingers and left hip dysplasia. Cerebral and renal ultrasound were normal, while echocardiography
showed atrial septal defect. The baby was discharged from hospital at the age of 6 days, with diagnosis
of “arthrogryposis with ulnar deviation of fingers, left hip dysplasia, and congenital heart disease”,
and later he was fitted with a finger extension device and was given pelvic bimalleolar hip plaster for
left hip dysplasia. He was seen at our Medical Genetics Unit at 3 months of age (Figure 2): length and
weight, calculated by taking into account the hip plaster, were respectively 51 cm (3rd–10th centile)
and 4900 g (3rd centile), and head circumference was 41 cm (25th centile). The physical examination
showed: round flat face, mild proptosis, slightly blue sclerae (Figure 2A–D), joint hypermobility
especially evident in the hands, mesomelic shortening of the arms, abnormal prono-supination of the
left upper limbs, often flexed, short hands and feet with soft skin, bilateral ulnar deviation of fingers,
2nd finger clinodactyly, 2nd–5th finger camptodactyly on the left, and 3rd and 4th finger camptodactyly
on the right (Figure 2F–G).
During the clinical follow-up, we noticed an improvement in the finger alterations, but a worsening
of the cutaneous hyperextensibility and joint hypermobility. At the age of 3 years and 7 months,
he presented with round face, blue sclerae, proptosis (Figure 2D), soft hyperextensible skin and extreme
joint hypermobility (Beighton score: 5) in particular of hands and feet, with significant improvement
in finger ulnar deviation, clinodactyly, camptodactyly and overlapping toes (Figure 2H–K). Height
and weight were 87 cm (<3rd centile) and 9920 g (<3rd centile), head circumference was 49 cm (10th
centile). Span was 82 cm and span/height ratio was 0.94. Early psychomotor development was delayed
at least in part owing to his orthopedic conditions. He gained head control at 3 months, was able to sit
at 3 years and walk aided at the age of 4 years. He uttered his first words at 2 years, but his language
skills improved rapidly and significantly thereafter: at 5 years, psychological evaluation reported
an IQ of 105.
The skeletal X-rays demonstrated wide anterior ribs, bilateral bowed ulna and radius with
dislocation/subluxation and radioulnar synostosis, bilateral metaphyseal widening of the radius,
bilateral short and dysmorphic 2nd finger middle phalanx, short first metacarpal (Figure 3A–F).
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Figure 2. Patient 1 A) Age 3 months: ulnar deviation of fingers; B) Age 3 months: round flat face,
mild proptosis, mesomelic shortening of upper limbs, folded skin on forearm; C) Age 3 months: flat
profile; D, F–G) Age 3 months: ulnar deviation of fingers, 2nd finger clinodactyly, 2nd–5th finger
camptodactyly on the left hand, 3rd and 4th finger camptodactyly on the right hand; E) Age 3 years 7
months: round face, blue sclerae, proptosis; H–K) Age 3 years 7 months: soft, hyperextensible skin and
extreme joint hypermobility (Beighton score: 5) in particular of hands and feet; significant improvement
in finger ulnar deviation, clinodactyly, camptodactyly of the second finger, and overlapping toes.
Figure 3. Patient 1 A–B, D–E) Bilateral bowing of ulna and radius with dislocation/subluxation and
radioulnar synostosis, metaphyseal widening of the radius; C) bilateral short and dysmorphic 2nd
finger middle phalanx, short first metacarpal; F) hip dysplasia.
Electrencephalography, electromyography and brain magnetic resonance imaging were all normal.
At the age of 5 years, molecular analysis of B4GALT7 was performed, showing the presence of two
novel pathogenic mutations, indicative of spEDS.
3.1.2. Molecular and Functional Analysis
Karyotype was normal, 46,XY. Our first diagnostic hypothesis was either myopathy or collagen
VI pathology, but molecular analysis of the COL6A1, COL6A2, COLA613, RAPSN genes did not
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reveal any rare or pathogenic variant. Subsequently, by analyzing a panel of EDS-related genes,
two variants were identified in compound heterozygosity in exons 2 and 3 of the B4GALT7 gene:
NM_007255:c.[277dupC];[628C>T], NP_009186:p.[(His93Profs*73)];[(His210Tyr)] (Figure 4).
Figure 4. A) Pedigree of Family 1; B) Schematic representation of the B4GALT7 protein: TM =
transmembrane domain, GalT = Galactosyl-transferase catalytic domain. Protein variants reported
in the literature are annotated in the cartoon (see Table 1 for references). Top half: missense variants
(black). Bottom half: truncating variants (red).
The single nucleotide insertion c.277dupC, inherited from the mother, creates a new reading
frame, terminating with a premature stop codon 73 residues downstream, and its transcript is
predicted to undergo nonsense-mediated decay (https://nmdprediction.shinyapps.io/nmdescpredictor/).
This variant was also described in another patient by Salter et al. in 2016 [32]. The heterozygous
C>T transition at nucleotide 628, inherited from the father, results in a non-conservative Histidine to
Tyrosine substitution at codon 210 and occurs in a highly conserved residue. This variant has not been
reported before, but it is considered deleterious by multiple prediction algorithms (MutationTaster,
PolyPhen2, SIFT) and is absent from reference population databases (gnomAD, 1000 Genomes). Based
on these criteria and on the clinical features of the patient, we assume that the combination of these
variants in trans is causative.
The study of PG synthesis on patient’s fibroblasts obtained by skin biopsy did not reveal any
significant differences compared to normal controls, neither at basal conditions nor in the presence
of beta-xyloside to enhance glycosaminoglycan synthesis. However, the level of PG synthesis in the
patient’s fibroblasts was at the lower normal limit. Analysis through gel filtration to assess the fraction
of whole PGs with respect to glycosaminoglycans did not show any differences. Although these
results were not significant per se, the slightly reduced PG levels combined with the genetic testing
offered some indication that the variants identified in B4GALT7 may in fact have a deleterious effect on
protein function.
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3.2. Second Patient
3.2.1. Clinical Report
This patient was partially described in Nakajima et al., 2013 as P9 [45]. He is the first child of
healthy non-consanguineous parents, born at the 40th week of gestation by vaginal delivery. During
pregnancy, no known exposures to potential teratogens were detected. The mother reported normal
fetal movements. Prenatal ultrasound showed bilateral megaureter. At birth, weight was 2870 g
(10th centile), length was 48 cm (3rd–10th centile) and head circumference measured 34 cm (25th
centile). He presented with: joint hypermobility, soft skin, bilateral congenital talipes equinovarus and
right hip dysplasia, which was treated with a Pavlik harness. Renal ultrasound showed a mild bilateral
caliceal dilatation, while renal scintigraphy was normal. During the first year of life he was diagnosed
with early-onset scoliosis, and he began to wear an orthopedic corset from the age of 4 years. Two years
later. he was operated for scoliosis after correction with Halo Gravity Traction and he subsequently
received three operations for the lengthening of the pins (until the age of 10 years). He suffered from
frequent fractures: a fracture of the left femur after a low trauma at the age of 5 years and 6 months and
to the right femur at the age of 8 years and 8 months and a micro-fracture of the right proximal fibula in
an area of reduced bone density, compatible with an osseous cyst, at the age of 10 years. Furthermore,
he had recurrent luxation of the toes.
Early psychomotor development was normal, but he later suffered from motor delay due to
his skeletal and large joint anomalies. He gained head control at the age of 2 months and could sit
up at the age of 8 months. He could walk unaided at the age of 2 years and uttered his first words
at the age of 1 year. He currently attends the first year of middle school with a support teacher
owing to a diminished ability to concentrate. He does not present with intellectual disability or other
behavioral disturbances.
At the age of 12 years and 7 months (Figure 5), height was 109cm (<3rd centile<-6SD), weight 29 kg
(<3rd centile), head circumference 54 cm (50th–75th centile), span 114 cm, span/height ratio 1.06.
Pubertal stage was A0P1B1, with testicular volume 1–2 ml on the left side and 2–3ml on the right. He had
sparse hair, high and prominent forehead, large ears, sparse eyebrows, large deeply-set eyes, blue-gray
sclerae, hypoplastic columella and misalignment of teeth, which were small, with abnormal enamel and
yellow-brown discoloration (Figure 5A–C). He had thin, pale, extremely soft skin, with a prominent
venous patterning on the trunk and limbs, limited elbow extension, skin hyperextensibility and distal
joint hypermobility especially of the hands (Beighton scale: 6), long and tapered fingers, normal nails.
His feet had hypoplastic nails, short and overlapping toes, hallux valgus (Figure 5D–H).
The skeletal X-rays demonstrated severe kyphoscoliosis, osteopenia, thin metacarpals and
phalanges (Figure 6A–H).
Audiometric and ophthalmological evaluations were normal. Abdominal ultrasound showed
ptosic kidneys, bilateral pelvic ureteral dilatation and thickening of the bladder walls. Echocardiography
demonstrated mild dilatation of the aortic bulb and mild mitral valve prolapse.
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Figure 5. Patient 2 A–C) Sparse hair, high and prominent forehead, sparse eyebrows, deeply-set eyes,
blue sclerae, hypoplastic columella, large ears; D–H) Thin, pale, extremely soft skin, with prominent
veins on the trunk and limbs, limited elbow extension, skin hyperextensibility and distal joint
hypermobility especially of the hands, long and tapered fingers. Feet: hypoplastic nails, short,
overlapping toes, hallux valgus.
Figure 6. Patient 2 A–H) Severe, early onset kyphoscoliosis, osteopenia, thin metacarpals and phalanges.
3.2.2. Molecular Analysis
Sanger sequencing confirmed the two previously reported variants in the single exon of the
B3GALT6 gene [45]: NM_080605:c.[353delA];[925T>A], NP_542172:p.[(Asp118Alafs*160)];[(Ser309Thr)]
(Figure 7A,B).
The frameshift variant was inherited from the father and the missense variant from the mother. Both
variants can be considered pathogenic, according to the predicted effect on the protein, the consistency
of the clinical phenotypes, and their rarity in reference population databases such as gnomAD
(MAF=0.0026% and absent, respectively). Variant c.353delA has also been found in our third
patient (reported below), while variant c.925T>A had already been reported in other patients in the
literature [45,48]. Since this gene is encoded by a single exon, its frameshift variants, identified in various
patients, are expected to escape nonsense-mediated mRNA decay. They probably exert a pathogenic
effect by leading to an unstable transcript or an unstable/non-functional protein, as suggested by
experimental evidence [48].
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Figure 7. A) Pedigree of Families 2 and 3; B) Schematic representation of the B3GALT6 protein: TM =
transmembrane domain, GalT = Galactosyl-transferase catalytic domain. Protein variants reported
in the literature are annotated in the cartoon (see Table 2 for references). Top half: missense variants
(black). Bottom half: frameshift variants (red), in-frame indels (green), other length-altering variants




He is the second child of non-consanguineous parents, born at 35th week of gestation by caesarean
section, owing to the premature rupture of the amniotic sac. During pregnancy, no known exposures
to potential teratogens were detected. Prenatal ultrasound indicated bilateral talipes equinovarus.
The mother reported normal fetal movements. At birth, weight was 2500 g (50th centile), length was
47 cm (50th–75th centile) and head circumference measured 34 cm (90th centile). Apgar scores
were 1’:7 5’:9. He presented with joint hypermobility, soft skin, adducted thumbs, right talipes
equinovarus. In the second year of life he was diagnosed with early-onset scoliosis, and he began to
wear an orthopedic corset.
At age 6 years, he was operated for bilateral cryptorchidism and at age 9 years, he underwent
a gastrostomy to correct Barrett’s oesophagus.
His motor development was delayed. He gained head control at the age of 4–5 months and could
sit up at the age of 24 months. He could walk aided at the age of 5 years, he was able to walk alone at
the age of 6 years and 6 months and uttered his first words at the age of 1 year. He currently attends
the second year of middle school with a support teacher owing to a diminished ability to concentrate.
He does not present with intellectual disability or other behavioral disturbances.
Examination at the age of 12 years and 11 months showed (Figure 8A–F): height 123 cm (<<3rd
centile), weight 28 kg (<3rd centile), head circumference 52 cm (10th centile), span 113 cm, span/height
ratio 0.91. Pubertal stage were A0P1B1, with testicular volume of 1-2 ml bilaterally. He had sparse
hair, high and prominent forehead with high hairline, mild bitemporal depression, fairly large ears,
blue-gray sclerae, malar hypoplasia, hypoplastic columella, short philtrum, small misaligned teeth in
the lower jaw, flat palate with longitudinal median mucous thickening (Figure 8A–B). He had thin,
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pale, soft skin, with slightly prominent veins on trunk, limited elbow extension, skin hyperextensibility
and distal joint hypermobility especially of the hands (Beighton scale: 6), long and tapered fingers
with a tendency to ulnar deviation (Figure 8C–E), hypoplastic nails on the feet (Figure 8F).
Figure 8. Patient 3 A,B) Sparse hair, high and prominent forehead with high hairline, mild bi-temporal
depression, fairly large ears, blue-gray sclerae, malar hypoplasia, hypoplastic columella, short philtrum,
thin, pale, soft skin with prominent veins on the trunk; C–E) Skin hyperextensibility and distal joint
hypermobility especially of the hands, long and tapered fingers, with a tendency to ulnar deviation; F)
Feet: hypoplastic nails.
Skeletal X-rays demonstrated severe kyphoscoliosis, osteopenia (especially in the acetabula,
femurs, tibiae and fibulae), and thin metacarpals, metatarsals and phalanges (Figure 9A–F).
Figure 9. Patient 3 A–F) Severe early onset kyphoscoliosis; osteopenia of the acetabula, femur, tibiae
and fibulae; thin metacarpals, metatarsals and phalanges.
Audiometric and ophthalmological evaluations were normal. Abdominal ultrasound was normal.
Echocardiography demonstrated an atrial septal defect and mild mitralic insufficiency with thickened
mitralic valve.
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3.3.2. Molecular Analysis
Karyotype was normal, 46XY. Genetic testing revealed three variants in the B3GALT6 gene:
NM_080605:c.[308C>T;353delA];[987_989delCTG], NP_542172:p.[(Ala103Val);(Asp118Alafs*160)];
[(*330Alaext*73)] (Figure 7A–C).
Variant c.353delA, already described as pathogenic (patient 2 and Nakajima et al., 2013 [45]),
has been found in cis with variant c.308C>T, both inherited from the healthy father. This missense
variant is absent from the reference population databases (gnomAD, 1000 genomes), but occurs
at a poorly conserved position and is predicted as benign by multiple algorithms (MutationTaster,
PolyPhen2, SIFT). It should be classified as a variant of uncertain significance, as there is not enough
evidence to suggest whether this variant alone would be tolerated or damaging to protein function,
or to indicate a possible contribution to the deleterious effect of the frameshift variant.
Variant c.987_989delCTG, inherited from the healthy mother, disrupts the constitutive stop codon
leading to an extended open reading frame, encoding a 72aa longer protein. It is absent from reference
population databases (gnomAD, 1000 genomes), and by analogy with the frameshift variants in this
gene, it is expected to produce an unstable or non-functional protein. Since it was found in trans with
a recognized deleterious mutation, this variant can be considered as likely pathogenic.
4. Discussion
Biallelic variants in the B4GALT7 and B3GALT6 genes are responsible for conditions characterized
by a combined skeletal and connective tissue phenotype. Their recent classification as spEDS [46]
provides a valid assistance for their diagnosis, but the observation of new patients and the study of the
clinical signs of those already reported in the literature can further improve our knowledge. In an effort
to better define both the similarities and the peculiarities of these syndromes, we reviewed the notable
features of our three patients and compared them to those of molecularly confirmed B4GALT7- and
B3GALT6-related cases reported in the literature (Tables 1 and 2) [18,21–24,29–33,44,45,48,51–56]
All three of our patients display a remarkably short stature. Pt. 2 and 3 are more severely affected,
in part because of their kyphoscoliosis, with a stature progressing from moderately short (or normal
for Pt. 3) at birth to well below the 3rd percentile during childhood. Nearly all patients reported in the
literature (65/66 evaluated cases) share this feature, confirming short stature as a main aspect of spEDS.
Joint hypermobility and soft, doughy and hyperextensible skin are some of the most striking
characteristics in our patients. These qualities are particularly remarkable in the hands and, to a lesser
extent, in the feet, and helped us restrict the diagnosis to an EDS-related condition. Since these features
are shared by more than 90% of cases reported in the literature (63/66 and 62/68, respectively), in our
opinion their combination should be considered a major diagnostic criterion for spEDS.
Craniofacial features for both B4GALT7- and B3GALT6-related conditions are quite variable
among our patients and the reported individuals for whom either pictures or descriptive data could
be evaluated, and do not seem suggestive of a facial gestalt. There are, however, some recurring
features that may sometimes help to set the two conditions apart: i. proptosis is more frequent in
spEDS-B4GALT7 (32/33 vs 20/32); ii. midface retrusion has been frequently noted in both conditions,
but in spEDS-B3GALT6 it is often associated with a prominent forehead (31/38), sometimes emphasized
by sparse hair (12/26) as in the case of our Pt. 2 and 3, while it would be more appropriate to state
that spEDS-B4GALT7 patients have an entirely flat face, usually short or round (31/33) and with
a narrow mouth (31/33). The progeroid aspect of spEDS-B4GALT7 described in Kresse’s child [24] and
previously pointed out by Hernandez [21–23] was absent in all other patients, suggesting that it is
not strongly associated with mutations in B4GALT7. As current terminology indicates, a progeroid
facial appearance is the subjective interpretation of a series of facial features which should rather be
evaluated individually. Some features such as thin skin or excessive wrinkles may occasionally appear
in the description of the cases we reviewed, but never in a combination suggestive of premature aging,
and none of these were observed in our patient. Therefore, as already suggested by other authors,
117
Genes 2019, 10, 799
we endorse the necessity to remove the term “progeroid type” from this syndrome, because it could
be misleading.
The radiological findings are undoubtedly the most significant evidence in distinguishing
B4GALT7-related and B3GALT6-related spEDS: the latter includes more numerous and pronounced
elements of skeletal dysplasia, and for this reason has often been classified as such in the past.
Radioulnar synostosis has been observed recurrently and almost exclusively in spEDS-B4GALT7 (19/32
cases, including our patient, vs 3 documented cases of spEDS-B3GALT6 [53,56]. On the other hand,
most of the individuals affected by B3GALT6-related spEDS, including our patients, display severe
kyphoscoliosis, usually congenital or early onset and progressive (36/39), and several of the skeletal
changes associated with SEMDJL1, such as platyspondyly, short iliac bones, elbow dislocation with
misalignment of the long bones (33/36). Osteopenia has been noted in both conditions. It has been
reported more frequently in B3GALT6-related cases (22/26), usually in conjunction with fractures and
luxations, as in the case of our patients. In B4GALT7-related cases there are significantly fewer records
of this feature, but in most reports its absence or presence cannot be verified. Therefore, the actual
prevalence of osteopenia is unknown and should probably deserve more consideration when referring
spEDS suspects for a radiological exam.
A consequence of skeletal involvement (bowing of limbs) is considered one of the main criteria
for suspecting spEDS, and it is possibly more common in the spEDS-B4GALT7 series (30/32 vs 16/20);
in fact, our Pt. 2 and 3 do not have this phenotype. Joint contractures of the upper limbs have been
noted for both conditions, though they are usually reported at the elbow in spEDS-B4GALT7 and
at the hands in spEDS-B3GALT6. In our experience, it was actually our B3GALT6-mutated patients
who displayed limited elbow extension, but this is a non-specific clinical sign that is often found in
skeletal dysplasia.
Other clinical features appear to be peculiar of B3GALT6-related spEDS. The most notable
are talipes equinovarus (23/37 patients, including ours), possibly with hypoplastic nails (cfr EDS
classification of 2017 [46] and our patients 2 and 3), and abnormalities of the dentition (13/17 patients,
including ours), sometimes with yellow-brown discoloration of the teeth (also observed in our Pt. 2).
Motor delay has been noted in the majority of reports in which developmental milestones were
evaluated (27/36), including our three patients. It is most likely related to the recurrent skeletal anomalies
(bowing of limbs, scoliosis, hip dysplasia) as well as to the frequent reports of hypotonia, also observed
in all of our patients (36/48 evaluated cases). In order to overcome the difficulties in sitting and walking,
these children often need assistance in the form of rehabilitation with appropriate physiotherapeutic
interventions. Depending on the severity of the musculoskeletal features, some individuals may be able
to walk without help at a later age than their peers, while others can only manage walking with help.
Developmental delay appears to be present in only about half of the documented spEDS cases
(26/49). In many instances, psychomotor development is only mildly delayed, possibly because of
the confounding effect of minor behavioral abnormalities. Of our three patients, Pt. 1 IQ has been
demonstrated to be average, while Pt. 2 and 3 require a support teacher during school only because of
a diminished ability to concentrate, and actually have good comprehensive and expressive skills.
In summary, among all of these clinical features, the most relevant in order to suspect spEDS,
because of their rarity in other syndromic conditions, are:
i. the extreme distal joint hypermobility and soft, hyperextensible skin, particularly of the hands;
ii. the radiological signs, which are the main indicator for discriminating spEDS-B4GALT7,
associated with radioulnar synostosis, and spEDS-B3GALT6, characterized by kyphoscoliosis
(congenital or early onset and progressive) and by the skeletal signs of SEMDJL1 (platyspondyly,
short iliac bones, elbow dislocation).
Current EDS classification includes a third type of spEDS, caused by biallelic defects in SLC39A13
(OMIM *608735), which encodes a zinc transporter involved in connective tissue development [57].
(Radiological findings suggest a minor skeletal involvement compared to other spEDS, but overall,)
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the small number of reported families is inadequate to discuss a differential diagnosis with good
confidence [58,59].
The differential diagnosis of spEDS-B3GALT6 may be placed with kyphoscoliotic EDS (kEDS),
primarily owing to early onset kyphoscoliosis, but the two conditions are very different from the
clinical point of view, because the latter is not characterized by significantly short stature, and the joint
hypermobility with dislocations/subluxations involves mainly shoulders, hips and knees rather than
hands and feet.
The differential diagnosis may be placed also with musculocontractural EDS (mcEDS), but the latter
is characterized by congenital multiple contractures, characteristically adduction-flexion contractures,
and typical craniofacial features, which are distinct from spEDS.
The main differential diagnosis of spEDS-B4GALT7 can be given with arthrochalasia EDS (aEDS),
which is characterized by congenital bilateral hip dislocation and laxity of small joints, but generally
aEDS also presents subluxation of the knees and dorso-lumbar kyphosis.
A clinician should consider the differential diagnosis between spEDS-B4GAL7 and the
B3GAT3-related linkeropathy, mainly because of prominent eyes, short stature with joint laxity
and radioulnar synostosis. However, it should be noted that patients with B3GAT3 variants often have
cardiovascular abnormalities, and that the rarity of the cases described in the literature does not allow
definite conclusions [14,15]. Additional clinical descriptions of these disorders are required in order to
characterize the linkeropathies both individually and as a disease group.
The radiological feature of spEDS may further warrant consideration for differential diagnosis with
several other skeletal dysplasias. The main discriminating features of B4GALT7- and B3GALT6-related
conditions, i.e. respectively radioulnar synostosis and scoliosis with early onset and rapid evolution,
can be found in various skeletal dysplasias, but are associated with such a remarkable degree of joint
hypermobility and soft, hyperextensible skin almost exclusively in spEDS.
5. Conclusions
The most striking aspect of spEDS is the combination of clinical signs affecting both the connective
tissue and the skeletal system. The criteria identified in the International Classification of EDS by
Malfait et al. (2017) clearly show that there is significant overlap between the clinical features of
spEDS-B4GALT7 and spEDS-B3GALT6. This is confirmed and expanded upon by the clinical reports
and literature review tables (Tables 1 and 2) presented here.
Overall, although skin and joints are similarly affected in both conditions, B3GALT6 mutations
lead to a more extensive and severe involvement of the skeletal system, with features often found in
SEMDJL1 such as kyphoscoliosis, platyspondyly, short iliac bones and elbow disclocation.
Careful observation of the hands, with their very soft and hyperextensible skin and extreme distal
joint laxity, in combination with the specific radiological signs, can immediately evoke the suspicion of
either spEDS-B4GALT7 (radioulnar synostosis) or spEDS-B3GALT6 (severe progressive kyphoscoliosis
and other SEMDJL1-like skeletal features).
The extreme hypermobility of distal joints and the soft, doughy skin on the hands and feet are
rarely seen in other EDS types (except, to some degree, in kEDS and aEDS) and are a valuable clue for
the diagnosis, which should be supported by skeletal radiographs and by molecular analysis.
Once spEDS is suspected, direct Sanger sequencing is still a viable and cost-effective option for
molecular analysis, since B4GALT7 and B3GALT6 have short coding regions and only a few exons (6 and
1, respectively). This should be considered especially if the radiological signs restrict the hypothesis
to either gene. However, particularly when attempting a molecular analysis early on, when some of
the distinctive clinical signs have not yet evolved, an NGS panel specific for EDS would be advisable,
since it can help confirm the differential diagnosis.
Being able to distinguish between spEDS-B3GALT6 and spEDS-B4GALT7 is important for clinicians,
because some patients in the B3GALT6-related group may develop life-threatening complications such
as aortic dilatation, aneurysms and cervical spine instability.
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In conclusion, accurate diagnosis will help in excluding other causes of peripheral hypotonia,
such as neuromuscular disorders, and allow for appropriate physiotherapeutic interventions.
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Grigelioniene, G.; et al. Spondyloocular Syndrome: Novel Mutations in XYLT2 Gene and Expansion of the
Phenotypic Spectrum. J. Bone Miner. Res. 2016, 31, 1577–1585. [CrossRef] [PubMed]
120
Genes 2019, 10, 799
14. Baasanjav, S.; Al-Gazali, L.; Hashiguchi, T.; Mizumoto, S.; Fischer, B.; Horn, D.; Seelow, D.; Ali, B.R.;
Aziz, S.A.A.; Langer, R.; et al. Faulty initiation of proteoglycan synthesis causes cardiac and joint defects.
Am. J. Hum. Genet. 2011, 89, 15–27. [CrossRef] [PubMed]
15. Von Oettingen, J.E.; Tan, W.H.; Dauber, A. Skeletal dysplasia, global developmental delay, and multiple
congenital anomalies in a 5-year-old boy-Report of the second family with B3GAT3 mutation and expansion
of the phenotype. Am. J. Med. Genet. Part A 2014, 164, 1580–1586. [CrossRef] [PubMed]
16. Jones, K.L.; Schwarze, U.; Adam, M.P.; Byers, P.H.; Mefford, H.C. A homozygous B3GAT3 mutation causes
a severe syndrome with multiple fractures, expanding the phenotype of linkeropathy syndromes. Am. J.
Med. Genet. Part A 2015, 167, 2691–2696. [CrossRef]
17. Budde, B.S.; Mizumoto, S.; Kogawa, R.; Becker, C.; Altmüller, J.; Thiele, H.; Rüschendorf, F.; Toliat, M.R.;
Kaleschke, G.; Hämmerle, J.M.; et al. Skeletal dysplasia in a consanguineous clan from the island of
Nias/Indonesia is caused by a novel mutation in B3GAT3. Hum. Genet. 2015, 134, 691–704. [CrossRef]
18. Alazami, A.M.; Al-Qattan, S.M.; Faqeih, E.; Alhashem, A.; Alshammari, M.; Alzahrani, F.; Al-Dosari, M.S.;
Patel, N.; Alsagheir, A.; Binabbas, B.; et al. Expanding the clinical and genetic heterogeneity of hereditary
disorders of connective tissue. Hum. Genet. 2016, 135, 525–540. [CrossRef]
19. Yauy, K.; Mau-Them, F.T.; Willems, M.; Coubes, C.; Blanchet, P.; Herlin, C.; Arrada, I.T.; Sanchez, E.;
Faure, J.M.; Le Gac, M.P.; et al. B3GAT3-related disorder with craniosynostosis and bone fragility due to
a unique mutation. Genet. Med. 2018, 20, 269–274. [CrossRef]
20. Paganini, C.; Costantini, R.; Superti-Furga, A.; Rossi, A. Bone and connective tissue disorders caused by
defects in glycosaminoglycan biosynthesis: A panoramic view. FEBS J. 2019, 286, 3008–3032. [CrossRef]
21. Hernández, A.; Aguirre-Negrete, M.G.; Liparoli, J.C.; Cantú, J.M. Third case of a distinct variant of the
Ehlers–Danlos Syndrome (EDS). Clin. Genet. 2008, 20, 222–224. [CrossRef]
22. Hernández, A.; Aguirre-Negrete, M.G.; González-Flores, S.; Reynoso-Luna, M.C.; Fragoso, R.; Nazará, Z.;
AND, G.T.; Cantú, J.M. Ehlers-Danlos features with progeroid facies and mild mental retardation: Further
delineation of the syndrome. Clin. Genet. 1986, 30, 456–461. [CrossRef] [PubMed]
23. Hernandez, A.; Aguirre-Negrete, M.G.; Ramírez-Soltero, S.; González-Mendoza, A.; Martínez, R.M.;
Velázquez-Cabrera, A.; Cantú, J.M. A distinct variant of the Ehlers–Danlos syndrome.pdf. Clin. Genet. 1979,
16, 335–339. [CrossRef] [PubMed]
24. Kresse, H.; Rosthøj, S.; Quentin, E.; Hollmann, J.; Glössl, J.; Okada, S.; Tønnesen, T. Glycosaminoglycan-free
small proteoglycan core protein is secreted by fibroblasts from a patient with a syndrome resembling
progeroid. Am. J. Hum. Genet. 1987, 41, 436–453. [PubMed]
25. Quentin, E.; Gladen, A.; Roden, L.; Kresse, H. A genetic defect in the biosynthesis of dermatan sulfate
proteoglycan: Galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome.
Proc. Natl. Acad. Sci. USA 1990, 87, 1342–1346. [CrossRef] [PubMed]
26. Almeida, R.; Levery, S.B.; Mandel, U.; Kresse, H.; Schwientek, T.; Bennett, E.P.; Clausen, H. Cloning and
expression of a proteoglycan UDP-galactose: β-xylose β1,4- galactosyltransferase I. A seventh member of
the human β4- galactosyltransferase gene family. J. Biol. Chem. 1999, 274, 26165–26171. [CrossRef] [PubMed]
27. Okajima, T.; Fukumoto, S.; Furukawat, K.; Urano, T.; Furukawa, K. Molecular basis for the progeroid variant
of Ehlers–Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I
gene. J. Biol. Chem. 1999, 274, 28841–28844. [CrossRef] [PubMed]
28. Rahuel-Clermont, S.; Daligault, F.; Piet, M.-H.; Gulberti, S.; Netter, P.; Branlant, G.; Magdalou, J.; Lattard, V.
Biochemical and thermodynamic characterization of mutated β1,4-galactosyltransferase 7 involved in the
progeroid form of the Ehlers–Danlos syndrome. Biochem. J. 2010, 432, 303–311. [CrossRef]
29. Faiyaz-Ul-Haque, M.; Zaidi, S.H.E.; Al-Ali, M.; Al-Mureikhi, M.S.; Kennedy, S.; Al-Thani, G.; Tsui, L.-C.;
Teebi, A.S. A novel missense mutation in the galactosyltransferase-I (B4GALT7) gene in a family exhibiting
facioskeletal anomalies and Ehlers–Danlos syndrome resembling the progeroid type. Am. J. Med. Genet.
2004, 128, 39–45. [CrossRef]
30. Guo, M.H.; Stoler, J.; Lui, J.; Nilsson, O.; Bianchi, D.W.; Hirschhorn, J.N.; Dauber, A. Redefining the progeroid
form of Ehlers–Danlos syndrome: Report of the fourth patient with B4GALT7 deficiency and review of the
literature. Am. J. Med. Genet. Part A 2013, 161, 2519–2527.
121
Genes 2019, 10, 799
31. Cartault, F.; Munier, P.; Jacquemont, M.L.; Vellayoudom, J.; Doray, B.; Payet, C.; Randrianaivo, H.; Laville, J.M.;
Munnich, A.; Cormier-Daire, V. Expanding the clinical spectrum of B4GALT7 deficiency: Homozygous p.
R270C mutation with founder effect causes Larsen of Reunion Island syndrome. Eur. J. Hum. Genet. 2015, 23,
49–53. [CrossRef]
32. Salter, C.G.; Davies, J.H.; Moon, R.J.; Fairhurst, J.; Bunyan, D.; Foulds, N. Further defining the phenotypic
spectrum of B4GALT7 mutations. Am. J. Med. Genet. Part A 2016, 170, 1556–1563. [CrossRef] [PubMed]
33. Arunrut, T.; Sabbadini, M.; Jain, M.; Machol, K.; Scaglia, F.; Slavotinek, A. Corneal clouding, cataract,
and colobomas with a novel missense mutation in B4GALT7—A review of eye anomalies in the linkeropathy
syndromes. Am. J. Med. Genet. Part A 2016, 170, 2711–2718. [CrossRef] [PubMed]
34. Beighton, P.; Kozlowski, K. Spondylo-Epi-Metaphyseal dysplasia with joint laxity and severe, progressive
kyphoscoliosis. Skelet. Radiol. 1980, 5, 205–212. [CrossRef] [PubMed]
35. Beighton, P.; Kozlowski, K.; Gericke, G.; Wallis, G.; Grobler, L. Spondylo-epimetaphyseal dysplasia with joint
laxity and severe, progressive kyphoscoliosis. A potentially lethal dwarfing disorder. S. Afr. Med. J. 1983, 64,
772–775. [PubMed]
36. Kozlowski, K.; Beighton, P. Radiographic features of spondylo-epimetaphyseal dysplasia with joint laxity
and progressive kyphoscoliosis. In RöFo-Fortschritte Auf Dem Gebiet der Röntgenstrahlen und der Bildgebenden
Verfahren; Georg Thieme Verlag Stuttgart: New York, NY, USA, 1984; Volume 141, pp. 337–341.
37. Beighton, P.; Gericke, G.; Kozlowski, K.; Grobler, L. The manifestations and natural history of
spondylo-epi-metaphyseal dysplasia with joint laxity. Clin. Genet. 1984, 26, 308–317. [CrossRef] [PubMed]
38. Torrington, M.; Beighton, P. The ancestry of spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL)
in South Africa. Clin. Genet. 2008, 39, 210–213. [CrossRef]
39. Beighton, P. Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL). J. Med. Genet. 1994, 31, 136–140.
[CrossRef]
40. Christianson, A.L.; Beighton, P. Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL) in three
neonates. Genet. Couns. 1996, 7, 219–225.
41. Hall, C.M.; Elçioglu, N.H.; Shaw, D.G. A distinct form of spondyloepimetaphyseal dysplasia with multiple
dislocations. J. Med. Genet. 1998, 35, 566–572. [CrossRef]
42. Vorster, A.A.; Beighton, P.; Ramesar, R.S. Spondyloepimetaphyseal dysplasia with joint laxity (Beighton
type); mutation analysis in eight affected South African families. Clin. Genet. 2015, 87, 492–495. [CrossRef]
43. Bonafe, L.; Cormier-Daire, V.; Hall, C.; Lachman, R.; Mortier, G.; Mundlos, S.; Nishimura, G.; Sangiorgi, L.;
Savarirayan, R.; Sillence, D.; et al. Nosology and classification of genetic skeletal disorders: 2015 revision.
Am. J. Med. Genet. Part A 2015, 167, 2869–2892. [CrossRef] [PubMed]
44. Malfait, F.; Kariminejad, A.; Van Damme, T.; Gauche, C.; Syx, D.; Merhi-Soussi, F.; Gulberti, S.; Symoens, S.;
Vanhauwaert, S.; Willaert, A.; et al. Defective initiation of glycosaminoglycan synthesis due to B3GALT6
mutations causes a pleiotropic Ehlers–Danlos-syndrome-like connective tissue disorder. Am. J. Hum. Genet.
2013, 92, 935–945. [CrossRef] [PubMed]
45. Nakajima, M.; Mizumoto, S.; Miyake, N.; Kogawa, R.; Iida, A.; Ito, H.; Kitoh, H.; Hirayama, A.; Mitsubuchi, H.;
Miyazaki, O.; et al. Mutations in B3GALT6, which encodes a glycosaminoglycan linker region enzyme, cause
a spectrum of skeletal and connective tissue disorders. Am. J. Hum. Genet. 2013, 92, 927–934. [CrossRef]
[PubMed]
46. Malfait, F.; Francomano, C.; Byers, P.; Belmont, J.; Berglund, B.; Black, J.; Bloom, L.; Bowen, J.M.; Brady, A.F.;
Burrows, N.P.; et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am. J. Med. Genet.
Part C 2017, 175, 8–26. [CrossRef] [PubMed]
47. Brady, A.F.; Demirdas, S.; Fournel-Gigleux, S.; Ghali, N.; Giunta, C.; Kapferer-Seebacher, I.; Kosho, T.;
Mendoza-Londono, R.; Pope, M.F.; Rohrbach, M.; et al. The Ehlers–Danlos syndromes, rare types. Am. J.
Med. Genet. Part C 2017, 175, 70–115. [CrossRef] [PubMed]
48. Van Damme, T.; Pang, X.; Guillemyn, B.; Gulberti, S.; Syx, D.; De Rycke, R.; Kaye, O.; de Die-Smulders, C.E.M.;
Pfundt, R.; Kariminejad, A.; et al. Biallelic B3GALT6 mutations cause spondylodysplastic Ehlers–Danlos
syndrome. Hum. Mol. Genet. 2018, 27, 3475–3487. [CrossRef]
49. Paganini, C.; Monti, L.; Costantini, R.; Besio, R.; Lecci, S.; Biggiogera, M.; Tian, K.; Schwartz, J.M.; Huber, C.;
Cormier-Daire, V.; et al. Calcium activated nucleotidase 1 (CANT1) is critical for glycosaminoglycan
biosynthesis in cartilage and endochondral ossification. Matrix Biol. 2019, 81, 70–90. [CrossRef]
122
Genes 2019, 10, 799
50. Nizon, M.; Huber, C.; De Leonardis, F.; Merrina, R.; Forlino, A.; Fradin, M.; Tuysuz, B.; Abu-Libdeh, B.Y.;
Alanay, Y.; Albrecht, B.; et al. Further delineation of CANT1 phenotypic spectrum and demonstration of its
role in proteoglycan synthesis. Hum. Mutat. 2012, 33, 1261–1266. [CrossRef]
51. Ritelli, M.; Dordoni, C.; Cinquina, V.; Venturini, M.; Calzavara-Pinton, P.; Colombi, M. Expanding the clinical
and mutational spectrum of B4GALT7-spondylodysplastic Ehlers–Danlos syndrome. Orphanet J. Rare Dis.
2017, 12, 153. [CrossRef]
52. Sandler-Wilson, C.; Wambach, J.A.; Marshall, B.A.; Wegner, D.J.; McAlister, W.; Cole, F.S.; Shinawi, M.
Phenotype and response to growth hormone therapy in siblings with B4GALT7 deficiency. Bone 2019, 124,
14–21. [CrossRef]
53. Sellars, E.A.; Bosanko, K.A.; Lepard, T.; Garnica, A.; Schaefer, G.B. A newborn with complex skeletal
abnormalities, joint contractures, and bilateral corneal clouding with sclerocornea. Semin. Pediatr. Neurol.
2014, 21, 84–87. [CrossRef] [PubMed]
54. Ritelli, M.; Chiarelli, N.; Zoppi, N.; Dordoni, C.; Quinzani, S.; Traversa, M.; Venturini, M.;
Calzavara-Pinton, P.; Colombi, M. Insights in the etiopathology of galactosyltransferase II (GalT-II) deficiency
from transcriptome-wide expression profiling of skin fibroblasts of two sisters with compound heterozygosity
for two novel B3GALT6 mutations. Mol. Genet. Metab. Rep. 2015, 2, 1–15. [CrossRef] [PubMed]
55. Trejo, P.; Rauch, F.; Glorieux, F.H.; Ouellet, J.; Benaroch, T.; Campeau, P.M. Spondyloepimetaphysial Dysplasia
with Joint Laxity in Three Siblings with B3GALT6 Mutations. Mol. Syndromol. 2017, 8, 303–307. [CrossRef]
[PubMed]
56. Ben-Mahmoud, A.; Ben-Salem, S.; Al-Sorkhy, M.; John, A.; Ali, B.R.; Al-Gazali, L. A B3GALT6 variant in
patient originally described as Al-Gazali syndrome and implicating the endoplasmic reticulum quality
control in the mechanism of some β3GalT6-pathy mutations. Clin. Genet. 2018, 93, 1148–1158. [CrossRef]
[PubMed]
57. Fukada, T.; Civic, N.; Furuichi, T.; Shimoda, S.; Mishima, K.; Higashiyama, H.; Idaira, Y.; Asada, Y.;
Kitamura, H.; Yamasaki, S.; et al. The zinc transporter SLC39A13/ZIP13 is required for connective tissue
development; its involvement in BMP/TGF-β signaling pathways. PLoS ONE 2008, 3, e3642. [CrossRef]
58. Giunta, C.; Elçioglu, N.H.; Albrecht, B.; Eich, G.; Chambaz, C.; Janecke, A.R.; Yeowell, H.; Weis, M.;
Eyre, D.R.; Kraenzlin, M.; et al. Spondylocheiro Dysplastic Form of the Ehlers–Danlos Syndrome—An
Autosomal-Recessive Entity Caused by Mutations in the Zinc Transporter Gene SLC39A13. Am. J. Hum. Genet.
2008, 82, 1290–1305. [CrossRef] [PubMed]
59. Dusanic, M.; Dekomien, G.; Lücke, T.; Vorgerd, M.; Weis, J.; Epplen, J.T.; Köhler, C.; Hoffjan, S. Novel
Nonsense Mutation in SLC39A13 Initially Presenting as Myopathy: Case Report and Review of the Literature.
Mol. Syndromol. 2018, 9, 100–109. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




G C A T
T A C G
G C A T
Article
Further Defining the Phenotypic Spectrum of B3GAT3
Mutations and Literature Review on
Linkeropathy Syndromes
Marco Ritelli 1, Valeria Cinquina 1, Edoardo Giacopuzzi 2, Marina Venturini 3, Nicola Chiarelli 1
and Marina Colombi 1,*
1 Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of
Brescia, 25123 Brescia, Italy
2 Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy
3 Division of Dermatology, Department of Clinical and Experimental Sciences, Spedali Civili University
Hospital, 25123 Brescia, Italy
* Correspondence: marina.colombi@unibs.it; Tel.: +39-030-3717-240; Fax: +39-030-371-7241
Received: 25 June 2019; Accepted: 19 August 2019; Published: 21 August 2019
Abstract: The term linkeropathies (LKs) refers to a group of rare heritable connective tissue disorders,
characterized by a variable degree of short stature, skeletal dysplasia, joint laxity, cutaneous anomalies,
dysmorphism, heart malformation, and developmental delay. The LK genes encode for enzymes that
add glycosaminoglycan chains onto proteoglycans via a common tetrasaccharide linker region. Biallelic
variants in XYLT1 and XYLT2, encoding xylosyltransferases, are associated with Desbuquois dysplasia
type 2 and spondylo-ocular syndrome, respectively. Defects in B4GALT7 and B3GALT6, encoding
galactosyltransferases, lead to spondylodysplastic Ehlers-Danlos syndrome (spEDS). Mutations in
B3GAT3, encoding a glucuronyltransferase, were described in 25 patients from 12 families with variable
phenotypes resembling Larsen, Antley-Bixler, Shprintzen-Goldberg, and Geroderma osteodysplastica
syndromes. Herein, we report on a 13-year-old girl with a clinical presentation suggestive of spEDS,
according to the 2017 EDS nosology, in whom compound heterozygosity for two B3GAT3 likely
pathogenic variants was identified. We review the spectrum of B3GAT3-related disorders and provide
a comparison of all LK patients reported up to now, highlighting that LKs are a phenotypic continuum
bridging EDS and skeletal disorders, hence offering future nosologic perspectives.
Keywords: linkeropathies; B3GAT3; Larsen-like syndrome; B4GALT7; B3GALT6; spondylodysplastic
Ehlers-Danlos syndrome; XYLT1; XYLT2; Desbuquois dysplasia; spondylo-ocular syndrome
1. Introduction
Ehlers-Danlos syndrome (EDS) comprises a clinically variable and genetically heterogeneous group
of heritable connective tissue disorders (HTCDs) sharing the triad of (generalized) joint hypermobility,
cutaneous abnormalities, and internal organ/vascular fragility and dysfunctions. The 2017 EDS
nosology recognizes 13 different clinical subtypes and 19 causal genes mainly encoding fibrillar
collagens, collagen-modifying proteins, or processing enzymes [1]. A fourteenth subtype has been
recently associated with biallelic variants in AEBP1, which encodes the aortic carboxypeptidase-like
protein (ACLP) associating with collagens in the extracellular matrix (ECM) [2–5]. In addition to
the clinical classification, the 2017 EDS nosology introduced a pathogenetic scheme that regrouped
the EDS subtypes into seven functional classes (i.e., disorders) of (a) collagen primary structure and
collagen processing, (b) collagen folding and crosslinking, (c) structure and function of the myomatrix,
(d) glycosaminoglycan (GAG) biosynthesis, (e) intracellular pathways, (f) the complement pathway,
and (g) unresolved forms of EDS. The clinical manifestations of EDS are broad and often overlap
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other HCTDs including some types of skeletal dysplasias, cutis laxa, hereditary myopathies, and
TGFβ-related disorders [6,7]. Hence, intermediate or bridging phenotypes presenting the EDS triad
are expected at the boundaries of an evolving nosology.
The multisystemic clinical variability of EDS reflects the numerous functions of collagens and
their interactors, among which proteoglycans (PGs) are particularly notable. PGs are structurally
complex biomacromolecules that are essential in the development, signaling, and homeostasis of
many tissues and organs including bone, cartilage, skeletal muscle, eyes, heart, and skin [8–13]. PGs
contain one or more variable GAG chains, which are linear polysaccharides consisting of repeating
disaccharide blocks attached to a core protein. Depending on the composition of these blocks, the PG
superfamily can be subdivided into two major groups: heparan sulfate (HS) and chondroitin sulfate
(CS)/dermatan sulfate (DS) PGs. The biosynthesis of GAG chains starts with the formation of a common
so-called tetrasaccharide linker region that is covalently attached to a serine residue of the PG core
protein (Figure 1). The linker region synthesis is a stepwise process that involves the action of specific
glycosyltransferases. It starts with the transfer of a xylose (Xyl) residue by xylosyltransferases I/II
(XylT-I/II encoded by XYLT1 and XYLT2, respectively), followed by the addition of two galactose (Gal)
residues by galactosyltransferase type I (GalT-I encoded by B4GALT7) and type II (GalT-II encoded
by B3GALT6). The linker region is completed by the transfer of glucuronic acid (GlcA) catalyzed by
glucuronosyltransferase I (GlcAT-I encoded by B3GAT3), upon which polymerization of the HS or
CS/DS chains begins. HS is formed by the alternating addition of disaccharides of N-acetyl-glucosamine
(GlcNAc) and GlcA residues, CS by N-acetyl-galactosamine (GalNAc) and GlcA residues, subsequently
modified by several sulfotransferases. The formation of DS requires the epimerization of GlcA toward
iduronic acid (IdoA), an event accomplished by dermatan sulfate epimerases (DS-epi1 encoded by DSE).
This allows dermatan 4-o-sulfotransferase 1 (D4ST1 encoded by CHST14) to catalyze the 4-o-sulfation
of GalNAc, which prevents back-epimerization of the adjacent IdoA (Figure 1) [8–13].
The importance of the correct initiation of GAG synthesis is exemplified by the identification
of biallelic variants in all genes encoding the key enzymes in the linker region synthesis, leading to
a spectrum of severe multisystemic disorders (Figure 1), a.k.a., linkeropathies (LKs) [11–13].
Two of these LKs, GalT-I- and GalT-II-deficiency, fit with the EDS spectrum and are recognized in
the 2017 EDS nosology as spondylodysplastic EDS (spEDS) that also includes patients with mutations in
SLC39A13 encoding the ZIP13 protein involved in the influx of zinc into the cytosol [1,14]. According to
the 2017 nosology, spEDS is suggested by two major criteria, short stature and muscle hypotonia,
plus characteristic radiographic abnormalities and at least three other minor criteria (general or
gene-specific) [1]. At present, 10 patients with molecularly confirmed B4GALT7-spEDS have been
reported [14–21], 46 with B3GALT6-spEDS [14,22–28], and nine with SLC39A13-spEDS [14,29–31].
A further 22 patients, all with the same homozygous B4GALT7 p.(Arg270Cys) missense variant, have
been characterized in the ethnic group called white creoles living on Reunion Island (Larsen of Reunion
Island syndrome) [32].
Molecular defects in XYLT1 have been associated with Desbuquois dysplasia type 2 (DBQD2)
with 28 molecularly proven patients reported hitherto [33–40], while XYLT2 mutations cause the
so-called spondylo-ocular syndrome (SOS), which has been described in 20 patients thus far [41–46].
Concerning B3GAT3, 25 patients from 12 families have been recognized, but range in severity from mild
to severe and resemble Larsen (LR)-, Antley-Bixler (AB)-, Shprintzen-Goldberg (SG)-, and Geroderma
osteodysplastica (GO)-like syndromes [26,47–53]. Further downstream in the GAG biosynthetic
pathway, mutations in the CHST14 and DSE genes have been reported in musculocontractural EDS
(mcEDS) type 1 and 2, respectively [14].
Herein, we report on a 13-year-old girl ascertained as a suspect of EDS. Trio-based exome
sequencing (ES) revealed compound heterozygosity for two likely pathogenic variants in B3GAT3.
We provide a comparison of the patient’s clinical features with those of the other LK patients reported
so far, thus offering future perspectives for clinical research in this field.
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Figure 1. Biosynthetic assembly of the glycosaminoglycan (GAG) backbones of heparan sulfate (HS)
and chondroitin sulfate (CS)/dermatan sulfate (DS) chains and related genetic disorders. Each enzyme
(in red) and its coding gene (in black) are described near the sugar symbols. After the synthesis of
specific core proteins, the synthesis of the GAG-protein linker region is initiated by XylT-I/II, which
transfers [Xyl] to the specific Ser residue in the endoplasmic reticulum. The synthesis of the linker
region is completed by the consecutive addition of two molecules of [Gal], added by GalT-I/II, followed
by the transfer of [GlcA] catalyzed by GlcAT-I in the Golgi. The addition of a [GalNAc] to the linker
region commits the growing GAG chain to CS/DS. CS synthesis proceeds with the alternating addition
of [GlcA] and [GalNAc] and can be further modified by sulfotransferases. A DS chain is generated after
the formation of the chondroitin backbone, when [GlcA] is converted into [IdoA] by DS-epi1, resulting
in the formation of the dermatan backbone, where [GalNAc] is sulfated by D4ST1. Alternatively,
the addition of the [GlcNAc] to the linker region induces HS biosynthesis. The polymerization of
the HS chain is catalyzed by enzymes encoded by the EXT1 and EXT2 genes. Abbreviations: Ser,
Serine; HS, heparin sulfate; CS, chondroitin sulfate; DS, dermatan sulfate; XylT-I/II, xylosyltransferases
I/II; GalT-I, galactosyltrasferase I; Galt-II, galactosyltrasferase II; GlcAT-I, glucuronasyltransferase I;
DE-epi1; dermatan sulfate epimerases; D4ST1; dermatan 4-o-sulfotransferase 1; Xyl, xylose; Gal,
galactose, GlcA; glucuronic acid, GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactisamine;
IdoA, iduronic acid; DBQD2, Desbuquois dysplasia type 2, SOS, spondylo-ocular syndrome; spEDS,
spondylodysplastic EDS; LRS-like, Larsen-like syndrome; ABS-like, Antley-Bixler-like syndrome;
SGS-like, Shprintzen-Goldberg-like syndrome; GO-like, Geroderma osteodysplastica-like; mcEDS,
musculocontractural EDS.
2. Patient and Methods
2.1. Ethical Compliance
The patient was evaluated at the specialized outpatient clinic for the diagnosis of EDS and
related connective tissue disorders (i.e., the Ehlers-Danlos Syndrome and Inherited Connective Tissue
Disorders Clinic, CESED), at the University Hospital Spedali Civili of Brescia. Molecular analysis was
achieved in compliance with Italian legislation on genetic diagnostic tests and the patient’s parents
provided written informed consent for the publication of clinical data and photographs according to
the Italian bioethics laws. This study followed the Declaration of Helsinki’s principles and was carried
out from routine diagnostic activity; a formal ethics review was therefore not requested.
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2.2. Amplicon-Based Exome Sequencing
Genomic DNA from the proband and her parents was extracted from peripheral blood leukocytes
by standard procedures. Mutational screening was performed by trio-based ES using the Ion Proton
platform and the AmpliSeq technology following the manufacturer’s recommendations (Thermo
Fisher Scientific, South San Francisco, CA, USA). Briefly, whole exome libraries were prepared using
the AmpliSeq Exome RDY kit for library preparation. The template preparation of the libraries was
performed using the Ion PI Hi-Q OT2 200 kit on the Ion OneTouch 2 starting from 8 μl of the 100 pM
libraries. Template preparation and sequencing runs were performed with the Ion PI Hi-Q Sequencing
200 kit. The templated Ion Sphere Particles (ISP) were enriched for positive ISP using the Ion OneTouch
ES and sequenced on the Ion Proton with the Ion PI chip v3. Basecalling and sequence alignment
against hg19 genome assembly were performed using Ion Torrent Suite software 5.6, and genetic
variants were identified using Torrent Suite Variant Caller pipeline 5.6. Variants were decomposed and
normalized using the vt tool [54], filtered for quality using GARFIELD-NGS [55], and annotated using
ANNOVAR [56]. Variants were filtered according to the following criteria: (i) MAF < 0.01 in 1000G
and ExAc v.0.3 populations; (ii) predicted to alter protein product, namely missense, stop-affecting
or splice-affecting variants; and (iii) not present in our internal database. Filtered variants were then
prioritized based on DANN [57] and M-CAP [58] scores to retain the most likely deleterious variants.
RVIS [59] and GDI [60] scores were used to prioritize more intolerant genes. Finally, we only considered
variants with a perfect segregation among the parents and proband according to a recessive/de novo
model of transmission. To evaluate the putative pathogenicity of the B3GAT3 variants, we used the
following mutation prediction programs: SIFT [61], Mutation Taster [62], CADD [63], PROVEAN [64],
GERP++ [65], UMD_prediction [66], LRT [67], Fathmm-MKL [68], VEST [69], and FitCons [70].
2.3. Sanger Sequencing
The B3GAT3 variants identified by ES (reference sequences: NM_012200.3, NP_036332.2) were
confirmed by Sanger sequencing with the BigDye Terminator v1.1 Cycle Sequencing kit on an ABI
3130XL Genetic Analyzer according to the manufacturer’s protocols (Thermo Fisher Scientific, South
San Francisco, CA, USA) with specific primer sets amplifying exon 3 and exon 4 of B3GAT3, respectively
(Supplementary Table S1). The sequences were analyzed with Sequencer 5.0 software (Gene Codes
Corporation, Ann Arbor, MI, USA) and variants were annotated according to the Human Genome




The proband (LOVD ID #00235371), an Italian 13-year-old girl, was born to non-consanguineous
healthy parents and had a healthy sister. Clinical history was remarkable for birth at 41 weeks (height
49 cm, weight 3.2 kg) after induced labor associated with perinatal respiratory distress, anterior
ectopic anus, and congenital hip dislocation treated with hip abduction braces, severe neonatal
hypotonia, and delayed motor development (delay in walking, first step at three years of age, and
acquisition of fine motor skills). She was discharged from the neonatology unit with a diagnosis of
generalized joint hypermobility. Medical history further included propensity to develop ecchymoses
and surgically treated umbilical hernia. At one year of age, total skeletal x-ray disclosed severe
kyphoscoliosis unsuccessfully treated with orthopedic corset, atlantooccipital instability, bilateral
radio-ulnar synostosis, abnormalities of the proximal humeral epiphyses, metaphyseal flaring, long
and thin bones with widened metaphyses, and delayed bone age. Cervical spine imaging showed
significant atlantoaxial and atlanto-occipital instability with flexion and extension. At the age of two,
a heart ultrasound revealed an atrial septal defect, which was surgically treated three years later due to
tachyarrhythmia and pulmonary hypertension. At ages two and three, respectively, either a clinical
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diagnosis of SGS or of an unspecified EDS was given. Genetic analyses were not performed. At age
four, dual-energy x-ray absorptiometry (DEXA) disclosed severe low bone mineral density for sex and
age (z-score < 2 SD) and bisphosphonate treatment was commenced. The progressive kyphoscoliosis
and cervical spine instability were surgically treated at age six and 12 without satisfactory improvement.
Ophthalmologic evaluation revealed refractive errors such as astigmatism and strabismus. At six years
of age, progressive height deficit related to GH deficiency was noticed. GH therapy was started with
a discrete outcome, but treatment was interrupted two years later due to the worsening of side effects.
Since infancy, the patient suffered from recurrent dislocation of the elbows, shoulders, and knees as
well as chronic myalgia of the lower limbs and severe foot pain.
On examination, at 13 years of age, she presented with short stature (height 130 cm; genetic target
169 cm, arm span/height ratio, normal value < 1.05), a weight of 25 kg, severe kyphoscoliosis, short
neck, pectus carinatum, genua valga, and muscle hypotonia (Figure 2). Facial dysmorphism included
enophthalmos, midface hypoplasia, dolichocephaly, prominent forehead, low-set ears, blue sclerae,
downslanting palpebral fissures, long philtrum, narrow palate, and micrognathia. Foot deformities
such as sandal gaps, severe pes planovalgus, and clinodactyly of the toes were present (Figure 2).
The patient also showed skin hyperextensibility over the neck, elbow, forearm and knees, easy bruising,
mild atrophic scarring, generalized joint hypermobility with a Beighton score (BS) of 6/9, clinodactyly of
the fifth finger, and long fingers with spatulate distal phalanges. Cognitive development and mentation
were normal. DEXA confirmed severe osteopenia and delayed bone age despite bisphosphonates
treatment; no fractures were reported. Echocardiogram revealed minimal mitral, tricuspid, and aortic
valves insufficiency.
Figure 2. Clinical findings of the patient. Facial dysmorphism: enophthalmos, midface hypoplasia,
prominent forehead, micrognathia, low-set ears, and short neck (a), skin hyperextensibility over the
neck (b), long fingers with spatulate distal phalanges and clinodactyly of the fifth finger (c), joint laxity
of the fifth finger (d), foot deformities: sandal gaps, severe pes planovalgus and clinodactyly of the
toes (e), elbow deformity with reduction in the range of motion (f), radioulnar synostosis (g), severe
kyphoscoliosis (h–l), pectus carinatum (h), muscle hypotonia (h–k), and metaphyseal flaring (m).
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Overall, the patient fulfilled the minimal criteria suggestive for spEDS according to the 2017
EDS nosology [1], since she presented two major (short stature, muscle hypotonia), four general
minor (skin hyperextensibility, foot deformity, delayed motor development, osteopenia), and several
gene-specific minor criteria either for B4GALT7-spEDS or B3GALT6-spEDS (craniofacial dysmorphism,
characteristic radiographic findings including severe kyphoscoliosis, radioulnar synostosis, metaphyseal
flaring, bilateral elbow deformities, peculiar fingers, and gJHM with recurrent dislocations) (Table 1,
Supplementary Table S2). Nevertheless, since the patient also presented some peculiar features not
previously reported in spEDS patients such as dolichocephaly, atrial septal defect, and anterior ectopic
anus, we performed trio-based ES.
Table 1. Candidate genes after selecting variants.




































Summary results of ES are reported in Supplementary Table S3 and Figure S1. After application
of the filtering pipeline and prioritization of variants by considering only recessive or de novo variants
with perfect segregation among trio members (Supplementary Table S4), six candidate genes were
identified (Table 1). Among these, five genes with a de novo variant were excluded, since only B3GAT3,
associated with multiple joint dislocations, short stature, and craniofacial dysmorphism with or without
congenital heart defects (OMIM #245600), was consistent with the patient’s phenotype.
In particular, the trio analysis revealed the paternally inherited c.481C>T transition in exon 3,
leading to the substitution of a highly conserved and positively charged arginine residue with a larger
and neutral tryptophan at position 161 [p.(Arg161Trp)] within the donor substrate binding subdomain of
the protein [71,72], and the maternal c.889C>T variant in exon 4, which also resulted in the substitution
of an arginine residue with a tryptophan [p.(Arg297Trp)], but within the acceptor substrate binding
subdomain (Figures 3A and 4) [71,72].
Both variants are annotated in dbSNPs and have extremely low frequencies in population
genomic databases. In particular, the paternal variant was observed in three individuals in GnomAD
(rs765246909, 3/251290, no homozygotes, total MAF: C = 0.00001194), and the maternal substitution was
also observed in three individuals (rs759636773, 3/251080, no homozygotes, total MAF: C = 0.00001195)
(queried on 28 May, 2019). Their putative pathogenicity was estimated through 12 different in silico
prediction algorithms that agreed to define p.(Arg161Trp) and p.(Arg297Trp) as high impacting variants
(Figure 3B).
By using the InterVar (Clinical Interpretation of Genetic Variants) tool [73], both variants were
classified as likely pathogenic (class 4) according to the guidelines of the American College of Medical
Genetics and Genomics (ACMG) [74] since (i) both variants are missense substitutions in a gene that
has a low rate of benign missense variation and where missense variants are a common mechanism of
disease (Table 2); (ii) both variants are located in a critical and well-established functional domain of the
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protein, i.e., the glycosyltransferase domain; (iii) their extremely low frequency in a publicly available
population database; (iv) the multiple lines of computational evidence supporting a deleterious effect;
and (v) the patient’s phenotype was highly suggestive for a disease with a single genetic etiology.
Figure 3. Molecular findings. (A) ES data alignments show the compound heterozygosity of the
paternal c.481C>T (p.Arg161Trp) and the maternal c.889C>T (p.Arg297Trp) missense variants. Sanger
sequencing confirmed the presence of both variants in the proband (arrows). Healthy parents were
heterozygous carriers. Mutations are annotated according to HGVS nomenclature (reference sequences:
NM_012200.3, NP_036332.2). (B) In silico predictions of the pathogenicity of the p.(Arg161Trp) and
p.(Arg297Trp) missense substitutions by using 12 different algorithms [61–70].
The two variants were submitted to the Leiden Open Variation Database (LOVD variants identifiers:
#0000480198 and #0000480199). The functional effect of the missense substitutions on reduced/absent
enzymatic activity was not verified due to the unavailability of the patient’s fibroblasts.
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4. Discussion
The umbrella term LK refers to a group of extremely rare and consequently poorly characterized
genetic disorders caused by mutations in genes encoding enzymes responsible for the synthesis of
GAG side chains of PGs. Nosologic uncertainty characterizes these disorders, thus contributing to the
clinical diagnosis of challenging patients, which is not straightforward at all. Indeed, although the
linker region is the identical tetrasaccharide sequence for all PGs in all tissues, biallelic variants in the
LK genes are associated with apparently different phenotypes that variably affect the skeletal system
and skin, even if remarkable similarities between the different LKs are recognizable [8–13].
In the 2017 EDS nosology, some patients with defects in two out of the five LK genes (i.e.,
B4GALT7 and B3GALT6) were grouped as spEDS together with those harboring SLC39A13 mutations,
in consideration of the reliable clinical overlap [1], whereas the 22 Larsen of Reunion Island syndrome
patients were not included. We have previously suggested that, though some phenotypic variations
between Larsen of Reunion Island syndrome and B4GALT7-spEDS exist, these conditions should not
be considered as different entities [20]. Patients with B3GAT3, XYLT1, and XYLT2 mutations were
also not classified as spEDS, even though there is a common pathogenic mechanism and numerous
shared clinical features. The patient reported in this study corroborates the awareness that LKs are
a phenotypic continuum bridging EDS and skeletal disorders. Indeed, the patient was referred to our
clinic with a well-founded suspicion of EDS, since she respected the EDS triad and fulfilled the minimal
suggestive criteria of spEDS (Supplementary Table S2). In consideration of some peculiar signs not
previously associated with spEDS, we performed ES, which revealed compound heterozygosity for
two likely pathogenic B3GAT3 variants.
B3GAT3 is involved in a spectrum of connective tissue and skeletal disorders. Table 2 summarizes
the clinical features of the 26 patients from 13 different families, 11 of which were consanguineous with
B3GAT3 mutations reported so far ([26,47–53], present study). Among the B3GAT3-related disorders,
a LRS-like presentation similar to that of our patient was the most common, but more severe phenotypes
resembling ABS, SGS, and GO have also been reported (Table 2).
Historically, Baasanjav et al. [47] first described five patients with short stature, radioulnar synostosis,
brachycephaly, and cardiac abnormalities. The authors suggested naming this condition as Larsen-like
syndrome, B3GAT3 type. All patients carried the homozygous c.830G>A, p.(Arg277Gln) missense
mutation in the acceptor substrate binding subdomain of the protein. Von Oettingen et al. [48] described
a 5-year-old boy with a similar phenotype and the same missense variant. Novel findings were
developmental delay, refractive errors, pectus carinatum, atlantoaxial and atlanto-occipital instability,
and excessive skin wrinkling. Budde et al. [49] reported eight patients from a large consanguineous
family with a LRS-like phenotype without cardiac involvement carrying the c.419C>T, p.(Pro140Leu)
pathogenic variant in the donor substrate binding subdomain of the protein. Job et al. [51] described
the first compound heterozygous patient, a 6-year-old boy, who presented in addition to the typical
LRS-like features, hypotonia, hyperextensible skin, and generalized osteoporosis with multiple fractures.
The identified mutations were a null allele (c.1A>G, p.Met1?) and the c.671T>A, p.(Leu224Gln) missense
substitution in the acceptor substrate binding subdomain of the protein, respectively. Very recently,
Colman et al. [53] characterized a 13-year-old girl with a rather mild phenotype with short stature,
short neck, craniofacial dysmorphism, joint hypermobility with dislocation, foot deformities, and mild
osteopenia without fractures. The patient was homozygous for the c.416C>T, p.(Thr139Met) missense
variant in the donor substrate binding subdomain.
Alazami et al. [26] reported a GO–like syndrome in a patient carrying the homozygous c.245C>T,
p.(Pro82Leu) missense variant in the donor substrate binding subdomain of the protein. A detailed
clinical description is lacking, but short stature, spondyloepimetaphyseal dysplasia, cutis laxa,
generalized osteoporosis with fractures, and several bony chondromas were reported.
Finally, Jones [50], Yauy [52], and Colman et al. [53] described the most severely affected patients
reported hitherto, all harboring the same c.667G>A, p.(Gly223Ser) missense mutation in the acceptor
substrate binding subdomain of the protein. Jones et al. [50] reported a 12-month-old boy with
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short stature, hypotonia, global developmental delay, radioulnar synostosis, metaphyseal flaring,
craniofacial dysmorphism, sandal gap, bilateral club feet, septal defects, and multiple fractures. Novel
findings included blue sclerae, bilateral glaucoma, diaphragmatic hernia, small chest, arachnodactyly,
lymphedema, hearing loss, and perinatal cerebral infarction. Colman et al. [53] characterized
an infant, who died at the age of 2.5 months and showed cutis laxa, contractures of large and small
joints, finger and foot anomalies, short neck, severe asymmetric thorax, dolichocephaly and other
facial dysmorphic features, multiple long bones fractures, and bilateral corneal clouding. Likewise,
Yauy et al. [52] reported six patients, who all died before one year of age, with craniosynostosis, midface
hypoplasia, radioulnar synostosis, multiple neonatal fractures, dislocated joints, joint contractures,
and cardiovascular abnormalities. The authors suggested that a B3GAT3-related disorder with
craniosynostosis and bone fragility should be considered as a differential diagnosis in the prenatal
period for ABS and in the postnatal period for SGS. Indeed, ABS is suspected during pregnancy if
ultrasonography shows craniofacial deformities due to craniosynostosis (a hallmark of ABS), midface
hypoplasia, bilateral radiohumeral, or radioulnar synostosis [52,75]. In the postnatal period, SGS
can also be suspected, based on the association of craniosynostosis and arachnodactyly. Indeed,
SGS is characterized by craniosynostosis and distinctive craniofacial features, skeletal anomalies
(arachnodactyly, dolichostenomelia, camptodactyly, pes planus, pectus excavatum or carinatum,
kyphoscoliosis), cardiovascular anomalies, intellectual deficiency, and brain anomalies [76].
Interestingly, our patient received a diagnosis of SGS in infancy, though there was the absence of
several cardinal features, above all intellectual disability and brain abnormalities. Overall, the clinical
presentation of our patient is consistent with a moderate-severe LRS-like phenotype, characterized
by short stature, hypotonia, joint hypermobility with recurrent dislocations, radioulnar synostosis,
peculiar fingers, foot deformities, midface hypoplasia, short neck, and cardiovascular abnormalities.
Of note, although severe osteopenia was present, our patient never experienced fractures. Other
features observed in our patient such as skin hyperextensibility, pectus carinatum, atlantoaxial and
atlanto-occipital instability, severe kyphoscoliosis, and blue sclerae have been rarely reported in other
individuals with B3GAT3 mutations, while easy bruising, atrophic scarring, and anterior ectopic anus
are novel findings (Table 2). Since most of the initial reports focused on a particular aspect of the
phenotype, mostly skeletal features, it remains possible that cutaneous and other systemic features
that were present have not been described.
The heterogeneous LK phenotypes, ranging from mild to severe and even lethal presentations,
seem to be related to specific B3GAT3 mutations, though there has been a limited number of patients
and pathogenic variants described so far (Table 2, Figure 4) [52,53].
In particular, the more severe phenotypes appear to harbor mutations located within the
acceptor substrate binding subdomain of the catalytic domain of the protein, whereas more mildly
affected patients seem to have mutations in the donor substrate binding subdomain [52,53,77].
The intermediated phenotype of our patient, compound heterozygous for missense variants in both
these subdomains (p.(Arg161Trp) in the donor and p.(Arg297Trp) in the acceptor substrate binding
subdomain, respectively), corroborates this preliminary genotype–phenotype correlation.
Concerning the p.(Arg161Trp) missense variant, Fondeur-Gelinotte et al. [78] previously
demonstrated the importance of this residue in the uridine-diphosphate (UDP)-GlcA donor binding
site by site-directed mutagenesis and biochemical analyses. Concerning the consequence of the
p.(Arg297Trp) missense variant in the acceptor substrate binding subdomain, in silico modeling using
the Hope software [79] suggested that its 3D structure should be severely compromised. Indeed,
the wild type residue forms either a hydrogen bond with a glutamic acid at position 295 or a salt
bridge with glutamic acid at positions 206 and 295. The differences in size and hydrophobicity between
the wild type and mutant residue are predicted to perturb both the hydrogen bond and the ionic
interaction, thus likely abolishing the GlcAT-I activity.
136
Genes 2019, 10, 631
Figure 4. Schematic illustration of the B3GAT3 structure and glucuronosyltransferase I protein domains.
The different B3GAT3 pathogenic variants found in all patients reported thus far [1-8, present study]
are shown over the diagram. The variants identified in this study are in red. Variants are annotated
according to HGVS nomenclature (reference sequences: NM_012200.3, NP_036332.2). (Below) The
protein structure of GlcAT-I is reported with its multiple domains. In different grey scales from
the N-terminus (NH2) to the C-terminus (COOH), the small cytoplasmic domain (residues 1–7),
the transmembrane domain (residues 8–25), and the proline-rich stem region (residues 26–74); in blue
and green the catalytic domain consisting of the UDP-GlcUA (uridine diphosphate—(β-D-) glucuronic
acid) donor substrate binding subdomain (residues 75–197, in blue), and the acceptor substrate binding
subdomain (residues 198–308, in green), according to references [71,72,78].
The impression that LKs, even though likely not fully characterized yet, should be considered as
a phenotypic continuum emerges from the comparison of all LK patients reported up to now (Table 3),
which shows several overlapping clinical features, but also some differences. These data support the
idea that the enzymes involved in the biosynthesis of the PG linker region may be part of a larger
enzyme complex rather than functioning independently, and that the existing phenotypic disparity
could be due to varying levels and spatiotemporal gene expression in different tissues [23,48].
Table 3. Clinical features of linkeropathies.
Genes B3GAT3 B4GALT7 B3GALT6 SLC39A13 XYLT1 XYLT2
Number of patients n = 26 n = 32 n = 46 n = 9 n = 28 n = 20
Skeletal
Short stature 18/23 29/29 36/46 + + 7/17
Joint hypermobility 10/19 + 37/46 + 13/14 2/5
Joint dislocation 9/25 + 37/46 + 14/14 na
Joint contractures (hands, elbow) 19/24 4/9 30/46 3/9 4/5 na
Low bone density/osteopenia 10/11 6/32 20/46 7/9 2/2 15/15
Multiple fractures 8/18 1/10 21/46 na na 19/19
Kypho/scoliosis 8/24 7/32 32/46 1/7 10/12 12/13
Platyspondyly 1/20 - 13/36 + 5/9 18/18
Peculiar fingers a 25/25 1/30 13/36 7/7 19/20 9/12
Foot deformity b 22/25 9/10 24/46 8/8 9/13 12/12
Pectus excavatum/carinatum 3/19 1/1 2/10 na 10/12 4/4
Radioulnar synostosis 11/13 18/31 1/36 - na na
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Table 3. Cont.
Genes B3GAT3 B4GALT7 B3GALT6 SLC39A13 XYLT1 XYLT2
Metaphyseal flaring 3/5 4/8 23/46 4/6 4/4 0/1
Monkey-wrench femora 0/4 1/2 na na 11/12 na
Iliac abnormalities 2/4 - 27/46 - 4/4 2/2
Radial head subluxation or
dislocation
3/5 17/31 15/36 3/6 1/1 na
Bowing of limbs 5/19 7/32 13/46 8/8 5/5 na
Advance bone age/carpal
ossification
0/10 1/32 5/16 na 13/14 -
Craniofacial
Midface hypoplasia 24/25 na 8/10 0/6 1/1 na
Flat face 1/4 29/32 22/36 1/1 18/18 na
Craniosynostosis 12/15 6/8 1/36 - na na
Frontal bossing 4/12 - 29/46 + na na
Wide forehead 2/5 29/32 na na 1/1 1/1
Blue sclerae 8/17 6/10 30/46 + 5/6 2/6
Proptosis or prominent eyes 12/14 28/30 20/46 + 6/7 na
Wide-spaced eyes 3/7 28/32 - 1/1 1/1 4/4
Low-set ears 2/8 7/10 20/46 na na 4/4
Depressed nasal bridge 13/20 - 10/46 1/1 21/21 4/4
Small mouth/microstomia 10/19 28/30 - - 2/2 na
Long upper lip/long philtrum 4/4 - 15/36 na 6/6 1/1
Cleft palate/bifid uvula 4/4 4/31 6/46 3/8 7/16 na
Micrognathia 9/17 3/32 14/46 - 3/3 na
Short and/or webbed neck 13/19 - - 8/8 5/5 4/4
Abnormal dentition 1/2 6/10 17/46 8/9 3/5 2/14
Ocular
Refractive errors/hypermetropia 3/5 12/29 1/10 1/9 1/5 14/14
Clouded cornea 2/4 1/30 1/46 - 0/5 na
Cataract 0/26 0/30 na na 0/5 18/20
Retinal detachment 0/26 Na na na 0/5 9/16
Cutaneous
Hyperextensible, soft, doughy,
thin, translucent skin; cutis laxa
4/15 30/32 29/46 + 2/2 1/5
Atrophic scarring 1/5 4/32 10/46 5/7 na na
Other
Cardiovascular abnormalities 13/20 - 2/36 - 1/9 7/19
Muscle hypotonia 6/7 10/32 21/46 3/3 2/2 10/10
Delayed motor development 5/5 8/10 12/46 3/6 10/13 6/13
Delayed cognitive development 1/18 19/32 14/46 0/6 17/19 9/17
Deafness 1/3 2/32 2/46 - 2/8 12/20
Note: na, not available; +, present in all patients; -, absent in all patients; a: Peculiar fingers including long, slender,
tapered, broad, thin, arachnodactyly; b: Foot deformity including pes planus, hallux valgus, club feet, sandal gap;
B3GAT3: ([26,47–53], present patient); B4GALT7: [15–21,32]; B3GALT6: [22–28], SLC39A13: [29–31], XYLT1: [33–40];
XYLT2: [41–46].
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The phenotypic features with a high rate of incidence shared among all LKs include short stature,
joint laxity with dislocations, craniofacial dysmorphism (especially prominent forehead/eyes and blue
sclerae), pectus abnormalities, peculiar fingers, foot deformities, and to a variable degree hypotonia
and developmental delay. Delayed cognitive development is instead more frequently observed in
XYLT1-related DBQD2, followed by XYLT2-related SOS, and B4GALT7- and B3GALT6-spEDS (Table 3).
While joint hypermobility is a common trait of all LKs, joint contractures are more frequently
observed in patients with B3GAT3 and B3GALT6 mutations. Low bone mineral density/osteopenia
and radiographic abnormalities are also very common, whereas generalized osteoporosis and
multiple fractures are more frequently encountered in B3GALT6-spEDS and in SOS. Likewise, among
the numerous radiographic findings, severe progressive kyphoscoliosis is particularly frequent in
B3GALT6-spEDS, SOS, and DBQD2. In addition to progressive (kypho)scoliosis, short long bones
with a monkey wrench or Swedish key appearance of the femora, and advanced carpal and tarsal
ossification are also more frequently observed in DBQD2 (Table 3). Of note, the presence or absence
of specific hand anomalies, comprising an extra-ossification center distal to the second metacarpal,
delta phalanx, or bifid distal thumb phalanx, together with dislocations of the interphalangeal joints
are considered radiographic hallmarks distinguishing DBDQ1 (resulting from pathogenic variants
in CANT1) from DBDQ2 [34]. Platyspondyly, a hallmark of “spondylo”-dysplasia, has never been
recognized in B4GALT7-spEDS and B3GAT3-related disorders, except in the patient reported by
Alazami et al. [26], whereas it is frequently reported either in B3GALT6- and SLC39A13-spEDS or in
SOS, whereas in DBDQ2 it was recognized in five out of the nine investigated patients. Radioulnar
synostosis seems more specific for B3GAT3-and B4GALT7-related disorders, the latter including either
B4GALT7-spEDS (8/10) or Larsen of Reunion Island syndrome (10/21). Radiographic anomalies that
are more common in B3GALT6-spEDS when compared to other LKs comprise metaphyseal flaring,
iliac abnormalities, radial head subluxation/dislocation, which is also frequent in B4GALT7-spEDS,
and bowing of limbs, which is shared with SLC39A13-spEDS (Table 3).
Among the plethora of craniofacial dysmorphism, midface hypoplasia, craniosynostosis, and
short/webbed neck are particularly frequent in B3GAT3-related disorders. Wide forehead, hypertelorism,
and microstomia are more common in B4GALT7-spEDS, whereas frontal bossing, micrognathia, and
abnormal dentition characterize B3GALT6- and SLC39A13-spEDS. Flat face is shared among all spEDS
subtypes and DBDQ2 (Table 3).
Ocular involvement might facilitate the differential between SOS and other LKs. In particular,
the presence of cataract, retinal detachment has been described thus far only in patients with XYLT2
mutations. Refractive errors/hypermetropia is also frequent in SOS, but has also been found in
B4GALT7-spEDS and B3GAT3-disorders. Apart from eye involvement, deafness is also more frequent
in SOS when compared to the other LKs (Table 3).
Marked cutaneous anomalies including hyperextensible, soft, doughy, thin and translucent skin,
and atrophic scarring seem to distinguish spEDS patients, party justifying their inclusion within
the EDS spectrum. On the other hand, in all the other LKs, several patients (including ours) with
skin hyperextensibility and other abnormalities (including even cutis laxa-like features) have been
published (Table 3). As above-mentioned for B3GAT3, it remains possible that in more than a few
patients, the cutaneous involvement was not investigated. Therefore, further reports are needed to
define the real incidence of skin abnormalities in LKs.
Concerning cardiovascular involvement, anomalies such as septal defects, aortic valve dysplasia,
aortic root and ascending aorta dilatation, and mitral valve prolapse, are more recurrent in B3GAT3-related
disorders as well as in SOS (Table 3).
5. Conclusions
In summary, our findings expand the B3GAT3 allelic repertoire, corroborate the emergent
genotype-phenotype correlations, and confirm the extended phenotypic range of B3GAT3 mutations
overlapping skeletal dysplasia and soft HCTDs including EDS. Furthermore, we provided a comprehensive
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overview of the phenotypic features of B3GAT3-related disorders and of all the LKs, thus offering future
nosologic perspectives for either EDS or skeletal dysplasias. Given the convergent pathogenic pathway
and the important clinical overlap not only among B3GAT3-associated diseases and spEDS (a term that,
in our opinion, is unfortunate, since platyspondyly is not present in all subtypes), but also with DBDQ2
and SOS, this group of HCTDs should be considered as a phenotypic continuum and not as distinct
entities.. In the genetic era of the classification of disorders, we propose that the term LK is preceded by the
specific causal gene. Further reports on additional patients are awaited as well as functional studies on
the spatiotemporal expression of the different glycosyltransferases to unravel the molecular mechanisms
involved in the pathophysiology of LKs needed to identify potential therapeutic options.
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Grigelioniene, G.; et al. Spondyloocular Syndrome: Novel Mutations in XYLT2 Gene and Expansion of the
Phenotypic Spectrum. J. Bone Miner. Res. 2016, 31, 1577–1585. [CrossRef]
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Abstract: Recessive loss-of-function variants in SLC39A13, a putative zinc transporter gene, were
first associated with a connective tissue disorder that is now called “Ehlers–Danlos syndrome,
spondylodysplastic form type 3” (SCD-EDS, OMIM 612350) in 2008. Nine individuals have been
described. We describe here four additional affected individuals from three consanguineous families
and the follow up of two of the original cases. In our series, cardinal findings included thin and finely
wrinkled skin of the hands and feet, characteristic facial features with downslanting palpebral fissures,
mild hypertelorism, prominent eyes with a paucity of periorbital fat, blueish sclerae, microdontia,
or oligodontia, and—in contrast to most types of Ehlers–Danlos syndrome—significant short stature
of childhood onset. Mild radiographic changes were observed, among which platyspondyly is a
useful diagnostic feature. Two of our patients developed severe keratoconus, and two suffered from
cerebrovascular accidents in their twenties, suggesting that there may be a vascular component
to this condition. All patients tested had a significantly reduced ratio of the two collagen-derived
crosslink derivates, pyridinoline-to-deoxypyridinoline, in urine, suggesting that this simple test
is diagnostically useful. Additionally, analysis of the facial features of affected individuals by
DeepGestalt technology confirmed their specificity and may be sufficient to suggest the diagnosis
directly. Given that the clinical presentation in childhood consists mainly of short stature and
characteristic facial features, the differential diagnosis is not necessarily that of a connective tissue
disorder and therefore, we propose that SLC39A13 is included in gene panels designed to address
dysmorphism and short stature. This approach may result in more efficient diagnosis.
Keywords: Ehlers–Danlos syndrome; SLC39A13; dysmorphology; short stature; connective tissue;
DeepGestalt technology
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1. Introduction
The Ehlers–Danlos syndrome (EDS) is a group of disorders that affect connective tissues in the
skin, ligaments, joints, blood vessels, and other organs. Defects in connective tissue cause a wide
range of clinical manifestations, from mildly loose joints to life-threatening conditions, such as arterial
bleeds. From the original description as a disorder of hyperelastic skin and lax joints at the beginning
of the 20th century [1], a first classification with four main types was proposed in 1970 [2]; molecular
advances have allowed the recognition of many distinct disorders that, although different from the
classic EDS types described by Beighton, have been given the moniker of “Ehlers–Danlos syndrome” as
a reflection of the presence of connective tissue fragility. Thus, the recent version of EDS classification
has been expanded to include a wide range of disorders, including skeletal dysplasia [3]. However, the
clinical criteria remain relatively non-specific, and clinical diagnosis can be difficult.
A connective tissue disorder associated with recessive biallelic variants in SLC39A13, and a
mouse knock-out model for the same gene, were described in 2008 by two separate but collaborating
groups [4,5]. The features noted in these eight patients were postnatal-onset short stature, protuberant
eyes with bluish sclerae and down-slanting palpebral fissures, thin and moderately hyperelastic skin
with bruisability, and hands with finely wrinkled palms, tapering fingers, thenar atrophy, and moderate
hypermobility of the small joints. Skeletal radiographs showed a moderate degree of platyspondyly
with irregular vertebral end plates as well as minor epimetaphyseal changes in appendicular bones.
A reduced molar ratio of pyridinoline-to-deoxypyridinoline in urine was observed, indicating reduced
collagen lysyl hydroxylation. The latter finding is typically observed in collagen lysyl hydroxylase
deficiency (EDS type VI-A), but in that condition, there is severe muscular hypotonia from birth,
progressive kyphoscoliosis, and normal height (apart from kyphoscoliosis). Additionally, there were no
pathogenic mutations in PLOD1; instead, the patients reported by Giunta et al. (2008) were homozygous
for an in-frame 9-bp deletion in SLC39A13, c.483_491del (p.F162_164del), while those reported by
Fukada et al. (2008) were homozygous for the SLC39A13 variant c.221G>A (p.G74D). The novel
condition was given the name of “spondylo-cheiro-dysplastic EDS” for the distinguishing features of
the hand and the platyspondyly [4,5]. Later, the EDS nosology has used the name “spondylodysplastic
EDS” for a group of three conditions, B3GALT6 deficiency (better known as spondyloepimetaphyseal
dysplasia with joint laxity, Beighton type), B4GALT7 deficiency, and SLC39A13 deficiency (the original
spondylo-cheiro-dysplastic type) [3]. Of note, these three conditions are also included in the 2019
revision of the skeletal dysplasia nosology [6]. SLC39A13 deficiency is rare and following the initial
eight affected individuals, only a single case report has been published [7]. We present a follow up
of two of the original patients [5] as well as clinical, radiological, and genetic findings on four new
patients from three families.
2. Materials and Methods
All affected individuals and/or their legal representatives in the study gave their informed consent
to the use of their clinical data, as well as for molecular studies in a diagnostic context (see below).
2.1. Molecular Analysis
Molecular studies for patients 1 and 2 were done in the Lausanne laboratory as described [5].
Molecular studies in patients 3 to 6 were done for diagnostic purposes with appropriate informed
consent from patients and their guardians. The studies were done using routine diagnostic sequencing
procedures in certified diagnostic laboratories: Analysis for patients 3, 5, and 6 was done in Lausanne,
while the analysis of patient 4 was done in Nijmegen.
2.2. Analysis of Pyridinium Crosslink Products by HPLC
Spot urine samples were acid hydrolyzed and analyzed by reverse-phase HPLC as previously
described [4].
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2.3. Analysis of Facial Features
Anonymized frontal facial photographs of individuals with confirmed biallelic SLC39A13 variants
were used to capture the facial gestalt of SLC39A13 deficiency and to compare it to individuals who
are clinically normal. All images were fully de-identified through the use of the DeepGestalt image
analysis technology [8]. De-identified data of images from 8 patients (the six patients reported here,
plus two of the patients described by Giunta et al. (2008) whose photographs had been submitted to us
for clinical consultation) were uploaded to the Face2Gene Research app [9] and matched to controls by
age, sex, and ethnicity to produce artificial composite images. Because of the small number of patients,
the comparison was run twice [10] with two different sets of matched controls. The comparison
and separation quality between the three groups was evaluated by measuring the area under the
curve (AUC) of the receiver operating characteristic (ROC) curve. To estimate the statistical power
of DeepGestalt in distinguishing affected individuals from controls, a cross-validation scheme was
used, including a series of binary comparisons between all groups. For these binary comparisons, the
data was split randomly multiple times into training sets and test sets. Each such set contained half of
the samples from the group, and this random process was repeated 10 times [8,10]. The results of the
binary comparisons were reported both numerically and graphically.
2.4. Clinical Reports
2.4.1. Individuals 1 and 2 (reported in part by Fukada et al., 2008 [5])
The parents, of Portuguese origin, were of average stature and clinically unremarkable. They were
not knowingly related, although molecular workup showed that they shared a common haplotype
harboring the SLC39A13 pathogenic variant [5]. The affected children, a boy and a girl, were born
at term from uncomplicated pregnancies and were of normal size and weight at birth but showed
progressive short stature beginning in the second half of the first year of life. Among the clinical
signs in early childhood were muscular hypotonia and soft skin, leading to the diagnostic suspicion
of the Ehlers–Danlos syndrome (EDS). During childhood, the main clinical signs and features were
thin, fragile, but not hyperelastic skin that bruised easily and was particularly thin on the hands and
feet; varicose veins; moderate joint laxity; blueish or greyish sclerae; down-slanting palpebral fissures;
and the absence of one or more teeth in permanent dentition. Both had astigmatism in childhood.
Radiographic examination revealed moderate osteopenia, flattened or biconcave vertebral bodies with
flaky irregularity of the endplates as well as mild dysplastic changes at the metaphyses of long bones
and of the phalanges. At the time of the first report, they were 28 years old and 145 cm tall (individual
1, male); and 20 years old and 135 cm tall (individual 2, female). Their body proportions were normal,
indicating that the platyspondyly was accompanied by shortening of the long bones. Their skin
remained thin and fragile, and the subcutaneous fat tissue was sparse. Both individuals had marked
venous varicosities on their legs and feet. Individual 1 suffered from a cerebral hemorrhage posteriorly
to the left putamen at age 22 years, from which he recovered completely. He has successfully completed
higher education.
Subsequent to the initial publication in 2008, individual 1 has had no further complications;
he is professionally active, has married, and his wife has given birth to a healthy child. Individual
2, his younger sister, had obtained higher education degrees at age 22 and 25 years. At age 25 years,
cerebral vascular imaging was obtained, and no abnormalities were observed. At age 26 years, two
weeks after the interruption of hormonal contraception prescribed because of irregular cycles, she
suffered from arterial thromboembolism that caused cerebral ischemia with right arm paresis and
Broca’s aphasia. Several days after initiation of aspirin therapy, she developed cerebral hemorrhage
leading to complete right hemiparesis. Fortunately, she was able to partially recover over four years
on physiotherapy but still has partial function of the right hand and myoclonus on the right arm.
She received speech/language therapy; however, she still has some degree of dysphasia. Nevertheless,
she was able to return to her previous work.
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2.4.2. Individual 3
This is a girl born by caesarean section at 33 weeks of gestation from a dizygotic twin pregnancy.
Both the patient and her twin sister were 2500 g at birth. The patient developed progressive short stature
over her first years of life, while her twin sister grew normally. Motor and intellectual development
were normal. The parents are first cousins of Turkish origin and measure 148 cm and 170 cm with
normal proportions. An elder brother had normal growth and body proportions. During her teenage
years, she developed severe keratoconus with no complications so far. She complains about back
pain and her skin bruises easily, with hematomas and blood blisters at sites of friction. Radiographic
examination of the spine at age 15 revealed platyspondyly of the thoracic and lumbar vertebrae with
mild anterior beaking. On physical examination at age 23, she had short stature. There was moderate
diffuse joint laxity most marked on the finger joints. The skin on her hands is thin and wrinkled and
she has tapering fingers with narrow end phalanges. Facial features include downslanting palpebral
fissures, a flat face, protuberant eyes with reduced periocular tissue, greyish sclerae, and a small mouth.
2.4.3. Individual 4
This boy was the fourth child from healthy parents of Turkish descent. The parents were second
cousins and measured 165 cm (father) and 158 cm (mother). His three older sibs have normal growth.
He was born after an uneventful term pregnancy with a birthweight of 3500g. He developed progressive
short stature over his first years of life and was first seen by a pediatrician at age 8 1/2 years. Height
was 113.4cm (−3.8 SDS) and weight was 23.5kg (−1.5 SDS). Psychomotor development was normal.
He complained of knee and ankle pain after exercise. He had mild weakness of the hands, making
it difficult to open bottles. He had no clear dysmorphic features, but his palpebral fissures were
down-slanting and he had oligodontia (missing five teeth). He has had no eye complication so far.
He had a short trunk and stands with lumbar hyperlordosis. He had loose skin on hands and feet,
moderate hyperlaxity of fingers and toes, valgus deformity of the ankles, and bilateral pes planus.
Radiological examination showed platyspondyly of the thoracic and lumbar spine with mild anterior
beaking and mild metaphyseal irregularities especially of the distal ulna. He first received a clinical
diagnosis of spondylometaphyseal dysplasia. Molecular analysis of SHOX, FGFR3, TRPV4, and
LTBP3 were negative, but further studies showed a biallelic missense change in SLC39A13 (Table 1).
Additional urine analysis showed a low ratio of pyridinoline-to-deoxypyridinoline (Figure 3).
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2.4.4. Individuals 5 and 6
The family originates from Syria and access to early medical records is impossible. The parents,
who are first cousins, are clinically healthy and measure 150 cm in height (mother) and 160 cm (father).
The proband (patient 6; Figure 1) is a 9-year-old boy referred for evaluation for small stature. We found
that his elder sister is similarly affected (patient 5), while a younger sister is clinically normal. Individual
6 was born at term after an uneventful pregnancy, although IUGR was noted and the mother reports
reduced fetal movements throughout the pregnancy. Birth data were not recorded, but the mother
remembers his length to be reduced. At birth, the mother noted the he had no spontaneous movements,
had edema on both feet, and increased palmar creases on his hands and feet. Throughout childhood,
psychomotor development was slightly delayed, but intelligence and behavior at age 9 years were
normal. At this age, his growth parameters were height 111 cm (−3.9 SD), weight 19 kg (−3.3 SD),
and head circumference 51.5 cm (−0.78 SD). He had down-slanting palpebral fissures, protruding
eyes, hypertelorism, and a large forehead. An ophthalmologic evaluation revealed bilateral myopia
and marked keratoconus. Hearing was normal. Four teeth of the permanent dentition were found
to be missing. His elbow joints appeared prominent, but he had no other signs of joint deformity or
scoliosis. He had hyperlaxity of small joints and complained occasionally of joint pain particularly
in his knees. The skin was thin and wrinkled, particularly on the palmar side of his hands and feet,
and the thenar muscles were underdeveloped. Radiographic studies showed small epiphyses and
posterior subluxation of the radii and mild platyspondyly. Routine blood tests were unremarkable.
Analysis of SHOX done prior to referral was negative.
 
Figure 1. Clinical and radiographic findings. Individuals 5 (panels A and B) and 6 (panels A and
C) at the age of eight and ten years. Panels D and E: missing upper incisives, and missing lower
incisives with persistence of primary teeth in individuals 6 at age 9 years. Panel F: foot of individual 6
showing finely wrinkled skin and abnormally deep furrows. Panel G: Palmar aspects of the hands
of individual 5 showing thin skin with increased number of fine wrinkles and mild thenar and
hypothenar atrophy. Panel H shows the hand radiograph of individual 5 at age ten years. There is
mild diaphyseal overconstriction of radius and ulna, metacarpals, and phalanges; bone maturation is
roughly appropriate; overall, the changes are mild and non-diagnostic. Panels I and K: lateral spine
radiographs of individual 3. At age 6 years, there is moderate platyspondyly. At age 15, the end plates
have a marked concave conformation.
Individual 5 is the older sister of individual 6. According to the birth date declared at immigration,
she would be 10 years old. However, we doubt the accuracy of this date and suspect that she is older
than the stated age. Birth parameters have not been recorded. Her growth parameters were as follows:
height 131.5 cm (−1 SD for age 10), weight 29 kg (−0.81 SD for age 10), and head circumference 51.5 cm
(−0.55 SD for age 10). Shortly after she was referred, she had menarche and her growth has slowed
down significantly. She had protruding eyes and a large forehead, but her facial appearance was
less conspicuous than that of her brother or other affected individuals. She had myopia, and four
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incisor teeth were missing. Intelligence and hearing were normal. She had long tapering fingers and
her interphalangeal joints were hyperextensible. The skin was thin and wrinkled, particularly on the
palmar side of her hands and feet.
3. Results
Figure 1 shows some clinically relevant clinical and radiographic features in SLC39A13-deficient
individuals.
Table 1 shows the genetic variants identified in SLC39A13. Of note, the variants were homozygous
in all patients, underlining the rarity of the disorder.
Figure 2 shows the results of the automated DeepGestalt technology. Both comparisons (SLC39A13
group vs. control group 1, and SLC39A13 group vs. control group 2) gave highly significant results
(AUC= 0.991 p = 0.006 and AUC= 0.986 p = 0.004).
Figure 2. DeepGestalt technology analysis of facial features in SLC39A13 deficiency. The upper part
shows the “averaged” artificial composite facial gestalt image of individuals with SLC39A13 deficiency
(panel A) vs. two matched control groups (panels B and C). The lower part shows the result of the
comparisons between A vs. B, and A vs. C.
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Figure 3 shows the ratio of the collagen crosslink derivates, pyridinoline and deoxypyridinoline,
in the urine of five patients and five roughly age-matched controls. The ratio of pyridinoline-to-
deoxypyridinoline is reduced in the SLC39A13-deficient subjects, indicating a relative deficiency of the
hydroxylated form, pyridinoline, relative to the non-hydroxylated form, deoxypyridinoline. The values
clearly segregated in two distinct clusters with no overlap. In addition to confirming the notion of
reduced lysyl hydroxylation as a pathogenic mechanism in these patients, the findings show that
determination of urinary crosslink derivates can be a useful diagnostic screening method. Anecdotally,
because of the role of vitamin C in collagen hydroxylation, individuals 1 and 2 took an oral dose of
1000 mg of vitamin C over four weeks and sent us urine samples for analysis before and twice during
the test period. Unfortunately, there was no change in the pyridinoline-to-deoxypyridinoline ratio.
Figure 3. Ratio of the collagen crosslink derivates, pyridinoline and deoxypyridinoline, in the urine of
five SLC39A3-dificient individuals and in five roughly age-matched controls. The ratio is consistently
lower in SLC39A13-deficient individuals, with no overlap to the control group.
4. Discussion
4.1. Clinical Aspects of SCL39A13 Deficiency
Our observations confirm the previous findings of Giunta et al. (2008), Fukada et al. (2008), and
Dusanic et al. (2018) that SLC39A13 deficiency is associated with a clinical phenotype characterized by
post-natal short stature, connective tissue weakness affecting mainly the skin and peripheral joints,
a characteristic facial appearance, and a moderate skeletal dysplasia. These additional observations
help to delineate a more precise phenotype.
Muscular hypotonia—This has been seen in several SLC39A13 patients in the neonatal period
and in early childhood; in the patient described by Dusanic et al. (2018), muscular hypotonia was
conspicuous enough to lead to investigations for myopathy with some abnormal (though non-specific)
findings in a muscle biopsy at adolescence. While the prevalence of myopathy in SLC39A3 deficiency
and its structural features remain to be investigated, the observations confirm the well-known
phenomenon that connective tissue diseases, and particularly EDS type VI-A (lysyl hydroxylase
deficiency), may present as the “floppy infant” phenomenon and/or with hypotonia with delayed
motor development.
Growth and stature—postnatal reduced linear growth seems to be a salient and consistent feature
of SLC39A13 deficiency; this is in contrast to other types of connective tissue disease and EDS types,
where short stature is not a prominent feature. The two other forms of “spondylodysplastic EDS”,
namely B3GALT6 deficiency and B4GALT7 deficiency, are also associated with short stature, but in
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those conditions, short stature can be explained by skeletal dysplasia. In SLC39A13, body proportions
are normal and short stature seems to be more intrinsic and represents a true growth failure and not a
consequence of bone dysplasia.
Eye findings—Myopia has been reported in several SLC39A13 patients and also seems to be a
direct (though non-specific) manifestation of the primary genetic defect. This may be connected to
the thin sclerae that often have a blueish or greyish color, particularly in individuals with darker
pigmentation. Keratoconus, as seen in three patients, is potentially dangerous because of the possibility
of perforation or rupture; ophthalmologic investigation should be recommended in all confirmed cases.
Dental features—Absence of one or several incisor teeth in the permanent dentition has been
observed in a majority of SLC39A13-deficient individuals. In our case 6, the lower incisors of the
primary dentition were also small and dysplastic. Hypodontia and oligodontia are consistent, if perhaps
not obligate, features of the disorder.
Vascular complications—marked varicosities of the lower legs have been described in a number
of SLC39A13 patients. Clinically, more importantly, the two elder patients known (patients 1 and 2 in
Fukada et al. (2008) and in this study) have both suffered cerebral hemorrhage. While this may not be
statistically significant and may even be causally unrelated (e.g., hormonal contraception in patient 2),
it is worth keeping in mind as a potential complication. Fortunately, other major vascular events have
thus far not been recorded.
Facial features—analysis of the facial features with the DeepGestalt technology and comparison
with age-matched controls confirms that there is an SLC39A13-associated facial phenotype that is
significantly divergent from that of control individuals. This phenotype includes a rather flat face,
mild hypertelorism, downslanting palpebral fissures, lack of periocular connective tissue giving the
impression of prominent eyes, and a small mouth. The Face2Gene system evoked a few other syndromes
with some resemblance to the SLC39A13 phenotype, such as Noonan syndrome (downslanting
palpebral fissures), Stickler syndrome (flat face; associated with COL2A1 haploinsufficiency), as well
as—interestingly—the vascular type of EDS (EDS IV; dominant COL3A1), probably because of the
“hollow eyes”. Thus, analogy between SLC39A13 deficiency and vascular EDS may include vascular
fragility as well as a moderate resemblance of facial features.
4.2. What Are the Pathogenetic Mechanisms Leading from SLC39A13 Loss of Function to the Complex
Clinical Phenotype?
The pathogenesis of SLC39A13 deficiency remains poorly understood. The observation of reduced
collagen hydroxylation indicates that a partial failure of collagen crosslinking is one pathogenic
mechanism [4], and the determination of pyridinoline-to-deoxypyridinoline is a useful diagnostic
help. As correctly indicated by Giunta et al. (2008), the hydroxylation defect probably involves
collagens other than collagen 1, such as collagen 2 and collagen 3, and this may explain the mild
chondrodysplastic features (collagen 2) as well as the thin and fragile skin and the putative vascular
fragility (collagen 3). However, it is difficult to ascribe the short stature, facial features, and oligodontia
solely to reduced collagen hydroxylation. The hypothesis that part of the pathogenesis may involve
the role of zinc as an intracellular messenger [5] may be justified, but experimental evidence is lacking;
in particular, SLC39A13 individuals do not show signs of immune system dysfunction in contrast with
the mouse model [5,11].
4.3. Diagnosis
From the diagnostic perspective, presentation with short stature and dysmorphic facial features
may lead pediatricians and clinical geneticists to classify these patients within the group of genetic
syndromes rather than connective tissue disorders; this “syndromic” presentation of SLC39A13 is not
well known and this report may help raise awareness of this condition and its presenting features
among clinical geneticists and dysmorphologists.
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Abstract: Musculocontractural Ehlers–Danlos Syndome (mcEDS) is a type of EDS caused by biallelic
pathogenic variants in the gene for carbohydrate sulfotransferase 14/dermatan 4-O-sulfotransferase 1
(CHST14/D4ST1, mcEDS-CHST14), or in the gene for dermatan sulfate epimerase (DSE, mcEDS-DSE).
Thus far, 41 patients from 28 families with mcEDS-CHST14 and five patients from four families with
mcEDS-DSE have been described in the literature. Clinical features comprise multisystem congenital
malformations and progressive connective tissue fragility-related manifestations. This review
outlines recent advances in understanding the pathophysiology of mcEDS. Pathogenic variants
in CHST14 or DSE lead to reduced activities of relevant enzymes, resulting in a negligible amount of
dermatan sulfate (DS) and an excessive amount of chondroitin sulfate. Connective tissue fragility
is presumably attributable to a compositional change in the glycosaminoglycan chains of decorin,
a major DS-proteoglycan in the skin that contributes to collagen fibril assembly. Collagen fibrils in
affected skin are dispersed in the papillary to reticular dermis, whereas those in normal skin are
regularly and tightly assembled. Glycosaminoglycan chains are linear in affected skin, stretching
from the outer surface of collagen fibrils to adjacent fibrils; glycosaminoglycan chains are curved in
normal skin, maintaining close contact with attached collagen fibrils. Homozygous (Chst14−/−) mice
have been shown perinatal lethality, shorter fetal length and vessel-related placental abnormalities.
Milder phenotypes in mcEDS-DSE might be related to a smaller fraction of decorin DS, potentially
through residual DSE activity or compensation by DSE2 activity. These findings suggest critical roles
of DS and DS-proteoglycans in the multisystem development and maintenance of connective tissues,
and provide fundamental evidence to support future etiology-based therapies.
Keywords: musculocontractural Ehlers–Danlos Syndome; carbohydrate sulfotransferase-14
(CHST14)/dermatan 4-O-sulfotransferase-1 (D4ST1); CHST14; dermatan sulfate epimerase (DSE);
DSE; dermatan sulfate (DS); decorin; collagen
1. Introduction
Musculocontractural Ehlers–Danlos Syndome (mcEDS) is a type of EDS, caused by biallelic
pathogenic variants in the gene for carbohydrate sulfotransferase 14/dermatan 4-O-sulfotransferase 1
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(CHST14/D4ST1, mcEDS-CHST14) (MIM#601776), or in the gene for dermatan sulfate epimerase (DSE,
mcEDS-DSE) (MIM#615539) [1–3]. mcEDS-CHST14 was originally described as three independent
conditions: A rare type of arthrogryposis syndrome “adducted thumb-clubfoot syndrome” [4];
a specific type of EDS “EDS, Kosho type” [5,6]; and a subset of kyphoscoliosis type without
lysyl hydroxylase deficiency [7]. To date, 41 patients from 28 families have been reported to have
mcEDS-CHST14 [4–22]. mcEDS-DSE was identified in a patient with a phenotype similar to that of
patients with mcEDS-CHST14 [23], as well as in four additional patients from three families [18,24].
These disorders were defined as subtypes of EDS, based on the International Classification of the EDSs [3].
Clinical features are highly characteristic, comprising multisystem congenital malformations such as
craniofacial features (e.g., large fontanelle, hypertelorism, short and downslanting palpebral fissures,
blue sclerae, short nose with hypoplastic columella, low-set and rotated ears, high palate, long philtrum,
thin upper lip vermilion, small mouth and micro-retrognathia), multiple congenital contractures
(e.g., adduction–flexion contractures of thumbs and talipes equinovarus), and visceral and ocular
malformations. Features also include progressive connective tissue fragility-related manifestations,
such as skin hyperextensibility, bruisability, and fragility with atrophic scars; recurrent dislocations;
progressive talipes or spinal deformities; pneumothorax or pneumohemothorax; large subcutaneous
hematomas; and/or diverticular perforation (Figure 1) [1,2]. Major diagnostic criteria of the disorder are
as follows: 1) congenital multiple contractures, characteristically adduction–flexion contractures and/or
talipes equinovarus (clubfoot); 2) characteristic craniofacial features, which are evident at birth or in early
infancy; 3) characteristic cutaneous features including hyperextensibility, bruisability and fragility with
atrophic scars, as well as increased palmer wrinkles [3]. Minor criteria as follows: 1) recurrent/chronic
dislocations, 2) pectus deformities (e.g., flat or excavated), 3) spinal deformities (e.g., scoliosis or
kyphoscoliosis), 4) peculiar fingers (e.g., tapered, slender, or cylindrical), 5) progressive talipes
deformities (e.g., valgus, planus, or cavum), 6) large subcutaneous hematomas, 7) chronic constipation,
8) colonic diverticula, 9) pneumothorax/pneumohemothorax, 10) nephrolithiasis/cystolithiasis, 11)
hydronephrosis, 12) cryptorchidism in males, 13) strabismus, 14) refractive errors (e.g., myopia or
astigmatism) and/or 15) glaucoma/elevated intraocular pressure [3].
In this review, we describe the comprehensive pathophysiological findings of mcEDS,
as demonstrated in previous studies including our recent reports.
Figure 1. Cont.
156
Genes 2020, 11, 43
Figure 1. Clinical photographs and radiological images of patients with mcEDS-CHST14. Clinical
photographs of a patient with heterozygous variants Pro281Leu/Try293Cys at age 23 days (A), 3 years
(B), and 16 years (C,D); those of a patient with a homozygous variant Pro281Leu at age 2 months
(H,M,N), 3 months (I), 6 years (O,P), and 28 years (J,Q); photographs of a patient with a homozygous
variant “P281L” in the neonatal period (E) and at age 30 years (F,G,T); and photographs of a patient
with heterozygous variants Pro281Leu /Cys289Ser at age 1 month (K), 16 years (V), and 19 years
(L,R,S) [5]. Radiological image of a patient with heterozygous variants Pro281Leu /Try293Cys at age 6
years (U); images of a patient with a homozygous variant Pro281Leu at age 28 years (W–Z,a) [5,13].
(U, reproduced from Kosho et al. Am. J. Med. Genet. Part A 2005, 138A, 282–287, with permission from
Wiley-Liss, Inc.; the other images, reproduced from Kosho et al. Am. J. Med. Genet. Part A 2010, 152A,
1333–1346, with permission from Wiley-Liss, Inc.).
2. Molecular Findings
Pathogenic variants have been detected throughout CHST14 (NM_130468.4): 11 missense
variants, five frameshift variants, and three nonsense variants in patients with mcEDS [4,6,7,14–19,22]
(Figure 2). The p.(Pro281Leu) variant is most common (n = 10 families), followed by
p.(Try293Cys) (n = 4), p.(Val49*) (n = 3), p.(Arg213Pro), and p.(Phe209Ser) (n = 2);
p.(Arg29Glyfs*113), p.(Lys69*), p.(Gln113Argfs*14), p.(Arg135Gly), p.(Leu137Gln), p.(Cys152Leufs*10),
p.(Arg218Ser), p.(Gly228Leufs*13), p.(Glu262Lys), p.(Tyr266*), p.(Arg274Pro), p.(Met280Leu),
p.(Cys289Ser), p.(Trp327Cysfs*29), and p.(Glu334Glyfs*107) variants are particularly uncommon
(n = 1 for all). Furthermore, p.(Gly19Trpfs*19) and p.(Lys26Alafs*16) variants have been detected in
patients with features similar to those of mcEDS, among patients with hereditary connective tissue
disorders and skeletal dysplasia, respectively (Figure 2A) [25,26]. Three missense variants have been
detected in DSE (NM_013352.4): p.(Arg267Gly), p.(Ser268Leu), and p.(His588Arg); and one frameshift
variant, p.(Pro384Trpfs*9), has also been detected (Figure 2B) [18,23,24]. Another frameshift variant,
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p.(Gly216Glufs*3), was detected in a patient with features similar to those of mcEDS, among patients
with chondrodysplasia who exhibited multiple dislocations (Figure 2B) [27].
Figure 2. Published pathogenic protein changes of D4ST1 and DSE in mcEDS. (A) Previously published
truncating and non-truncating protein alterations in D4ST1 are shown in upper and lower panels,
respectively. Black box indicates 5′-phosphosulfate binding site and gray box indicates 3′-phosphate
binding site. (B) Previously published truncating and non-truncating protein alterations in DSE are
shown in upper and lower panels, respectively. Black box indicates the signal peptide.
No apparent genotype-phenotype correlations have been reported in patients with mcEDS-CHST14.
Phenotypes of patients with mcEDS-DSE seem to be milder than those of patients with
mcEDS-CHST14 [18,24].
3. Glycobiological Findings
Normal, biosynthetic pathways of chondroitin sulfate (CS) and dermatan sulfate (DS) are shown in
Figure 3A. Reduced activity of D4ST1 in fibroblast cultures of skin from a patient with mcEDS-CHST14
caused by compound heterozygous p.(Pro281Leu)/(Tyr293Cys) substitutions in CHST14, as well as in
fibroblasts from a patient with mcEDS-CHST14 caused by a homozygous p.(Pro281Leu) substitution in
CHST14, showed a marked reduction in D4ST1 activity (Figure 3B); this change in activity resulted in
a negligible amount of DS and an excessive amount of CS (Figure 3C) [6].
Decorin, which consists of a core protein and a single glycosaminoglycan (GAG) chain, is a major
DS-proteoglycan (PG) that plays an important role in the assembly of collagen fibrils in the skin [28];
it also plays roles in the pathophysiology of mcEDS-CHST14 [1–4,6,7]. GAG chains of decorin-PG
from skin fibroblasts of a patient with p.(Pro281Leu)/(Tyr293Cys) substitutions, as well as from
skin fibroblasts of a patient with a homozygous p.(Pro281Leu) substitution, contained only CS and
no DS; in contrast, GAG chains of decorin-PG from skin fibroblasts of healthy controls contained
mainly DS (Figure 3D) [6,18]. 4-O-Sulfation in CS and DS chains functions as an inhibitor of DSE [29].
Thus, impaired 4-O-sulfation inhibition due to D4ST1 deficiency enables back-epimerization from
L-iduronic acid (IdoUA) to D-glucuronic acid (GlcUA) (Figure 3E) [4,6,7]. In our laboratory, we have
established a urinary disaccharide analysis of CS/DS chains through an anion-exchange chromatography
after treatment with DS-specific degrading enzymes; this analysis method showed that no DS was
present in the urine of eight patients with mcEDS-CHST14 [30]. This result suggested a systemic
depletion of DS in patients with mcEDS-CHST14; thus we presume that our urinary disaccharide
analysis method can be implemented to allow a non-invasive screening for mcEDS-CHST14 [30].
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Figure 3. Biosynthesis of CS/DS and glycobiological analysis in mcEDS-CHST14.
(A) Biosynthetic assembly of CS and DS chains by glycosyltransferases, epimerases, and
sulfotransferases. It starts with the biosynthesis of a tetrasaccharide linker region, glucuronic
acid-β1,3-galactose-β1,3-galactose-β1,4-xylose-β1-O-(GlcUA-Gal-Gal-Xyl-), onto serine residues
of specific core proteins of PGs by β-xylosyltransferase (XylT), GalT-I, GalT-II and
β1,3-glucuronosyltransferase-I (GlcAT-I), respectively. Subsequently, a repetitive disaccharide region
[N-acetyl-d-galactosamine(GalNAc)-GlcUA)]n of chondroitin is elongated by the actions of N-acetyl-
d-galactosaminyltransferase-I (GalNAcT-I), N-acetyl-d-galactosaminyltransferase-II (GalNAcT-II) and
glucuronyltransferase-II (GlcAT-II), which are encoded by CS N-acetylgalactosaminyltransferase-1 and
-2, chondroitin synthase-1, -2, and -3 and chondroitin polymerizing factor genes. Chondroitin chains
are matured to CS through modifications by chondroitin 4-O-sulfotransferase (C4ST), chondroitin
6-O-sulfotransferase (C6ST) and uronyl 2-O-sulfotransferase (UST). A disaccharide-repeating region
of dermatan is synthesized through epimerization of a carboxyl group at C5 from GlcUA to IdoUA
by DSE. A mature DS chain is synthesized through modification with sulfation by D4ST1 and
UST. (B) Sulfotransferase activity toward dermatan in fibroblast cultures of skin from two patients
with mcEDS-CHST14 (patient 12 with heterozygous variants Pro281Leu/Tyr293Cys; patient 14 with
a homozygous variant Pro281Leu), the mother of patient 12, and a sex- and age-matched healthy
volunteer [6]. * p < 0.0001 by two-tailed unpaired t-test. (C) Total amounts of CS and DS derived from
fibroblast cultures of skin [6]. Total disaccharide contents of CS (white box) and DS (black box) were
calculated based on the peak area in the chromatograms of the digests with chondroitinase AC and
chondroitinase B, respectively. (D) Proportion of the disaccharide units in the CS-DS hybrid chain in
decorin-PGs secreted by the fibroblasts [6]. Cyan, green, red and orange boxes are GlcUA-GalNAc(4S),
GlcUA-GalNAc(6S), IdoUA-GalNAc(4S), and IdoUA(2S)-GalNAc(4S), respectively. Abbreviations
of 2S, 4S and 6S indicate 2-O-, 4-O- and 6-O-sulfate, respectively. (E) Schematic diagram of the
biochemical mechanism in the replacement of DS by CS in mcEDS-CHST14. Defect in D4ST1 enables
a back-epimerization reaction that converts IdoUA back to GlcUA to form chondroitin by DSE, followed
by the 4-O-sulfation and/or 6-O-sulfation of GalNAc residues in chondroitin by C4ST1 and C6ST1,
respectively. (B–D, reproduced from Miyake et al. Hum. Mutat. 2010, 31, 1233–1239, with permission
from Wiley-Liss, Inc.).
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Regarding patients with mcEDS-DSE, reduced activity of DSE in fibroblast cultures of skin
from a patient with a homozygous p.(Ser268Leu) substitution resulted in marked reduction of DS
disaccharides, compared with healthy controls [23]. The total amount of CS in the cell fraction from
affected skin fibroblasts was increased by approximately 1.5-fold, which might reflect increased
synthesis and/or reduced conversion of CS chains [23]. A minor fraction of DS from decorin-PG
was present in skin fibroblasts from a patient with a homozygous p.(Ser268Leu) substitution [23];
this suggested residual DSE activity or compensation by DSE2, which might be related to milder
phenotypes in patients with mcEDS-DSE than in patients with mcEDS-CHST14 [18].
4. Pathological Findings
The pathology of mcEDS-CHST14, as the simplest model for complete depletion of
DS, has been extensively investigated using affected skin specimens. Light microscopy of
skin specimens (hematoxylin and eosin staining) from patients with compound heterozygous
p.(Pro281Leu)/(Cys289Ser) or p.(Pro281Leu)/(Tyr293Cys) substitutions showed that fine collagen
fibers were predominantly present in the reticular to papillary dermis; marked reduction of normally
thick collagen bundles were also observed (Figure 4A) [6]. Immunohistochemistry staining of decorin
core protein in skin specimens from patients with compound heterozygous p.(Pro281Leu)/(CYs289Ser)
or p.(Pro281Leu)/(Tyr293Cys) substitutions showed that decorin core protein was present on collagen
fibers that were thin and filamentous without clear boundaries; in contrast, skin specimens
from healthy controls showed decorin core protein on collagen fibers that were thick bundles
with clear boundaries [31] (Figure 4B). Transmission electron microscopy of skin specimens from
five patients with compound heterozygous p.(Pro281Leu)/(Cys289Ser), p.(Pro281Leu)/(Tyr293Cys),
or p.(Phe209Ser)/(Pro281Leu) substitutions showed that collagen fibrils were dispersed in the papillary
to reticular dermis, whereas skin specimens from healthy controls exhibited collagen fibrils that
were regularly and tightly assembled (Figure 4C) [6,31]. Transmission electron microscopy-based
cupromeronic blue staining to visualize GAG chains on affected skin samples showed that GAG
chains were linear, stretching from the outer surface of collagen fibrils to adjacent fibrils, whereas
skin samples from healthy controls exhibited curved GAG chains that maintained close contact with
attached collagen fibrils (Figure 4D) [31]. This structural alteration of GAG chains of decorin is
presumably related to the biochemical alteration from DS to CS: the structure of DS-GAG chains is
flexible because L-IdoUA residues in DS can easily adopt any of the nearly equi-energetic 1C4, 2S0,
and 4C1 conformations, whereas the structure of CS-GAG chains is rigid because D-GlcUA in CS only
adopts the 4C1 conformation [6,32,33].
Furthermore, focused ion beam scanning electron microscopy using cupromeronic blue staining
uncovered the structure of collagen fibrils in association with GAG chains (likely comprising decorin):
GAG chains form a ring mesh-like structure with each ring surrounding a collagen fibril at its D band,
fusing with adjacent rings to form a planar network [34]. Abnormally stretching CS-GAG chains of
decorin in the affected skin would disrupt the ring-mesh structure of collagen fibrils (Figure 4E), which
could result in substantial fragility.
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Figure 4. Skin pathology of mcEDS-CHST14. (A) Light microscopy (hematoxylin and eosin staining).
In the skin specimen from a patient with heterozygous variants Pro281Leu/ Cys289Ser (panel p),
fine collagen fibers are present predominantly in the reticular to papillary dermis with marked
reduction of thick collagen bundles; thick collagen bundles are observed in a skin specimen from
a healthy control volunteer (panel c) [6]. (B) Immunohistochemical staining for decorin core protein.
Decorin core protein is present on collagen fibers in thick bundles in a skin specimen from a healthy
control volunteer (panel c), but on thin and filamentous collagen fibers without clear boundaries
in a skin specimen from a patient with heterozygous variants Pro281Leu/ Cys289Ser (panel p) [31]
(C) Transmission electron microscopy. Collagen fibrils are regularly and tightly assembled in a skin
specimen from a healthy control volunteer (panel c), but are dispersed in the papillary to reticular
dermis in skin specimens from a patient with heterozygous variants Pro281Leu/ Tyr293Cys (panel p1)
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and a patient with a novel homozygous variant (panel p2) [31]. (D) Transmission electron
microscopy-based cupromeronic blue staining. GAG chains are curved and maintain close contact
with attached collagen fibrils in the skin specimens from a healthy control volunteer (panels c-a, c-b);
conversely, they are linear and stretch from the outer surface of collagen fibrils to adjacent fibrils in skin
specimens from a patient with heterozygous variants Pro281Leu/ Tyr293Cys (panel p1), a patient with
a novel homozygous variant (panels p2a and p2b) and another patient with heterozygous variants
Pro281Leu/ Tyr293Cys (panel p3) [31]. (E) Schematic representations of collagen fibrils and GAG chains.
Decorin core protein binds to D bands of collagen fibrils both in normal skin and in affected skin.
GAG chains composed of DS adhere to collagen fibrils along D bands, beginning from the core protein
(panels a and c), whereas GAG chains composed of CS extend linearly and perpendicularly to collagen
fibrils from the core protein (panels b and d) [31]. Putative spatial disorganization of collagen fibril
networks in the skin of patients (panel e) (A, reproduced from Miyake et al. Hum. Mutat. 2010, 31,
1233–1239, with permission from Wiley-Liss, Inc.; B–E, reproduced from Hirose et al. Biochim. Biophys.
Acta Gen. Subj. 2019, 1863, 623–631, with permission from Elsevier, Inc.).
5. Animal Model-Based Findings
Knockout (Chst14−/−) mice were generated through homologous recombination that targeted the
only coding exon 1 (i.e., exon 1) of Chst14 [35,36]. F2 mice showed reduced weight and/or length and
reduced bone volume/thickness/density of their lumbar vertebrae [35]. Chst14−/− mice showed reduced
neurogenesis and diminished proliferation of neural stem cells, accompanied by increased expression of
glutamate aspartate transporter and epidermal growth factor, compared with findings in both wild-type
(Chst14+/+) mice and other knockout (Chst11−/−) mice, a model for chondroitin 4-O-sulfotransferase
1 (C4ST1) deficiency [36]. Chst14−/− mice also had a smaller body mass (Figure 5A, B), reduced
fertility, a kinked tail, and increased skin fragility compared with their wild-type (Chst14+/+) littermates;
however, brain weight and gross anatomy were not affected [36,37]. Schwann cells from Chst14−/− mice
formed longer processes in vitro and exhibited greater proliferation than those from Chst14+/+ mice.
Functional recovery and axonal regrowth in Chst14−/− mice were initially accelerated after femoral
nerve transection and suture; after 3 months, these characteristics were similar to those in Chst14+/+
littermates. These findings suggested that DS, synthesized by Chst14/D4st1, might be of limited
importance for neural development; moreover, it might contribute to the regeneration-restricting
environment in the adult mammalian nervous system [38]. Only a few adult Chst14−/− mice were
generated because of perinatal lethality in most of the homozygous mice; these adult Chst14−/− mice
showed significantly shorter crown-rump length, compared with wild-type or heterozygous mice
(Figure 5A–C) [37,38]. The placentas of Chst14−/− fetuses showed a reduced weight, alterations in the
vascular structure and ischemic and/or necrotic-like changes (Figure 5D–G). Transmission electron
microscopy of homozygous placentas demonstrated an abnormal capillary basement membrane
structure in the placental villus, compared with wild-type or heterozygous placentas (Figure 5H–J).
These findings showed that DS was essential for placental vascular development and perinatal fetal
survival. In addition, DS was suggested to be related to the structure and/or function of capillary
basement membranes, which constitutes an extracellular matrix [37].
C4st1, encoded by Chst11, transfers a sulfate group from 3′-phosphoadenosine 5′-phosphosulfates
to the C4 position of GalNAc residues in chondroitin (Figure 3A). Chst11-mutant mice died within 6
hours of birth due to respiratory failure, severe dwarfism and chondrodysplasia (i.e., abnormalities
in the cartilage growth plate and chondrocyte columns) [39]. Furthermore, marked reductions in
the content and 4-O-sulfation of CS, as well as the downregulation of bone morphogenetic protein
signaling and upregulation of transforming growth factor-β, have also been observed in Chst11-mutant
mice. These findings suggest that Chst11/C4st1 and the 4-O-sulfation of CS chains are essential for
early development and for bone morphogenetic protein and transforming growth factor-β in signaling
pathways in cartilage. When considered in the context of Chst14−/− mouse phenotypes, the above
findings suggest that 4-O-sulfation is required for the maturation of both CS and DS; moreover, CS and
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DS exert distinct functions in the development of cartilage and skin, respectively. However, the DS
content in Chst11-mutant mice remains to be elucidated [39].
Figure 5. Mouse model for mcEDS-CHST14. (A) Numbers (percentages) of each type at embryonic
(E18.5) and postnatal (adult) ages. Markedly greater numbers of homozygous fetuses are observed,
compared with homozygous adults. (B) General appearances of wild-type (Chst14+/+), heterozygous
(Chst14+/−) and homozygous (Chst14−/−) fetuses [37]. (C) Crown-rump length of each type of fetus
(bar: 5 mm). Homozygous mice demonstrate significantly shorter crown-rump length, compared
with wild-type or heterozygous mice [37]. (D) Appearance of each type of placenta (bar: 5 mm) [37].
(E) Homozygous placentas exhibit appearances indicative of hypoxia (left) and necrosis (right) [37].
(F) Microphotographs of the chorionic plate side of the placentas (bar: 1 mm). Homozygous placentas
demonstrate smaller vascular diameters, compared with wild-type or heterozygous placentas [37].
(G) Weight of each type of placenta (mean + standard error of the mean). (H) Transmission electron
microscopy of capillary basement membrane in the labyrinth zone of each type of placenta (bar: 200 nm).
Arrows indicate capillary basement membrane [37]. (I) Homozygous placentas show a significantly
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thinner capillary basement membrane, compared with wild-type or heterozygous placentas [37].
(J) Homozygous placentas show structural abnormalities (arrows) in capillary basement membrane
(bar: 0.2 μm) [37]. * p < 0.05, ** p < 0.01, compared with wild-type; # p < 0.05, ## p < 0.01, compared
with heterozygous; one-way analysis of variance (ANOVA) followed by the Tukey–Kramer post hoc
test. (A–J, reproduced from Yoshizawa et al. Glycobiology 2018, 28, 80–89, with permission from Oxford
University Press, Inc.).
Biosynthesis of DS requires D4st1, dermatan sulfate epimerase 1 (DS-epi1) and dermatan sulfate
epimerase 2 (DS-epi2), which are encoded by Chst14, Dse and Dsel, respectively [40–43]. Furthermore,
D4ST1 interacts directly with DS-epi1, but not with DS-epi2, to form a hetero-complex that is required
for the formation of IdoUA blocks in DS chains [44]. DS-epi1−/− mice showed greater skin fragility
compared with wild-type littermates, due to altered collagen fibril morphology [45]; this phenotype
was similar to that of Chst14−/− mice [38]. The numbers of IdoUA blocks were dramatically reduced in
DS side chains of decorin-PG and biglycan-PG from the skin of DS-epi1−/− mice [45], which suggests
that DS-epi1 mainly synthesizes IdoUA blocks in vivo. DS-epi1−/− embryos and newborn mice showed
kinked tails, which is a common feature in Chst14−/− mice [38]; the DS-epi1−/− embryos and newborn
mice also showed significantly thicker epidermal layers through histological staining, compared with
heterozygous or wild-type littermates [45,46]. Immunohistochemical staining of epidermal layers
in DS-epi1−/− newborns showed increased expression of keratin 5 in the basal layer and keratin 1 in
the spinous layer [46]. Furthermore, a small portion of DS-epi1−/− embryos showed an abdominal
wall defect with herniated intestines, exencephaly and spina bifida. Defective collagen structure in
the dermis and imbalanced keratocyte maturation were presumed to cause developmental defects
in DS-epi1−/− mice [46]. These observations indicate that DS-epi1−/− mice may constitute a useful
model of mcEDS-DSE. DS-epi2−/− mice displayed no significant defects and DS-epi1 compensated
for the absence of DS-epi2 in most tissue, which indicated that DS-epi1 is the major contributor of
epimerase activity [47]. DS-epi2 exhibits higher expression than DS-epi1 in developing the mouse
brain [48]. Although CS/DS chains in the brains of DS-epi2−/− newborn mice demonstrated a 38%
reduction in IdoUA content, compared with wild-type littermates, the brains of adult knockout mice
showed normal extracellular matrix features [47]. DS-epi1−/−/DS-epi2−/− mice experienced perinatal
death with variable phenotypes at late embryological stages and birth; these phenotypes included
umbilical hernia, exencephaly, and a kinked tail, as well as complete loss of IdoUA residues in CS/DS
chains [49]. However, a minority of embryos exhibited normal lung, bone, and cartilage features.
These findings indicate that DS, DS-PGs, DS-epi1 and/or DS-epi2 are important in early embryonic
development and perinatal survival [49].
6. Ongoing Projects and Future Perspectives
Our group established a multicenter collaboration network to promote comprehensive basic
research on mcEDS. In this network, genetic testing is provided as part of routine medical care
covered by national health insurance, using a custom next generation sequencing-based panel that
includes all EDS-related genes and genes for hereditary connective tissue disorders [50]. Whole exome
sequencing is performed to identify other potential causative genes for mcEDS in patients with
similar features who do not exhibit pathogenic variants in CHST14 or DSE. Biochemical abnormalities
of the extracellular matrix are investigated (e.g., various types of collagen and DS-PGs, including
decorin and biglycan), using patient skin fibroblasts. Furthermore, mass spectrometry is performed to
identify appropriate serum/plasma biomarker(s) that may be useful in the diagnosis or surveillance of
disease progression. A subsequent pathological approach includes an elucidation of the structural
alterations of collagen fibril networks and GAG chains of decorin in skin specimens from patients with
mcEDS-DSE. Determination of the crystal structure of D4ST1 would be useful for understanding the
effects of common missense variants (e.g., p.(Pro281Leu)) in CHST14. A technical breakthrough in the
efficient generation of knockout mice for Chst14 (e.g., CRISPR/cas9) is needed to continue mouse-based
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phenotypic and pathophysiological investigations. Considering the differences in the phenotypes
between patients with mcEDS and Chst14−/− or DS-epi1−/− mice, experiments using other models that
could reflect phenotypic and pathophysiological abnormalities in patients with mcEDS, such as induced
pluripotent stem cells, would be particularly useful. All of these approaches will be valuable for further
elucidating the critical roles of DS and DS-PGs, including decorin and biglycan, in the multisystem
development and maintenance of connective tissues; in addition, they provide fundamental evidence
for future etiology-based therapies, such as adeno-associated virus-based gene therapy.
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Abstract: Occipital horn syndrome (OHS) is a rare connective tissue disorder caused by pathogenic
variants in ATP7A, encoding a copper transporter. The main clinical features, including cutis laxa,
bony exostoses, and bladder diverticula are attributed to a decreased activity of lysyl oxidase (LOX),
a cupro-enzyme involved in collagen crosslinking. The absence of large case series and natural history
studies precludes efficient diagnosis and management of OHS patients. This study describes the
clinical and molecular characteristics of two new patients and 32 patients previously reported in
the literature. We report on the need for long-term specialized care and follow-up, in which MR
angiography, echocardiography and spirometry should be incorporated into standard follow-up
guidelines for OHS patients, next to neurodevelopmental, orthopedic and urological follow-up.
Furthermore, we report on ultrastructural abnormalities including increased collagen diameter,
mild elastic fiber abnormalities and multiple autophagolysosomes reflecting the role of lysyl oxidase
and defective ATP7A trafficking as pathomechanisms of OHS.
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1. Introduction
Occipital horn syndrome (OHS, OMIM#304150), previously known as Ehlers–Danlos syndrome
type IX or X-linked cutis laxa, is a rare disorder characterized by prominent connective tissue
abnormalities including cutis laxa, hernias, joint laxity and bladder diverticula, and pathognomonic
exostoses with “occipital horns” or downward pointing exostoses situated in the tendinous insertions
of the sternocleidomastoid and trapezius muscles. In addition, patients may show mild to moderate
intellectual disability [1–6]. Being allelic with Menkes disease (MD, OMIM#30011), OHS is considered
the milder end of the phenotypic spectrum due to pathogenic variants in ATP7A [4] that encodes
a copper transporter. Several clinical features in both disorders are related to the malfunctioning
of cupro-enzymes, including lysyl oxidase, dopamine ß-hydroxylase, tyrosinase and cytochrome C
oxidase [7–10].
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ATP7A mediates (1) copper transport from the gastrointestinal tract into the bloodstream,
(2) intracellular delivery of copper to cupro-enzymes in the secretory pathway and (3) efflux of excess
copper from the cell [11,12]. Intracellular ATP7A trafficking is essential for copper homeostasis.
Under basal low copper conditions, ATP7A is found in the trans-Golgi network, where it is essential
for cupro-enzyme biogenesis. At higher copper concentrations, it reversibly localizes to the plasma
membrane and post-Golgi compartments, where it is responsible for the extrusion of excess copper
from the cell [13–15]. The ATP7A gene maps to Xq13.3 and spans a genomic region of ~140 kb.
Its predominant transcription product contains 23 exons [16–20]. ATP7A belongs to the large P-type
ATPase family, which are ATP-driven membrane pumps essential in the maintenance of electrochemical
gradients (such as Na+/K+-, H+/K+- and Ca2+-pumps), as well as lipid and cationic homeostasis [21],
including ATP7A and ATP7B, both important for copper homeostasis [13,22]. P-type ATPases share
a structural core containing a transmembrane (TM) domain responsible for transport and an N-,
P- and A- soluble catalytic domain, respectively involved in nucleotide binding, phosphorylation and
dephosphorylation [23]. The transmembrane domain of ATP7A contains eight transmembrane helices
(TM1–TM8). Six amino terminal domains contain metal-binding CXXC motifs (MBD1–MBD6) [24,25].
MD is mostly caused by truncating variants, including nonsense variants, frameshift variants and
splice-site variants that lead to out of frame transcripts and large deletions, which result in very low
to absent ATP7A levels [12,26]. On the contrary, the milder symptoms in OHS are the consequence
of pathogenic variants in ATP7A, mostly “leaky” splice-site variants resulting in exon-skipping,
which permit the production of a small amount of normal ATP7A mRNA [6,13,27–30]. This low
amount of normal mRNA can result in residual protein activity and allow effective cation transfer to
some copper-dependent enzymes. ATP7A levels as low as 2–5% have been shown to be sufficient to
result in the milder OHS phenotype [31]. Connective tissue abnormalities in OHS have been attributed
to a decreased activity of lysyl oxidase (LOX), a cupro-enzyme that normally deaminates lysine and
hydrolysine residues in the first step of collagen crosslinking [7,32]. Patients may also encounter mild
neurological signs and dysautonomia due to partial defects in dopamine-ß-hydroxylase enzyme activity,
that converts dopamine to norepinephrine, a crucial neurotransmitter in norepinephrinergic neurons.
As such, patients with OHS typically have low to normal levels of serum copper and ceruloplasmin
together with abnormal plasma and cerebrospinal fluid (CSF) catecholamine levels [3,33,34].
Due to the rarity of OHS and the limited number of cases scattered in literature, the natural
history and clinical phenotype remain incompletely studied. This study reports the clinical, molecular
and ultrastructural data for two new cases of OHS. In addition, we performed a clinical review of 32
previously described patients [6,7,11,27–31,35–51].
2. Materials and Methods
2.1. Patients
Informed consent was obtained from subject 1 and his parents, and from subject 2. Additional
consent was given to publish the clinical pictures in Figure 1. Clinical information was obtained by
evaluating both patients at our center with the use of a detailed clinical checklist. We performed
a literature review of 32 OHS patients with confirmed ATP7A pathogenic variants in the Pubmed
and Embase databases, only including studies with ample clinical data. Selection of the reports was
undertaken independently by two different authors (A.B and K.V.M). Clinical data from the literature
were evaluated using the same methodology (Supplementary Table S1). This study was conducted in
accordance with the Declaration of Helsinki and approved by the Ghent University Hospital ethics
committee (registration number B670201319316).
170
Genes 2019, 10, 528
2.1.1. Clinical Reports
Case 1
Subject 1 (F1:II-1) was born at term after an uncomplicated pregnancy. At birth, his weight
was 2400 g, length 45.5 cm and head circumference 32.4 cm. Developmental milestones were
achieved normally. At three years of age, he presented with micturition problems evolving to urinary
retention, which led to the discovery of giant bladder diverticula. Over subsequent years, several
diverticulectomies were performed, followed by continent diversion and intermittent catheterization.
Clinical examination at 11 years of age showed mild facial dysmorphism (Figure 1) with a flat face,
deep-set eyes, a long narrow nose, large ears and mild webbing of the neck. His weight was 24.9 kg (P1,
−2.37 SD), height 139.2 cm (P26, −0.649 SD) and head circumference 56.2 cm (P98, +2.1 SD). Skeletal
abnormalities included joint hyperlaxity of the wrists, metacarpophalangeal joints and fingers, a flat
back, marked bony thickening of the proximal radius and tibia, genua valga and pedes plani. There was
skin webbing between the second and third toe. His skin was soft and mildly hyperextensible with fine
wrinkles over the abdomen and dorsum of hands and feet. He had no hair abnormalities. Neurological
examination was normal. He had recurrent inguinal hernias. He reported bruising easily, but no
impaired wound healing. He suffered from chronic joint pain. The patient attended normal education.
Additional examinations included a total skeletal radiography and MRI/MRA (Figure 2).
X-rays show severe skeletal dysplasia, occipital horns, undertubulation of bony structures and
broadening of the ventral end of the first left rib, the distal end of both claviculae and the scapular
neck. The long bones showed bowing with mid-diaphyseal broadening. There was bilateral luxation
of the radial heads, bilateral overgrowth of the ulnar coronoid processes and prominent trochanter
minor of both femurs. We observed a short fibula and bilateral coxa valga with rounded iliac wings.
The metatarsals were broad. The vertebrae showed platyspondyly. Brain MRI and angiography
showed tortuous intracranial arteries. Echocardiography, lung radiography and spirometry were
normal. Serum copper and ceruloplasmin levels were within normal ranges (89.6μg/dL (70–140) and
0.287 g/L (0.2–0.6), respectively).
Figure 1. Clinical characteristics in subjects F1:II-1 and F2:II-1. Subject F1:II-1 displays mild facial
dysmorphism with a flat face, deep-set eyes, a long and narrow nose, large ears and mild webbing
of the neck. Craniofacial features in patient F2:II-1 are more pronounced and include dolichocephaly,
a high forehead, biparietal narrowing, downslanting eyes, a convex nasal ridge, midfacial hypoplasia,
micrognathia and low-set ears. No hair abnormalities were observed. Both have lax and hyperextensible
skin, marked joint hypermobility and deformities of the proximal radius.
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Figure 2. Total skeletal radiography and MRI/MRA studies in subject F1:II-1 showing severe skeletal
dysplasia with occipital horns, undertubulation of bony structures and broadening of the ventral end
of the first left rib, both claviculae and scapular neck, bowing of the long bones with mid-diaphyseal
broadening, bilateral luxation of the radial heads, bilateral overgrowth of the ulnar coronoid processes,
prominent trochanter minor of both femurs, short fibula, bilateral coxa valga with rounded iliac wings
and broad metatarsals. Brain MRI and angiography showed tortuous intracranial arteries and normal
brain structure.
Case 2
Subject 2 (F2:II-1) was evaluated at the age of 30. He was born at term after an uncomplicated
pregnancy. He developed an inguinal hernia at six weeks of age. Since then, he had multiple inguinal
and femoral hernias requiring repeated mesh repairs. Starting from two years of age, he had severe
bladder problems, including recurrent urinary tract infections and urinary retention, due to multiple
bladder diverticula. After more than 20 surgical bladder repairs, he started self-catheterization at 8
years of age. Aged 20 years, he underwent left nephrectomy for a non-functioning kidney. He reported
a mild motor delay and walked at two years of age. Joint hypermobility resulted in repeated shoulder
and elbow subluxations. He was of normal intelligence and pursued higher education. He suffered
from migraine, worsening musculoskeletal pain, fatigue, and depression for which he was treated
with gabapentin and amitriptyline. He had a history of mitral valve prolapse, orthostatic hypotension,
palpitations and a prolonged QT interval on electrocardiogram. Finally, he had a longstanding history
of upper and lower gastrointestinal symptoms including nausea, post-prandial vomiting and chronic
diarrhea, possibly in the context of dysautonomia. He was diagnosed with asthma.
His height was 169 cm, his weight was 50.6 kg and his head circumference was 58.5 cm. Craniofacial
features consisted of dolichocephaly, a high forehead, biparietal narrowing, downslanting eyes, a convex
nasal ridge, midfacial hypoplasia, micrognathia and low-set ears. He had lax and hyperextensible skin
(Figure 1). He had no hair abnormalities. Skeletal abnormalities included occipital horns, a loss of
sagittal spine curvature, scoliosis, pectus excavatum, and restricted elbow extension. He had bowing
of the ulna and radius, bilateral exostoses of the radii and tibiae, bilateral rounding of the iliac wings,
cranial displacement of the right humeral head and genua vara. Neurological examination and brain
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MRI were normal. Serum copper and ceruloplasmin levels were 8.3 μmol/L (11–20) and 0.13 g/L
(0.20–0.50), respectively.
2.2. Molecular Analysis
For individual 1, genomic DNA was extracted from blood leukocytes using standard
procedures. Array comparative genomic hybridization (180 k arrayCGH, Agilent
Technologies, Santa Clara, CA, USA) showed a 300 kb deletion of chromosome band 1q31.1
(1q31.1.1q31.1(188407205-188707983)x1)(hg19/GRCh37), which does not contain any known genes.
FBLN5 (OMIM#219100, GenBank RefSeq accession number NM_006329.3), LTBP4 (OMIM#613177,
NM_003573.2) and ATP7A (OMIM#304150, NM_000052.7) gene sequencing was performed without the
identification of a pathogenic mutation. Total RNA was extracted from cultured fibroblasts using the
RNeasy Kit (Qiagen, Hilden, Germany) and cDNA was synthesized with the iScript cDNA Synthesis
Kit (Bio-Rad Laboratories, Hercules, CA, USA). ATP7A cDNA analysis was performed followed by
confirmation with long-range RT-PCR and next-generation sequencing (Miseq, Illumina, San Diego,
CA, USA). For individual 2, array comparative genome hybridization was normal after which ATP7A
gene sequencing (GenBank RefSeq accession number NM_000052.7) was performed.
2.3. Transmission Electron Microscopy (TEM)
For transmission electron microscopy, 3 mm skin fragments from both individuals and an age- and
sex-matched control were immersed in a fixative solution of 2.5% glutaraldehyde and 4% formaldehyde
in Na-Cacodylate buffer 0.1 M, placed in a vacuum oven for 30 min and left rotating for 3 hours at
room temperature. This solution was later replaced with fresh fixative and samples were left rotating
over night at 4 ◦C. After washing, samples were post-fixed in 1% OsO4 with K3Fe(CN)6 in 0.1 M
NaCacodylate buffer, pH 7.2. After washing in double-distilled H2O, samples were subsequently
dehydrated through a graded ethanol series, including bulk staining with 2% uranyl acetate at the 50%
ethanol step, followed by embedding in Spurr’s resin. To select the area of interest on the block and in
order to have an overview of the phenotype, semi-thin sections were first cut at 0.5 μm and stained
with toluidine blue. Ultrathin sections of a gold interference color were cut using an ultramicrotome
(Leica EM UC6, Wetzlar, Germany), followed by post-staining in a Leica EM AC20 for 40 min in uranyl
acetate at 20 ◦C and for 10 min in lead stain at 20 ◦C. Sections were collected on formvar-coated copper
slot grids. Grids were viewed with a JEM 1400plus transmission electron microscope (JEOL, Tokyo,
Japan) operating at 80 kV.
2.4. Collagen Biochemical Analysis
Fibroblast cultures were started from skin biopsies from individuals 1 and 2, and a matched control.
Biochemical (pro)collagen sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE
analysis) was performed on the medium and cellular fractions of the cultured skin fibroblasts.
When confluent, cells were labeled with 14C-proline [52]. After SDS-PAGE separation, further
processing of the gels was performed as described previously by our group [53].
3. Results
3.1. Clinical Characteristics
We describe the clinical characteristics of two new individuals with OHS and 32 patients described
in the literature (Table 1, Supplementary Table S1). All patients were male, except for patient F17:II-2.
The mean reported age of patients was 19.6 years (mean 17, range 1–50). Disease-related mortality was
observed in 5 out of 34 patients. The mean age at death was 21.2 years and causes included respiratory
failure (post-surgery apnea), gastric perforation and diffuse intravascular coagulation due to a large
cephalhematoma at birth.
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Table 1. Overview of the phenotypic presentation in occipital horn syndrome.
Total (Percentage)
Craniofacial
Long face 6/13 (46%)
Large ears 5/13 (38%)
Sagging/ full cheeks 5/11 (45%)
Hair abnormalities 14/19 (74%)
Pili torti on trichoscopy 7/10 (70%)
Connective tissue
Cutis laxa 25/27 (93%)
Inguinal hernia 15/24 (63%)
Umbilical hernia 1/22 (5%)
Osteoarticular
Occipital horns 25/26 (96%)
Radial/tibial exostoses 6/16 (38%)
Hammer-shaped clavicula 9/19 (47%)
Bowing of long bones 4/17 (23%)
Mid-diaphyseal broadening 2/17 (11%)
Rounding of the iliac wings 3/17 (18%)
Coxa valga 6/16 (38%)
Genu valgum 6/17 (35%)
Metaphyseal spurring 2/16 (13%)
Scoliosis 8/21 (38%)
Pectus deformity 13/23 (57%)
Dislocations 12/20 (60%)
Contractures of large joints 3/19 (16%)
Joint hyperlaxity 16/26 (62%)
Fractures 2/21 (10%)
Neurological
Intellectual disability 17/33 (52%)
Seizures 5/25 (20%)
Muscle hypotonia 10/25 (40%)
Stroke 1/23 (4%)
Cardiovascular
Aneurysm formation 5/7 (71%)
Dilatation of the large veins 2/6 (33%)
Intracranial tortuosity 7/11 (64%)
Extracranial tortuosity 3/4 (75%)
Dysautonomia 13/15 (87%)
Urogenital
Bladder diverticula 25/30 (83%)
Renal abnormalities 6/20 (30%)
Urinary tract infections 17/23 (74%)
Vesicourethral reflux 7/23 (30%)
Laboratory findings
Serum copper 20/28 (71%)
Serum ceruloplasmin 20/27 (74%)
Initial presentations leading to the diagnosis are presented in Table 2. One-third of patients
presented with neurological features including hypotonia, developmental delay, and seizures.
Nine individuals presented with connective tissue problems such as cephalhematoma and inguinal
hernia. Other presenting symptoms included bladder problems such as bladder diverticula, urinary
tract infections and skeletal problems.
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Table 2. Initial presentations leading to the diagnosis in occipital horn syndrome.






















“CTD”: connective tissue disease.
Patients displayed variable craniofacial features, including a long face (6/13, 46%), large ears
(5/13, 38%), sagging cheeks (5/11, 45%) and hair abnormalities (14/19, 74%). Trichoscopy confirmed
pili torti in 7 out of 10 examined individuals. Connective tissue abnormalities were reported in
all subjects. Cutis laxa was present in the majority of patients (25/26, 94%), as well as inguinal
hernias (15/25, 63%). An umbilical hernia and hiatal hernia were observed in only one patient each
(F25:II-1 and F15:II-1, respectively). Wound healing was reported to be normal after trauma or surgery.
Occipital horns were reported in nearly all cases (25/26, 96%). Other recurrent skeletal manifestations
included hammer-shaped claviculae (9/19, 47%), scoliosis (8/21, 38%), pectus deformities (13/23, 57%),
radial/tibial exostoses (6/16, 38%), coxa valga (6/16, 38%) and genua valga (6/17, 35%). Dislocations,
mainly of the radial heads and joint hypermobility were present in about two-thirds of individuals,
12/20 (60%) and 16/26 (62%), respectively. Less frequently reported skeletal manifestations include
bowing of the long bones, mid-diaphyseal broadening, metaphyseal spurring and rounding of the
iliac wings. Osteopenia or osteoporosis was reported in four patients and fractures were observed in
two subjects.
Mild, mainly motor, developmental delay, was observed in 17 subjects (17/30, 57%). Intellectual
disability was present in an equal number of patients (17/33, 52%) of whom seven had mild, four had
moderate and three had severe intellectual disability. In three patients, the severity of intellectual
disability was not specified. Several subjects displayed muscle hypotonia, especially at a young age
(before the age of two). Seizures were documented in five patients (5/25, 20%). One individual was
diagnosed with a spontaneous intracerebral hemorrhage at the age of 15, resulting in aphasia and
spastic quadriparesis. MRI brain studies were performed in 11 patients and documented to be abnormal
in 7 subjects, showing mild atrophy and/or delayed myelination. Intracranial tortuosity was present in
two-thirds of patients (7/11, 64%). Tortuosity of extracranial arteries was found in three cases and was
located in the cervical, splenic and hepatic arteries. Aneurysm formation was found in five patients,
mainly affecting the same arteries. One individual was diagnosed with a type A aortic dissection
at the age of 39, which was successfully surgically manage. Two patients showed dilatation of the
large veins. Orthostatic hypotension, temperature instability, chronic diarrhea, and other symptoms of
dysautonomia were seen in a high number of patients (13/15, 87%). Severe urological complications are
an important concern in OHS, with bladder diverticula in 83% (25/30) of reported patients, of which
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three were eventually diagnosed with a bladder rupture. Recurrent urinary tract infections based
on incomplete emptying of the bladder were seen in 74% (17/23) of patients. One-third of patients
had vesicourethral reflux (VUR), sometimes complicated by secondary renal problems. Asthma was
reported in four cases. Low levels of serum copper and ceruloplasmin were found in two-thirds of
cases, 20/28 (71%) and 20/27 (74%), respectively.
3.2. Molecular Characteristics
After normal ATP7A gene sequencing, cDNA analysis showed a deletion of exon 10 in subject
F1:II-1. Subsequent confirmation with long-range RT-PCR revealed a deep intronic c.2407-516G>T
variant, underlying the exon 10 skipping, likely due to the activation of a cryptic splice acceptor.
In patient F2:II-1, ATP7A gene sequencing identified a hemizygous c.2917-4A>G splice-site variant
in ATP7A.
A total of 16 different ATP7A pathogenic variants were reported (Figure 3); these included seven
splice-site, four missense and two frameshift variants, two deep intronic variants and one deletion.
In eight patients, the specific variant was not reported, including a 98-bp deletion in the regulatory
region (F9:II-1), a deep intronic intron six splice donor site variant (F12:II-1) and a duplication in exon 11
and 12 (F23:II-1). Nonsense ATP7A variants were not observed. Pathogenicity information and CADD
scores can be found in Supplementary Table S2. We did not observe any clear genotype-phenotype
correlation and there was no correlation with serum copper and ceruloplasmin levels (Supplementary
Table S3).
Figure 3. ATP7A pathogenic variants reported in this study. ATP7A consists of six amino terminal
metal binding domains (MBD1-MBD6), a transmembrane domain containing eight transmembrane
helices (TM1-TM8) and an N-, P- and A- soluble catalytic domain. The pathogenic variants identified
in subjects F1:II-1 and F2:II-1 are indicated in bold and outlined.
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3.3. Transmission Electron Microscopy
Transmission electron microscopy (TEM) findings in skin samples of subjects F1:II-1, F2:II-1 and
a matched control are shown in Figure 4. Collagen fibrils in the dermis of the control sample are
regularly organized in curvilinear bundles with uniform diameters. In the dermis of both OHS patients,
the collagen fiber diameter appears to be larger and more variable. The fibrils are more loosely packed
(especially in F2:II-1) but retain a normal shape. TEM of a control elastic fiber demonstrates a solid and
dense core of elastin surrounded by a sparse mantle of microfibrils. In both individuals, the elastin core
is surrounded by a debris extending outside the elastic fiber with loss of the microfibrillar organization.
In addition, the elastin core in subject F2:II-1 is almost completely disrupted and difficult to discriminate.
Fibroblast abnormalities are observed in both patients, with multiple autophagolysomes containing
sickle-shaped electron dense deposits (Supplementary Figure S1). The mitochondria, Golgi complex,
and endoplasmatic reticulum appear normal.
Figure 4. Transmission electron microscopy findings in occipital horn syndrome. Transmission electron
microscopy (TEM) findings in skin samples of patients F1:II-1 and F2:II-1 and a matched control showing
collagen (column 1), elastic fibers (column 2) and a fibroblast (column 3). col = collagen; ef = elastic
fiber; fb = fibroblast. Magnification for column 1: ×15,000, column 2: ×8000 and column 3: ×4000.
3.4. Collagen Biochemistry
Considering the collagen abnormalities observed in both individuals with transmission electron
microscopy, SDS-PAGE analysis of the intracellular and secreted (pro)collagen proteins produced by
skin fibroblasts was performed for subjects 1 and 2 and a matched control. In both cases, we observed
normal SDS-PAGE migration patterns (Supplementary Figure S2).
4. Discussion and Conclusions
The absence of large case series and natural history studies precludes efficient diagnosis and
management of OHS patients. This study describes the clinical and molecular characteristics of two
new patients and 32 patients previously reported in the literature. OHS is considered a mild but rare
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allelic variant of Menkes disease. OHS patients show prominent connective tissue abnormalities and
have a better prognosis and survival rate than patients with MD [3], with low childhood mortality (1/34)
in OHS. However, there is still significant mortality in (young) adults, often related to gastrointestinal,
respiratory, or bleeding complications, such as an intestinal perforation due to a gastric ulcer and
(post-surgery) apnea.
The clinical characteristics of OHS are listed in Table 2. Craniofacial features include mild facial
dysmorphism with a long face, large ears and sagging cheeks in about half of reported patients.
Hair abnormalities, including coarse hair and pili torti, are frequently present. Ubiquitous connective
tissue manifestations in OHS include increased skin laxity and inguinal hernia.
Concerning the skeletal features, the pathognomonic occipital horns are present in all patients
but one, which is probably an age-dependent discrepancy [41,54,55]. Other less specific skeletal
abnormalities include hammer-shaped claviculae and radial/tibial exostoses. Scoliosis, pectus
deformities, coxa and genua valga, joint luxations, mainly of the radial heads and general joint
hypermobility are frequent but non-specific. These skeletal problems may limit daily activities and
often require multiple surgical interventions.
Urological complications, mostly giant bladder diverticula and vesicourethal reflux, are found in
over 80% of subjects. Secondary problems such urinary tract infections, urinary retention, bladder
rupture, or VUR-mediated renal failure, which are all related to the bladder diverticula, are of great
concern. Surgical interventions removing the diverticula often fail, with frequent relapse of the
diverticula. Self-catheterization, vesicostomy, or continent diversion are often required for proper
emptying of the bladder.
Previous reports describe a mild neurological phenotype limited to slight generalized muscle
weakness and symptoms of dysautonomia [3,27], however, more detailed case studies reveal some
conspicuous observations including developmental delay and intellectual disability in two-thirds of
subjects and documented seizures in five individuals. Nevertheless, neurological affliction remains
rather mild and normal intelligence is possible. Symptoms of dysautonomia, including chronic
diarrhea, temperature instability, and orthostatic hypotension are present in almost 90% of patients
and can be disabling.
Brain imaging studies are rarely performed in OHS patients and are often reported as normal.
However, intracranial arterial tortuosity are noted in approximately two thirds of patients. Extracranial
arterial tortuosity is less frequently observed, but has been reported in the cervical, splenic and hepatic
vasculature. Aneurysm formation may complicate pre-existing tortuosity and may affect the arterial
and venous circulation.
OHS is often diagnosed upon the identification of connective tissue anomalies, including cutis laxa,
joint hypermobility with hypotonia, mild intellectual impairment and bladder diverticula. Later on,
the pathognomonic occipital horns become more evident. The initial differential diagnosis includes other
forms of cutis laxa, including FBLN5- and LTBP4-related cutis laxa (OMIM#219100 and #613177) [56] and
the dermatosparaxis type of Ehlers–Danlos syndrome (EDS type VIIC, OMIM#225410) [57], which may
present with cutis laxa, hypotonia and bladder diverticula, but with normal mental development.
However, in OHS there is no early onset emphysema as in FBLN5- and LTBP4- related cutis laxa,
nor easy bruising or severe skin fragility as in the dermatosparaxis type of EDS. ATP6V0A2-related
cutis laxa (OMIM#219200) may also present with mild intellectual impairment but does not commonly
show bladder diverticula or exostoses. Later on the exostoses can be mistaken for hereditary multiple
exostoses due to defects in EXT1 or EXT2 (OMIM#133700 and #133701) [58].
Concerning follow-up, routine evaluation of neurodevelopment and early intervention with
physiotherapy is recommended, as well as regular urological evaluation, including video urodynamic
studies of bladder function. Any pain, or vascular or neurological symptoms that may relate to exostoses
should be promptly investigated. To date, there are no data on a possible risk for chondrosarcomas
in exostoses although these have been described in hereditary multiple exostoses [59]. It could be
recommended to perform MR angiography and echocardiography from puberty onwards. Indeed,
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aortic root dilatation and dissection, and an increased risk for intracranial bleeds and ischemic
complications have been described in other related connective tissue disorders such as Ehlers–Danlos,
arterial tortuosity, Marfan and some cutis laxa syndromes. Furthermore, spirometry might detect
asthma at an early stage as it was reported in four individuals. Prolonged vigilance for apnea is
necessary following surgery.
The molecular data confirmed that pathogenic variants in ATP7A causing OHS mainly
included splice-site variants, while missense and frameshift variants were less frequently observed.
This observation may fit the hypothesis that a low amount of normal ATP7A mRNA and residual
ATP7A functioning is sufficient to prevent the more severe MD [13,27,29,31,60]. No mutational hot
spots were observed (Figure 3). Importantly, nearly all pathogenic variants are located in the endofacial
domains and only two affect a transmembrane domain or cytosolic loop, respectively. This highlights
the critical role of the transmembrane domains forming the channel for copper translocation [13].
Variants in OHS mainly affect residues implicated in ATPase-coupled copper transport. Some of these
variants are predicted to inhibit the catalytic dephosphorylation leading to permanent distribution of
the protein to the plasma membrane and cytosolic vesicles [14,15,21,61,62].
Our transmission electron microscopy data in skin samples of OHS individuals show larger
diameters of collagen fibrils that were more loosely packed compared to those of the control sample.
Elastic fibers were affected to a lesser extent but are fragmented and/or surrounded by extracellular
matrix debris. OHS is associated with decreased activity of the copper dependent lysyl oxidase (LOX),
that oxidates lysyl and hydroxylysyl residues in collagen and lysyl residues in elastin to aldehydes [7].
These aldehyde residues are than condensed to form cross-links, essential for collagen fibril stabilization
and the integrity and elasticity of mature elastin [32,63]. Overall, this would not affect the amount
or migration of soluble collagens from the medium or cellular fraction upon electrophoresis but will
affect the assembly in the extracellular matrix. Also, lysyl oxidase may form cross-links with the
N-propeptide domain of collagen type V, essential in collagen diameter regulation [64,65]. Fibroblasts
synthesize only low amounts of type V collagen which is difficult to evaluate by electrophoresis [66,67].
Indeed, irregular fibril diameters are reminiscent of classic Ehlers–Danlos syndrome, despite the
absence of cauliflower fibrils [68].
The observation of major fibroblast abnormalities, with multiple autophagolysosomes containing
sickle-shaped electron dense deposits, is novel and might point to defective trafficking and trapping of
proteins needing cuproenzyme-dependent processing in the post-Golgi network [14,15,21].
In conclusion, this study sheds light on the natural history of OHS by describing two new patients
and 32 patients reported in the literature. Mortality in adulthood warrants long-term specialized
care and follow-up, incorporating MR angiography, echocardiograpy and spirometry into standard
follow-up guidelines for OHS patients, next to orthopedic and urological follow-up. Ultrastructural
abnormalities including increased collagen diameter, mild elastic fiber abnormalities, and multiple
autophagolysosomes reflect the role of LOX and defective ATP7A trafficking in the pathomechanism
of OHS.
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procollagen fraction on fibroblasts in culture for three days. Panel B: cellular collagen fraction; Supplemental
Table S1. Clinical characteristics of all patients. ‘”+”: present, “-“: absent, “M”: male, “F”: female, “y”:
year(s), “mo”: month(s), “d”:day(s), “CVA”: cerebrovascular accident, “DIC”: diffuse intravascular coagulation,
“FTT”: failure to thrive, “GER”: gastro-esophageal reflux, “SC”: subcutaneous, “UTI”: urinary tract infection;
Supplemental Table S2. Pathogenicity information for the ATP7A variants in this study. The pathogenicity
classification used in this table is based on the Alamut®mutation analysis software, which uses the following
prediction tools: Align GVGD (Huntsman Cancer Institute, University of Utah) combines the biophysical
characteristics of amino acids and protein multiple sequence alignments to where missense substitutions in genes
of interest fall from enriched deleterious to enriched neutral. SIFT predicts whether amino acid substitution
affects protein function. The MutationTaster prediction program integrates information from different biomedical
databases, evolutionary conservation, splice-site changes and loss of protein features. Protein conservation is
based on MARRVEL®multiple protein alignment. The splice prediction predicts the chance of variants having
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an impact on alternative splicing. Gnomad allele frequencies and Clinvar data can also be found. In the last
column, CADD scores are depicted (Kircher et al., 2014). “NS”: not specified, “NA”: not applicable; Supplemental
Table S3. Copper and ceruloplasmin levels in all patients.
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Abstract: FBN1 encodes fibrillin 1, a key structural component of the extracellular matrix, and its
variants are associated with a wide range of hereditary connective tissues disorders, such as Marfan
syndrome (MFS) and mitral valve–aorta–skeleton–skin (MASS) syndrome. Interpretations of the
genomic data and possible genotype–phenotype correlations in FBN1 are complicated by the high
rate of intronic variants of unknown significance. Here, we report two unrelated individuals with the
FBN1 deep intronic variants c.6872-24T>A and c.7571-12T>A, clinically associated with MFS and
MASS syndrome, respectively. The individual carrying the c.6872-24T>A variant is positive for aortic
disease. Both individuals lacked ectopia lentis. In silico analysis and subsequent mRNA study by
RT-PCR demonstrated the effect of the identified variant on the splicing process in both cases. The
c.6872-24T>A and c.7571-12T>A variants generate the retention of intronic nucleotides and lead to
the introduction of a premature stop codon. This study enlarges the mutation spectrum of FBN1
and points out the importance of intronic sequence analysis and the need for integrative functional
studies in FBN1 diagnostics.
Keywords: fibrillin 1; Marfan syndrome; MASS syndrome; mRNA; splicing
1. Introduction
The FBN1 gene is located in 15q21.1 and includes 65 exons which encode for fibrillin 1, a
large glycoprotein constituted by 47 cysteine-rich epidermal growth factor (EGF)-like domains and
seven motifs homologous to the binding protein for transforming growth factor beta (TGFβ) [1,2].
Fibrillin 1 is a major structural component of the extracellular matrix microfibrils and thus,
gives stability and elasticity to many tissues [2]. Variants in FBN1 cause a wide range of
autosomal dominant heritable connective tissue disorders, including Marfan syndrome (MFS; OMIM
154700), mitral valve–aorta–skeleton–skin syndrome (MASS syndrome; OMIM 604308), Marfan
lipodystrophy syndrome (OMIM 616914), isolated autosomal dominant ectopia lentis (OMIM 129600),
Weill–Marchesani syndrome type 2 (OMIM 608328), acromicric dysplasia (OMIM 102370), geleophysic
dysplasia type 2 (OMIM 614185), stiff skin syndrome (OMIM 184900), and autosomal dominant thoracic
aortic aneurysms and dissections [3].
To date, over 1800 different FBN1 germline variants have been identified so far (UMD-FBN1,
http://www.umd.be/FBN1/) [4,5] and only a few genotype–phenotype correlations are available [6,7].
For example, nonsense, frameshift, and some splicing variants appear correlated with a more severe
skin and skeletal phenotype, as compared to in-frame variants [8]. Other studies suggest that variants
affecting or creating cysteine residues are more commonly associated with ectopia lentis, while null
Genes 2019, 10, 442; doi:10.3390/genes10060442 www.mdpi.com/journal/genes185
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alleles typically combine with an increased rate of aortic events in young age and thoracic deformities [7].
In the suspicion of a FBN1-related disorder, the identification of the causative variant is not only relevant
for diagnosis confirmation and genetic counseling but is also increasingly useful for personalized
medicine approaches, comprising preventive drug treatment and aortic surgery planning [9].
The introduction of next generation sequencing (NGS) technologies in molecular diagnostics
improved turnaround time and costs but did not significantly affect the clinical interpretation of
variants of uncertain significance, such as intronic nucleotide changes which potentially affect splicing.
The burden associated with uncertain results related to these variants is still high in MFS and related
disorders, as point variants possibly impacting FBN1 pre-mRNA splicing seem to account for ~10%
of reported molecular findings in MFS [10]. In these cases, optimal clinical interpretation should
integrate molecular findings with customized studies exploring variant effects at the transcriptional or
translational levels.
Here, we report two unrelated individuals with MFS and MASS syndrome, respectively, which
were associated with different intronic variants in FBN1. Characterization of the effects of these variants
on mRNA allowed us to support their pathogenicity and, therefore, to use them for patient and
family management.
2. Materials and Methods
All investigated subjects signed informed consent for molecular testing and research use of
biological and related clinical data. Molecular testing on cDNA and mRNA in individual 1 and 2
were carried out within the routine clinical diagnostic activities of the Division of Medical Genetics of
Foundation IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo (Italy). The results of this
work are part of a larger research project approved by our local ethics committee (approval protocol
no. GTB12001).
2.1. Clinical Description: Individual 1
This was a 27-year-old man, the second child of unrelated parents. His father was 50-year-old,
191 cm tall and affected by dilatation of the aortic root and ascending aorta, which required surgery
at 45 years. The mother and sister were healthy, and 172 and 161 cm tall, respectively. The proband
was born at term after an uneventful pregnancy. At birth, he presented respiratory distress, which
needed intensive care support for a few days. The neonatal period was otherwise normal, as well as
psychomotor development, scholarship, and mentation. At 11 years, progressive scoliosis required an
orthopedic corset for some years. The patient suffered from recurrent spontaneous pneumothorax
with four episodes between 12 and 14 years of age. For this, he successfully underwent pleurodesis at
14 years. At 18 years, the previous diagnosis of aortic disease in the father prompted full cardiologic
assessment in the proband who showed dilatation of the aortic root and mitral valve prolapse. Since
then, he was under preventive pharmacologic therapy. Current treatment includes losartan 50 mg/day
(single dose) and nebivolol 50 mg/day (single dose), without significant side effects. The last heart
ultrasound, at 27 years, showed a stable dilatation of the aortic root (48 mm; Z score 171.13 = 4.66
SD [11]) with normal ascending aorta (34 mm), minimal insufficiency of the aortic valve, prolapse of
the anterior mitral leaflet with minimal insufficiency, and mild insufficiency of the tricuspid valve.
Dilatation of the aortic root (48 × 43 mm) was also confirmed by angio-computer tomography. A total
spine MRI at 23 years showed bilateral dural ectasias of the lumbar spine. A recent ophthalmologic
exam excluded lens dislocation and revealed mild myopia (−2 diopters on the right and −1.5 diopters
on the left).
Physical examination included height 196 cm, weight 72 kg, arm span 198 cm, arm span/height
ratio 1.01 (normal), bilateral positive wrist sign, bilateral negative thumb sign, apparent enophthalmos,
down slanting palpebral fissures, malar hypoplasia, high-arched palate, severe scoliosis, pectus
carinatum, bilateral valgus deformity of the elbow, bilateral metatarsus varus, some mildly atrophic
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post-surgical scars of the thorax, and striae rubrae of the back (Figure 1A–D). The combination of aortic
root dilatation (Z-score > 2 SD) and 10 points of systemic features lead to the clinical suspect of MFS.
 
Figure 1. Clinical features. Individual 1 showing high-arched palate (A), pectus carinatum (B), scoliosis
(C) and arachnodactyly (D). Lumbar spine MRI of Individual 2 demonstrating bilateral dural ectasias
at axial (E), coronal (F), and sagittal (G) views. Asterisks indicate the dilated dural sac.
2.2. Clinical Description: Individual 2
Individual 2 was a 48-year-old, nullipara woman, the seventh child of a sibship of eleven. All
brothers and sisters were healthy, but two brothers were described with tall stature (~194 cm). The
mother was 165 cm tall and died at 65 years due to rupture of a cerebral aneurysm. The father
was 175 tall and died at 78 years due to a stroke. Family history was negative for aortic disease.
The proband was sent to clinical genetics assessment by the neurosurgeon, who first evaluated the
woman for chronic back pain, diffuse spondylosis, and marked dural ectasias of the lumbar spine
(Figure 1E–G). Relevant additional clinical features included moderately severe scoliosis since her
teens, severe myopia (−6 diopters on the right and −8 dipters on the left), and chronic fatigue. A heart
ultrasound repeatedly showed normal aortic diameters, prolapse, and mild insufficiency of the mitral
valve. At 47 years, aortic root diameter was 36 mm (Z score 1.26 SD [11]). Routine ophthalmologic
assessments always excluded lens dislocations. Physical examination showed height 181 cm, weight
80 kg, arm span 188 cm, arm span/height ratio 1.038 (normal), bilaterally positive wrist and thumb
signs, hypermobility of fingers (but the Beighton score was 0/9), elbow limitation on both sides,
enophthalmos, down slanting palpebral fissures, retrognathia, high-arched palate, striae distensae
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of the shoulders. The presence of 10 points of systemic features and an aortic root diameter <2 SD
suggested a diagnosis of the MASS syndrome. Positive family history for tall stature and absence of
aortic disease in relatives were in accordance with the diagnosis. Molecular testing in Individual 2 was
carried out with a multigene panel approach including extended intronic regions around exon–intron
junctions (see below).
2.3. Genomic DNA Extraction
Genomic DNA was extracted from individuals’ peripheral bloods by using Bio Robot EZ1 (Qiagen,
Hilden, Germany), according to standard procedures. The DNA was quantified with Nanodrop 2000
C spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
2.4. Genetic Testing (Sanger Sequencing): Individual 1
Molecular analysis for individual 1 was performed by Sanger sequencing. Primers were designed
using the Primer 3 Output program (http://frodo.wi.mit.edu/primer3/) to amplify extended intronic
sequences and exon–intron flanking sequences of FBN1 (RefSeq NM_000138). Primers were checked
both by BLAST and BLAT against the human genome to ensure specificity. Amplified products
were subsequently purified and sequenced with a ready reaction kit (BigDye Terminator v1.1 Cycle,
Applied Biosystems, Foster City, CA, USA). Fragments were then purified using DyeEx plates (Qiagen,
Hilden, Germany) and resolved on an automated sequencer (3130xl Genetyc analyzer DNA Analyzer,
ABI Prism, Foster City, CA, USA). Sequences were analyzed using the Sequencer software (Gene
Codes, Ann Arbor, MI, USA). To investigate familial segregation, both parents were sequenced for the
identified variant.
2.5. Genetic Testing (Next-Generation Sequencing): Individual 2
Individual 2’s DNA underwent sequencing with a HaloPlex gene panel (Agilent Technologies,
Santa Clara, CA, USA) designed to selectively capture known genes associated with syndromic and
non-syndromic thoracic aneurysms and/or Mafanoid habitus, including: ACTA2 (NM_001141945),
BGN (NM_001711.5), CBS (NM_000071.2), COL3A1 (NM_000090), COL4A1 (NM_001303110), COL5A1
(NM_000093), COL5A2 (NM_000393), DLG4 (NM_001365.4), EFEMP2 (NM_016938), ELN (NM_000501),
EMILIN (NM_007046.3), FBN1 (NM_000138), FBN2 (NM_001999), FLNA (NM_001110556),
FOXE3 (NM_012186), GATA5 (NM_080473), LOX (NM_002317), MAT2A (NM_005911), LTBP3
(NM_001130144.2), MAT2A (NM_005911.5), MED12 (NM_005120.2), MFAP5 (NM_003480), MYH11
(NM_001040113), MYLK (NM_053025), NOTCH1 (NM_017617), PLOD1 (NM_001316320), PRKG1
(NM_006258), SKI (NM_003036), SLC2A10 (NM_030777), SMAD2 (NM_005901.5), SMAD3
(NM_005902), SMAD4 (NM_005359), TAB2 (NM_015093), TGFB2 (NM_001135599), TGFB3
(NM_003239), TGFBR1 (NM_001306210), TGFBR2 (NM_001024847), UPF3B (NM_080632.2), and
ZDHHC9 (NM_016032.3). Targeted fragments were then sequenced on a MiSeq platform (Illumina,
San Diego, CA, USA) using a MiSeq Reagent kit V3 300 cycles flow cell. Data analysis was performed
considering the frequency, impact on the encoded protein, conservation, and expression of variants
using distinct tools, as appropriate ANNOVAR (http://annovar.openbioinformatics.org/en/latest/),
dbSNP (https://www.ncbi.nlm.nih.gov/snp), 1000 Genomes (http://www.internationalgenome.org),
ExAC (http://exac.broadinstitute.org). Selected variants are interpreted according to the American
College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMGG/AMP) [12].
The identified variant was confirmed by Sanger sequencing. We checked the selected variant in the
UMD-FBN1 database, a computerized database that currently contains information about the published
mutations of the FBN1 gene.
2.6. Variant Designation
Nucleotide variant nomenclature follows the format indicated in the Human Genome Variation
Society (HGVS, http://www.hgvs.org) recommendations. DNA variant numbering system refers to
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cDNA. Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference
sequence, with the initiation codon as codon 1.
2.7. In Silico Prediction
In silico analysis of identified intronic variants was conducted by running three independent
algorithms for splice signal detection: NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/), Berkeley
Drosophila Genome Project (BDGP, http://www.fruitfly.org/seq_tools/splice.html), and Human Splicing
Finder (HSF, http://www.umd.be/HSF3/).
2.8. RNA Extraction and Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from lymphocytes fraction isolated from peripheral blood. Total
RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany), treated with DNase-RNase
free (Qiagen, Hilden, Germany), quantified by Nanodrop (Thermo Fisher Scientific, Waltham, MA,
USA), and reverse-transcribed using QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Primers used for DNA amplification and reverse
transcription–polymerase chain reaction are reported in Table 1.
Table 1. Primers used for DNA amplification reverse transcription of FBN1 fragments carrying the
investigated variants (RefSeq NM_000138) in individual 1 and individual 2.













Molecular testing was carried out on the Individual 1 DNA by Sanger sequencing of the FBN1
gene, and this gave normal results. Multiple ligation-dependent probe amplification analysis for FBN1
intragenic deletions/insertions resulted normal. Given the convincing clinical picture and positive
family history, re-analyzing raw data from the Sanger sequence of extended intronic sequences was
carried out and revealed a novel FBN1 heterozygous splicing variant c.6872-24T>A, p.(?) (Figure 2A).
Co-segregation with the disease was demonstrated on the father’s DNA.
Computational predictions conducted using NetGene2, BDGP, and HSF revealed that the intronic
c.6872-24T>A variant might influence the splicing process by differentially affecting canonical versus
cryptic splice site utilization. The newly detected variant was predicted to insert 22 nucleotides
(nt) of intron 56 into the mature mRNA (Figure 2B). This should give rise to frameshift and a PTC
(p.(Asp2291Glyfs*9)), leading to the loss of the TGFβ binding protein homologous motifs, the last
seven cysteine-rich EGF-like domains, and the FibuCTDIII-like motif.
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Figure 2. Molecular analyses of individual 1. (A) Sanger sequencing in an unaffected (unrelated)
control (CTRL), the proband and his father of the FBN1 region spanning the 56 to 57 exon–intron
junction. The FBN1 genomic variant is indicated by an arrow. (B) Schematic representation of FBN1
region including 55 to 57 exons and introns. Rectangles represent exons; thin horizontal lines represent
introns. The position of the identified variant is indicated with an asterisk. Wild type and abnormal
transcripts generated by the c.6872-24T>A splicing variant are shown. (C) Total RNA of a normal
(unrelated) control, the proband, and his father were used for RT-PCR of the FBN1 transcript. The
same amounts of patient’s and control cDNA were PCR amplified. PCR products were analyzed
by electrophoresis on 3.5% agarose gel. M, DNA marker; C, control; P, proband; F, father. Affected
individuals (lane P and F) present both the wild-type mRNA (lower band) and aberrantly spliced
transcript (upper band). (D) Sanger sequencing of the FBN1 transcript, including exons 56 to 57 in an
unaffected (unrelated) control (C), the proband (P), and his father (F). Variant position on mRNA level
was annotated (r.6871_6872ins6872-22_6872-1). The intronic region was reported at the bottom of the
Sanger chromatograms of all affected individuals.
The effect of the FBN1 splice site variant c.6872-24T>A at the mRNA level was ascertained
by in vitro RT-PCR amplification of FBN1 RNA of Individual 1 and his father. The sequencing
of the RT-PCR products spanning the 55 to 57 exons of FBN1 showed the insertion of 22 nts of
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intron 56–57 in the FBN1 mRNA of Individual 1 and his father (r.6871_6872ins6872-22_6872-1)
(Figure 2C,D). Electropherogram showed a significant reduction of the peaks corresponding to the
mutated allele. The aberrantly spliced transcript is not present in the expressed sequence tag database
(EST, https://www.ncbi.nlm.nih.gov/dbEST/index.html) of FBN1. Following available standards for
the interpretation of sequence variants [12], the FBN1 c.6872-24T>A variant was classified as likely
pathogenic and submitted to the Leiden Open Variation Database (LOVD, https://www.lovd.nl;
accession number: # 00229824).
3.2. Individual 2
Targeted NGS analysis revealed the FBN1 heterozygous c.7571-12T>A variant in intron 61
(Figure 3A). No other candidate variant was found in the remaining genes. The c.7571-12T>A variant
was not reported in the UMD-FBN1 and was absent in the proband’s healthy sister. Both parents died,
and the other brothers and sisters were not available for genetic testing.
Figure 3. Molecular analyses of individual 2. (A) Sanger sequencing in an unaffected (unrelated)
control and the proband of the FBN1 region spanning 61 to 62 exon–intron junction. The FBN1 genomic
variant is indicated by an arrow. (B) Schematic representation of FBN1 region including 61 to 62 exons
and introns. Rectangles represent exons; thin horizontal lines represent introns. The position of the
identified variant is indicated with an asterisk. Abnormal transcripts generated by the c.7571-12T>A
splicing variant. (C) Total RNA of a normal (unrelated) control and the proband were used for RT-PCR
of the FBN1 transcript. The same amounts of patient and control cDNA were PCR amplified. PCR
products were analyzed by electrophoresis on 3.5% agarose gel. M, DNA marker; C, control; P, the
proband. M, DNA marker; C, control; P, proband; F, father. Affected individual (lane P) presents
both wild-type (lower band) and aberrant transcript (upper band). (D) Sanger sequencing of the
FBN1 transcript, including exons 61 to 62 in an unaffected (unrelated) control (C) and the proband (P).
Variant position on mRNA level was annotated (r.7570_7571ins7571-10_7571-1). The intronic region
was reported at the bottom of the Sanger chromatogram of the affected individual.
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The splicing predictor tools showed that the variant might alter the splicing process. In particular,
all predicted with high probability that the c.7571-12T>A intronic variant activates a cryptic acceptor
splice site within intron 61 that, in turn, leads to an inefficient recognition of the canonical splice site
(Figure 3B) and insertion of intronic nucleotides in the FBN1 mRNA. Sequence analysis on cDNA
confirmed the c.7571-12T>A variant causes a shift from canonical toward cryptic splicing that leads to
the inclusion of 10 nts of the 61 to 62 intronic sequence (r.7570_7571ins7571-10_7571-1) (Figure 3C,D)
and a frameshift which generate a PTC in exon 61 (p.(Asp2524Argfs*5)). The truncated protein loses the
last seven cysteine-rich EGF-like domains and the FibuCTDIII-like motif. Electropherogram showed a
reduction of the peaks corresponding to the mutated allele. The sequence of the alternative mRNA
was absent in the EST database. The FBN1 c.7571-12T>A variant was therefore interpreted as likely
pathogenic and submitted to LOVD (accession number: #00229832).
4. Discussion
In this work, we added two novel intronic variants to the FBN1 mutational repertoire and
demonstrated their effect at the mRNA level. Our findings highlight the impact of variants affecting
non-coding DNA in MFS and related disorders, and the opportunity to re-consider the standard
diagnostic approaches, at least, in specific cases. In particular, molecular studies revealed that the novel
c.6872-24T>A and c.7571-12T>A FBN1 variants induce aberrant pre-mRNA splicing by the generation
of a new cryptic acceptor site that outcompetes the canonical splice site and generate exonization
of intronic sequences. This, in turn, results in a frameshift with the introduction of a PTC. In both
cases, PTC is predicted to produce a truncated fibrillin 1 with a loss of critical C-terminal domains of
fibrillin 1 [13].
The mechanism(s) by which FBN1 splicing variants might exert their pathogenic effect is (are)
complex, and both dominant negative and loss-of-function effects have been proposed based on the
predicted consequences on mRNA, and protein structure and function(s) [14–16]. In splicing variants
generating out-of-frame deletions/insertions, the introduction of a PTC and the synthesis of a truncated
protein are assumed. However, PTC might elicit nonsense-mediated mRNA decay (NMD), with a
variable proportion of the mutated allele acting as a null allele. If NMD affects ~100% of the transcripts,
haploinsufficiency is the leading molecular pathogenesis. Conversely, the production of a truncated
fibrillin 1 due to complete NMD escape, can impact its function due to truncated protein production.
In proteins with pleiotropic effects and distinct domains with different functions, such as fibrillin 1 [3],
the length of the synthesized truncated protein and the differential expression of the gene in the
different tissues are the leading modulator factors of its residual functions. A mixed pathogenesis
should also be considered for PTC that allow only in part NMD. In splicing variants leading to in-frame
deletions/insertions, the predicted consequence might mirror the dominant negative effect attributed
to point variants [17].
Literature on FBN1 intronic variants affecting non-canonical splice sites is currently limited to
single reports, and the emerging genotype–phenotype correlations are purely speculative. For example,
Wang et al., by reporting a small case series of familial aortic aneurysms and dissection, studied the
effect of the FBN1 c.5917+6T>C variant in HEK293 cells and concluded that skipping of exon 47 seems
to associate with a higher rate of cardiovascular involvement [18]. Wypasek and coworkers reported
an adult with MFS, severe cardiac involvement but normally placed lens, and the FBN1 c.1589-9T>A
affecting splicing by in silico and in vitro investigations [19]. Recently, a further MFS patient with
full cardiac, ocular, and skeletal phenotype has been reported with the FBN1 c.2678-15C>A variant
affecting splicing by minigene approaches [20].
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In our study, both variants are predicted to result in a truncated protein. Although we did not
further investigate their effect, both transcripts are likely destined, at least in part, to NMD, as the
PTC falls in more than 50 nts upstream of the last exon–exon junction within the mRNA [21]. This
might be hypothesized by the differences in peak heights in the electropherograms of FBN1 transcripts
(Figures 2 and 3). This result suggests that a portion of aberrantly FBN1-spliced transcripts could be
degraded by NMD process in both cases. FBN1 haploinsufficiency due to NMD-mediated degradation
of aberrant mRNA might be the leading candidate molecular mechanism causing disease for the
novel c.6872-24T>A and c.7571-12T>A variants. However, we cannot exclude that a proportion of the
mutated transcripts escapes NMD at least in blood cells. Therefore, both NMD and the synthesis of
a truncated protein may result from the identified causative variants. In Individual 1 the predicted
truncated protein (p.(Asp2291Glyfs*9)) losses the seven TGFβ binding protein homologous motifs,
the last seven cysteine-rich EGF-like domains, and the FibuCTDIII-like motif; while in Individual 2,
protein truncation should occur later (p.(Asp2524Argfs*5)) preserving the loss of TGFβ binding protein
homologous motifs. Individual 1 (and his affected father) showed severe aortic disease, a feature that
was not observed in Individual 2, and both individuals lack ectopia lentis.
The reasons underlying the different clinical diagnoses in these two patients are hard to define. We
can speculate that in Individual 1 aortic involvement might be, at least in part, due to the loss of TGFβ
binding domain, which, in turn, is preserved in the truncated protein predicted in Individual 2 (MASS
syndrome), who showed normal aorta. In fact, perturbed binding with TGFβ results in the alteration
of elasticity and microfibrils stability, two factors primary influencing aortic wall integrity [22]. A trend
toward an increased risk for ectopia lentis was reported in cysteine-destroying or cysteine-creating
variants [2,15], a mechanism not easily evoked in our two Individuals. Therefore, our observation
testifies once more the difficulties in tracing consistent genotype–phenotype correlations in MFS and
the need for international collaborations working towards this aim.
In this work, we highlighted the importance of including extended intronic regions in the analysis
of FBN1 for clinical purposes. This remains valid in the era of NGS and should be considered at the
stage of (virtual) multigene panel design, as well as during variant prioritization and post-analytical
phase. Such an approach also needs the availability of additional tests validated for diagnostics and
able to explore variant effects at the mRNA or post-transcriptional levels for supporting the clinical
interpretation of the genomic data. Therefore, this work points out the need for introducing functional
investigations in the diagnostic workflow of at least selected disorders or gene panels, for which a
high rate of intronic variants with a potential pathogenic effect is expected. The description of further
individuals with splicing variants with documented effects at the various post-genomic levels seems
critical for improving our knowledge on this issue.
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Abstract: Loeys-Dietz syndrome (LDS) is a connective tissue disorder first described in 2005
featuring aortic/arterial aneurysms, dissections, and tortuosity associated with craniofacial,
osteoarticular, musculoskeletal, and cutaneous manifestations. Heterozygous mutations in 6 genes
(TGFBR1/2, TGFB2/3, SMAD2/3), encoding components of the TGF-β pathway, cause LDS. Such genetic
heterogeneity mirrors broad phenotypic variability with significant differences, especially in terms
of the age of onset, penetrance, and severity of life-threatening vascular manifestations and multiorgan
involvement, indicating the need to obtain genotype-to-phenotype correlations for personalized
management and counseling. Herein, we report on a cohort of 34 LDS patients from 24 families all
receiving a molecular diagnosis. Fifteen variants were novel, affecting the TGFBR1 (6), TGFBR2 (6),
SMAD3 (2), and TGFB2 (1) genes. Clinical features were scored for each distinct gene and matched
with literature data to strengthen genotype-phenotype correlations such as more severe vascular
manifestations in TGFBR1/2-related LDS. Additional features included spontaneous pneumothorax
in SMAD3-related LDS and cervical spine instability in TGFB2-related LDS. Our study broadens
the clinical and molecular spectrum of LDS and indicates that a phenotypic continuum emerges
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as more patients are described, although genotype-phenotype correlations may still contribute
to clinical management.
Keywords: hereditary connective tissue disorders; Loeys-Dietz syndrome; Ehlers-Danlos syndrome;
arterial aneurysms; TGFBR1; TGFBR2; SMAD2; SMAD3; TGFB2; TGFB3
1. Introduction
Loeys–Dietz syndrome (LDS) is a rare hereditary connective tissue disorder (HCTD) with an
autosomal dominant inheritance characterized by a widespread systemic involvement. The disorder
was first described in 2005 and in its most typical presentation it features aortic/arterial aneurysms
and/or dissections, as well as arterial tortuosity in association with variable craniofacial, osteoarticular,
musculoskeletal, and cutaneous manifestations [1,2]. LDS is caused by pathogenic variants
in transforming growth factor β (TGF-β) signaling pathway-related genes, i.e., TGFBR1, TGFBR2,
SMAD2, SMAD3, TGFB2, and TGFB3, which alter the physiological development and function of the
extracellular matrix, leading to cardiovascular and multisystem abnormalities [3]. Mutations in
the genes encoding the TGF-β receptor subunits (TGFBR1 and TGFBR2) were firstly identified and an
initial clinical classification of LDS type I and type II was proposed based on the presence of typical
craniofacial features in LDS type I [2]. Over the years, the discovery of novel disease-causative
genes, eased by the advent of next-generation sequencing techniques, paved the way for novel
genotype-phenotype correlations. For example, the identification of a subset of LDS patients
with pathogenic variants in SMAD3 displaying high frequency of osteoarthritis, prompted some
authors to define the resulting phenotype as “aneurysms-osteoarthritis syndrome” or LDS type
III [4]. McCarrick and coworkers argued that this phenotype fits within the LDS spectrum based
on the analysis of large cohorts of mutated patients [5]. In particular, the authors concluded that,
in the absence of formal diagnostic criteria for LDS, a pathogenic variant in any of the six LDS
disease-causative genes in combination with the presence of arterial aneurysm or dissection or
a positive family history should be considered sufficient for the diagnosis of LDS [5]. This stimulated
the study of genotype-phenotype correlations, which are of paramount value for correct management
of patients and to plan appropriate prevention programs in clinical practice. Even if wide inter-
and intrafamilial variability in the distribution and severity of clinical features is observed, a more
accurate gene-based categorization of LDS may have a great clinical impact in early diagnosis and
management and guide treatment strategies for patients and family members with this life-threatening
condition. Of note, the diagnosis of patients with LDS prompting molecular testing is not always
straightforward, since the spectrum of clinical manifestations is broad and often overlaps other
HCTDs, including Marfan syndrome (MFS), Shprintzen-Goldberg syndrome, some types of cutis
laxa, Ehlers-Danlos syndromes (EDS) (particularly the vascular type), arterial tortuosity syndrome,
congenital contractual arachnodactyly, and biglycan (BGN)-associated aortic aneurysm syndrome.
Additionally, in some cases further genetic testing may be indicated for the differential diagnosis
with other hereditary thoracic aortic disorders caused by pathogenic variants in distinct genes
including NOTCH1, ACTA2, MYH11, MYLK, PRKG1, MAT2A, FOXE3, MFAP5, and LOX [6]. Herein,
we describe 34 patients from 24 families with LDS in which we identified the genetic defect in one of the
known genes; 15 variants were novel, expanding the mutational repertoire. We further strengthened
genotype-phenotype correlations by fitting our data with available studies in literature and updated
the gene-to-phenotype categorization of LDS.
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2. Patients and Methods
2.1. Patients
Twenty-four index patients and 10 relatives with LDS, mostly of Italian origin but two from
Philippines and Sri Lanka, were evaluated from 2010 to 2018 in specialized outpatient clinics for the
diagnosis of HCTDs, namely: (i) the Ehlers-Danlos Syndrome and Inherited Connective Tissue
Disorders Clinic at the University Hospital Spedali Civili of Brescia, (ii) the Medical Genetics Unit of the
Sant’Orsola-Malpighi Hospital of Bologna, (iii) the Clinical Genetics Unit of the Regional Hospital
of Bolzano, (iv) the Centre of Expertise for Marfan syndrome and Marfan-related disorders at Policlinico
Tor Vergata University Hospital of Rome and (v) the Medical Genetics Unit, Department of Life, Health,
and Environmental Sciences of the University of L’Aquila.
2.2. Molecular Investigations
Molecular analyses were performed in the laboratory of genetic testing at the Division
of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia.
Mutational screening was achieved on genomic DNA purified from peripheral blood leukocytes
of affected and unaffected family members by standard procedures. All exons and their
intron-flanking regions of TGFBR1 (NM_004612.4, NP_004603.1), TGFBR2 (NM_003242.5, NP_0033233.4),
SMAD3 (NM_003242.5, NP_005893.1), and TGFB2 (NM_001135599.3, NP_001129071.1) were PCR
amplified by using optimized genomic primers (Supplementary Table S1, primers were designed
by using the Primer Express software v. 3.0.1 (Thermo Fisher Scientific, South San Francisco, CA, USA)
and purchased by Metabion International AG, Planneg, Germany), which were analyzed for the
absence of known variants using the GnomAD database [7]. After enzymatic cleanup of the PCR
products, all fragments were sequenced in both orientations using the Big Dye Terminator Cycle
Sequencing kit protocol (Thermo Fisher Scientific, South San Francisco, CA, USA) followed by
capillary electrophoresis on the ABI3130XL Genetic analyzer. The sequences were analyzed with
the Sequencher 5.0 software (Gene Codes Corporation, Ann Arbor, MI, USA) and variants were
annotated according to the Human Genome Variation Society (HGVS) nomenclature with the Alamut
Visual software version 2.11 (Interactive Biosoftware, Rouen, France), which was also used for splice
site prediction, since it includes four different prediction algorithms: SpliceSiteFinder-like, MaxEntScan,
NNSplice, and GeneSplicer. When available, fresh blood samples were collected in patients carrying
variants affecting canonical splice sites. In order to verify the effect on splicing, RT-PCR was
carried out on total RNA extracted from patients’ whole blood stabilized in Paxgene tubes following
the manufacturer’s protocol by using the Paxgene Blood RNA Extraction Kit (PreAnalytiX, Qiagen,
Hilden, Germany). In particular, amplification of cDNA covering exons 2–4 of TGFBR2 (TGFBRex2-forw:
5′-GTGGCTGTATGGTAAGAGA-3′ and TGFBR2ex4-rev: 5′-CCAGGTTGAACTCAGCTTCTG-3′)
and exons 6-8 of SMAD3 (SMAD3ex6-forw: 5′-CCTAGGGCTGCTCTCCAATG-3′ and SMAD3ex8-rev:
5′-GTGCACATTCGGGTCAACTG-3′) was performed, respectively, and followed by Sanger sequencing
of the RT-PCR products. All identified variants were submitted to the Leiden Open Variation Database
(LOVD) [8].
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2.3. Genotype-Phenotype Analysis and Literature Review
The medical records of 34 patients with a molecularly proven diagnosis of LDS were accessed and
their phenotypes were defined using the Human Phenotype Ontology (HPO) terms by a careful review
of clinical notes. Phenotypic categories were created based on the number of observations in the patient’s
cohort and their relationship to LDS. In reporting the frequency of clinical features of our case series,
the used denominator refers to the number of subjects for which information on a specific feature was
available (Table 1). We reviewed the medical literature on the clinical manifestations of patients with
a confirmed genetic diagnosis of LDS, i.e., patients from large cohorts harboring mutations in one
of the six known disease-causative genes. The primary search was completed in the PubMed database
and limited to articles in the English language literature without restrictions on the date of publication.
Keywords used were “Loeys-Dietz syndrome” AND “genotype”, “Loeys-Dietz syndrome” AND
“phenotype” as well as “Loeys-Dietz syndrome” AND “review.” A secondary search was performed
to identify pertinent articles cited in those selected in the primary search. We tried to identify all
papers for which genotype-phenotype correlation data were available, focusing on reviews and large
cohort studies.
2.4. Ethical Compliance
This study was approved by the relevant Ethical Authorities of the: Policlinico Tor Vergata University
Hospital (Progetto di Ricerca PGR00229, R.S. 204/16); University of L’Aquila, Medical Genetics Section,
Department of Life, Health, and Environmental Sciences (PGR00229, prot. 20251); and local Ethical
Committees. This study was performed in agreement with the principles of the 1964 Helsinki Declaration.
All subjects (or their legally authorized representative) enrolled into the genetic study provided written
informed consent.
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3. Results
3.1. Demographic Data and Genotype-Phenotype Analysis of LDS Patient’s Cohort
We report the clinical and genetic features of 34 individuals from 24 families. The female-to-male
ratio of affected probands was 1/1. The mean age at diagnosis of the 24 unrelated probands was
26 years (range 1–51 years). Thirteen of them had a positive family history, while 11 were sporadic.
Ten individuals were diagnosed upon familial segregation. The detailed clinical and molecular
features of each affected individual are summarized in Supplementary Table S2. The overall frequency
of selected clinical features observed in our cohort, categorized for each distinct gene as compared
to in the literature, is shown in Table 1. An overview of characteristic features observed in the patients
of our cohort is presented in Figure 1.
Figure 1. Clinical and instrumental findings observed in our Loeys-Dietz syndrome (LDS) patients.
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(a–c) Proband of family 1 (p.Asp400Gly,TGFBR1), aged 7 years manifesting dolichocephaly (a),
milia (b) and enamel defect of permanent dentition. (d,e) Family 4 (p.Gly271Asp, TGFBR1),
proband (d) and his brother (e) outlining intrafamilial variability of palpebral fissures, horizontal
in the proband (d) and downslanted in his brother (e) in the presence of severe milia in both.
(f) CT-angiography of the abdomen in the proband of family 7 (p.Gly353Arg, TGFBR1), aged 23 years,
showing aneurysm of the abdominal aorta (asterisk) with intimal blister flap (arrow head).
(g) Proband of family 15 (p.Asp522Asn, TGFBR2), aged 36 years: CT-angiography of head and
neck showing fusiform aneurysm of the left subclavian artery (asterisk), middle cerebral artery stenosis
(arrow heads), diffuse tortuosity of vertebral arteries (area within the circle). (h–k) Proband of family
16 (p.Asp446Asn, TGFBR2), aged 7 years, displays asymmetry of iliac crest, thin and translucent skin
with highly visible subcutaneous venous reticulum (h); Limited function of the feet after corrective
surgery for bilateral clubfoot (i); hind foot deformity with bilateral pronated valgus pes planus (j);
X-ray frontal view performed at 6 years shows the displaced heart in the left thorax due to severe pectus
excavatum and scoliosis with lumbar left rotation and asymmetric iliac wings (k). (l–n), Proband of
family 24 (p.Phe160Leufs*14, TGFB2), aged 48 years featuring facial asymmetry and dysmorphism
(highly arched eyebrows, hypertelorism, bilateral exophthalmos, bifid nasal tip, long philtrum with
thin upper lip, micrognathia) in addition to premature aging appearance (l); Joint laxity of the thumb
(m) and the knee (n); Note the thin and translucent skin with visible subcutaneous veins.
3.2. Molecular Findings
In this study, 24 different variants in four distinct LDS-related genes were identified in the proband
of each family by direct sequencing (Table 2). All variants were deposited in LOVD. The majority
of variants affected the TGFBR1 (9/24) and TGFBR2 (10/24) genes, four families showed variants
in SMAD3, and 1 patient harbored a TGFB2 variant. No variants were identified in SMAD2 and
TGFB3. Fifteen variants affecting TGFBR1, TGFBR2, SMAD3, and TGFB2 were novel, while nine
in TGFBR1, TGFBR2, SMAD3 were previously reported either in the literature or in the ClinVar database
(Supplementary Table S2 and Table 2).
Among novel variants, 10 missense substitutions and one in-frame deletion of two highly
conserved amino acid residues p.(Lys232_Ile233del) were evaluated for their putative pathogenicity
through different in silico prediction algorithms, all predicted them as being high impacting variants.
Given that they are: (i) located in critical and well-established functional domains without benign
variation; (ii) absent in publicly available population databases, (iii) predicted as deleterious my
multiple lines of computational evidence and based on the matching of the clinical phenotypes, all
these variants were classified as pathogenic (class 5) according to the American College of Medical
Genetics and Genomics (ACMG) guidelines [9].
Likewise, the novel c.480del variant in TGFB2 was classified as pathogenic (class 5), since it leads
to frameshift and formation of a premature termination codon p.(Phe160Leufs*14) that likely activates
nonsense-mediated mRNA decay (NMD).
For two out of three variants affecting splice sites, we obtained fresh blood samples and
demonstrated an effect on the splicing process, corroborating their pathogenicity. In particular,
the c.263+6C>T variant in TGFBR2 (rs758501054, Minor allele frequency in ExAC, MAF = 0.000008)
was classified as likely pathogenic (class 4) according to the ACMG, since it creates a new splice donor
site 6 bases downstream of the wild-type donor with retention of 4 nucleotides of intron 3, formation of
a stop codon (p.Arg114*) and activation of NMD. The c.1009+1G>A variant in SMAD3 was classified
as pathogenic (class 5), since it abolishes the canonical splice donor site of exon 7 causing in-frame
exon skipping (p.Arg292_Gly337del). Lastly, although RNA was not available to investigate its effect,
the c.862_871+8del pathogenic variant (class 5) variant in SMAD3, thought formally a frameshift
variant, likely leads to abnormal splicing as well (i.e., in-frame exon 6 skipping), as the canonical splice
donor site is lost.
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4. Discussion
Since the relatively recent description of LDS in 2005, six disease-causative genes have been
identified, namely TGFBR1 (MIM #190181) [1], TGFBR2 (MIM#190182) [1], SMAD2 (MIM #601366) [10],
SMAD3 (MIM #603109) [4], TGFB2 (MIM #190220) [11], and TGFB3 (MIM#190230) [12]. This advised
the subdivision of LDS into multiple classes based on the causative gene (LDS1-5) providing
a general indication of the spectrum of disease severity, from most to least severe form:
LDS1=LDS2>LDS3>LDS4>LDS5 [6]. Still, there are not enough data on LDS caused by heterozygous
mutations in SMAD2 to place this form (LDS6) in this spectrum [13]. Recently, it has been suggested that
mutations in genes different from TGFBR1/2 may give rise to a phenotypic continuum hard to categorize
in clear-cut genotype-phenotype correlations [3,6]. In this study, we performed a retrospective
multi-center study on clinical and mutational analyses in 24 novel LDS families with 34 patients.
Furthermore, a systematic overview of LDS patient’s features for each mutated gene was conducted
to verify if observed genotype-phenotype correlations fitted current knowledge.
Overall, we noticed significant overlaps for TGFBR1/2, SMAD3, and TGFB2 patients (Table 1),
while emerging genotype-phenotype correlations are described below, subdivided for each gene.
4.1. TGFBR1/2 Genes
According to previous studies, most of the identified mutations affected TGFBR1 (9/24) and TGFBR2
(10/24) genes. While nearly all mutated patients displayed ascending/aortic root aneurysm, severe arterial
involvement was recorded in half. Early aortic dissection was more rarely reported together with arterial
tortuosity. Interestingly, we noticed a high number of different arteries being affected. These findings
highlight the need for extended arterial imaging, as was already recommended [5]. Valve abnormalities,
in particular mitral valve prolapse and insufficiency, affected nearly half of the patients; isolated mitral
valve prolapse was also present in seven out of 10 TGFBR2 patients. As previously described,
craniofacial features may be considered to be characteristics of TGFBR1/2-LDS including dolichocephaly,
hypertelorism, malar hypoplasia and highly arched palate, while abnormal palate/bifid uvula was
not as frequently found as described in the literature. Recurrent skeletal anomalies included scoliosis,
pes planus, long slender fingers, marfanoid habitus, and pectus deformity. Hernias were of different
types (diaphragmatic, inguinal, or umbilical) and together with joint laxity were registered in half
of patients. Cutaneous findings appeared extremely frequent including translucent skin, easy bruising
and striae; together with facial milia, described in half mutated patients, skin features appeared
as extremely useful handle for diagnosis [14]. Overall, our data confirm broad overlap between
LDS phenotypes caused by TGFBR1/2 pathogenic variants, as previously assessed [6]. Also, in four
families the presence of significant craniofacial malformations correlated with a higher risk of vascular
manifestations [5,6]. Finally, two children had tooth abnormalities, in particular enamel defects,
a possibly underestimated features in LDS in line with the role of TGF-β signaling in dental and enamel
formation [15].
4.2. SMAD3 Gene
Among our three SMAD3-mutated families, early osteoarthritis, considered a hallmark of this
subset of patients, was described only in one, although it segregated in the proband and his father. In line
with our data, despite early studies reported osteoarthritis in all SMAD3 patients [4], others noticed
a lower incidence [16]. Interestingly, this family presented very mild cardiovascular anomalies, with only
mitral valve prolapse registered in the proband. Generally, SMAD3-LDS patients displayed a less severe
degree of cardiovascular complications. In fact, despite all the presence of thoracic aortic (and renal
arteries) aneurysms, dissection was reported only once, as well as arterial tortuosity and varices.
Additional clinical findings overlapped with those recorded in other LDS patients, including recurrent
craniofacial dysmorphism such as hypertelorism, malar hypoplasia, micrognathia and highly arched
palate, cleft palate and/or uvula, cutaneous features with translucent skin, striae and facial milia,
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hernias and skeletal manifestation like pes planus, pectus deformity, marfanoid habitus, and scoliosis.
It is worth noting that one subject had spontaneous pneumothorax, recorded in a single SMAD3 patient
in the literature [3]. The causes of spontaneous pneumothorax in LDS have not been clearly elucidated
but its association with LDS independently from the genetic subtype as well as the occurrence in other
HCTD such as Marfan syndrome argues in favor of a common role for TGF-beta signaling. Several lines
of evidence based on mouse models, knockout for genes encoding members of the TGF-beta pathway,
support this observation (reviewed in reference [17]). In particular, perturbed TGF-beta signaling
was implicated in abnormal pulmonary alveolarization and alveolar destruction, leading with age
to emphysema and spontaneous lung rupture (i.e., primary spontaneous pneumothorax).
4.3. TGFB2 Gene
We identified only one patient with a TGFB2 pathogenic variant, whose cardiovascular features
consisted in mitral valve prolapse and insufficiency, mild arterial tortuosity and varicose veins,
in the absence of aneurysms. Additional features included bifid uvula, striae, translucent and
hyperextensible skin, facial milia, hernias, joint hypermobility, pectus deformity, scoliosis, and pes
planus observed in other LDS genetic subtypes. In line with previous observations, this patient
presented the mildest end of LDS phenotypic spectrum [18]. However, it should be noted that
phenotypic variability ranging from mild to severe expression was also recorded in TGFB2-LDS [19].
Further broadening the clinical picture of this genetic subtype, she also showed cervical spine
instability, which was not previously registered in association with TGFB2, although it has been
commonly encountered in LDS [3]. Interestingly, in Tgfb2 heterozygous knockout mice severe skeletal
defects are also observed including skull base and vertebral malformations, in line with the human
phenotype [20]. These data corroborate the importance to investigate and diagnose malformation
of cervical spine and/or instability, which should be carefully monitored to prevent severe complications
in these patients.
4.4. Other Genes
No mutations were identified in the latest described LDS genes, namely SMAD2 and TGFB3.
Still, limited numbers are available in literature about genotype-phenotype correlation. To date, 9 (likely)
pathogenic variants in SMAD2 have now been described in 15 subjects displaying a broad range
of features, including aneurysms, tortuosity of the entire arterial tree, and coronary artery dissections,
even in the absence of prominent connective tissue characteristics [13]. Concerning TGFB3, 15 different
variants were reported in 56 individuals presenting with phenotypic overlap between LDS and MFS [12].
5. Conclusions
In this work, we broadened the clinical and molecular spectrum of LDS, corroborated, and expanded
previously delineated genotype-phenotype correlations, paving the way for a gene-based classification
of different disease subtypes. Larger cohort screenings are needed to unravel the thorough clinical and
molecular repertoires in LDS to accurately establish diagnostic criteria, define genotype-phenotype
correlations, and collect natural history data for clinical prognostication.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/10/764/s1,
Table S1: Primers, Table S2: Clinical and molecular features of LDS patients described in this cohort.
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